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Objectives: To assess the effectiveness and cost-
effectiveness of schools-based skills building behavioural 
interventions to encourage young people to adopt and 
maintain safer sexual behaviour and to prevent them 
from acquiring sexually transmitted infections (STIs).
Data sources: Electronic bibliographic databases (e.g. 
MEDLINE, MEDLINE In-Process & Other Non-Indexed 
Citations, EMBASE, CINAHL, PsycINFO, CCRCT, NHS 
EED and DARE) were searched for the period 1985 to 
March 2008. Bibliographies of systematic reviews and 
related papers were screened and experts contacted to 
identify additional published and unpublished references. 
Review methods: A systematic review of effectiveness 
and economic evaluation of cost-effectiveness were 
carried out.  A descriptive map of studies that met 
inclusion criteria was produced, and keywords were 
developed and systematically applied to these studies 
to identify a policy-relevant subset of studies for the 
systematic review. Outcome data for variables including 
sexual behavioural were extracted.  An economic model 
was developed to compare the costs and consequences 
of the behavioural interventions.  A Bernoulli statistical 
model was constructed to describe the probability of 
STI infection.
Results: There were few significant differences 
between the interventions and comparators in terms of 
changes in sexual behaviour outcomes, although there 
were some significant differences for knowledge and 
some measures of self-efficacy. The studies included 
in this review  conducted relatively short follow-up 
assessments at a time when many young people were 
becoming sexually active. It is therefore possible that 
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favourable behaviour change may have occurred, and 
become more cost-effective, with time, as sexual 
activity becomes more routine in young people’s lives. 
The quality of the intervention provider influenced 
whether or not young people found the interventions 
to be acceptable and engaging; enthusiasm and 
considerable expertise were important for effective 
class management and delivery of skills-building 
activities, and a supportive school culture was also 
helpful. Recognition of young people’s individual needs 
in relation to sexual health was another important 
factor. No conclusions could be drawn on the impact of 
the interventions on sexual health inequalities due to a 
lack of relevant data on socioeconomic status, gender 
and ethnicity. The results of the economic evaluation 
were considered to be illustrative, mainly due to the 
uncertainty of the effect of intervention on behavioural 
outcomes. The results were most sensitive to changes 
in parameter values for the intervention effect, the 
transmission probability of STIs and the number of 
sexual partners. The costs of teacher-led and peer-
led behavioural interventions, based on the resources 
estimated from the relevant randomised controlled 
trials in our systematic review, were £4.30 and £15 
per pupil, respectively. Teacher-led interventions were 
more cost-effective than peer-led interventions due 
to the less frequent need for training. The incremental 
cost-effectiveness of the teacher-led and peer-led 
interventions was £20,223 and £80,782 per quality-
adjusted life-year gained, respectively. An analysis of 
individual parameters revealed that future research 
funding should focus on assessing the intervention effect Abstract
iv
for condom use from a school-based intervention.
Conclusions: School-based behavioural interventions 
for the prevention of STIs in young people can bring 
about improvements in knowledge and increased 
self-efficacy, but the interventions did not significantly 
influence sexual risk-taking behaviour or infection rates. 
Future investigation should include long-term follow-up 
to assess the extent to which safer sexual behaviour is 
adopted and maintained into adulthood, and prospective 
cohort studies are needed to look at the parameters 
that describe the transmission of STIs between 
partners. Funding should focus on the effectiveness of 
the interventions on influencing behaviour.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Background
Rates of sexually transmitted infections (STIs) 
continue to increase, particularly amongst 
young people. STIs can be either bacterial (e.g. 
chlamydia, gonorrhoea) or viral [e.g. human 
immunodeficiency virus (HIV), genital herpes, 
human papillomavirus]. Interventions to encourage 
young people to adopt and maintain safer sexual 
behaviour are one approach to preventing STIs 
and promoting sexual health. The prevention of 
STIs and teenage pregnancy is a high priority 
for health policy because of the adverse impact 
on individuals and on health service resources. 
We conducted a systematic review and economic 
evaluation to assess the effectiveness and cost-
effectiveness of behavioural interventions for the 
prevention of STIs in young people.
Methods
Systematic review of 
effectiveness
A two-stage process was followed: (1) development 
of a descriptive map of the key characteristics 
of studies evaluating behavioural interventions, 
followed by (2) a detailed systematic review of a 
subset of interventions.
Search strategies  Electronic bibliographic databases 
(for example, MEDLINE, MEDLINE In-Process & 
Other Non-Indexed Citations, EMBASE, PsycINFO 
and CINAHL) were searched for the period 1985 
to March 2008. Bibliographies of systematic reviews 
and related papers were screened and experts 
contacted to identify additional published and 
unpublished references.
Study selection  Titles (and abstracts, where available) 
were screened for eligibility by one reviewer using 
a priori inclusion criteria. Studies eligible for 
inclusion in the descriptive map were: controlled 
trials, evaluating a behavioural intervention 
(defined as any activity to encourage young 
people to adopt sexual behaviours that would 
protect them from acquiring STIs), in young 
people aged 13–19 years, which reported a sexual 
behavioural outcome. Full papers were obtained 
for those abstracts and/or titles that appeared 
relevant, and these were screened by two reviewers 
independently.
Descriptive map  Keywords were developed and 
systematically applied to included studies to 
produce a detailed map of the evidence base 
that was used to prioritise a subset of studies for 
inclusion in the systematic review in consultation 
with stakeholders.
Data extraction and quality assessment  Two reviewers 
independently quality assessed the studies included 
in the systematic review. Differences in judgement 
were resolved by discussion and involvement of a 
third reviewer if necessary. Outcome data from the 
studies that were judged to be methodologically 
sound were extracted by one reviewer and checked 
by a second. Process evaluation data were coded 
by two reviewers and classified into higher-order 
themes.
Data synthesis  Studies were synthesised in both a 
narrative synthesis and meta-analysis.
Process evaluation  Findings from process evaluations 
that had been conducted alongside the included 
original randomised controlled trials (RCTs) were 
summarised narratively.
Economic evaluation
A systematic review was conducted of economic 
evaluations of behavioural interventions for the 
prevention of STIs in young people. A number of 
electronic bibliographic databases (for example, 
CCRCT, MEDLINE, MEDLINE In-Process & 
Other Non-Indexed Citations, EMBASE, NHSEED 
and DARE) were searched for the period 1990 to 
February 2008, and references screened according 
to a priori inclusion criteria.
An economic model was developed to compare 
the costs and consequences of behavioural 
interventions for the prevention of STIs in young 
people. The cost-effectiveness of two types of 
behavioural intervention (teacher- and peer-led 
school-based intervention) compared with standard 
sexual health education was assessed.
Executive summaryExecutive summary
x x
A Bernoulli statistical model was constructed, 
which described the probability of STI infection 
based upon STI prevalence; single-act transmission 
probability; condom effectiveness and condom 
use; number of sexual episodes; and number of 
sexual partners. The parameters for the model 
were derived from a systematic search of the 
literature on the natural history and epidemiology 
of STIs; sexual behaviour and lifestyles; health-
related quality of life; and costs. Costs were derived 
from primary data from previous studies, and 
national and local NHS unit costs. The analysis 
was conducted from the perspective of the NHS 
and Personal Social Services. In the model, the 
intervention effects last for 1 year, on the basis that 
the majority of the trials included in our systematic 
review assessed outcomes up to 1 year. The model 
estimates the lifelong costs and benefits from 
averted STI cases.
The model estimates the probability of becoming 
infected for the intervention and comparator 
groups according to changes in parameters that 
may be affected by the intervention (i.e. condom 
use, number of sexual partners, number of 
sexual episodes). The number of cases averted 
is estimated by multiplying the reduction in risk 
of STI infection by the number of people who 
receive the intervention. The total number of STI 
cases averted, and consequent quality-adjusted 
life-year (QALY) gain and saving in medical costs 
is estimated for males and females for all STIs for 
one year.
Results of the systematic 
review of effectiveness
A descriptive map of 136 studies meeting the 
inclusion criteria was produced. The results 
illustrated the predominance of North American 
trials of educational interventions conducted in 
schools with young people targeted primarily 
because of their age.
Discussion with the project’s advisory group 
enabled the prioritisation of a policy-relevant 
subset of studies for systematic review. To be 
included studies had to be an RCT; evaluate 
a behavioural intervention including factual 
information on STIs, in addition to an element 
of skills development for negotiation of safer 
sex; be delivered in a school; and report a sexual 
behavioural outcome (in addition to other 
outcomes).
A total of 15 RCTs met the inclusion criteria for the 
systematic review. The majority were conducted in 
the USA, with only two in the UK. Of the 15 RCTs, 
12 were judged to be methodologically sound 
and were included in the analysis of effectiveness. 
Studies reported on five main types of behavioural 
outcome: initiation of sexual intercourse; condom 
use; sexual intercourse; contraception and 
pregnancy; and sexual partners. Outcome data for 
variables that may mediate behavioural change 
were also often reported: knowledge; skills and 
self-efficacy; attitudes; and behavioural intentions. 
Rates of infection were not reported.
Five studies contributed data on sexual initiation. 
Three of the five studies found that there was no 
significant difference for this outcome between 
the intervention and the comparison group. Two 
studies reported a statistically significant difference 
in favour of the intervention, although in one the 
difference was only observed for girls in the peer-
led group, which was compared with a teacher-led 
group. Data from four of these studies could be 
combined in a meta-analysis, the odds ratio (OR) 
of 1.03 [95% confidence interval (CI) 0.74 to 1.43] 
indicated no overall significant difference between 
groups.
A variety of condom use outcomes were reported. 
Statistically significant effects in favour of the 
intervention group over the comparison group 
were only reported by two of the studies, with one 
further study reporting a statistically significant 
effect in favour of the intervention for a subgroup 
of participants. A meta-analysis was conducted for 
the general outcome of condom use (an outcome 
incorporating some of the various measures 
of condom use). The fixed-effect OR for the 
combined effect was 1.07 (95% CI 0.88 to 1.30), 
again indicating no significant difference overall 
between groups.
For the remaining behavioural outcomes of 
sexual intercourse, contraception and pregnancy, 
and number of sexual partners there were very 
few statistically significant differences between 
intervention and comparators. The interventions 
did not lead to a significant increase in initiation of 
sexual activity by young people, or to an increase in 
the number of their sexual partners.
The success of the skills component of 
interventions was generally assessed by self-efficacy 
measures. Eight of the 12 studies reported a self-
efficacy measure, most commonly condom use DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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self-efficacy which was reported by seven studies. 
Refusal or abstinence self-efficacy (n = 6 studies), 
communication/negotiation self-efficacy (n = 4 
studies), and situational self-efficacy (n = 2 studies) 
were also reported by some studies. Statistically 
significant effects were reported for some, but 
not all, of the self-efficacy measures assessed. All 
the methodologically sound studies included a 
knowledge outcome measure, and statistically 
significant effects in favour of the intervention 
group over the comparison group were found by all 
but two of the studies.
Eight of the methodologically sound studies 
included an assessment of attitudes among their 
outcomes, and six studies reported participants’ 
intentions, with a variety of different attitudes and 
intentions being assessed. However, few studies 
reported statistically significant effects in favour of 
the intervention group for these outcomes.
Nine of the 12 methodologically sound RCTs 
conducted a process evaluation. Synthesis of 
the process findings to explore reasons for the 
limited impact of school-based skill-development 
interventions revealed two sets of factors. Firstly, 
interventions were not always implemented 
as intended. Variation in implementation was 
affected by whether or not there was a supportive 
school culture, flexible school administration, 
and enthusiasm and expertise from teachers and 
peers for delivering interactive sexual health 
sessions such as role plays. Secondly, not all young 
people found the interventions as engaging 
or as acceptable as they might have done. The 
qualities of the intervention providers – namely 
enthusiasm, credibility and expertise (in content 
and in managing classrooms) – was one factor that 
influenced whether or not young people found 
the interventions to be acceptable and engaging. 
Other factors were whether the interventions met 
young people’s own needs in relation to sexual 
health, including sexual feelings, emotions and 
relationships, the operation of gendered norms, 
the age appropriateness of the intervention and the 
level of discomfort felt in the classroom setting.
No conclusions could be drawn about the impact of 
the interventions on sexual health inequalities due 
to a lack of relevant data in the primary studies on 
factors, such as socioeconomic status (SES), gender 
and ethnicity.
Results of the economic 
evaluation
Systematic review of cost-
effectiveness studies
Five economic evaluations of behavioural 
interventions for the prevention of STIs in young 
people were included. The studies were conducted 
in the USA and focused on the prevention of 
HIV. All studies used mathematical models 
extrapolating the changes in sexual behaviour. All 
interventions were effective at encouraging safer 
sexual behaviour in the study groups and thus led 
to cases of HIV averted. As the studies used a wide 
range of assumptions and parameter values in the 
mathematical models, substantial differences in 
the estimated cost-effectiveness of the behavioural 
interventions were reported.
Modelled cost-effectiveness 
analysis
An economic model was developed to assess the 
cost-effectiveness of behavioural interventions 
for preventing STIs in young people. However, 
as our meta-analysis did not show a statistically 
significant intervention effect, the results presented 
should be treated with caution and only be 
regarded as illustrative. The costs of teacher- and 
peer-led behavioural interventions, based on the 
resources estimated from the relevant RCTs in our 
systematic review, were £4.30 and £15 per pupil, 
respectively. We assumed the same benefit for 
teacher- and peer-led interventions. The teacher-
led interventions were cheaper because of the need 
to train a new cohort of peers each year, whereas 
the teachers are only likely to need retraining after 
a number of years.
For a cohort of 1000 boys and 1000 girls, aged 15 
years, the model estimated that the behavioural 
interventions would avert three STI cases and save 
0.5 of a QALY. The incremental cost-effectiveness 
of the teacher- and peer-led interventions 
was £20,223 and £80,782 per QALY gained, 
respectively. Sensitivity analyses show the results 
were most sensitive to the intervention effect 
(condom use), the STI transmission probability, 
and the number of sexual partners in the base-case 
analysis. The model results were also sensitive to 
changes to the model parameters for chlamydia 
and especially for parameters related to tubal 
infertility. In a probabilistic sensitivity analysis, the Executive summary
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probability of the teacher-led intervention being 
cost-effective was 46%, where a decision-maker is 
prepared to pay £20,000 per QALY and 54% at a 
threshold of £30,000 per QALY.
At a cost-effectiveness threshold of £20,000 per 
QALY, the population expected value of perfect 
information (EVPI) is £12.5M, assuming a 10-year 
lifetime for the intervention (i.e. the time until a 
new intervention supersedes or replaces it). This 
constitutes an upper limit on research expenditure 
to reduce decision uncertainty. An analysis of the 
individual parameters used in the model revealed 
that research would be best funded to assess the 
intervention effect for condom use from a school-
based behavioural STI intervention.
Conclusions
School-based behavioural interventions which 
provide information and teach young people 
sexual health negotiation skills can bring about 
improvements in knowledge and increased self-
efficacy. However, in this systematic review there 
were few significant differences between the 
interventions and comparators in terms of changes 
in behavioural outcomes, such as condom use. 
The studies conducted relatively short follow-up 
assessments at a time when many young people 
were only just becoming sexually active. It is 
possible that favourable behaviour change may 
have occurred with time, particularly as sexual 
activity becomes more routine in young people’s 
lives.
The results of the economic evaluation are 
considered illustrative primarily due to the 
uncertainty around the effect of intervention on 
behavioural outcomes, but also due to limitations 
in the data for other input parameters. The results 
were most sensitive to changes in parameter 
values for the intervention effect, the transmission 
probability of STIs and the number of sexual 
partners. Teacher-led interventions are likely to 
be cheaper than peer-led interventions due to 
less frequent need for retraining. Behavioural 
interventions for young people potentially may 
become more cost-effective as they get older and a 
greater proportion become sexually active.
Implications for practice
Policy-makers and practitioners should be cautious 
in their expectations about the impact of such 
interventions on sexual behaviour and incidence 
of infection. Nonetheless, school-based skills-
building behavioural interventions can be effective 
in influencing behaviour-mediating outcomes, 
such as knowledge, attitudes and self-efficacy. This 
is in accordance with current UK government 
health policy, which stresses the need to provide 
high-quality information to enable young people 
to make informed decisions. Interventions need to 
be culturally relevant and context specific, taking 
into account the needs of subgroups of young 
people (e.g. young men, young women) and, where 
possible, be part of a whole school approach to 
sexual health promotion. Young people will benefit 
from being involved as equal stakeholders in the 
design and delivery of interventions. Providers of 
school-based interventions need to be enthusiastic 
and credible, with considerable expertise in 
classroom management and the delivery of skills-
building activities, such as role plays and group 
discussions. A supportive school culture is also 
important.
Implications for research
If further primary evaluation of behavioural 
interventions is to be conducted there should be 
long-term follow-up to assess the extent to which 
safer sexual behaviour is adopted and maintained 
into adulthood. The impact of booster sessions 
should be further evaluated. All trials should be 
accompanied by rigorous process evaluation to 
assess the factors that contribute to success or 
failure, and economic evaluations to assess cost-
effectiveness. Where appropriate, trials should 
collect, analyse and report data on the likely effects 
of the intervention on sexual health inequalities. 
Other markers of risk reduction (e.g. STI testing) 
should be measured.
For many of the parameters for the economic 
evaluation there were no available data for the 
< 16-year-old age group and we have had to make 
assumptions to extrapolate data from older age 
groups. Data on the sexual behaviour of under-16s 
is therefore needed. Furthermore, there is a need 
for prospective cohort studies to determine the 
parameters that describe the transmission of STIs 
between partners. The analysis of EVPI suggested 
an upper limit of £12.5M on funding for further 
research to reduce decision uncertainty, which 
should focus on the effectiveness of interventions 
on changing behaviour (e.g. increasing condom 
use).DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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exual health is influenced by a complex 
interplay between a number of factors, 
including the individual, their sexual partners, 
and their social and economic environment. The 
mechanisms by which the social and economic 
environment in which young people live influence 
the risk of acquiring a sexually transmitted 
infection (STI) remain complex and unclear. 
However, it is clear that some groups of young 
people are disproportionately affected by STIs. 
These groups are often characterised by factors that 
are also associated with the broader determinants 
of social and health inequalities, such as gender, 
ethnicity and sexuality. For example, young women 
(aged 16–19 years) have the highest incidence of 
both chlamydia and genital warts; young men who 
have sex with men remain at high risk of acquiring 
human immunodeficiency virus (HIV) in the UK, 
and rates of diagnosed STIs vary among young 
people of different racial and ethnic groups.1 Little 
is known about which interventions are likely to 
reduce inequalities in sexual health.
Sexually transmitted infections are preventable, 
but individuals may put themselves at risk due to 
factors such as a lack of knowledge about STIs, low 
self-efficacy (the expectation that one can perform 
a particular task or activity, such as using condoms), 
poor condom use and/or sexual negotiation skills. 
Risk-taking by individuals may also be influenced 
by peer-group norms. Behavioural interventions 
have been developed which are designed to 
prevent or reduce risk behaviour, for example, by 
providing factual information and skills training.2,3
For young people, information about STIs is 
available from a wide range of sources that have 
varying degrees of reliability. Informal information 
sources about STIs and sex more generally may 
come from friends, family, the internet, magazines 
and other media. Most formal information and 
skills development around STIs is likely to come 
from sex education lessons provided in schools 
or from health services (see under Sexually 
transmitted infection prevention in the UK). The 
objective of school-based sex and relationships 
education (SRE) is to help and support young 
people through their physical, emotional and 
moral development – to help them learn to 
respect themselves and others, and to move with 
confidence from childhood through adolescence 
into adulthood. Effective SRE is essential for young 
people to be able to make informed decisions 
about their lives. However, there is uncertainty 
and sometimes controversy about how and when 
sex education should be taught. It should also be 
acknowledged that providing young people with 
information and skills does not mean that they 
will always choose the healthiest decisions, but, 
nonetheless, they have a right to high-quality 
sexual health promotion. At present, sex education 
is not compulsory in England and Wales; however, 
the introduction of a new personal, social and 
health education (PSHE) curriculum in 2010 will 
ensure that sex education is a compulsory element 
of the curriculum.
There is a need to base interventions to prevent 
STIs in young people, whether in school or any 
other setting, upon sound evidence of effectiveness. 
It is also necessary to assess the costs of such 
interventions and the gains to health in terms of 
the infections averted, associated gains in health-
related quality of life (HRQoL), and lives saved.
The objective of this systematic review and 
economic evaluation, therefore, is to assess the 
effectiveness and cost-effectiveness of behavioural 
interventions for the prevention of STIs in young 
people.
Epidemiology and natural 
history of STIs
Rates of STIs continue to increase in the UK, 
particularly among young people. Increases in 
diagnoses may reflect greater ascertainment of 
cases through more testing and better diagnostic 
methods. They may also reflect an increase in 
unsafe sexual behaviour among young people. 
Most STIs are caused by either bacteria (e.g. 
chlamydia, gonorrhoea) or viruses [e.g. HIV, 
genital herpes, human papillomavirus (HPV)].
The impact of increases in the incidence and 
prevalence of STIs over recent years has placed 
great demand on health service resources for 
screening, treatment, and prevention of infections 
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and their complications. Data from the British 
National Surveys of Sexual Attitudes and Lifestyles 
(NATSAL) show an increase in the number of 
individuals attending genitourinary medicine 
(GUM) services over a 10-year period.4 Between 
1990 and 2000 there was an increase of 4.3–7.6% 
in men and 3.3–6.6% among women. This may be 
explained not only by increases in rates of STIs, but 
also by improvements in access to clinic services, 
and increased asymptomatic screening. STIs can 
lead to a range of serious long-term complications, 
such as infertility, pelvic inflammatory disease 
(PID) (in women), and epididymitis (in men), 
particularly if undiagnosed and untreated. HIV, 
though treatable, currently remains incurable, and, 
if not successfully managed, is associated with faster 
disease progression to acquired immune deficiency 
syndrome (AIDS) and related complications, and to 
mortality.
More detailed descriptions of the characteristics 
of individual STIs, including their causes, 
symptoms, treatment, incidence, prevalence and 
complications, are provided in the following 
subsections.
Chlamydia
Chlamydia is caused by the bacterium Chlamydia 
trachomatis, which is almost always transmitted 
through sexual intercourse, but can also be 
passed from an infected pregnant woman to her 
baby during delivery. In women, the symptoms 
of chlamydia tend to be non-specific and may 
include cystitis, change in vaginal discharge, post-
coital and intermenstrual bleeding, and mild 
lower abdominal pain. In men, chlamydia is the 
most common identifiable cause of discharge 
from the penis. This may be accompanied by a 
mild irritation of the urethra that may disappear 
after two or three days. In both men and women, 
chlamydia infection may be asymptomatic (50% of 
male and 70% of female cases5) and persistent, and 
therefore a test is required to confirm infection. 
In women, the test can be carried out on a urine 
sample or from a swab taken within the vagina. In 
men, the test can also be carried out on a urine 
sample, but may sometimes be done on a swab 
taken from inside the tip of the urethra. Nucleic 
acid amplification tests (NAATs) are recommended 
for testing for chlamydia because of their high 
sensitivity and good specificity.6 Chlamydia 
is treated with antibiotics, most commonly a 
macrolide, such as azithromycin, or a tetracycline, 
such as doxycycline. As with any STI it is important 
that sexual partners also receive treatment to avoid 
reinfection.
Chlamydia is the most common STI that is 
diagnosed and treated in the UK. In 2006 there 
were 113,585 new episodes seen at GUM clinics, 
and significant numbers of diagnoses originated 
from within the general practice setting.7 The 
highest rates of undiagnosed infection, ascertained 
by the National Chlamydia Screening Programme 
(NCSP), and of GUM clinic-diagnosed chlamydia 
in 2006, were in young women (aged 16–19 years) 
and young men (aged 20–24 years).8 In 2007 the 
NCSP in England performed 270,729 screens in 
under-25-year-olds: 9.5% of screens in women and 
8.4% in men were positive for chlamydia. A further 
79,557 diagnoses of genital chlamydia infection 
were made among young people in GUM clinics in 
the UK in 2007 (a rate of 1102 per 100,000 16- to 
24-year-olds) – a rise of 7% on 2006.1
TABLE 1  Incidence of newly diagnosed chlamydia in the UK in 2006
Incidence7,10 [number (population rate per 100,000)]
Men Women
Overall 113,585
All adults 56,008 (190) 57,577 (187)
MSM 3239 –
Age < 15a 40 346
Age 15 120 1045
Age 16–19 8886 (544) 20,636 (1337)
Age 20–24 22,643 (1144) 22,059 (1145)
MSM, men who have sex with men.
a  Incidence for all age groups: for 2006, 32 clinics did not report one-quarter or more of the KC60 returns.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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Whilst the incidence of newly diagnosed chlamydia 
can be obtained from routine data (Table 1), 
estimates of the prevalence of undiagnosed 
chlamydia vary according to studies that have been 
conducted in diverse settings with different age 
groups. A review of prevalence studies conducted 
in the UK9 found 25 studies that reported the 
prevalence of chlamydia. In males, estimates varied 
between 0% and 33%, and females between 0% and 
41%.
Gonorrhoea
Gonorrhoea is caused by the bacterium Neisseria 
gonorrhoeae. The bacterium is highly infectious 
and mainly transmitted during sexual intercourse, 
but can also be passed from an infected pregnant 
woman to her baby during delivery. Like 
chlamydia, many women and men with gonorrhoea 
do not exhibit any symptoms. The most common 
symptom, if one is present, in men and women, 
is painful urination. In men this is accompanied 
by discharge from the urethra, whilst women 
experience an increase in vaginal discharge. 
Men and women who have anal sex can develop 
gonorrhoea in the rectum. Again, this infection 
may be asymptomatic or may lead to a painful 
discharge of blood and pus from the rectum. 
Men and women who have oral sex can develop 
gonorrhoea in the pharynx, which is usually 
asymptomatic. To confirm infection, the preferred 
test for routine use is culture of a specimen taken 
from the pharynx, urethra, cervix or rectum.6 
Other methods that can be used are NAATs and 
direct observation of the bacteria smeared on to a 
glass slide, Gram-stained and examined under a 
microscope. Gonorrhoea is treated with antibiotics, 
depending on local sensitivity patterns; most 
commonly a single dose of antibiotics is prescribed 
– usually ceftriaxone, cefiximine or spectinomycin.
Gonorrhoea is the second most common bacterial 
STI in the UK. In 2006, 19,007 new episodes were 
seen at GUM clinics. Gonorrhoea particularly 
affects certain population subgroups: young adults, 
men who have sex with men (MSM) and some 
ethnic groups.8 Rates of gonorrhoea diagnosis in 
GUM clinics were highest among women aged 16–
19 years (128 per 100,000) and men aged 20–24 
(188 per 100,000). Of the women diagnosed with 
gonorrhoea, 40% (2147/5380) were teenagers (Table 
2).8
HIV and AIDS
HIV is the virus that causes AIDS. The most 
common way for the virus to be transmitted 
is through sexual intercourse (vaginal or anal 
sex), but since it can be transmitted through the 
exchange of any bodily fluid it can also be spread 
by sharing needles and from a pregnant women to 
her baby (either during delivery or breastfeeding). 
HIV infects a type of lymphocyte known as a 
T-helper cell, which is a key component of the 
immune system. Because these cells express a 
protein called CD4 (cluster of differentiation 4) on 
their surface they are also known as CD4 cells.
Many people who become infected with HIV will 
not have any immediate symptoms, but about 60% 
of people will develop symptoms of primary HIV 
infection after about 2–6 weeks.11 The symptoms 
are often mild and non-specific, such as fever, sore 
throat, swollen glands, joint and muscle pain, chest 
TABLE 2  Incidence of newly diagnosed gonorrhoea in the UK in 2006
Incidence7,10 [number (population rate per 100,000)]
Men Homosexually acquired cases Women
Overall 19,007
All adults 13,627  – 5380 (18)
MSM 4524 (967a) – –
Age <15b 7  0 41
Age15 23 4 137
Age 16–19 1642 252 1969 (128)
Age 20–24 3723 (188) 810 1780
MSM, men who have sex with men.
a  For MSM aged 15–44.
b  Incidence for all age groups: for 2006, 32 clinics did not report one-quarter or more of the KC60 returns.Background
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rash and tiredness. The immune system is not able 
to combat the virus, which continues to infect and 
destroy CD4 cells, but this phase of the infection 
often causes no further symptoms for many years.
An HIV infection can only be detected by testing 
a sample of bodily fluid (most commonly a blood 
sample, but plasma or saliva can also be tested). 
Current tests for HIV usually look for antibodies to 
HIV and these antibodies may take up to 3 months 
to appear following infection. Therefore, it cannot 
be assumed that a negative test result indicates no 
infection unless a second HIV test, taken at least 3 
months later, is also negative.6 HIV infection can 
also be detected by testing for protein components 
of HIV, or HIV nucleic acids. Testing for HIV 
antigens can provide a positive result 6 weeks after 
infection. Testing for HIV is important as this 
enables people with the infection to be identified, 
thus enabling them to benefit from early treatment 
with highly active antiretroviral therapy (HAART) 
and providing the opportunity for behavioural 
change to reduce onwards transmission. HAART 
has proved successful in slowing the progression of 
the HIV infection and prolonging life.
Human immunodefficiency virus and AIDS 
diagnoses observed at GUM clinics in 2006 are 
presented in Table 3, which shows that the total of 
new diagnoses was 6,137. The overall estimated 
new diagnoses of HIV are slightly higher, at 7800 
(range: 7700–7950)8 and over half were among 
heterosexuals, most of whom were infected abroad. 
Cases of sexually acquired HIV in those under 15 
(if any) are not documented within a recent Health 
Protection Agency (HPA) report.8 However, in 
2006 there were 745 new diagnoses of HIV in the 
16- to 24-year age group. About half of the new 
HIV diagnoses in young adults were in women 
(48%, 359/7458) and, where reported, most young 
adults were infected through heterosexual contact 
(55%, 374/686). Infection through sex between 
men resulted in 41% (281/686) of the new HIV 
diagnoses in young adults. Most of the children 
(aged under 15) in the UK diagnosed with HIV in 
2006 acquired the infection perinatally, and about 
half of these were born abroad.
The estimated prevalence of HIV can be seen in 
Table 4. In the different population groups, between 
25% and 39% were undiagnosed and therefore 
unaware of their infection. African-born people 
accounted for 35% of those with HIV and 31% of 
the total were unaware of their HIV status.
Genital herpes
Genital herpes is caused by the herpes simplex 
virus (HSV). There are two forms of this virus. Type 
2 is more likely to cause herpes on the genitals, 
whilst Type 1 is more likely to cause herpes on the 
face (e.g. cold sores). It should be remembered that 
both types can cause herpes on either the face or 
the genitals. The virus is very contagious and is 
passed between people during skin-to-skin contact, 
such as during sexual activity (including orogenital 
contact in the case of HSV-1). The majority of cases 
of genital herpes are undiagnosed because they are 
not associated with any symptoms, or the symptoms 
are mild, for example a slight itching or red patch 
of skin in the genital area. If symptoms do occur 
TABLE 3  Incidence of new HIV and AIDS diagnoses in the UK in 2006
Incidence of new 
asymptomatic HIV 
diagnosis7,10 [number 
(population rate per 
100,000)]
Incidence of new 
symptomatic HIV diagnosis 
(not AIDS)7,10 [number 
(population rate per 
100,000)
Incidence of new 
AIDS diagnosis (first 
presentation)7,10 [number 
(population rate per 
100,000)]
All adults 4819 (8) 1035 (1.7) 283 (0.5)
Men (all) 2956 (10) 673 (2.3) 192 (0.6)
MSM 1400 256 63
Women 1863 (6) 362 (1.2) 91 (0.3)
Young adults  
(aged 16–24)
New diagnoses of HIVa 745 (11) – –
MSM, men who have sex with men. (It is not possible to provide population rates for MSM because information on sexual 
orientation is not collected by the UK census.)
Population rates for adults, men (all) and women have been calculated by the reviewer, based on mid-2006 population 
estimates.
a  Not stated whether asymptomatic, symptomatic or at first presentation with AIDS.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 4  Estimated HIV prevalence in the UK
Estimated HIV prevalencea (95% 
confidence interval, CI)8 Estimated population rate per 100,000
All adultsb 69,400 (64,800 to 75,500) 115
MSM 30,100 (27,600 to 33,700) 151 (all men)
Heterosexual men 14,700 (12,700 to 18,400) –
Heterosexual women 21,600 (20,000 to 23,700) –
MSM, men who have sex with men. (It is not possible to provide population rates for MSM and heterosexual women 
because information on sexual orientation is not collected by the UK census.)
Population rates for all adults and a combined value for all men have been calculated by the reviewer, based on mid-2006 
population estimates.
a  Estimate includes both those diagnosed and those undiagnosed.
b  Individuals aged 15–59 years.
they usually begin 2–7 days after infection and the 
initial phase of infection (primary infection) may 
last for up to 21 days.
Symptoms in this phase can be variable but may 
include mild fever, aches and pains, and swollen 
lymph glands in the groin. Some people may also 
experience painful red spots in the genital area, 
which gradually blister and then burst to leave 
painful ulcers. These ulcers will heal within about 
10–14 days.
In women, genital herpes is usually localised 
to the vulva and, sometimes, the cervix. The 
infection may be accompanied by vaginal discharge 
and urination may be very painful. In men, the 
symptoms of infection are mainly present on the 
end and shaft of the penis, the foreskin, and, 
sometimes, the scrotum, and urination may also 
be painful. Some people experience recurrent 
episodes of genital herpes, occurring because 
the virus has not been completely cleared by the 
immune system and can lie dormant in nerve 
cells. The period between recurrences varies 
greatly between people, but recurrences generally 
become less frequent with age. Symptoms during 
a recurrence are not usually as severe as they are 
following the primary infection and they do not 
last as long. In order to diagnose genital herpes 
accurately a swab of the blisters should be taken 
during the active phase of infection. The fluid in 
the blisters or open sore that follows contains viral 
particles that can be detected in laboratory assays. 
During the active phase of the infection general 
advice for ameliorating the effects include using 
paracetamol or anaesthetic ointments as pain 
relief. Treatment with oral antiviral drugs may be 
indicated within 5 days of the start of the episode 
and while new lesions are still forming. For people 
who are prone to recurrent episodes of genital 
herpes antiviral medication may be prescribed as 
a suppressive therapy to help reduce the intensity 
and frequency of the recurrences.12
Genital herpes is the most common ulcerative 
STI in the UK. In 2006, 21,698 new diagnoses 
of a first attack of genital herpes were made in 
GUM clinics, with the number of diagnoses being 
50% higher in women than in men (Table 5). In 
common with other STIs, such as chlamydia and 
gonorrhoea, genital herpes diagnoses were most 
common in young adults. Those in the 20- to 24-
year age group had the highest rates of diagnosis 
in GUM clinics. The overall prevalence of genital 
herpes in the general population of England and 
Wales is estimated at about 3% for men and 5% for 
women.13
Syphilis
Syphilis is caused by the spirochaete bacterium 
Treponema pallidum and is mainly transmitted 
during sexual intercourse, but can also be 
transmitted during blood transfusions or by 
sharing infected needles during intravenous 
drug use. Additionally, infected pregnant women 
can pass the infection to their unborn child 
(congenital syphilis). There are three phases to the 
natural history of syphilis infection: primary (the 
incubation period is 9 – 90 days after exposure), 
secondary (3–6 weeks after the primary phase) 
and tertiary (a number of years after the primary 
phase).
Diagnosis of syphilis can be made by dark ground 
microscopy of specimens from any chancres 
of primary syphilis, but is more usually made 
following a blood test. Recommended regimes for 
the treatment of primary and secondary syphilis are Background
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TABLE 5  Incidence of genital herpes in the UK in 2006
First attack incidence7,10 [number 
(population rate per 100,000)]
Recurrence incidence7,10 [number 
(population rate per 100,000)]
Men Women  Men Women
Overall 21,698 (36) 16,354 (27)
All adults 8392 (29) 13,306 (43) 7256 (24) 9098 (29)
MSM 604 – 573 –
Age <15a 1 (0.02) 33 (0.63) – –
Age 15 5 (1.2) 121 (31) – –
Age 16–19 610 (37) 2803 (181) – –
Age 20–24 2016 (102) 4014 (208) – –
MSM, men who have sex with men. (It is not possible to provide population rates for MSM because information on sexual 
orientation is not collected by the UK census.)
Population rates for overall group, all adults (recurrence rates only), age < 15, age 15 and age 16–19 have been calculated by 
the reviewer, based on mid-2006 population estimates.
a  Incidence for all age groups: for 2006, 32 clinics did not report one-quarter or more of the KC60 returns.
benzathine penicillin as a single dose, or procaine 
penicillin for 10 days. Other antibiotic regiments 
may also be used.14 Tertiary syphilis can also be 
treated with antibiotics, but any damage that has 
already been done to the heart or nervous system 
is irreversible. After treatment, a repeat blood test 
will be necessary to confirm that the infection has 
been cleared.
Syphilis is a relatively rare infection and diagnoses 
tend to be concentrated in large urban areas (e.g. 
London, the West Midlands and the north-west of 
England) and/or in particular core groups of the 
population. In 2006, the majority of diagnoses 
were in MSM, contributing to a ratio of 7 : 1 
diagnoses of primary and secondary syphilis cases 
in men for every one case in women (Table 6). In 
contrast with some of the other STIs, patients with 
syphilis tended to be older, with the highest rates of 
primary and secondary syphilis in 35- to 44-year-
old men (19 per 100,000) and 20- to 24-year-old 
women (4.3 per 100,000).
Researchers investigating characteristics of a 
recent outbreak of 21 cases of syphilis in Sheffield 
describe two major outbreak patterns that 
differed between groups of heterosexuals and 
MSM. Amongst the former they found a relatively 
straightforward and accessible cluster of cases, 
and more sporadic, ‘starburst’ network of non-
connected cases in the latter.15
Human papillomavirus
The virus can cause genital warts. There are over 
100 subtypes of HPV, of which about 40 infect the 
genital tract.8 Genital warts are highly infectious 
because each wart releases virus particles. The 
virus is most commonly transmitted during sexual 
contact.
The symptoms of genital warts take at least 2–4 
weeks to develop, but may not appear for several 
months. They may be flat or rough (rough warts 
are often described as being cauliflower-like in 
appearance), can be hard on dry hairy skin, or soft 
on moist hairless skin, may be very small (hardly 
visible) or larger, and there may be a single wart, 
a cluster of warts in one location or several warts 
in different places. In women, genital warts may 
develop on the vulva, inside the vagina, on the 
cervix, by the urethra and in, or around, the anus. 
In men, they may develop on the shaft of the penis, 
under the foreskin, on the perineum, in or at the 
tip of the urethra and in, or around, the anus. In 
general, warts are painless but flat warts may be 
accompanied by an itching or burning sensation. 
Genital warts can usually be diagnosed by clinical 
examination.
It is not possible to treat the underlying HPV 
infection that causes genital warts, but it is possible 
to treat the warts and there are several treatment 
options. The choice of treatment will depend 
on the size and location of the warts. In general, 
warts are easier to treat when they are small and 
few in number. Chemical treatments, such as 
podophyllotoxin, or, more rarely, tricholoroacetic 
acid, or immune response modifiers, such as 
imiquimod, are applied to the surface of the wart. 
With some treatments the surrounding uninfected 
skin must be protected from the treatment. These 
treatments can be used to treat only external warts. DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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7
TABLE 6  Incidence of syphilis in the UK in 2006
Primary and secondary syphilis incidence7,10 
[number (population rate per 100,000)]
Syphilis early latent (first 2 years) incidence7,10 
[number (population rate per 100,000)]
Men Women  Men Women
Overall 2766 (5) 936 (1.5)
All adults 2424 (8) 342 (1.1) 745 (2.5) 191 (0.6)
MSM 1417 – 456 –
Age <15a 0 1 (0.02) – –
Age 15 2 (0.5) 8 (2.1) – –
Age 16–19 61 (3.7) 51 (3.3) – –
Age 20–24 290 (14) 83 (4.2) – –
MSM, men who have sex with men. (It is not possible to provide population rates for MSM because information on sexual 
orientation is not collected by the UK census.)
a  Incidence for all age groups: for 2006, 32 clinics did not report one-quarter or more of the KC60 returns.
Internal and external warts can be treated by 
cryotherapy (freezing), laser treatment or surgery. 
Because none of these treatments clears the 
underlying HPV infection there is a chance that the 
warts will re-occur after treatment.
Genital warts were the most common viral STI that 
was diagnosed in GUM clinics in 2006 and 2007. 
HPV subtypes 6 and 11 are the main causative 
agents of genital warts. In 2006 there were 83,745 
diagnoses of first-episode genital warts in GUM 
clinics in the UK (Table 7). This represented 22% 
of all the new STI diagnoses made within this 
setting, with an additional 44,655 people attending 
GUM clinics for recurrent episodes, and a further 
17,821 cases that required treatment for more than 
3 months. Rates of newly diagnosed genital warts 
were highest in men aged 20–24 and in women 
aged 16–19.
In addition to the HPV subtypes that are commonly 
associated with genital warts, subtypes 16 and 18 
are two of about 13 subtypes that are associated 
with human cancers (known as high-risk subtypes), 
particularly cervical cancer. The prevalence of the 
two key low- and high-risk subtypes of HPV are 
given in Table 8.
TABLE 7  Incidence of HPV in the UK in 2006
HPV first attack incidence7,10 
[number (population rate per 100,000)]
HPV recurrence7,10 
[number (population rate per 100,000)]
Men Women Men Women
Overall 83,745 (138) 44,655 (74)
All adults 44,445 (151) 39,300 (128) 27,772 (94) 16,883 (55)
MSM 2691 – 1894 –
Age <15a 30 (0.55) 134 (2.6) – –
Age 15 70 (17) 497 (128) – –
Age 16–19 4846 (294) 11,845 (767) – –
Age 20–24 15,716 (794) 13,484 (682) – –
MSM, men who have sex with men. (It is not possible to provide population rates for MSM because information on sexual 
orientation is not collected by the UK census.)
Population rates for overall group, men (recurrence only), women (recurrence only), age < 15, age 15, age 16–19 (men only), 
and age 20–24 (women only) have been calculated by the reviewer, based on mid-2006 population estimates.
a  Incidence for all age groups: for 2006, 32 clinics did not report one-quarter or more of the KC60 returns.Background
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TABLE 8  Prevalence of HPV subtypes in young women in England. 
Seroprevalences for females aged 10–29 (age standardised)
Prevalence of HPV subtypes16 (95% CI)
Low-risk subtype HPV 6: 10.7% (9.0 to12.3)
Low-risk subtype HPV 11: 2.7% (1.8 to 3.6)
High-risk subtype HPV 16: 11.9% (10.2 to 13.6)
High-risk subtype HPV 18: 4.7% (3.5 to 5.8)
Any of the four types: 20.7% (18.6 to 22.7)
Complications of STIs
Complications in women
In women, untreated chlamydia and gonorrhoea 
can lead to a number of complications including 
PID. PID is a syndrome that is believed to be 
caused by an infection that passes from the vagina 
through the cervix, the womb and up to the 
fallopian tubes and ovaries. When spread to the 
fallopian tubes, it causes inflammation (salpingitis) 
and narrowing of the tubes. This can result in 
fertilised eggs being unable to move along the 
fallopian tubes normally, thus increasing the risk 
of ectopic pregnancy and infertility. PID is difficult 
to diagnose by symptoms alone and diagnosis 
may require a combination of gynaecological 
examination, examination of vaginal and cervical 
swabs, blood tests, ultrasound scans and, in 
some cases, laparoscopy. Many women with PID 
experience few or no symptoms, whilst others may 
experience symptoms such as pelvic pain. If the 
infection remains untreated, the inflammation will 
eventually spread to the whole wall of the fallopian 
tubes, which can cause abscesses and adhesions 
to surrounding organs, such as the bladder and 
rectum.
Syphilis, if treated quickly, can be cured without 
causing any serious complications to health. 
However, if untreated it can progress to affect 
all areas of the body, including the joints, heart 
and lungs, spinal cord and brain. People with 
tertiary syphilis are at risk of blindness, deafness, 
muscle control problems, seizures and dementia. 
Complications of syphilis are similar for both 
men and women, though pregnant women are 
at increased risk of serious complications of 
pregnancy and childbirth (see Complications in 
pregnancy and childbirth).
Of all the viral STIs, HIV is associated with the 
most serious health complications, with significant 
morbidity and high costs of treatment and care. 
Whilst it remains an infection associated with 
significant mortality and a high number of 
potential years of life lost, disease progression to 
AIDS and death has been substantially reduced 
in the UK since the introduction of HAART in 
the mid- to late 1990s. The average lifetime 
treatment costs for an HIV-positive individual are 
estimated to be between £135,000 and £181,000.17 
HIV presents specific problems for women and 
babies both during and after pregnancy (see 
Complications in pregnancy and childbirth).
As described earlier, there are more than 100 
types of HPV, 13 of which are ‘high-risk’ types 
that are associated with cervical cancer, the 12th 
most common cancer in females in the UK, and 
responsible for 949 deaths in the UK in 2006.18 
Around 70% of cervical cancers are attributed 
to two high-risk types: HPV 16 and 18. At least 
10 other HPV types are also associated with a 
high risk of cervical cancer. In the autumn of 
2008 the UK government introduced a national 
HPV immunisation programme for the routine 
vaccination of girls aged 12 to 13 years of age 
against cervical cancer. A catch-up campaign, 
targeting girls up to 18 years of age, will begin in 
Autumn 2009. The cost of the routine programme 
is expected to be in the region of £100M per year, 
with the catch-up programme costing up to £200M 
per year.19
Complications in pregnancy and 
childbirth
All bacterial STIs can transfer to the child when the 
mother gives birth, whereas syphilis can also cross 
the placenta during pregnancy. Both gonorrhoea 
and chlamydia can lead to pre-term birth, stillbirth 
and serious eye infections, and chlamydia can 
lead to neonatal pneumonia. Trichomoniasis is 
associated with both pre-term birth and low birth 
weight. Infective syphilis in pregnant women can 
lead to miscarriage, pre-term birth, stillbirth or 
a congenitally infected baby, which can result in 
physical deformity and neurological complications 
in children who survive. Maternal infection of all 
these STIs is detectable, however, treatment can 
prevent transmission to the baby.
Unlike the bacterial STIs, which can be treated 
and potentially cured during pregnancy, viral 
STIs cannot. The risk of transmission of genital 
herpes from mother to baby is greatest for babies 
born to a woman with first episode genital herpes 
around the time of delivery. Women with recurrent 
herpes prior to pregnancy are at very low risk of 
transmitting the infection to their babies. Herpes 
can be transferred in the birth canal during 
delivery, but rarely crosses the placenta during 
pregnancy. Transmission of the genital herpes 
virus can cause severe systemic disease in newborn DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
9
infants. However, whilst potentially life-threatening, 
neonatal herpes occurs very rarely in the UK.
In relation to conception, an HIV-positive woman 
with an HIV-negative partner may choose to 
conceive using artificial insemination to avoid 
transmission of the virus to her partner. Where a 
woman is HIV negative and her partner is HIV 
positive, options to avoid transmission of the virus 
include conception using artificial insemination 
or sperm-washing techniques. Pregnancy itself 
is not known to worsen the health of an HIV-
positive woman.20 Whilst it may slightly reduce 
her CD4 cell count, this is likely to return to pre-
pregnancy levels shortly after the birth. An HIV-
positive woman can transmit the virus to her baby 
during pregnancy, childbirth and breastfeeding. 
Antiretroviral medication can be given to the 
mother during pregnancy and labour to reduce 
or prevent transmission of the virus to the baby. If 
viral load on HAART is undetectable then elective 
vaginal delivery is supported.
Complications in men
Untreated chlamydia and gonorrhoea can cause 
epididymitis in men, and chlamydia can lead to 
Reiter’s disease. Epididymitis is an inflammation 
of the tubular part (epididymis) of the testicle. The 
inflammation makes the testicle hot, swollen and 
extremely tender. It can lead to an accumulation of 
fluid in the area (hydrocele), abscesses and sterility. 
Reiter’s disease is a condition that can affect both 
men and women; however, it mainly affects men. 
It usually occurs 1–3 weeks after infection with 
chlamydia. Symptoms include inflammation of the 
joints (arthritis), the urethra and, quite often, the 
eyes. It is the most common cause of arthritis in 
young men.
The complications of syphilis are similar for 
both men and women and have been described 
earlier (see Syphilis). Complications are rare with 
trichomoniasis, and mostly relate to pregnancy 
and childbirth. The genital herpes virus does not 
usually cause serious health problems for men. In 
men, high-risk HPV infections are associated with 
cancer of the penis, anus, mouth and oropharynx. 
These cancers are rare and much less common than 
cervical cancer. The serious health complications 
and impact of HIV are similar for men and women, 
excluding pregnancy and childbirth.
Sexually transmitted infection 
prevention in the UK
Sexually transmitted infection prevention for 
young people in the UK is provided by a number of 
agencies, including schools and colleges, the NHS, 
the youth service and non-statutory organisations. 
Sometimes prevention interventions are 
undertaken through multi-agency collaboration, 
such as school health clinics that are run by health 
professionals. [The subject of a separate systematic 
review and economic evaluation funded by the 
National Institute for Health Research (NIHR) 
Health Technology Assessment programme – see 
www.hta.ac.uk.]
Policy context
The prevention of STIs and teenage pregnancy 
has been a high priority for health policy for 
some time. In 2001 the National Strategy for Sexual 
Health and HIV was published, demonstrating 
a commitment to tackling sexual ill-health and 
unintended pregnancies through improved 
prevention and treatment.17 A key aim of the 
strategy was to address health inequalities and the 
needs of vulnerable groups, including (amongst 
others) young people, particularly those in, or 
leaving, care. Sexual health was also one of the 
priority areas of the public health strategy for 
England ‘Choosing Health’, with particular 
emphasis on addressing the needs of younger men 
and women.21
More recently the National Institute for Health and 
Clinical Excellence (NICE) has published public 
health guidance on sexual health for England 
and Wales.22 The guidance covers one type of 
behavioural approach, one-to-one interventions, 
and it makes recommendations to NHS and 
non-NHS agencies with a role in the promotion 
of sexual health. There is particular emphasis 
on interventions for groups considered to be at 
higher risk, including MSM, vulnerable young 
people aged under 18 (including those from 
disadvantaged backgrounds, those in, or leaving, 
care, those with low educational attainment) 
and young women who are pregnant or already 
mothers.
The National Institute for Health and Clinical 
Excellence is also currently preparing guidance on 
NHS provision of contraceptive services for socially 
disadvantaged young people (up to the age of 
25) – publication expected to be in October 2010. 
Teenage pregnancy is one of the issues covered by 
‘Every Child Matters: Change for Children’, the 
strategy of the Department for Children, Schools 
and Families (DCSF) for the well-being of children 
and young people from birth to age 19.23 A key 
feature of the strategy is effective co-ordination 
between services to ensure that all needs are met.Background
10
Non-governmental organisations also have a role to 
play in influencing the policy agenda. For example, 
the Sex Education Forum, part of the National 
Children’s Bureau, brings together a wide range 
of stakeholders to promote and raise the profile of 
children and young people’s entitlement to SRE 
through policy and advocacy work. The forum 
provides advice to the Government, discusses 
research evidence, and promotes best practice in 
the delivery of SRE.
Schools
Sex and relationships education is embedded 
within the secondary school curriculum in the 
UK through PSHE lessons [personal and social 
education (PSE) in Wales and Scotland]. Schools 
vary in the amount of time that they assign to 
SRE, with provision in some areas reported to be 
‘patchy’24 (p. 5). Variability depends on a number 
of factors, including the time available within 
the curriculum, and the availability, skills and 
motivation of teaching staff. Schools usually assign 
particular teaching staff to deliver PSHE, and 
they may have different titles in different schools 
(e.g. the citizenship manager or the PSHE co-
ordinator).
There is also variability in the topics covered 
and the format of the lessons. Some schools 
primarily provide factual information, whilst 
others supplement this with interactive learning, 
such as role play, condom use demonstrations 
and educational theatre, often with input from 
outside agencies (e.g. health promotion services). 
There are a wide variety of voluntary and statutory 
agencies that can work with schools around PSHE 
and SRE (see sections Health services and Non-
statutory agencies). To date, schools have been 
largely autonomous in terms of which agencies 
they work with, and the depth to which sex 
education is covered. However, in 2008 it was 
announced that PSHE will become a compulsory 
part of the curriculum from Key Stage 1–4 (ages 
5 to 16). There will be greater emphasis upon 
the role of healthy personal relationships, STIs 
and unplanned pregnancy, in addition to basic 
information on reproductive health.
Personal, social and health education is also one 
of the four core themes of the National Healthy 
Schools Programme (NHSP), which is run by the 
DCSF and the NHS. The other theme relevant to 
sexual health is ‘emotional health and well-being’. 
The aim is to ensure that health education becomes 
an integrated part of the school curriculum 
and that the wider community is involved in 
its planning, implementation, and evaluation. 
It is intended that there will be measurable 
improvements in both health and education in 
the school and wider community. The NHSP 
represents a ‘whole-school’ approach to sexual 
health education, whereby everyone involved with 
the school (pupils, parents, teachers, governors) 
has a role to play in the promotion of health. There 
is particular emphasis in involving parents in the 
planning and delivery of the curriculum.
Another programme, used currently in 15% of 
secondary schools, with a growing take up, which is 
relevant to the promotion of sexual health is ‘Social 
and Emotional Aspects of Learning’ (SEAL). The 
programme operates a whole-school approach to 
promoting social and emotional health, through 
all aspects of the school (including the curriculum, 
teaching and learning, staff development, setting 
of policy, liaison with parents, promoting pupil 
voice, etc). The acquisition of the social and 
emotional skills of self-understanding, managing 
feelings, motivation, social skills and empathy is 
the heart of the SEAL programme. These generic 
skills that young people learn are central to their 
ability to manage themselves and their feelings, 
create a positive lifestyle for themselves and 
communicate effectively about drugs and alcohol, 
as well as sexual health. SEAL was implemented 
nationally in September 2007, based on the Social, 
Emotional and Behavioural needs pilot study.
Health services
At the local level, statutory health promotion 
services are the responsibility of primary care trusts 
(PCTs) in England. In Wales, services are overseen 
by the Welsh Assembly Government/NHS Wales, in 
Scotland by the Scottish Government/NHS Health 
Scotland, and in Northern Ireland by the Health 
Promotion Agency.
Sexual health promotion specialists employed 
by the NHS have a broad remit to work with a 
number of stakeholders on a variety of strategies. 
A PCT will commonly host a health promotion 
team comprising specialists in various areas, such 
as tobacco, healthy eating, physical activity and 
sexual health. Some of these run specialist projects 
that are set up to meet the needs of particular 
target groups, such as gay and bisexual men, 
young offenders, people with learning disabilities, 
commercial sex workers, or minority ethnic groups.
Sexual health promotion is also provided in 
primary care by general practitioners and 
practice nurses, on an opportunistic basis during DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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consultations and via targeted campaigns and 
specialist clinics. In the acute sector the promotion 
of sexual health is primarily the responsibility of 
GUM and family planning services. For example, 
in the GUM setting health advisors provide advice 
and information about STIs within the context 
of testing and treatment. For a number of years 
specialist sexual health/family planning clinics 
have been run for young people, at which they 
can receive confidential advice, receive testing, 
treatment (where necessary) and access resources 
such as condoms [including Brook drop-in centres 
(see Non-statutory agencies, below)]. These 
services, sometimes termed ‘clinic in a box’, can 
also be located in settings where young people 
socialise, such as youth groups, and sports and 
leisure facilities.
At a broader level, sexual health is promoted via 
Department of Health policy initiatives, such as 
mass media campaigns featuring television and 
radio adverts that are specifically targeted at young 
people around the need for safer sex to protect 
against STIs (e.g. the ‘Condom Essential Wear’ 
campaign during 2007–8).
Non-statutory agencies
A number of non-statutory agencies offer 
sexual health services to young people, often in 
partnership with statutory health, education and 
youth services. One of the most significant of these 
is Brook (formerly Brook Advisory), a national 
voluntary sector provider of free and confidential 
sexual health advice and services specifically for 
young people under 25. Brook has a network of 
17 centres around the UK where young people 
can drop in and consult with a counsellor, nurse or 
doctor.
Other agencies in the UK which play a role in 
meeting young people’s sexual health needs 
include the Terrence Higgins Trust and the 
National AIDS Trust. These agencies offer a 
number of services locally and nationally, including 
the provision of written resources, interactive 
internet advice, referral for STI screening (e.g. 
chlamydia screening) and media campaigns.
Agencies that look after the general needs of 
children and young people, such as Barnardo’s, 
address sexual health issues amongst a range of 
other things, and refer young people to relevant 
statutory and non-statutory services when 
necessary.
Cost-effectiveness of behavioural 
interventions to reduce STIs
The rise in the number of STI diagnoses in the 
UK over recent years has led to greater burden on 
health services. As mentioned earlier, increases in 
the number of individuals accessing GUM services 
have been reported.4 There are also costs associated 
with treating the long-term complications 
of infections that are asymptomatic and/or 
undiagnosed. The prevention of STIs is a key 
policy imperative, not only to reduce morbidity and 
mortality, but also to reduce health service costs. 
There is, therefore, a need to identify and focus on 
those interventions which are both effective and 
good value for money in reducing STIs.
One of the few relevant published cost-effectiveness 
analyses on the prevention of STIs from a UK 
perspective was the NIHR Health Technology 
Assessment (HTA) programme-funded economic 
evaluation of the cost-effectiveness of population 
screening for genital chlamydia.25 It was found 
that proactive screening for chlamydia in women 
and men under 25 years of age, using home-
collected specimens, was feasible and acceptable, 
but screening was not found to be cost-effective. 
A number of research recommendations were 
made to fill gaps in the evidence base, including 
a randomised controlled trial (RCT) of chlamydia 
screening.
The systematic review used to underpin the 
aforementioned guidance from NICE on the cost-
effectiveness of one-to-one interventions to reduce 
STIs and teenage conceptions26 found that most 
commonly evaluated interventions were chlamydia 
screening. Most of the interventions were found 
to be cost-effective and it was suggested that they 
may have been even more cost-effective if they had 
included the effects of reducing other STIs in their 
analyses. However, it was noted that there were few 
studies from the UK context, and that relatively 
few studies reported quality-adjusted life-years 
(QALYs), which made it difficult to compare across 
interventions. The cost-effectiveness of behavioural 
approaches to preventing STIs, particularly from a 
UK context, remains a priority to inform decision-
making, given the paucity of cost-effectiveness 
assessments of this type of intervention that have 
been identified.26DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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T
he methods for the systematic review of 
effectiveness were described a priori in a 
research protocol (see Appendix 1) and adhered 
to accepted methodology for evidence synthesis 
as outlined in the Quality of Reporting of Meta-
analyses (QUOROM) checklist.27 A two-stage review 
was conducted.
The first stage was a descriptive mapping of 
included studies in order to prioritise a subset of 
the most policy-relevant studies in consultation 
with the project’s Advisory Group of stakeholders 
(the results of which are reported in Chapter 3).
The second stage was a systematic review of the 
prioritised subset of studies (the results of which 
are reported in Chapters 4 and 5).
Search strategy
Searching for primary 
evaluations
Sensitive search strategies were developed and 
tested by an experienced information scientist (see 
Appendix 2 for search strategies). The finalised 
strategies were applied to the following electronic 
bibliographic databases:
•  MEDLINE (via Ovid)
•  MEDLINE In-Process & Other Non-Indexed 
Citations (via Ovid) 
•  EMBASE (via Ovid)
•  PsycINFO (via Ovid)
•  Educational Resources Information Centre 
(ERIC) (via CSA)
•  CINAHL (via Ovid)
•  Cochrane Central Register of Controlled Trials 
(CCRCT)
•  Trials Register of Promoting Health 
Interventions [TRoPHI – the Evidence for 
Informed Policy and Practice Information and 
Co-ordination Centre (EPPI-Centre) register of 
RCTs and non-randomised controlled trials]
•  Applied Social Sciences Index and Abstracts 
(ASSIA) (via CSA)
•  Sociological Abstracts (SOCABS) (via CSA)
•  POPLINE (POPulation information online).
ASSIA was searched from 1987 to March 2008. All 
other databases were searched for the period 1985 
to March 2008. It was considered that evaluations 
of behavioural interventions to prevent STIs, 
notably HIV, would have started to be published 
from the mid-1980s onwards, hence the choice of 
1985 as the start of the search period.
The following websites were also searched to 
identify relevant studies:
•  The UK National Library for Health (NLH) – 
www.library.nhs.uk/Default.aspx
•  UNAIDS (Joint United Nations Programme on 
HIV/AIDS) – www.unaids.org/en/
•  CDC (Centers for Disease Control and 
Prevention) – www.cdc.gov/
•  Google Scholar – http://scholar.google.co.uk
Google Scholar was searched from 1989 to 2007; 
UNAIDS and CDC were searched for the period 
1998 to 2007. The NLH database does not permit 
restriction of searches to particular dates.
In addition, relevant articles were sourced from 
bibliographies of the studies included in the 
systematic review. For all searches, studies were 
limited to English-language articles. Full papers 
were obtained from University libraries, the British 
Library, and from the internet (e.g. Google). 
Search results were uploaded into the eppi-reviewer 
database28 (specialist systematic reviewing software 
developed by the EPPI-Centre), de-duplicated and 
stored, ready for screening.
Searching for systematic reviews
A separate search was conducted to identify other 
systematic reviews of behavioural interventions to 
prevent STIs. The aim was to scan the reference 
lists of relevant systematic reviews to identify 
studies, supplemental to those identified by our 
own searches, which might meet the inclusion 
criteria of our review. The systematic reviews 
Chapter 2  
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themselves were not subjected to data extraction 
and critical appraisal and their results were not 
assessed. However, some notable examples of 
these systematic reviews are discussed in relation 
to the findings of our review (see Chapter 8, 
Findings from other systematic reviews). The 
search for systematic reviews was based on those 
conducted for the Evidence briefings on STIs 
and HIV published by the (former) Health 
Development Agency (now the Centre for Public 
Health Excellence at NICE).29,30 As these briefings 
searched up to 2003, we carried out further 
database searches for the period 2003 to March 
2008 to identify more recent systematic reviews. 
The databases searched included: Cochrane 
Database of Systematic Reviews (CDSR); Centre 
for Reviews and Dissemination (CRD) (University 
of York) databases: DARE (Database of Abstracts 
of Reviews of Effectiveness) and HTA (Health 
Technology Assessment); MEDLINE (Ovid); 
MEDLINE In-Process & Other Non-Indexed 
Citations (Ovid); EMBASE (Ovid); CINAHL 
(Ovid); British Nursing Index; PsycINFO; 
ERIC (CSA); and SOCABS (CSA). The search 
identified 643 systematic reviews, of which 21 
met the inclusion criteria [i.e. the review focused 
on behavioural interventions targeted at young 
people aged 13–19 years, and could be considered 
systematic (in that they provided evidence of: 
search strategy; application of inclusion criteria; 
and use of quality assessment)]. The 21 reviews 
yielded 76 references to studies that had not 
been identified from our search of bibliographic 
databases. These were screened for inclusion, along 
with all of the other references that had already 
identified from the databases.
Inclusion criteria for descriptive 
mapping (stage one)
An inclusion worksheet was used for the screening 
process (see Appendix 3). Each reference was 
screened on the basis of title and abstract for 
potential inclusion by one reviewer. Full reports 
were obtained for those references that appeared 
to meet the criteria or where there was insufficient 
information from the title and abstract. Inclusion 
criteria were then applied independently to each 
report by two reviewers, with any differences in 
opinion on the inclusion of a particular study being 
resolved through discussion and recourse to a third 
reviewer where necessary. The numbers of studies 
included and excluded at each stage of the review 
are documented in a QUOROM style flow chart27 
(Appendix 4). The inclusion criteria were based 
on the commissioning brief issued by the HTA 
programme. Further details of the criteria are set 
out below.
Participants
The participants were young people aged 13–19 
years.
If the study included a broader age range (e.g. 
17–22 years), but the mean or median age was 
within the specified age range, then the study was 
included.
Study design
Outcome evaluations (RCTs or non-randomised 
controlled trials) were used.
These were defined as studies designed to establish 
whether the intervention changes the outcomes 
specified in the aims of the study. Only trials 
that compared the intervention with a control 
or comparison group were included. Outcome 
evaluations that included an integral cost-
effectiveness analysis and/or process evaluation 
were also included. Studies reported in abstract 
form only (e.g. conference proceedings) were only 
included if they were published in or after 2005. It 
was assumed that, in general, abstracts from before 
this date would have been fully published and 
hence identified by our search.
Intervention
Behavioural interventions that aim to prevent STIs 
were used.
The commissioning brief did not define what a 
behavioural intervention was, so we adopted an 
inclusive strategy that defined it as ‘any activity 
to encourage young people to adopt sexual 
behaviours that will protect them from acquiring 
STIs’. Sex education studies were included 
provided there was some indication that prevention 
of STIs was addressed by the intervention.
Comparator
The commissioning brief specified ‘standard 
practice’ as the comparator. We therefore did 
not restrict inclusion of studies on the basis 
of any particular comparator. (See Chapter 4, 
Comparators, for a description of the various 
comparators used in the studies which were 
systematically reviewed.)DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
15
Outcomes
Studies that reported the impact of the 
intervention on a sexual behavioural outcome were 
included, for example:
•  abstinence from sexual activity/delaying onset 
of sexual activity
•  self-reported condom use (e.g. frequency of 
use)
•  number of sexual partners
•  age at first experience of sexual intercourse.
Studies that reported incidence/prevalence of 
STIs or pregnancy-related outcomes (e.g. rate of 
conceptions) were included, providing they also 
reported a sexual behaviour outcome. Since self-
efficacy does not constitute a behaviour, studies 
that reported self-efficacy or sexual behavioural 
intentions were included only if they also reported 
a sexual behaviour outcome. Likewise, studies 
measuring variables considered to mediate 
behaviour change (e.g. knowledge, attitudes, 
beliefs, intentions) were included provided that a 
behavioural outcome was also measured.
The process of descriptive 
mapping
As mentioned, the purpose of the mapping exercise 
was to facilitate a description of the evidence base 
so that a subset of policy-relevant studies from the 
map could be identified and subjected to a detailed 
systematic review. This approach has been found 
to be useful in previously published EPPI-Centre 
systematic reviews.31–35 Included studies were 
classified on the basis of their key characteristics, 
using the web-based systematic review software eppi-
reviewer.28 Keywords to classify the characteristics 
of young people were allocated to each study, 
using a modified version of a classification 
system originally devised by Evans and Brown36 
and subsequently adapted for use in a previous 
systematic review.37 The classification system is 
known as ‘PROGRESS plus’ [Place of residence, 
Race/ethnicity, Occupation, Gender, Religion, 
Education, Socioeconomic status (SES) and Social 
Capital]38 and underwent a further modification 
for this review to accommodate keywords specific 
to sexual health. Application of ‘PROGRESS plus’ 
keywords enabled the identification of subgroups 
of young people based on markers of their risk of 
acquiring, or passing on, an STI.
Studies were also classified according to the STI 
under focus (e.g. HIV, chlamydia), the type of 
intervention evaluated (e.g. education, skills 
training, counselling), the intervention provider 
(e.g. teacher, peers, health professional), the 
setting, the country and location, and outcome 
measures. The interventions were also classified 
at the ‘level(s)’ at which they were delivered 
(individual, social, policy), based on a classification 
system used by a Cochrane Systematic Review of 
behavioural interventions to prevent HIV in racial 
and ethnic minorities.39 Keywords for these factors 
were devised specifically for this project by the 
review team.
The classification instrument was piloted on a 
sample of five studies to refine the keywords and 
to establish good inter-rater reliability within the 
team. Some changes were made as a result of 
the piloting, mostly to the keywords relating to 
the characteristics of the young people studied. 
Once finalised, the instrument was applied to the 
included studies by one reviewer. A random sample 
of 20% of the studies were then checked by a 
second reviewer to ensure consistency.
Inclusion criteria for the 
systematic review (stage two)
Once all of the studies had been classified, analysis 
was performed to construct the descriptive map 
(for results of the map, see Chapter 3). The 
preliminary results of the descriptive map were 
presented to our advisory group in June 2008 for 
discussion. The group assisted us in prioritising 
a subset of studies for systematic review that most 
closely resemble current UK practice, and which 
are most likely to address current policy and 
practice needs. Several different subsets of studies 
for potential systematic review were discussed 
(according to different groups of young people, 
types of intervention, outcome measures, etc.). It 
was noted that although young people who are 
considered to be at greatest risk for STIs may not 
regularly attend school, school-based behavioural 
interventions had the potential to reach a large 
number of young people (and as will be seen in 
Chapter 3, in Characteristics of the interventions, 
school was the most common intervention 
setting as identified in the mapping). It was also 
considered that interventions that provide factual 
information about STIs, in addition to the teaching 
of skills to avoid catching and/or transmitting 
them, would be a useful focus for the review. Based 
on the discussion, the inclusion criteria for the 
systematic review were set as follows:Methods for the mapping exercise and systematic review of effectiveness
16
•  Participants: young people aged 13–19 years.
•  Intervention: behavioural interventions based 
in (but not restricted to) schools in which 
an element of the intervention included the 
development of sexual behavioural skills (e.g. 
how to use a condom, to negotiate safer sex 
with partners). Studies evaluating interventions 
teaching skills outside the context of sexual 
health (e.g. life skills) were not included.
•  Study design: RCTs only.
•  Outcomes: self-reported sexual behaviour 
(studies reporting other outcomes could be 
included providing that behaviour was also 
measured).
Once the criteria for the systematic review had 
been set, all of the studies classified in the map 
were checked to ensure that the keywords regarding 
the type of intervention were accurate. This 
ensured that all studies which were based in schools 
and in which skills development was a feature of 
the intervention were identified.
Data extraction in the 
systematic review
A data extraction and quality assessment 
instrument was devised for the systematic 
review and loaded into eppi-reviewer software. 
The instrument contained 102 separate items 
and incorporated some of the items included 
in an existing EPPI-Centre quality assessment 
instrument40 as used in several published 
systematic reviews.33–35,41 Data were extracted 
from the included subset of RCTs using the eppi-
reviewer program. Data extraction was undertaken 
independently by two reviewers. eppi-reviewer 
compared their data extractions and identified 
discrepancies in coding. Differences were resolved 
by discussion and involvement of a third reviewer 
where necessary.
For outcome evaluations that also conducted a 
process evaluation, additional data were collected 
on: the types of processes evaluated, the data 
collection methods used, the groups from 
which data were collected, and the findings and 
conclusions of the process evaluation. A broad 
definition of process evaluation was adopted, 
which covered any assessment of how well the 
intervention was implemented and the factors 
influencing this, the acceptability and accessibility 
of the intervention, the quality of intervention 
content and materials, collaborations and 
partnership working, and the skills and training of 
the intervention providers.
Where available, we extracted outcomes data for 
the pre-specified population subgroups that are 
outlined above (see The process of descriptive 
mapping).
Quality assessment
The quality assessment instrument was devised by 
the EPPI-Centre in consultation with a statistician42 
and was designed to assess key biases to the results 
of evaluations, based on empirical methodological 
research (Appendix 5). The quality of each study 
was assessed by two reviewers, independently, with 
differences in opinion resolved by discussion. For 
one study a third opinion was sought regarding 
judgement of methodological quality.43 Included 
studies were categorised into two groups: ‘sound’ 
and ‘not sound’. Methodologically ‘sound’ studies 
were those deemed to have avoided selection bias, 
attrition bias, and bias due to selective reporting. 
Studies failing one or more of these criteria could 
be judged ‘sound despite discrepancy with the 
criteria’ if there were extenuating circumstances 
that both reviewers agreed did not pose a 
significant risk of bias (e.g. a study that did not 
report results for all outcome measures, but the 
outcomes that were reported were not statistically 
significant; it was therefore unlikely that the 
authors were trying to conceal ‘negative’ results) 
(see Chapter 4, Overall judgements on study 
quality).
The quality of the process evaluations was assessed 
according to a set of criteria developed specifically 
for this review. These criteria were based on our 
own previous work assessing the quality of process 
evaluations and qualitative research44–46 and the 
work of others in the field.47
•  Steps were taken to minimise bias and error/
increase rigour in sampling. (For example, 
was the sampling strategy appropriate to the 
questions being asked? Were all stakeholders 
included?)
•  Steps were taken to minimise bias and error/
increase rigour in data collection. (For example 
were data collection tools validated or piloted? 
Was data collection comprehensive, flexible 
and/or sensitive to provide a rich description of 
processes?)
•  Steps were taken to minimise bias and error/
increase rigour in data analysis. ( For exmple DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
17
were analysis methods systematic? Was diversity 
in perspective explored?)
•  Findings were grounded in/supported by 
the data. (For example were enough data 
presented to show how the authors arrived at 
their findings? Do the data presented fit the 
interpretation provided?)
•  There was good breadth and/or depth achieved 
in the findings. (For example were a range 
of processes issues covered in the evaluation? 
Were the perspectives of participants fully 
explored in terms of breadth – contrast of two 
or more perspectives – and depth – insight into 
a single perspective?)
•  The perspectives of young people were 
privileged. (For example were young people 
included in the evaluation? Was there a balance 
between open-ended and fixed-response 
options?)
As a final step in the quality assessment of the 
process evaluations, reviewers were requested to 
assign the studies two types of ‘weight of evidence’. 
First, reviewers were asked to assign a weight 
(low, medium or high) to rate the reliability or 
trustworthiness of the findings (the extent to 
which the methods employed were rigorous/
could minimise bias and error in the findings). 
Reviewers were also asked to assign a second weight 
(low, medium, high) to rate the usefulness of the 
findings in terms of how well the intervention 
processes were described and whether or not the 
process data could illuminate why or how the 
intervention worked or did not work. Guidance 
was given to reviewers to help them reach an 
assessment on each criterion and the final weight 
of evidence.
Data synthesis
Both a narrative synthesis and a meta-analysis were 
performed to analyse the results of the RCTs. For 
the narrative synthesis data were systematically 
retrieved from eppi-reviewer and summarised 
narratively and in tabular form.
Meta-analysis
Meta-analysis was conducted using eppi-reviewer. A 
fixed-effect model was used, with a random-effects 
model reserved to explore any significant statistical 
heterogeneity observed. Statistical heterogeneity 
was assessed using the chi-squared test, with a 
p-value greater than 0.10 indicating significant 
heterogeneity.48 The I2-statistic was used to quantify 
the magnitude of statistical heterogeneity. This 
describes the percentage of the variability in effect 
estimates that is due to heterogeneity rather than 
sampling error (chance).
As will be reported in more detail in Chapter 
4 (see Methodological quality of the outcome 
evaluations), 9 of the 12 methodologically sound 
outcome evaluations randomly allocated clusters 
rather than individuals to study groups. An 
estimate of the intracluster correlation coefficient 
(ICC) was therefore required. This is necessary to 
account for the tendency for individuals within a 
cluster to be similar, thus reducing the variability in 
the responses.49 The ICC is expressed as a value of 
between 0 and 1. The closer the figure is to 1 the 
greater the within-cluster correlation.49 Five of the 
nine cluster RCTs reported an ICC, and these were 
entered into the meta-analysis. For studies that 
did not report an ICC we imputed a value of 0.2, 
based on that used for the power calculation in one 
of the trials included in the systematic review [the 
RIPPLE (randomised intervention of pupil peer-
led sex education) trial].50 This value was higher 
than ICC values reported by the other included 
studies. Therefore, the effects of imputing lower 
ICC values, and of omitting an ICC value when 
none was reported, were tested. It was found that 
they did not alter the pooled effect estimates (data 
not reported).
The mean cluster size was calculated by adding the 
total number of young people randomised to each 
study group and dividing this total by the number 
of clusters. The majority of outcome measures 
for which sufficient data were available were 
dichotomous. Odds ratios (ORs) were chosen as the 
summary effect estimate for these outcomes.
Behavioural outcomes were prioritised for meta-
analysis because effect estimates of parameters 
such as condom use were required to inform 
the Bernoulli equation in our economic model 
(see Chapter 7, Methods for cost-effectiveness 
modelling of behavioural interventions for 
prevention of STIs in young people). The outcome 
measures reported by each of the RCTs judged 
methodologically sound in the systematic review 
were tabulated to determine whether sufficient 
data existed to permit meta-analysis. This was an 
intricate process, as there was much variability 
in the definition and reporting of behavioural 
outcomes, such as condom use. Once tabulated, 
specific behavioural outcomes were defined and 
data assembled into a format suitable for entry into 
the meta-analysis facility in eppi-reviewer. If the Methods for the mapping exercise and systematic review of effectiveness
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• Peer leader issues
• Age appropriateness (of intervention)
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• Parent involvement not feasible
• Intervention as extra demands on
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• Implementation failure for interactive sessions
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• Interactivity
Jointly agreed themes
primary studies assessed outcomes at several time 
points (e.g. 6 months’ follow-up, 12 months’ follow-
up), the data were entered for all of the reported 
follow-up time points.
Where possible, the outcome data were entered 
into the analysis based on an intention-to-
intervene (ITI) analysis (i.e. based on all young 
people randomised). For some behavioural 
outcomes, data were reported for subgroups of 
young people who were sexually active/inactive. 
Where necessary, study authors were contacted for 
clarification on figures reported in their papers 
or to supply missing data. However, few of the 
authors responded, which meant that certain 
studies could not be included in the meta-analysis 
for some outcomes. It was decided that the study 
by Borgia and colleagues51 would not be included 
in the meta-analysis as it compared two very similar 
behavioural interventions (the only difference 
between them being that one was teacher-led, while 
the other was peer-led), whereas the other studies 
generally compared a behavioural intervention 
with either a control or with standard practice. 
(Note: The trial by Stephenson and colleagues,50 
which also compared peer-led with teacher-led 
interventions, was included in the meta-analysis as 
the teacher-led intervention was standard practice 
– see Chapter 4, Synthesis of results of sound 
outcome evaluations.)
Where data allowed, we conducted separate 
meta-analyses for the subgroups based on gender 
(young men and young women). This was one 
of the subgroups specified in the protocol as a 
variable to be explored in the synthesis of outcome 
evaluations.
The feasibility of meta-analysis of behavioural 
mediators, such as knowledge and self-efficacy, was 
explored. Much of these data were measured using 
widely differing measurement scales, and in many 
cases no measure of variance was reported to allow 
meta-analysis of continuous data. Meta-analysis 
of these outcomes was therefore not considered 
feasible or appropriate.
Process evaluations
Narrative methods were used to synthesise findings 
from the process evaluations. These methods were 
based on those we have developed in previous 
work on the synthesis of process evaluations 
and qualitative research44,52–54 and from other 
FIGURE 1  Initial and jointly agreed themes.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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groups working on methods for synthesising 
process evaluations.55–57 Detailed evidence tables 
were prepared, describing the methodological 
quality of the process evaluation, contextual 
details (e.g. intervention content, setting) and 
the findings of process evaluation (Appendix 6). 
This was undertaken by one researcher (EBP), 
with contributions from the second reviewer (AH), 
based on the data extracted using the instrument 
described in Appendix 5.
Findings were assigned to one or more of eight 
predetermined categories (accessibility/programme 
reach; collaboration and partnerships; content of 
the intervention; intervention implementation; 
acceptability; quality of intervention materials; 
skills and training of intervention providers; and 
‘other’).
Both researchers independently read and re-read 
the tabulated details and noted down their initial 
thoughts on the main themes to arise from the 
findings. The two researchers met to discuss and 
compare their individual themes and compiled a 
jointly agreed list (Figure 1). These themes were 
used to generate hypotheses about intervention 
effectiveness and to illuminate issues around 
intervention acceptability as well as barriers and 
facilitators to implementation.
A narrative was written to describe and elaborate 
on these themes and this was reviewed and 
discussed by five members of the review team 
(AH, EBP, JS, JK and JP) to generate possible 
explanations for the effects of the outcome 
evaluations. The themes and notes from this 
meeting were reviewed again by two researchers 
(AH and EBP) who translated their initial themes 
across the process evaluations in order to answer 
two questions. Firstly, what factors facilitate 
or hinder the implementation of skills-based 
behavioural interventions in schools? Secondly, 
what factors impact on student engagement and 
intervention acceptability?DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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Results of the literature 
search
•  A total of 11,548 references were identified 
through electronic database searches. Of 
these, 3511 were duplicate references and were 
removed.
•  In total, 8037 titles (and, where available, 
abstracts) were screened, of which 7682 were 
excluded according to our criteria, primarily 
on the basis of irrelevant study population or 
study design.
•  Full reports of the remaining 355 references 
were obtained:
  – According to our criteria, 158 of these were 
excluded, again primarily on the basis 
of irrelevant study population or study 
design.
  – In total, 36 reports were unable to be 
retrieved (mostly Master’s and doctoral 
dissertations and unpublished reports).
  – An additional 16 papers were identified 
from checking reference lists and through 
contact with study authors.
  – A total of 136 separate evaluations were 
eligible for inclusion in the descriptive 
mapping exercise (as described by a total 
of 177 papers).
  – Of the 136, a subset of 15 RCTs were 
prioritised for inclusion in the systematic 
review (as described by a total of 45 
papers). (See Chapter 4.)
Please refer to Appendix 4 for a QUOROM flow 
chart illustrating the flow of references through the 
various stages of screening and mapping, and the 
reasons for study exclusion.
The characteristics of the 136 studies included in 
the mapping exercise are reported in the following 
subsections.
Characteristics of the young 
people studied
The factors targeted by the studies, as classified 
using the PROGRESS-Plus system, can be seen in 
Table 9.
Although all of the studies were included because 
their participants were aged between 13 and 19 
years, 71 of the studies were classified as targeting 
a particular age band within this age range. For 
example, some interventions were conducted to 
meet the specific needs of younger teenagers, 
whilst others were geared towards older teenagers 
who, it was considered, may be more sexually 
active. The next most frequently reported factors 
were ethnicity (n = 26) and place of residence 
(n = 24).
Gender was identified as an issue by some of the 
studies. Seventeen targeted young women, whilst 
half this amount targeted young men. Studies 
classified as targeting young people on the basis 
of sexual behaviour did so on the basis of self-
reported risk behaviour (e.g. having multiple 
partners), or through other indicators of sexual 
risk in a particular area. Factors which were rarely 
targeted included occupation, religion, disability, 
having a previous history of STI, and being HIV 
positive. Factors in the ‘other’ category included 
runaway (homeless) youths, young people with a 
previous history of abuse, and teenage mothers. 
Just under a fifth of the studies (n = 25) did not 
specifically target any of the factors. These were 
studies that aimed to promote the sexual health of 
young people, but did not make explicit reference 
to any particular target group.
Types of studies
Table 10 shows the different types of study design 
included in the map. Of the 136 studies, 70 were 
non-randomised and 66 were RCTs. Sixteen of the 
studies included integral process evaluations (not 
shown in the table – refer to Chapter 5 for further 
details of the process evaluations that are integral 
to the trials included in our systematic review). 
They evaluated the delivery of the intervention or 
resources used, or measured the acceptability of the 
intervention to its recipients, amongst other things.
As can be seen from Table 11, only one study 
reported the economic costs of the intervention 
programme, albeit limited information. This 
study, carried out in Switzerland, reported the 
Chapter 3  
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TABLE 9  Factors targeted by the studies included in the mapping 
exercise
PROGRESS-Plus factors Number of studiesa
Age 71
Ethnicity 26
Place of residence 24
Gender – female only 17
SES 15
Gender – male only 8
Sexual behaviour 9
Offenders 6
Alcohol use 4
Drug use 4
Education 3
Existing STI (other than HIV) 2
Housing status 2
Disability 1
HIV positive 1
Looked-after young people 1
Occupation 1
Previous STI 1
Religion 1
Other factor 13
No factors explicitly mentioned 25
a  Total exceeds 136 as studies could target more than 
one factor.
TABLE 10  Types of studies included in the mapping exercise
Study type Number of studies
Non-randomised controlled trial 70
RCT 66
TABLE 11  Reporting of economic costs by studies in the mapping 
exercise
Whether cost data reported Number of studies
No 135
Yes 1
total cost of the intervention and who funded 
the programme. No other details were reported. 
The fact that cost details were not reported in 
the vast majority of studies does not preclude the 
fact that some of the interventions may have been 
subjected to cost or cost-effectiveness analysis in 
separate publications that were not included in 
the map. Publications included in the map were 
not systematically assessed for cross-references to 
related publications (with the exception of those 
which were eventually included in our systematic 
review). However, at least one study which was 
subsequently included in the systematic review is 
known to have undergone economic evaluation.58 
The publication describing this economic 
evaluation was included in our systematic review of 
cost-effectiveness studies59,60 (see Chapter 6).
Study location
Table 12 shows the location where the studies were 
conducted. Around three-fifths of the studies were 
carried out in the USA (n  =  81), and 25 were 
based in Africa. Only six studies were carried out 
in the UK and a further seven in Europe. The 
remainder were carried out in South America, Asia 
or Canada.
Characteristics of the 
interventions
Table 13 shows the sexual health topics covered 
by the interventions. In over two-thirds of studies 
(n = 97), the aim of the intervention was to prevent 
young people from acquiring HIV. In nearly half of 
the studies, the aim was the prevention of STIs in 
general (n = 64). Thirty-six of these were classified 
as targeting both HIV and other STIs, but without 
any specific STI being mentioned (other than HIV) 
(not shown in table). Only two studies focused on a 
specific STI: chlamydia (n = 1) and genital herpes 
(n = 1). For the 26 studies in the ‘other’ category 
the intervention focused on reproductive health 
and prevention of pregnancy, and other risk factors 
such as alcohol, tobacco and drug use.
Table 14 shows the various different intervention 
components evaluated in the studies. The majority 
of studies (n = 123) incorporated an element of 
education and information relating to sex and 
sexual health into the intervention. These studies DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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TABLE 12  Location of the studies included in the mapping 
exercise
Location Number of studies
USA 81
Africa 25
South America 9
Other Europe 7
Asia 6
UK 6
Canada 2
New Zealand 0
Australia 0
Other Australasia 0
Republic of Ireland 0
TABLE 13  Number of studies included in the mapping exercise 
reporting sexual health topics
Sexual health topic Number of studiesa
HIV 97
STIs in general 64
Chlamydia 1
Genital herpes 1
Gonorrhoea 0
HPV/genital warts 0
NSU 0
Pubic lice 0
Scabies 0
Syphilis 0
Trichomonas vaginalis 0
Other 26
Not stated 2
NSU, non-specific urethritis.
a  Total exceeds 136 as studies could focus on more 
than one topic.
commonly provided training in how to use a 
condom or how to negotiate safe sex (n = 81). The 
majority of these studies also provided education 
and information (n = 74) (not shown in Table 14). In 
33 studies, resources and services were provided to 
participants, such as pamphlets, brochures, tapes, 
videos, group discussions, lectures, seminars, youth 
clubs and free condoms. Very few studies provided 
TABLE 14  Number of studies included in the mapping exercise 
reporting intervention components
Type of intervention 
component Number of studiesa
Education/information 123
Skills training 81
Provision of resources and 
services
33
Mass media 20
Professional training 14
Incentives 11
Counselling (group) 6
Social support 5
Policy and legislation 0
Screening 0
Other/unclear 18
Not stated 2
a  Total exceeds 136 as studies could include more than 
one component.
a group counselling or social support element in 
the intervention. Interventions classified under 
‘Other/unclear’ included a computer-based 
program, games/sports events, take-home exercises 
and role play.
Table 15 shows the different types of intervention 
provider in the studies. The intervention was 
provided most frequently by peers (n = 44) and 
teachers (n = 39). In 23 studies, the intervention 
was provided by a health-care professional (e.g. 
family planning clinic nurse, general practitioner). 
Parents were used infrequently (n = 5), as were 
researchers (n = 9). Least likely to provide the 
intervention were psychologists, school nurses, 
youth workers, community workers or social 
workers. In the ‘other’ category (n = 45), the 
intervention was given by such people as AIDS 
educators, counsellors, or other specially trained 
facilitators and health educators.
Table 16 reports the various locations in which 
the interventions were delivered. In more than 
half of the included studies, the intervention was 
provided in a school or college setting (n = 77), 
tying in with the finding that peers and teachers 
most commonly delivered the intervention (Table 
15). Approximately one-quarter of the included Results of the mapping exercise
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TABLE 15  Number of studies included in the mapping exercise 
reporting intervention providers
Person(s) providing 
intervention Number of studiesa
Peers 44
Teacher 39
Health-care professional 23
Researcher 9
Parent/carer 4
Community worker 3
Computer 2
Social worker 2
School nurse 2
Psychologist 1
Youth worker 1
Other 45
Not stated 21
a  Total exceeds 136 as an intervention could have more 
than one provider.
TABLE 16  Number of studies included in the mapping exercise 
reporting intervention locations
Intervention location Number of studiesa
School/college 77
Community  37
Health-care setting 25
Home 7
Correctional institution 5
Workplace 2
Other 10
Not stated 8
a  Total exceeds 136 as interventions could be provided 
in more than one location.
studies used a community setting (n = 37), whilst in 
25 studies the intervention took place in a health-
care setting (e.g. STI clinics, reproductive health 
clinics). The workplace was, not surprisingly, given 
the young age of the participants, infrequently 
used as a location (n = 2).
Table 17 reports the number of studies classified 
as different levels of behavioural intervention. 
The majority of studies (n = 126) were classified 
as evaluating an individual-level behavioural 
TABLE 17  Number of studies in the mapping exercise classified 
as evaluating different levels of behavioural intervention
Intervention type Number of studiesa
Individual-level interventions 126
Social interventions 15
Policy interventions 5
Unclear 2
a  Total exceeds 136 as studies could evaluate more than 
one type of intervention.
intervention, i.e. interventions in which the 
primary focus is on encouraging behaviour change 
in individuals rather than changing community 
or population norms. Components of this type of 
intervention included skills training, education, 
provision of resources and risk-reduction materials, 
and counselling. Fifteen studies were classified 
as social interventions, which aim to change not 
only individual behaviours, but also social norms 
or peer norms. Strategies such as community 
mobilisation, building networks, and structural 
and resource support were used in an attempt to 
bring about such changes. Very few studies (n = 5) 
were classified as evaluating policy interventions. 
These were defined as interventions that aim 
to change individual behaviour or peer/social 
norms or structures through implementation of 
legislation, administration and policy. Four of these 
were delivered in developing countries, with the 
fifth in the USA. The interventions featured the 
provision of youth-friendly sexual and reproductive 
health-care services, including condom availability 
schemes, and competitive voucher programmes. 
All of the five studies were evaluated using non-
randomised controlled trial designs.
Table 18 presents the number of studies included 
in the mapping which reported various sexual 
behaviour outcomes. All of the studies included in 
the mapping exercise reported at least one sexual 
behavioural outcome measure, in accordance with 
our inclusion criteria. Condom use was the most 
frequently reported sexual behaviour outcome, 
reported in over 80% (n = 113) of included studies. 
Fifty-eight studies reported the number of sexual 
partners, whilst approximately one-third of studies 
(n = 45) presented data on abstinence from, or 
delaying the onset of, sexual activity.
A relatively large number of studies were classified 
as ‘other’ in their reporting of sexual behavioural DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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TABLE 18  Number of studies included in the mapping exercise 
reporting various sexual behaviour outcomes
Sexual behaviour 
outcome Number of studiesa
Abstinence from sexual 
activity/delaying onset of 
sexual activity
45
Age at first experience of 
sexual intercourse
12
Condom use for vaginal/anal 
intercourse
113
Number of sexual partners 58
Other 82
a  Total exceeds 136 as studies could report more than 
one outcome.
TABLE 19  Number of studies included in the mapping exercise 
reporting STI outcomes
STI Number of studies
No STI incidence outcomes 
reported
109
STIs in general 19
Chlamydia 6
Gonorrhoea 2
Genital herpes 2
HIV 2
Pubic lice 1
Syphilis 1
Trichomonas vaginalis 1
Genital warts (including HPV) 0
NSU 0
Scabies 0
NSU, non-specific urethritis.
TABLE 20  Number of studies included in the mapping exercise 
reporting other outcomes
Outcome Number of studiesa
No other outcomes reported 17
Attitudes  72
Beliefs 24
Complications arising from STIsb 0
Conception rate 7
Behavioural intentions 41
Knowledge 87
Self-efficacy 52
Use of microbicides 0
Other 40
a  Total exceeds 136 as studies could report more than 
one outcome.
b  For example, PID, ectopic pregnancy, infertility.
outcomes. This was because the outcomes were 
heterogeneous and often ambiguous in definition, 
and did not appear applicable to our pre-existing 
categories. An example from one study was ‘sex 
with a high-risk partner’, with no definition 
of what a high-risk partner was. The two most 
common types of outcome classified under ‘other’ 
were the proportion of young people having sex/
becoming sexually active, and the frequency of sex 
(protected and unprotected). These outcomes were 
not anticipated when the classification system was 
designed, hence they did not appear as categories 
in the mapping instrument.
Table 19 presents the number of studies included in 
the mapping exercise that measured STI outcomes. 
The majority of studies (n = 109) did not report the 
incidence of STIs as an outcome. Where incidence 
was an outcome it was reported for STIs in general, 
rather than a specific STI (n = 19). Only a handful 
of studies reported outcome data on specific STIs, 
such as chlamydia, gonorrhoea and genital herpes.
Table 20 reports the number of studies included 
in the map that reported other (non-behavioural, 
non-biological) outcome measures. Other outcomes 
that were reported by studies largely included 
variables that are considered to mediate behaviour 
change. For example, two-thirds of the studies 
(n = 87) reported knowledge of STIs as an outcome 
measure, and just under half (n = 72) measured 
young people’s attitudes towards sex, STIs and 
safer sex. Self-efficacy, the expectation that one can 
perform a particular task or activity, was reported 
in 52 studies.
Mapping exercise – 
summary of results
The most commonly mentioned factors targeted by 
the studies included age (e.g. the needs of younger 
teenagers), followed by ethnicity, place of residence 
(e.g. urban or rural) and SES. Around one-fifth 
of the studies did not mention targeting any 
particular risk factors.Results of the mapping exercise
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Nearly one-half of the studies mapped were 
RCTs, with minimal reporting of costs and cost-
effectiveness. The majority were North American 
studies (just under two-thirds), with very few studies 
from the UK. The vast majority of studies aimed 
to prevent HIV, and many specified targeting 
HIV and other STIs, but without mentioning any 
specific infections of interest. The prevention of 
pregnancy was an additional focus in less than 10% 
of the studies.
The provision of information about STIs and 
sexual health was a staple of the vast majority of 
interventions. Training in skills was an additional 
feature of just over half of these interventions. Just 
over a quarter of the interventions were classified 
as providing services or resources to young people, 
but there were very few interventions involving 
the setting of policy or legislation. The bulk of 
the interventions were delivered in schools or, less 
commonly, community settings and were mostly 
provided by teachers or peers.
Condom use was the most commonly reported 
behavioural outcome, and changes in STI 
incidence were reported in only a minority 
of studies. Commonly reported mediators of 
behaviour change included knowledge, attitudes 
and self-efficacy.
In summary, the mapping exercise illustrated 
the predominance of North American trials of 
educational interventions conducted in schools, 
with young people considered at risk due, 
primarily, to their age. These interventions were 
often delivered by teachers and peers, focusing 
mainly on the prevention of HIV and STIs 
generally. The effectiveness of these interventions 
was mainly measured in terms of behavioural 
outcomes, such as condom use and mediators of 
behaviour change. Biological outcomes were rarely 
measured.
As mentioned earlier in Chapter 2 (The process of 
descriptive mapping), the results of the mapping 
exercise were discussed with the project’s advisory 
group. Various different inclusion criteria for the 
systematic review were discussed, based on the 
findings of the map. These discussions led to the 
identification of the following inclusion criteria for 
the systematic review:
•  Participants: young people aged 13–19 years.
•  Intervention: behavioural interventions based 
in (but not restricted to) schools in which 
an element of the intervention included the 
development of behavioural skills (e.g. how 
to use a condom, to negotiate safer sex with 
partners).
•  Study design: RCTs only.
•  Outcomes: self-reported sexual behaviour 
(studies reporting other outcomes could 
be included, providing that behaviour was 
measured).
Given that a number of RCTs and non-randomised 
trials of the relevant behavioural interventions 
(i.e. based in schools in which an element of 
the intervention included the development of 
behavioural skills) were identified, it was decided 
to restrict inclusion to just the RCTs as these were 
considered, generally, to provide more rigorous 
evidence.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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Chapter 4 
Results of the systematic 
review of effectiveness
A 
total of 15 RCTs met the inclusion criteria 
for the systematic review (see Appendix 
7 for a bibliography of these, including all 
linked publications; see also Appendix 4 for 
the QUOROM flow chart showing the process 
of inclusion and exclusion of studies). The next 
three subsections of this report (Characteristics 
of the interventions, Characteristics of the young 
people and Methodological quality of the outcome 
evaluations) present the key characteristics of all 15 
included studies. Subsequent sections present the 
outcome evaluation results of a subset of 12 studies 
that were judged to be methodologically sound 
(Synthesis of results of sound outcome evaluations), 
and the characteristics and results of the sounds 
studies that also included process evaluations 
(Chapter 5). Readers who are primarily interested 
in the results of the sound outcome evaluations may 
wish to prioritise the section ‘Synthesis of results of 
sound outcome evaluations’, whilst those interested 
in the characteristics of the wider evidence base, 
irrespective of methodological soundness, may 
wish to examine the sections ‘Characteristics of the 
interventions’, ‘Characteristics of the young people’ 
and ‘Methodological quality of the outcome 
evaluations’.
Characteristics of the 
interventions
Table 21 provides an overview of the 15 RCTs.
TABLE 21  Overview of the 15 RCTs included in the systematic review
Study Intervention Comparator
Borgia et al.51
Country: Italy
Ethnicity: NR
Sex: mixed
SES: representative of general population
Not named, peer led: 5 sessions, 10 
hours in total
Teacher led: same total length 
suggested over approximately 3 
months
n 1295 613 682
Agea 18.3 (1.1) 18.2 (1.1) 18.2 (1.1)
Coyle et al.58
Country: USA
Ethnicity: mixed
Sex: mixed
SES: representative of general population
‘Safer Choices’ led by teachers and 
trained project staff: 10 sessions in 
each of 2 consecutive yearsb
Standard HIV prevention curriculum, 
presumably teacher led – length not 
stated
n 4310 (3677 for baseline 
characteristics)
1983c 1886
Age 13 – 4.4%; 14 – 57.2%; 15 – 28.1%; 
16 – 8.6%; > 17 – 1.7%
13 – 4.6%; 14 – 57.4%; 15 – 27.7%; 
16 – 7.9%; > 17 – 2.4%
continuedResults of the systematic review of effectiveness
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Study Intervention Comparator
Coyle et al.61
Country: USA
Ethnicity: mixed
Sex: mixed
SES: NR
‘All4You!’ led by experienced health 
educators: 14 sessions, totalling 26 
hours, over 6–8 weeksd
Usual HIV, STI and pregnancy 
prevention activities, typically led by 
presenters from community-based 
agencies – length not stated
n 988 597 391
Age 14 – 7.3%;15 – 20.7%; 16 – 30.7%;  
17 – 32.2%; 18 or older – 9.1%
14 – 11.3%; 15 – 27.4%; 16 – 33.6%; 
17 – 21.8%; 18 or older – 5.9%
Jemmott et al.43
Country: USA
Ethnicity: black
Sex: male only
SES: low
Not named; single 5-hour session led 
by specially trained adult facilitators
Career opportunities: single 5-hour 
session led by specially trained adult 
facilitators
n 157 85 72
Age 14.64 (1.66) NR NR
Jemmott et al.62
Country: USA
Ethnicity: African-American
Sex: mixed
SES: low
Not named; single 5-hour session led 
by specially trained adult facilitators
General health promotion; single 
5-hour session led by specially 
trained adult facilitators
n 496 269 227
Age 13.2 (0.94) NR NR
Karnell et al.63
Country: South Africa
Ethnicity: predominantly Zulu
Sex: mixed
SES: low
‘Our Times, Our Choices’: 10 units, 
each 30 minutes, delivered over 
approximately 8 weekse by teachers 
and peer leaders (both trained)
Life orientation instruction, 
presumably teacher led; length not 
stated
n 661 325 336
Age 16 (median) 16 (median) 16 (median)
Klepp et al.64
Country: Tanzania
Ethnicity: NR
Sex: Mixed
SES: NR
‘Ngao’ (Swahili for ‘shield’); about 20 
hours of class time, over 2–3 months
Delayed intervention
n 1063 258 (for baseline characteristics) 556 (for baseline characteristics)
Age  13.6 (1.3) 13.5 (1.2) 13.6 (1.3)
Levy et al.65
Country: USA
Ethnicity: mixed
Sex: mixed
SES: low
‘Youth AIDS Prevention Project 
(YAPP)’ delivered by trained health 
educators; 10 sessions over 2 weeks; 
booster – 5 sessions over 1 week 
the following year
Basic AIDS education (current 
practice) presumably delivered by 
teachers; length not stated
n 2392 1459 (1001 for baseline 
characteristics)
933 (668 for baseline characteristics)
Age 12.5 12.6
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Study Intervention Comparator
Roberto et al.66
Country: USA
Ethnicity: predominantly European-American
Sex: mixed
SES: low
Not named: 6 computer activities 
for students, each approximately 15 
minutes, over 7 weeks
Not described (no intervention)
n 378 164 (139 for baseline characteristics) 214 (187 for baseline characteristics)
Age 15.50 (0.63) 15.68 (0.73)
Schaalma et al.67
Country: Netherlands
Ethnicity: NR
Sex: mixed
SES: NR
Not named; 4 class sessions, teacher 
led, each 60–76 minutes on average
AIDS/STI education led by teachers 
(current practice); approximately 5 
hours in total
n 3142 NR NR
Age School grade 9 (~ age 15) or grade 
10 (~ age 16)
NR NR
Stanton et al.68
Country: Namibia
Ethnicity: NR
Sex: Mixed
SES: NR
‘My Future is My Choice’: 14 
sessions, each 2 hours, led by a 
volunteer teacher and a youth, 
administered over 7 weeks
Delayed intervention
n 515 262 253
Age 17 (median) 17 (median presumed) 17 (median presumed)
Stanton et al.69
Country: USA
Ethnicity: predominantly white
Sex: mixed
SES: low
‘Focus on Kids (FoK)’ and ‘West 
Virginia FoK’: 8 weekly sessions, 
each approximately 1.5 hours, 
led by specially trained local 
interventionistsf; in community 
settings, 1 day or 2 half-day sessions
Training in environmental 
conservation: comparable length to 
FoK and presumably led by trained 
interventionists
n 1131 870 (combined intervention group) 261
Age 12–14: 46.9%; 15–16: 53.1% NR (for combined group) 12–14: 48.28%; 15–16: 51.52%
Stephenson et al.50
Country: England, UK
Ethnicity: NR
Sex: mixed
SES: representative of general population
‘RIPPLE’: 3 peer-led sessions, each 1 
hour, over the summer term
Teacher-led SRE (current practice); 
length not stated
n 8766 4516 4250
Age 13–14g 13–14 13–14
continued
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Study Intervention Comparator
Wight et al.70
Country: Scotland, UK
Ethnicity: NR
Sex: mixed
SES: representative of general population
‘SHARE’; 10 teacher-led sessions 
in each of 2 consecutive years, plus 
teacher training
Usual teacher-led sex education 
(current practice): 7–12 lessons in 
total, over 2 years
n 7616 2867 (follow-up) 2987 (follow-up)
Age 13–14 13–14 13–14
Zimmerman et al.71
Country: USA
Ethnicity: mixed
Sex: mixed
SES: NR
‘Reducing the Risk (RtR)’, and 
a modified version: 16–17 class 
sessions during one school year, 
delivered by specially trained 
teachers and peer leaders; booster 
session (not described) the next 
year
Non-skills based, HIV prevention, 
presumably teacher-led; 0 to 15 class 
sessions (presume current practice)
n 2647 (1944 for baseline 
characteristics)
RtR: 681
Modified RtR 1149
851
Age 13 – 0.6%; 14 – 53.0%; 15 – 35.1%; 
≥ 16 – 11.3%
NR NR
n, number; NR, not reported.
a  Age in years reported as mean (SD) unless otherwise stated.
b  This intervention involves a whole-school approach that was not assessed in the reported RCT.
c  Group ‘n’s do not sum to the baseline or follow-up n for the whole sample.
d  Based on two previously evaluated interventions: ‘Be Proud, Be Responsible’ and ‘Safer Choices’.
e  Adapted from two previously evaluated interventions: ‘Project Northland’ and ‘Reducing the Risk’.
f  Included face-to-face and long-distance interactive televised delivery formats.
g  Mean baseline age probably 14.1 years because mean age at the 6-month follow-up was 14.7 years.
TABLE 21  Overview of the 15 RCTs included in the systematic review (continued)
Intervention provider
Table 22 presents the number of studies using 
different types of intervention providers. Just over 
half of the studies involved teachers as intervention 
providers and nearly as many involved peer 
educators. Five were delivered by both teachers 
and peers (not shown in Table 22).51,58,63,68,71 Two of 
the studies, Levy and colleagues65 and Coyle and 
colleagues,61 which fell into the ‘Other’ category, 
used specially trained health educators. One study, 
Jemmott and colleagues,43 used a specially trained 
‘adult facilitator’. Stanton and colleagues,69 whose 
study took place in a number of rural locations, 
involved local people to deliver the intervention, 
including ministers, recreation centre directors, 
liaison officers, faculty members, graduate students 
and housewives.
Intervention setting
Table 23 presents the number of studies using 
various settings for the delivery of the intervention. 
All included studies took place in a school/college 
setting, in accordance with the inclusion criteria. 
Two studies, Stanton and colleagues69 and Jemmott 
and colleagues62 were also partly based in the 
community. In terms of country, eight interventions 
were delivered in the USA,43,58,61,62,65,66,69,71 three in 
Africa (South Africa,63 Tanzania64 and Namibia68), 
two in Europe (Italy51 and the Netherlands67) and 
two in the UK (Scotland70 and central southern 
England50).
Type of intervention component(s)
Table 24 presents the number of studies using 
various intervention components. As can be 
seen, the interventions featured more than one 
component. All provided skills training, in addition 
to information (a consequence of our inclusion 
criteria).
All interventions provided education/information 
and skills training. Fewer studies were classified as DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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TABLE 22  Intervention provider
Provider Number of studiesa
Teacher 8
Peers 6
Health-care professional 2
Community worker 1 
Computer 1
Parent or carer 1 
Social worker  1 
Other 5
a  Total exceeds 15 as interventions could have more 
than one provider.
TABLE 23  Intervention setting
Setting Number of studiesa
School/college 15
Community 2
a  Total exceeds 15 as interventions could be delivered 
in more than one setting.
and colleagues50), a computer-based interactive 
program (Roberto and colleagues66) and the use of 
drama (Klepp and colleagues64).
Sexual health topics covered
Table 25 presents the sexual health topics that were 
addressed by the interventions. Most of the studies 
covered HIV, and just over half also covered other 
STIs. None targeted any one particular STI (other 
than HIV). The studies in the ‘Other’ category 
covered the prevention of unintended pregnancy, 
in addition to STIs.58,61,66,70,71
Content of the interventions
The majority of the interventions encouraged 
risk reduction. Although not always clear 
from the descriptions provided, seven studies 
mentioned risk reduction only and a further five 
studies aimed at both risk reduction and delayed 
sexual intercourse. Only one study, Klepp and 
colleagues,64 focused solely on delayed initiation of 
sex. Two studies were not clear.
All studies aimed to increase knowledge of HIV 
and other STIs. Two-thirds of the studies covered 
negotiation/communication skills, one-third 
mentioned enhancing self-efficacy, and three 
studies mentioned attempting to alter peer norms 
regarding either the desirability of using protection 
during intercourse or of delaying intercourse. Most 
studies mentioned the promotion of condoms, and 
seven studies described actively modelling and 
practising condom use skills with the young people.
Three studies involved parents as part of the 
intervention, although the parents were not the 
official intervention providers. One further study 
aimed to increase young people’s communication 
with their parents. Only one study, Wight and 
colleagues70 mentioned including the promotion 
of local sexual health services (either by the 
TABLE 24  Components of the interventions
Component Number of studiesa
Skills training 15 
Education/information 15 
Professional training 3 
Provision of resources and 
services
3 
Mass media 2 
Incentives 1 
Other 5 
a  Total exceeds 15 as interventions could include more 
than one component.
providing resources and services. Two interventions 
included a mass media component: Wight and 
colleagues70 included videos to trigger discussion, 
whilst Stanton and colleagues69 used a long-
distance interactive televised format to deliver 
their intervention to some of the participants. 
Components in the ‘Other’ category included the 
use of games (Stanton and colleagues,68 Stephenson 
TABLE 25  Sexual health topics covered
Focus Number of studiesa
HIV 12
STIs generally 8
Other 5
a  Total exceeds 15 as interventions could address more 
than one topic.Results of the systematic review of effectiveness
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young people visiting the service or by a member 
of staff visiting the school), although Coyle and 
colleagues61 arranged visits to local ‘AIDS service 
organisations’. None of the interventions featured 
the distribution of contraception or referrals to 
sexual health clinics.
Additionally, the two UK-based studies (Wight and 
colleagues70 and Stephenson and colleagues50) both 
aimed to improve the quality of young people’s 
sexual relationships.
None of the interventions were described as having 
included either referrals to local sexual health 
services or the provision of contraception, although 
one (Coyle and colleagues56) required pupils to 
gather information on local resources and sexual 
health services. Furthermore, the studies did not 
tend to mention whether the interventions followed 
an empowerment or a directive approach to health 
promotion.
Length/intensity of the intervention
Although some authors provided only minimal 
details, the length/intensity of the interventions 
varied widely across studies. The shortest/least 
intense intervention was the single 5-hour session 
of Jemmott and colleagues.26 The lengthiest/most 
intense intervention appeared to be Wight and 
colleagues’ intervention,70 consisting of 20 sessions 
over 2 years. Not so lengthy, but also intense, were 
the studies of Coyle and colleagues,61 involving 26 
hours of intervention over 5–7 weeks, and Stanton 
and colleagues,68 comprising 14 2-hour sessions 
over 7 weeks.
Theoretical basis
Table 26 presents the number of studies that used 
specified theories of health-related behaviour in 
the conception of the interventions. All except 
two of the studies were explicitly informed by a 
named theory. Stephenson and colleagues50 noted 
that the RIPPLE intervention was not based on 
any particular theory, but was designed to be a 
pragmatic approach to sex education. Zimmerman 
and colleagues71 mentioned that their intervention 
was theory driven, but did not cite any specific 
theoretical models. The theories used in the 
studies were generally sociopsychological in origin. 
They included Social Learning Theory and Social 
Cognitive Theory (often associated with the work 
of Bandura72–74), the Theory of Reasoned Action 
(associated with the work of Ajzen and Fishbein75), 
as well as its successor the Theory of Planned 
Behaviour  (associated with Ajzen76). These models 
TABLE 26  Theoretical basis of the interventions
Theory Number of studiesa
Social Learning Theory 6
Traditional education/reasoned 
action model
4
Theory of Planned Behaviour 3
Social Cognitive Theory 3
Cognitive Theory 2
Not stated 2
Other 8
a  Total exceeds 15 as studies could use more than one 
theory.
predict how health-related behaviour can be 
influenced in social settings through role modelling 
to foster positive attitudes, intentions and self-
efficacy around negotiating safer sex. Most studies 
cited more than one theory in the development 
of the intervention, such as the trial by Karnell 
and colleagues,63 which included what the authors 
described as three overlapping theories (Social 
Learning Theory, Social Inoculation Theory and 
Cognitive Behaviour Theory).
A range of theories were classified as ‘Other’, 
including the Social Influences Model,77 
Inoculation Theory,78 the Extended Parallel Process 
Model,79 Protection Motivation Theory,80 the 
Health Belief Model81 and the Transtheoretical 
Model (stages of behaviour change).82 These 
theories vary in their tenets, but, in common with 
the theories mentioned above, generally seek 
to predict health-related behaviour through the 
role of attitudes, skills, self-efficacy and social 
influences.
Origin of the interventions
Some of the interventions were derivations of 
other interventions, some of which were included 
in our review. For example, ‘Safer Choices’, 
reported by Coyle and colleagues,58 was based on 
an intervention, in the USA, entitled ‘Reducing 
the Risk’ (originally evaluated by Kirby and 
colleagues,83 but did not meet the inclusion 
criteria for this systematic review). ‘Reducing the 
Risk’ was one of the Centers for Disease Control’s 
‘programmes that work’84 and was subsequently 
replicated and modified by Zimmerman and 
colleagues71 (included in this systematic review) 
for ‘high sensation seeking and impulsive 
youth’. Similarly, the ‘Our Times, Our Choices’ DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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intervention evaluated by Karnell and colleagues,63 
which was delivered in South Africa, was also a 
modification of ‘Reducing the Risk’.
‘Safer Choices’, itself, subsequently became one of 
six effective interventions selected by the National 
Institutes of Health in the USA for adaptation and 
replication in different settings.85 Evaluation of 
‘Safer Choices 2’, this time in an ‘alternative’ rather 
than a mainstream high school setting (e.g. for 
students with behavioural problems, truancy, poor 
educational attainment or pregnancy), has been 
conducted and results are awaited.86,87
Another of the six replication projects is the 
West Virginia Focus on Kids (FoK) intervention 
by Stanton and colleagues69 (included in our 
systematic review). This is an adaptation of the 
original FoK intervention, which was originally 
evaluated with urban, low-income, predominantly 
African-American young people in Baltimore, 
MD, USA.88 (Note: The original intervention is 
not included in our review as the mean age of 
the young people, 11 years, did not meet our 
inclusion criteria.). It was adapted to be relevant 
to the predominantly rural white population of 
West Virginia, with low HIV seroprevalence. The 
original FoK intervention has also been adapted for 
use outside of the USA – in Namibia.68 (Note: This 
study was included in the systematic review, but was 
judged not to be methodologically sound.)
Comparators
Table 27 presents a classification of the comparators 
used in the studies. The majority of studies used 
‘standard’ sex education as their comparator. 
This generally consisted of information provision 
and tended not to include active participation, 
exercises, role play and skills development. Nearly 
as many studies used an ‘attention’ control, in 
which an intervention of similar length and 
intensity, focusing on a non-sexual health-related 
topic, was provided.
Characteristics of the young 
people
Age
Studies reported age in a wide variety of ways. 
Some gave a mean, some a median age, and some 
a breakdown across the age range of those in 
their sample (see Table 21, earlier). Some reported 
TABLE 27  Comparators used in the studies
Comparator Number of studies
‘Standard’ sex education 5
‘Attention’ control 5
Delayed intervention 2
No intervention control 1
Teacher led vs peer led 2
for intervention and control groups separately, 
some for the total sample. This makes it difficult 
to summarise data on age across the 15 included 
studies. However, studies largely targeted young 
people in their early- to mid-teens (i.e. up to, 
and including, 16-year-olds). The exceptions to 
this were the study of Borgia and colleagues51 
– the mean for the total sample was 18.3 years 
[standard deviation (SD) = 1.1] – and Stanton and 
colleagues,68 who reported a median age of 17 
years. The youngest to be targeted were 12 years 
old (for example, in Levy and colleagues65 and 
Stanton and colleagues69).
Gender
Study samples were predominantly of mixed sex 
and were equally balanced between the sexes. The 
exceptions to this were the samples of Coyle and 
colleagues,61 of which around two-thirds were male, 
and Jemmott and colleagues,43 whose intervention 
was designed only for young men.
Race and ethnicity
Ten studies reported the racial/ethnic profile of 
the sample, but the level of detail given varied 
considerably.43,50,58,61–63,65,66,69,71 The ethnicity of 
the samples was largely a function of either the 
country or the aim of the study. In North American 
studies, the young people were generally ethnically 
diverse. The exceptions to this were the studies 
by Stanton and colleagues,69 whose sample was 
predominantly white (this study took place in a 
largely white, rural area of West Virginia, USA), 
and Jemmott and colleagues,62 who specifically 
targeted African-American young men. In the case 
of the two UK studies, Stephenson and colleagues’ 
sample was predominantly white,50 whereas Wight 
and colleagues70 did not report on the ethnic 
composition of their sample.Results of the systematic review of effectiveness
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Socioeconomic status
Eight of the included studies reported on the 
SES of the sample, and again the level of detail 
given also varied considerably.50,51,58,62,63,65,69,70 
Typically, these samples were either representative 
of the general population (white, middle class, 
but including some young people of lower SES, 
for example studies by Borgia and colleagues51 
and Wight and colleagues,70 or they specifically 
targeted young people of lower SES, for example 
studies by Jemmott and colleagues,62 and Levy 
and colleagues65). In four studies, low SES was 
implicit.43,63,66,69 A number of studies provided 
brief details about participants’ education and 
occupation. Unlike measures of parental education 
and occupation, these are not commonly used as 
indicators of participants’ SES.
Sexual behaviour
There was variability across the studies in terms 
of sexual experience and participation in risk 
behaviour. All but one of the included studies 
indicated what proportion of their sample was 
sexually active at baseline, with some studies 
reporting additional detail on sexual behaviours. 
The lowest proportion of sexually active 
participants were recorded by the two UK-based 
studies, where less than one-fifth of participants 
had ever had sex at baseline [6.7% in both study 
groups of the RIPPLE trial,50 15% in the control 
group and 19% in the intervention group of the 
SHARE (sexual health and relationships education) 
trial70]. Neither of these studies reported any 
further detail of the young people’s sexual 
behaviour prior to the study, but it is likely that 
participants in these studies constituted relatively 
low-risk groups in terms of STIs.
In six studies between one- and two-fifths of the 
participants reported ever having sex.58,63,65–67,71 
Four of these studies also reported on condom 
use.58,65,67,71 In one study,65 over 70% of participants 
had ever used a condom, two studies reported 
condom use at last sex58,67 of between 56.3% and 
61%, and, in a further study,71 54.6% of participants 
reported always using a condom. The sexual 
behaviour of participants in these studies also 
appears to be fairly low risk.
In three studies, approximately half of the 
participants reported ever having sex.51,62,68 In 
one of these studies68 almost three-quarters of 
participants had ever used a condom and nearly 
one-fifth had experienced more than two sexual 
partners. In another study,51 only about one-third 
of participants reported that they always used 
a condom, but only about 6% had experienced 
more than one partner. In the third study,62 17.7% 
of participants reported ever having anal sex, 
with 8.3% having had anal sex in the preceding 3 
months. The participants in these three studies had 
baseline sexual behaviour that may have put them 
at some risk.
Coyle and colleagues61 reported the highest 
proportion of participants who had ever had 
sex (82.0% in the intervention group, 84.7% in 
the control group). Although over three-fifths of 
the participants reported using a condom at last 
sex, about 20% of participants had ever had anal 
intercourse, and of these over two-fifths had not 
used a condom the last time they had anal sex. 
This group of participants was highly sexually 
active and some participants took part in risky 
sexual behaviour.
One study64 did not report an overall figure for the 
proportion of the participants who were sexually 
active at baseline. Instead this was reported 
separately for boys and girls, which indicated 
a large difference between sexual experience 
according to gender (50.8% of boys had ever had 
sex versus 10.4% of girls). No other markers of 
sexual risk were reported by this study.
The study by Jemmott and colleagues43 was the 
only one not to provide an indication of what 
proportion of their study participants (who were 
all males) were sexually active, but other measures 
of baseline sexual behaviour were reported, which 
indicated that this was a group with relatively 
high-risk sexual behaviour. Only about 30% of 
participants always used a condom, and over 30% 
had experienced more than one partner in the 
preceding month. Almost 13% had taken part in 
heterosexual anal sex in the previous 3 months.
Other characteristics
Eight studies took place in an urban 
setting,43,51,58,61–63,65,71 two in a rural setting,66,69 and 
two in a mixture of urban and rural settings.50,64 
The locations of the remaining studies were either 
unclear67,68 or not stated.70 Five studies collected 
data on drug use,43,51,61,62,65 but only one suggested 
levels of use to be problematic.61 Four studies 
reported alcohol use, in terms of ever having 
used it or frequency of use.51,63,65,68 Surprisingly, 
only three studies reported explicitly on sexual 
orientation: Roberto and colleagues reported 
their sample to be exclusively heterosexual,66 DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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Jemmott and colleagues,26,62 reported low levels of 
homosexual experience in both of their studies. 
Religious affiliation was only reported by three 
studies, in which the samples comprised a mixture 
of Catholics, Protestants or Muslims.64,67,68
Only one study reported whether or not the young 
people had ever been considered as offenders;61 in 
this study, 62% and 57% of the intervention and 
comparison groups, respectively, had offended. 
The respective figures for currently being on 
probation were 53% and 49%. None of the studies 
reported the HIV status of the young people 
or whether any currently had an STI, although 
Stanton and colleagues69 did mention that their 
study took place in a low HIV seroprevalence 
setting.
None of the studies provided any information on 
the following: levels of social capital, disability 
status, whether any of the sample were commercial 
sex workers, and whether any of the sample were 
looked-after young people.
Methodological quality of 
the outcome evaluations
The following sections report the methodological 
characteristics and quality of the 15 outcome 
evaluations. The information below is synthesised 
in the section ‘Overall judgements on study quality’ 
in order to determine which of the studies are at 
least risk of selection bias, attrition bias, and bias 
due to selective reporting.
Method of randomisation
Three trials43,62,68 randomised individuals to study 
groups. Stanton and colleauges68 indicated that a 
random number table had been used as part of the 
randomisation process, Jemmott and colleagues43,62 
stated that the sample had been stratified 
before randomisation,43 and indicated that both 
stratification and a random number table had been 
involved in the randomisation process.62
Twelve of the RCTs were cluster trials, 11 of which 
randomly allocated schools, with one allocating 
school districts. Six of the twelve studies did not 
provide details of the randomisation process,63–67,69 
although it should be noted that Roberto and 
colleagues66 only involved two schools. Of the 
remaining six studies, the process of Zimmerman 
and colleagues71 involved pairing clusters, Coyle 
and colleagues58 ranked and paired clusters, 
whilst Coyle and colleagues,61 Stephenson and 
colleagues,50 and Borgia and colleagues51 had used 
processes that involved stratifying or matching 
clusters. Wight and colleagues70 stated that 
‘balanced randomisation’ was used to allocate 
schools.
Allocation concealment/blinding
None of the studies stated whether allocation 
to intervention and comparison groups were 
concealed (blinded). It was also unclear in the 
majority (12 of the 15 studies) whether participants 
were aware or could have deduced which study 
group they had been allocated to.43,51,58,61,63–69,71 
Stephenson and colleagues50 and Jemmott and 
colleagues62 gave details that suggested either 
that the schools knew which group they had been 
allocated to50 or that young people had been 
given sufficient information about the programme 
content for each group to have been able to deduce 
which group they were in.62 It was clear in Wight 
and colleagues’ study70 that participants would have 
known which group they were in. Ten of the fifteen 
studies did not state whether outcome assessors 
were blind to group allocation43,58,61,63–67,69,71 
and in three studies it was not clear whether 
outcome assessors were aware of group allocation 
status.50,51,68 Only Wight and colleagues70 and 
Jemmott and colleagues62 specifically stated that 
data checks70 or data collection62 had been carried 
out in a blinded fashion.
Comparability of study groups at 
baseline
More than half of the studies reported baseline 
sociodemographic and other sexual health-related 
characteristics for each study group, including all 
of the individuals who participated in the baseline 
assessment.50,51,58,61,63,65,68–70 Wight and colleagues65 
and Levy and colleagues70 also provided some 
baseline data for the individuals who remained in 
the study at follow-up. Roberto and colleagues66 
and Klepp and colleagues64 only provided baseline 
data for the individuals who remained at follow-
up, whilst Zimmerman and colleagues71 restricted 
reporting to characteristics that differed between 
the study groups. Three studies did not report 
baseline characteristics for the intervention and 
control groups.43,62,67 The two studies by Jemmott 
and colleagues43,62 reported baseline values for 
the whole study population, but Schaalma and 
colleagues67 reported no numerical data on 
baseline variables at all.Results of the systematic review of effectiveness
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In five trials, the majority of sexual health-related 
characteristics were balanced between the study 
groups.50,61,64,66,70 Three of these trials, Coyle and 
colleagues,61 Stephenson and colleagues50 and 
Wight and colleagues,70 had reported data for all 
individuals in each study group at baseline. The 
other two trials, Roberto and colleagues66 and 
Klepp and colleagues,64 reported baseline data only 
for the individuals who remained at follow-up. Six 
studies reported that study groups were unbalanced 
for more than one of the reported characteristics 
– these were all studies that had reported baseline 
data for all individuals in each study group at 
baseline.51,58,63,65,68,69 A further three trials did not 
report baseline data separately for intervention 
and comparison groups, so it was unclear whether 
the groups were balanced.43,62,67 Zimmerman and 
colleagues71 reported some differences between 
the study groups, and implied that the imbalances 
were not significant, but then appeared to make a 
correction for imbalances in the analyses (although 
this was not clearly explained).
Of the six trials that reported that study groups 
were not balanced at baseline, five reported making 
a correction for this in the analyses,51,58,63,65,69 with 
Zimmerman and colleagues71 also appearing to 
make a correction for baseline differences as noted 
above. Only Stanton and colleagues68 reported 
imbalances between the groups at baseline, but did 
not report having corrected for this in the analyses.
Attrition
An overall attrition rate was reported by, 
or could be calculated from, data in 10 
studies.43,50,58,61–63,65,68,69,71 Attrition ranged from 
only 3.2% at 3 months in a study by Jemmott and 
colleagues62 to 55% at 2 years in a study reported 
by Levy and colleagues.65 Where studies reported 
on outcomes at more than one time point, attrition 
was generally seen to increase with increasing 
length of follow-up,58,61,62,65,68,71 although there 
was one study in which attrition remained fairly 
constant at 3, 6 and 9 months.69
Twelve of the fifteen studies reported the 
attrition rate separately according to study 
group,50,51,58,62–66,68,69–71 although Coyle and 
colleagues58 did so only for the first of their three 
follow-up periods. The remaining three studies 
did not report a numerical value for attrition rate 
separately according to study group.43,61,67 Attrition 
ranged from less than 5% in one or more study 
groups to over 50%, with greater attrition tending 
to occur after longer periods of follow-up.
Only two studies clearly reported that there was 
no statistically significant difference in attrition 
rates between the arms of the study, 61,62 and one 
study described attrition between study arms as 
fairly even.63 Six studies reported that attrition 
differed between study groups,50,51,64,68,69,71 with 
the differences being described as statistically 
significant in three studies,50,64,68 and statistically 
significant at some but not all study follow-up 
points in a further two studies.68,71 The remaining 
study51 did not state whether the noted difference 
in attrition between the groups was statistically 
significant or not. Four studies did not report 
whether attrition differed between the study 
groups.58,65,66,70
Nine studies51,58,61–65,68,71 commented on whether 
there were any differences between those 
participants who were lost to follow-up, and those 
who were retained. Only one study51 reported that 
they did not detect any statistically significant 
differences between participants lost to follow-up, 
and retained participants. The remaining studies 
commenting on this noted at least one statistically 
significant difference between lost and retained 
participants.
Selective reporting
Eight studies reported outcomes for all individuals/
groups,43,50,58,61,63,65,68,70 although there were 
inevitably some outcomes that only applied to 
certain subgroups of young people (e.g. those who 
were sexually active at the start of the study, and 
those who became sexually active during the study). 
The remaining seven studies51,62,64,66,67,69,71 reported 
outcomes only for some individuals/groups. Often 
these studies reported outcomes only for the subset 
of participants who contributed both baseline and 
follow-up data,62,64,67,71 but in other cases it was not 
clear which individuals or groups were contributing 
outcome data,51,66 and one study combined three 
intervention groups together in the reporting of 
outcomes.69 All but two studies reported data for all 
outcome measures.51,63
Validation of outcome instruments
Outcome data were gathered, in all studies, by 
self-completion reports, diaries or questionnaires. 
In addition, one study also interviewed the young 
people to assess outcomes.65 Seven of the fifteen 
studies reported that the questionnaire used to 
collect outcome data had been developed or tested 
in a pilot study50,51,61–64,70 and 11 studies reported DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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a coefficient of reliability for some, or all, of the 
scales used within questionnaires.43,58,61–67,69,71
Length of follow-up
Stephenson and colleagues50 assessed outcomes 
at four or more outcome assessment points. The 
remaining studies varied in reporting outcome 
data from either one,51,63,66,67,70 two43,64,65,71 or 
three58,61,62,68,69 assessment points. The ways the 
studies reported the timing of the outcome 
assessments were variable: some reported the 
time elapsed since the baseline assessment, some 
reported time elapsed since completion of the 
intervention, and some reported both. Ten of the 
fifteen studies followed up participants for less than 
a year,43,51,62,63,66–71 with the remaining five studies 
continuing to assess outcomes at 1–2 years,61,64,65 
2–3 years,58 and 3–7 years50 after the intervention 
took place. However, it is worth noting that some 
studies reported high attrition at later time points 
(see below).
Unit of data analysis
The three trials43,62,68 that randomised individuals 
to study groups also used individuals as the 
unit of data analysis. The remaining 12 trials 
randomised clusters of individuals to groups, but 
eight of these analysed data at the unit of the 
individual.50,58,61,63,65,69–71 In the studies by Roberto 
and colleagues66 and Borgia and colleagues,51 the 
unit of data analysis was unclear, but was most 
probably the individual. Schaalma and colleagues67 
described a hierarchical linear model, analysing 
data at both the student (individual) and school 
(cluster) level. Stephenson and colleagues50 
analysed the primary outcome by age 16 years at 
the school level (cluster) but the primary outcome 
at age 20 years, and all secondary outcomes were 
based on individual participant data. Only the 
cluster randomised trial reported by Klepp and 
colleagues64 used the cluster as the unit of data 
analysis for all of the study outcomes, with two 
others, Stephenson and colleagues,50 and Schaalma 
and colleagues,67 using the cluster as the unit of 
data analysis for some of the study outcomes.
Overall judgements on study 
quality
Five of the fifteen studies were considered to be 
methodologically sound (Table 28).50,62,64,66,70 A 
further seven were judged to be methodologically 
TABLE 28  Summary of judgements on study quality
Study
Selection bias 
avoided
Attrition bias 
avoided
Selective reporting 
bias avoided Overall judgement
Borgia et al.51 Yes No Yes Sound, despite discrepancy with 
criteria
Coyle et al.58 Yes No Yes Sound, despite discrepancy with 
criteria
Coyle et al.61 Yes No Yes Not sound
Jemmott et al.43 Yes No Yes Sound, despite discrepancy with 
criteria
Jemmott et al.62 Yes Yes Yes Sound
Karnell et al.63 Yes Yes No Sound, despite discrepancy with 
criteria
Klepp et al.64 Yes Yes Yes Sound
Levy et al.65 Yes No Yes Sound, despite discrepancy with 
criteria
Schaalma et al.67 No No Yes Not sound
Stanton et al.68 Yes No Yes Not sound
Stanton et al.69 Yes No Yes Sound, despite discrepancy with 
criteria
Stephenson et al.50 Yes Yes Yes Sound
Wight et al.70 Yes Yes Yes Sound
Zimmerman et al.71 Yes No Yes Sound, despite discrepancy with 
criteriaResults of the systematic review of effectiveness
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TABLE 29  Behavioural aims of included studies
Study
Delaying 
initiation of 
sexual activity
Increase in 
condom use
Reduction 
in number 
of sexual 
partners
Increase in protective 
behaviours and/
or decrease in risk 
behaviours
Reduction in 
unintended 
pregnancy
Intervention vs standard sex education
Coyle et al.58   
Karnell et al.63  
Levy et al.65 
Wight et al.70  
Zimmerman et al.71 
Intervention vs control (no intervention, delayed intervention, non-sex education intervention)
Jemmott et al.43 
Jemmott et al.62 
Klepp et al.64 
Roberto et al.66   
Stanton et al.69 
Peer-led vs teacher-led interventions
Borgia et al.51  
Stephenson et al.50   
sound despite a discrepancy with our quality 
assessment criteria (see Data extraction in 
the systematic review and Quality assessment, 
and Appendix 5), hereafter referred to as 
methodologically sound studies.43,51,58,63,65,69,71 Of 
these seven studies, five failed due to high and/
or unbalanced attrition at later time points65,71 
or because attrition at later time points was not 
reported for each study group.43,58,69 However, the 
earlier time point(s) provided data that could be 
considered sound according to our criteria and 
hence were used in our analysis (but data from the 
later time points were not).58,65,69,71 One other study 
did not provide clear details about attrition but did 
state that an ITI analysis had been conducted.51 We 
therefore considered that attrition bias was unlikely. 
Karnell and colleagues63 failed to report on all of 
the outcomes described in their methods; however, 
it appeared unlikely that reporting bias would 
have been introduced, as the majority of outcomes 
were reported and for many of these there were 
no statistically significant differences between the 
groups.
In summary then, the results of the systematic 
review of effectiveness as presented in the following 
sections are based on a total of 12 RCTs43,50,51,58,62–
66,69–71 (of which nine were cluster RCTs), hereafter 
referred to as being methodologically sound. Three 
studies were not judged to be methodologically 
sound and their results are not analysed in this 
review.61,67,68
Synthesis of results of sound 
outcome evaluations
The following sections present the results of the 
12 methodologically sound studies according to 
the outcomes measured. The results are stratified 
by the comparator used, grouped into three 
categories: (1) behavioural intervention compared 
with a standard sex education comparison group; 
(2) behavioural intervention compared with 
a control group (i.e. no intervention, delayed 
intervention, non-sex education intervention); and 
(3) peer-led behavioural intervention compared 
with teacher-led behavioural intervention. It should 
be noted that there is a key difference between the 
two studies that included a peer-led trial arm. In 
one study (Stephenson and colleagues50) the peers 
delivered the behavioural intervention, whilst 
the teachers delivered standard sex education 
(i.e. current practice). By contrast, in the study DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
39
by Borgia and colleagues,51 peers and teachers 
delivered very similar behavioural interventions, 
neither of which were standard practice. It is 
for this reason that the study by Borgia and 
colleagues was not included in our meta-analysis, as 
mentioned earlier in Chapter 2, Meta-analysis.
Sexual behaviour
In accordance with our inclusion criteria all of the 
methodologically sound studies reported on at least 
one behavioural outcome (the tabulated numerical 
results for each study are presented in Appendix 8).
The behavioural aims of the studies varied, and 
about half described more than one behavioural 
aim (Table 29). Eight studies stated that the aim 
of the intervention was to impact on risk and/
or protective behaviour.43,50,62,63,65,69,70,71 One of 
these, Karnell and colleagues,63 was also one 
of five studies that assessed whether or not the 
intervention delayed sexual initiation.50,58,63,64,66 
The authors of three studies hoped to see both 
an increase in condom use and a decrease in the 
number of sexual partners.51,58,66 The effect on 
rates of unintended pregnancy was assessed by two 
studies.50,70
The extent to which the active comparators, 
i.e. standard sex education or teacher-led 
interventions, aimed to affect behaviour was 
generally not well described.
The majority of the studies reported more than 
one behavioural outcome, with some reporting 
on a wide range of behavioural outcomes. The 
study by Klepp and colleagues64 was the only one 
to report a single behavioural outcome (Table 
30), and this was also the only study that did not 
report a condom use outcome.64 All of the other 
included studies reported on at least one of nine 
different condom use outcomes: last intercourse 
with a condom,50,58,63,66,69,71 last intercourse without 
a condom,70 first intercourse with a condom,50,58 
first intercourse without a condom,70 frequency of 
condom use,43,51,70 frequency of intercourse with 
a condom,69 frequency of intercourse without a 
condom,43,58,62 ever used a condom65 and condom 
use with foam.7 As indicated in Table 30, other 
behavioural outcomes included initiation of sexual 
activity, episodes of sexual intercourse (primarily 
vaginal), use of contraception and/or pregnancy 
rates, and number of sexual partners.
Each of the main types of behavioural outcomes 
reported by the included studies are presented 
below.
Initiation of sexual intercourse
Seven studies reported this outcome.50,58,64,66,69–71 
However, Zimmerman and colleagues,71 and 
Stanton and colleagues69 only reported data on 
this outcome for their final time points (12–18 
months and 9 months, respectively). These data 
were not included in our review because they did 
not meet our criteria for methodological soundness 
at these time points due to attrition bias. In the 
study by Stanton and colleagues69 the differential 
attrition rate between study groups was not clear, 
and in the study by Zimmerman and colleagues 
the attrition rate exceeded 70% (see Chapter 2, 
Quality assessment, and Appendix 5). Therefore, 
five studies contribute data to this outcome, which 
was assessed with reference to participants’ status 
at baseline50,58,64,66,70 (Appendix 8, Table 70). The 
time between baseline and the reported follow-up 
ranged between 5 and 18 months, but it should be 
noted that in two cases the intervention had not 
been completed70 or had been completed only 10 
weeks before follow-up66 when data were collected.
Three of the five studies, Coyle and colleagues58 
Wight and colleagues70 and Klepp and colleagues,64 
found that there was no significant difference 
between the intervention and comparison group 
in the initiation of sexual activity among those who 
were virgins at baseline. The other two studies50,66 
did report a statistically significant difference 
between groups. Roberto and colleagues66 found 
that young people in the control group were 
nearly three times more likely to have initiated 
sexual activity, in the 5 months since the pre-test 
questionnaire, than students in the intervention 
group. Stephenson and colleagues50 found that of 
those who were virgins at baseline, girls in the peer-
led group were significantly less likely to report 
having had sex by age 16 years than were those in 
the comparison group, but there was no statistically 
significant difference for boys.
The impact of the interventions on sexual initiation 
is summarised in Table 31. Data were in a suitable 
format for meta-analysis in three of the five 
studies.50,58,70 Roberto and colleagues66 did not 
provide the denominators for each group, but these 
were calculated (using the reported numerators 
and percentage values) in order to complete the 
2 × 2 table of data so that this study could also be 
included in the meta-analysis. It should be noted, 
however, that there appeared to be a reporting 
error in the paper published by Roberto and 
colleagues:66 once denominator values had been 
calculated, it was apparent that they did not sum 
to the reported total number of participants in the Results of the systematic review of effectiveness
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TABLE 30  Summary of types of behavioural outcomes reported
Study Initiation Condom use Intercourse
Contraception/
pregnancy Partners Other
Intervention vs standard sex education
Coyle et al.58  First intercourse 
witha
Frequency 
without
Last intercourse 
with
Frequency
With alcohol and 
drugs
Last intercourse 
with contraception
n without;
n overall
Test HIV
Test other 
STIs
Karnell et al.63 Last intercourse 
withb
With alcohol
Levy et al7 Ever
With foam
Frequency n
Wight et al.70  First intercourse 
withouta
Frequency
Last intercourse 
without
Last intercourse 
with oral 
contraception
Unintended 
pregnancy
Unprotected 
sex
Zimmerman et 
al.71
 Last intercourse 
with

With alcohol
Intervention vs control (no intervention, delayed intervention, non-sex education intervention)
Jemmott et al.43 Frequency
Frequency 
without
 (coitus)
Frequency (coitus)
 (anal)
Frequency (anal)
n (coital)
n (anal sex)
Behaviour 
risk index
Jemmott et al.62 Frequency 
without
 (coitus)
 (anal)
Frequency (anal)
n (coital)
n (anal sex)
Behaviour 
risk index
Klepp et al.64 
Roberto et al.66  Last intercourse 
with
n
Stanton et al.69  Frequency with
Last intercourse 
with
 Last intercourse 
with contraception
Peer-led vs teacher-led interventions
Borgia et al.51 Frequency n
Stephenson et al.50  First intercourse 
witha
Last intercourse 
with
 (> once) First intercourse 
with contraception
No unintended 
pregnancy
Abortions and live 
births
n, number of partners.
a  Sexually naive participants’ behaviour the first time they had intercourse.
b  The questionnaire used in the study by Karnell and colleagues asked about frequency of condom use but the outcome 
was not reported.
 Study reports the outcome indicated by the column heading.
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Item Effect (CI) Weight % Size
Sexual initiation
Coyle 1999
58 Safer 
Choices IT19200
1.13 (0.71 to 1.81) 49.0 0
Roberto 2007
66 0.40 (0.01 to 26.49) 0.6 308
Stephenson 2004
50
Ripple ITT1203818
0.94 (0.42 to 2.11) 16.5 7123
Wight 2002
70
SHARE IT18196
0.96 (0.55 to 1.70) 33.9 5043
1.03 (0.74 to 1.43)
Favours intervention
0.00 1.00 403.42
Favours control
FIGURE 2  Meta-analysis forest plot for outcome: ‘delaying sexual initiation’ (OR). Note: The zero value for Coyle and colleagues’ sample 
size was due to slightly different data entry for this study. The sample size was 2565. Coyle and colleagues did not report data that could be 
entered into a 2 × 2  table, but did provide an effect size and its standard error, which were entered directly into the eppi-reviewer software 
for meta-analysis.
study who were sexually naive at baseline. Data 
from Klepp and colleagues study64 could not be 
included in the meta-analysis because details were 
not provided that were necessary for calculating the 
numerators and denominators corresponding to 
the reported percentage values of those becoming 
sexually active in each group.64
Two of the studies50,70 reported data separately for 
young women and young men. The data for young 
men and young women were therefore combined 
for each group to provide an overall study value for 
use in the meta-analysis. The fixed-effect pooled 
OR was 1.03 [95% confidence interval (CI) 0.74 to 
1.43] indicating no significant difference between 
intervention and control (Figure 2). No statistically 
significant heterogeneity was detected (p = 0.929, 
I2 = 0%).
Condom use
All but one study, Klepp and colleagues,64 reported 
on condom use. Outcome measures included 
whether a condom was used at first sex,50,58,70 
whether a condom was used at the most recent 
episode of sexual intercourse50,58,63,66,69–71 and 
frequency of condom use,43,51,58,62,69,70 and one study 
reported whether condoms had ever been used and 
the use of foam (the term foam was used for any 
product containing the spermicide nonoxynol-9) 
with condoms.65 The numerical results are 
presented in Appendix 8, Table 71.
Statistically significant effects in favour of the 
intervention group over the comparison group 
were only reported by two of the studies. Coyle 
and colleagues58 found that participants in the 
intervention group significantly outperformed the 
comparison group, statistically, on the outcome 
of condom use at last sex58 (but there was no 
statistically significant difference in condom use 
at first sex) and frequency of condom use.58 A 
statistically significant reduction in unprotected 
sex (i.e. increase in frequency of condom use) 
was also observed by Jemmott and colleagues.62 
This study was one of four studies with a control 
group that reported on condom use. Outcomes 
measurement that we considered methodologically 
sound took place at 6 months62 and 7 months,58 
but, due to high attrition in the study by Coyle 
and colleagues,58 at later time points (19 and 31 
months) these outcomes were considered unsound 
and therefore were not data extracted. Whether 
improvements made in condom use behaviour can 
be maintained long term is therefore unknown.
Studies commonly reported either that there was 
no significant difference in condom use outcomes 
between the groups, or did not report whether 
a statistical comparison had been made. Of the 
studies comparing a behavioural intervention to 
standard sex education, statistically significant 
differences were not observed for condom use at 
first sex by Coyle and colleagues58 as noted above, Results of the systematic review of effectiveness
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and this was also true for the study reported by 
Wight and colleagues.70 The differences between 
the groups for outcomes of condom use at last 
sex,70,71 and frequency of condom use,70 were not 
significantly different, and Karnell and colleagues63 
did not report a statistical comparison for condom 
use at last sex. Two of the four studies with a 
control group reporting condom use outcomes 
also reported that there was no difference between 
the groups for the outcomes of condom use at last 
intercourse66,69 and frequency of condom use.69 The 
remaining study, Jemmott and colleagues,43 did 
not report a statistically significant effect for the 
intervention on either of the condom use outcomes 
reported (frequency of condom use, and number of 
days a condom was not used during coitus).
Of the two studies that compared peer-led 
with teacher-led interventions (Stephenson 
and colleagues50 and Borgia and colleagues51), 
neither demonstrated any statistically significant 
differences between the study groups for condom 
use at first sex,50 condom use at last sex50 or 
frequency of condom use.51 However, statistically 
significant improvements between the pre-test 
and post-test were observed in both groups for the 
frequency of condom use outcome.51
Levy and colleagues65 limited the reported findings 
on condom use to the subgroup of young people 
who had become sexually active in the period 
between the pre-test and first post-test measure. 
For one outcome, ever used condoms with foam, a 
statistically significant difference in favour of the 
intervention group over the comparison group 
was observed. But this was not the case for the 
remaining condom use outcomes of ever used 
condoms, used condoms in the past 30 days, and 
used condoms with foam in the past 30 days.
The effects of the interventions on condom use 
are summarised in Table 31. Although condom use 
was a commonly reported outcome, there were 
many different ways that this outcome could be 
measured. In order to obtain an overview of all 
possible condom use outcomes, a meta-analysis 
was conducted for the ‘general’ outcome of all 
condom use (shown below in Figure 3 – see also 
additional forest plots in Appendix 9 for some of 
the constituent condom use outcomes that were 
used in the general condom use outcome).
The fixed-effect pooled OR was 1.07 (95% CI 0.88 
to 1.30), with no statistically significant difference 
between intervention and comparator. No 
Item Effect (CI) Weight % Size
All condom use
Coyle 1999
58 Safer 
Choices IT19200
1.91 (1.13 to 3.24) 13.7 0
Levy 1995
65
1398D1451
0.64 (0.17 to 2.45) 2.1 310
Stanton 2005
69
FOK-WV ITT1203840
0.99 (0.63 to 1.54) 19.4 1131
Stephenson 2004
50
Ripple ITT1203818
0.98 (0.76 to 1.27) 57.7 1534
Wight 2002
70
SHARE IT18196
1.00 (0.37 to 2.73) 3.8 2145
Zimmerman 2008
71 1.02 (0.34 to 3.03) 3.2 2000
1.07 (0.88 to 1.30)
0.14 1.00 7.39
Favours intervention Favours control
FIGURE 3  Meta-analysis forest plot for the outcome: ‘all condom use’ (OR). Note: The zero value for Coyle and colleagues was due to 
slightly different data entry into the meta-analysis software for this study. The sample size was 1018 (see Appendix 12 for more detail).DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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statistically significant heterogeneity was detected 
(p = 0.333, I2 = 12.9%).
Sexual intercourse
Several different outcomes relating to sexual 
intercourse were reported (Table 30 and Appendix 
8, Table 72). Three studies, Coyle and colleagues,58 
Levy and colleagues65 and Jemmott and 
colleagues,43 reported on the frequency of sexual 
intercourse, whilst both studies by Jemmott and 
colleagues reported on abstinence.43,62 Jemmott 
and colleagues’ studies were also the only ones to 
report whether participants had engaged in anal 
sex, along with the frequency of anal sex. In one 
of the papers, Jemmott and colleagues,43 only 
heterosexual anal sex was reported, whereas the 
later paper (Jemmott and colleagues62) reported on 
anal sex without distinguishing a particular type. 
Zimmerman and colleagues71 reported whether 
participants had ever had sex, and Stanton and 
colleagues71 reported those who had had sex in 
the last 6 months.69 Stephenson and colleagues50 
reported the percentage of students who had 
sex more than once. Three studies also reported 
on the use of alcohol prior to or during sexual 
intercourse.58,63,71
Coyle and colleagues,58 and Levy and colleagues65 
found no significant differences between the 
intervention and comparison groups for the 
frequency of sexual intercourse. However, amongst 
those who became sexually active during the course 
of the study reported by Levy and colleagues (the 
subgroup termed ‘Changers’), there was a trend 
towards students in the intervention group being 
sexually active less often, although this was a 
statistically marginal result (p < 0.10).65 Jemmott 
and colleagues62 found that the intervention group 
were not more likely to practise abstinence,43,62 but 
in the later (1999) paper statistically significant 
differences in favour of the intervention group were 
reported for anal intercourse, and the frequency 
of anal intercourse.62 The remaining three studies 
that reported the proportion of participants 
engaging in sexual intercourse found no significant 
differences between the groups.50,69,71
The three studies that reported on the use of 
alcohol during or before sexual intercourse58,63,71 
found that there was no significant difference 
in this outcome between the intervention group 
and the comparison group receiving standard sex 
education. Karnell and colleagues63 reported a 
statistically significant difference between study 
groups in favour of the intervention for reducing 
the consumption of alcohol at last sex, but only 
amongst the subgroup who had not had sex at 
the pre-test. There were no significant differences 
between the intervention and comparison groups 
by gender, or for those who were already sexually 
active at the pre-test.
The effects of the interventions on sexual 
intercourse outcomes are summarised in Table 31. 
It was not possible to meta-analyse any of these 
outcomes due to heterogeneity in the types of 
outcome reported and incomplete reporting of 
data necessary to enter into meta-analysis.
Contraception and pregnancy
Four studies included an outcome measure that 
assessed broader methods of contraception 
use50,58,69,70 and two included a pregnancy 
outcome.50,70 One study reported on abortions.50 
The effects of the interventions on these outcomes 
is summarised in Table 31. Only Coyle and 
colleagues58 reported a statistically significant 
effect in favour of the intervention group for the 
outcome of protection against pregnancy at last 
sex (use of condom, oral contraceptive or both). 
The other three studies used slightly differing 
outcomes: Wight and colleagues70 found no 
significant difference between the groups on use 
of a condom with or without concomitant use 
of oral contraceptives, Stanton and colleagues69 
did not report a statistical comparison between 
groups for use of a condom and oral contraceptive, 
and Stephenson and colleagues50 reported no 
significant difference in contraception use (a 
condom or other method of contraception) at 
either first or last sex. At the 18-month follow-up, 
girls in the peer-led arm reported slightly fewer 
unintended pregnancies, but the difference was 
not significant. By age 20 there was no significant 
difference between the groups in the proportion 
who had had an abortion, and although the 
proportion of girls in the peer-led group who had 
had one or more live births by age 20.5 was lower 
than that in the teacher-led group, the difference 
was not statistically significant89 (Appendix 8, Table 
73).
It was not possible to meta-analyse contraception 
and pregnancy outcomes due to heterogeneity in 
the types of outcome reported and incomplete 
reporting of data necessary to enter into meta-
analysis.
Sexual partners
Six studies assessed intervention effect on the 
number of sexual partners,43,51,58,62,65,66 although 
one of these limited the reporting of this outcome Results of the systematic review of effectiveness
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to the subgroup of participants who had become 
sexually active during the course of the study.65 One 
study reported separately on the number of anal 
sex partners,62 and one on the number of female 
anal sex partners.43 The effects of the interventions 
on these outcomes are summarised Table 31 and 
full results are presented in Appendix 8, Table 74.
Only one of the studies by Jemmott and 
colleagues,62 which reported the number of anal sex 
partners, found a statistically significant difference 
between the groups in favour of the intervention 
at the 6-month post-intervention follow-up. 
However, there was no significant difference in 
the number of heterosexual (coital) sex partners 
in this study. Similarly, the other studies that 
reported on number of sexual partners also stated 
that there was either no significant difference or 
did not report a statistical comparison between 
intervention and comparison groups.43,51,58,66 The 
study that limited reporting to the subgroup of 
participants who had become sexually active during 
the study65 also found no statistically significant 
differences between the groups. Borgia and 
colleagues51 did report some significant differences 
between the number of partners reported pre-
test and the number reported post test within the 
teacher-led arm of the studies.
Other behavioural outcomes
Four studies reported on additional behavioural 
outcomes not applicable in the previous sections. 
The effects of the intervention on these outcomes 
are summarised in Table 31.
Coyle and colleagues58 reported on whether 
participants had been tested for HIV or another 
STI but found that there were no statistically 
significant differences between the study groups. 
Wight and colleagues70 identified participants 
who made any report of sex without condoms for 
three specific events of intercourse, or reported a 
pregnancy (or a girlfriend’s pregnancy), or who 
had not answered ‘always’ or ‘most of the time’ 
to the question ‘How often did you ever use a 
condom?’. This composite outcome was described 
as ‘Any evidence of sex unprotected against STDs 
ever’ and no statistically significant differences 
were found between the study groups. Jemmott 
and colleagues43,62 also reported a composite 
outcome measure – a risk behaviour index. The 
risk behaviour index was created from responses 
to questions within a questionnaire about sexual 
practices, for example unprotected sexual 
intercourse, number of sexual partners, intercourse 
and anal intercourse. These outcomes were 
converted and averaged to form a value on the ‘risk 
behaviour index’. Jemmott and colleagues43 found 
that after controlling for pre-intervention risk 
behaviour, participants engaged in significantly less 
risky sexual behaviour, statistically, in the 3 months 
following the intervention than the participants in 
the control group. Jemmott and colleagues62 found 
that 3 months after intervention delivery there was 
no significant difference between the study groups, 
but at the 6-month follow-up results of analysis of 
covariance (ANCOVA) on the risk behaviour index 
scores revealed that young people in the HIV risk-
reduction condition reported significantly less HIV 
risk-associated sexual behaviour, statistically, than 
the participants in the control group (Appendix 8, 
Table 75).
Summary – sexual behaviour
The impact of the interventions on the range 
of behavioural outcomes discussed above is 
summarised in Table 31. Few statistically significant 
effects on behaviour in favour of the intervention 
were reported by the included studies. Seven of 
the twelve studies reported that the intervention 
had at least one statistically significant effect on a 
behavioural outcome. However, in three cases this 
only applied to a subgroup of the participants50,63,65 
and for each study there were other behavioural 
outcomes for which no significant differences 
between groups were observed.43,50,58,62,63,65,66 
The other five studies did not report that the 
intervention had any statistically significant 
behavioural effects.51,64,69–71 The interventions did 
not lead to a significant increase in initiation of 
sexual activity by young people or to an increase in 
the number of their sexual partners.
Skills and self-efficacy
It was a condition of inclusion in our review that 
interventions had a skills component. However, 
not all the sound studies reported on whether 
participants felt that they had gained skills or 
increased in self-efficacy (their belief in their 
abilities) to perform certain skills. Where studies 
did report self-efficacy outcomes these varied 
depending on the focus of the skills component 
of the intervention employed in the study. The 
scales used to quantify self-efficacy varied among 
studies. Within studies, scales were often different 
for the various self-efficacy outcomes (the tabulated 
numerical results for each study are presented in 
Appendix 8, Table 77).
All twelve sound studies included a skills 
component within their intervention. These Results of the systematic review of effectiveness
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TABLE 32  Skills interventions
Skill component
Study
Communication and/
or negotiation
Decision-
making
Risk 
avoidance
Refusal or 
abstinence
Condom 
use
Intervention vs standard sex education
Coyle et al.58   
Karnell et al.63  
Levy et al.65   
Wight et al.70 
Zimmerman et al.71  
Intervention vs control (no intervention, delayed intervention, non-sex education intervention)
Jemmott et al.43 
Jemmott et al.62  
Klepp et al.64 
Roberto et al.66 
Stanton et al.69    ()
Peer-led vs teacher-led interventions
Borgia et al.51  
Stephenson et al.50  
, Study reported this outcome.
(), Ninety per cent of sites did not include this type of skill training.
skills components were described as focusing 
on communication and negotiation, decision-
making, risk avoidance, sex refusal or abstinence, 
and condom use (Table 32). The most commonly 
described skill was a refusal skill or abstinence 
skill component, present in seven of the twelve 
studies; communication and/or negotiation 
skills training were included by six studies; and 
six studies included condom use skills training. 
Condom use skills training involved participants 
handling condoms in three studies,58,62,70 but it was 
not clear whether participants handled condoms 
in the other three studies that included condom 
skills training.43,50,71 The intervention reported 
by Stanton and colleagues69 was to have included 
exercises relating to condom use. However, during 
intervention adaptation, communities or schools 
requested that this element should be removed 
and therefore over 90% of sites did not include this 
type of skills training. Decision-making skills were 
a component of three interventions51,65,69 and two 
studies taught risk avoidance skills.63,71
Four studies had interventions that were described 
as having only one skill component,43,64,66,70 but 
most studies described an intervention that 
contained either two50,51,62,63 or three 58,65,69,71 skill 
components.
The self-efficacy outcomes reported by the 
included studies did not always correlate with the 
skills components included within the interventions 
(Table 33), and four studies did not report a self-
efficacy outcome.43,64,65,70 The most commonly 
reported self-efficacy measure was condom use 
self-efficacy, which was reported by seven of 
the eight studies that reported a self-efficacy 
outcome.50,58,62,63,66,69,71
Six studies reported refusal or abstinence self-
efficacy,50,58,63,66,69,71 four reported communication/
negotiation self-efficacy,50,51,58,66 and two reported 
situational self-efficacy (the negotiation of 
potentially risky situations).66,71 Five studies assessed 
self-efficacy at more than one time point,50,58,62,69,71 
but the high attrition rate in two of these studies at 
the later time point meant that the data were not 
extracted.58,71
Two of the three studies that compared a 
behavioural intervention with standard sex 
education found there were no statistically DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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TABLE 33  Self-efficacy outcomes
Study
Communication and/or 
negotiation self-efficacy
Refusal or 
abstinence self-
efficacy
Condom use self-
efficacy
Situational self-
efficacy
Intervention vs standard sex education
Coyle et al.58   
Karnell et al.63  
Zimmerman et al.71   
Intervention vs control
Jemmott et al.62 
Roberto et al.66    
Stanton et al.69  
Peer-led vs teacher-led interventions
Borgia et al.51 a
Stephenson et al.50   
a  Described as prevention skills, but the questions assessing this outcome included prevention (not further defined), 
communication and negotiation skills.
significant differences in self-efficacy outcomes 
between the groups.63,71 Coyle and colleagues58 
reported a statistically significant effect for 
condom use self-efficacy, but not for the other 
two self-efficacy items they assessed. Karnell and 
colleagues63 reported a statistically significant 
intervention effect for refusal self-efficacy, but only 
in one subgroup: young women in the intervention 
group had greater refusal self-efficacy than young 
women in the comparison group. Conversely, 
the three comparisons between behavioural 
intervention groups and control groups (receiving 
no intervention) demonstrated a greater number of 
statistically significant intervention effects. Jemmott 
and colleagues62 found that the intervention group 
had significantly greater condom self-efficacy, 
statistically, immediately after the intervention, 
and at 3 and 6 months post intervention, than the 
control group. Similarly, a statistically significant 
difference in favour of the intervention group 
6-months’ post intervention (but not at 3 months 
post intervention) was reported by Stanton and 
colleagues69 for both condom self-efficacy and 
abstinence self-efficacy. Roberto and colleagues,66 
who reported four different self-efficacy 
outcomes, found statistically significant benefits 
of the intervention on condom negotiation and 
situational self-efficacy, but did not report any 
statistically significant effects for the other two 
measures – condom use and refusal self-efficacy.
Of the two studies that compared peer- with 
teacher-led interventions, one (Borgia and 
colleagues51) reported a statistically significant 
improvement in prevention skills (including 
communication and negotiation skills) in both 
groups following the intervention in comparison 
to pre-intervention scores. However, there were 
no statistically significant differences between 
the groups. The other study to compare peer- 
with teacher-led interventions, Stephenson 
and colleagues,50 also reported that there were 
no differences between the groups for the 
communication measure (confidence about 
discussing sex and contraception with a partner). 
Statistically significant differences were found for 
girls, at the 18-month follow-up, who were less 
confident in the peer-led arm than those in the 
teacher-led arm about refusing to do something 
they did not want to do sexually, but who became 
more confident about using condoms.
Skills and self-efficacy outcomes in 
subgroups
Stephenson and colleagues50 reported all of their 
results separately by gender. Three other studies 
also reported findings on self-efficacy according to 
one or more subgroups;51,63,69 however, none of the 
reports stated whether the study had been powered 
to detect an effect in the subgroups (and the three 
studies reporting on self-efficacy subgroups are Results of the systematic review of effectiveness
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different from the three studies that reported 
subgroup analyses for knowledge – see Knowledge, 
later). Three of the studies that analysed subgroups 
reported on differences according to gender.50,51,63 
Borgia and colleagues51 found that, regardless 
of trial arm, female participants improved their 
prevention skills more than males (no statistical 
significance reported). Karnell and colleagues63 
found that female students in the intervention 
group were significantly more confident, 
statistically, about their ability to refuse sex than 
female students in the comparison group, but 
there was no statistically significant difference 
for the intervention group versus comparison 
group as a whole, as noted above. Stephenson and 
colleagues,50 as noted above, found two statistically 
significant differences for girls (but not boys) at the 
18-month follow-up, which favoured the teacher-
led intervention in one case, and the peer-led 
intervention in the other.
Two studies also reported on subgroups of 
participants according to sexual experience.51,69 
Borgia and colleagues51 found that participants 
who were already sexually active at baseline 
had a greater improvement in prevention skills 
(a prevention skill was not defined) than those 
not sexually active at baseline but no statistical 
significance was reported. Similarly, Stanton and 
colleagues69 found that youth sexually experienced 
at baseline in the intervention group had a 
statistically significantly greater condom use self-
efficacy at the 6-month follow-up than those in 
the control group. Stanton and colleagues69 also 
reported that youth in the intervention group who 
were virgins at baseline demonstrated significantly 
greater perceptions, statistically, of abstinence 
self-efficacy 6 months after the intervention than 
those in the control group, whereas there was no 
difference in abstinence self-efficacy between the 
groups for the youth who were already sexually 
experienced at baseline.
The duration of most studies was 12 months or 
less.51,62,63,66,69 Of those with a longer follow-up, 
attrition was too great at the later time point in two 
studies to consider the results would be sound.58,71 
Therefore only Stephenson and colleagues50 
provide any evidence that an intervention effect on 
self-efficacy can be sustained for 18 months post 
intervention.
Summary: skills and self-efficacy
The effects of the interventions on self-efficacy 
outcomes are summarised in Table 34. A third of 
the included studies did not report a self-efficacy 
outcome, although their intervention included 
a skills component.43,64,65,70 Only two studies 
reported that their intervention had no statistically 
significant effect on any of the self-efficacy items 
assessed.51,71 The other six studies report mixed 
results with either statistically significant effects 
being reported in a subgroup of participants 
for one or more self-efficacy outcomes50,63,69 or 
statistically significant effects being reported for 
some, but not all, of the self-efficacy measures 
assessed,58,66 with one study reporting a statistically 
significant effect of the intervention on the single 
self-efficacy measure that was reported.62
Knowledge
All 12 sound studies attempted to measure 
participants’ knowledge, but the knowledge items 
that were measured varied depending on the focus 
of the educational component of the intervention 
employed in the study. The extent to which 
knowledge outcomes were reported also varied 
(the tabulated numerical results for each study are 
presented in Appendix 8, Table 76).
The majority of the studies tested participants’ 
knowledge of HIV51,64,65 or their knowledge of HIV 
and STIs more generally.43,50,58,62,63,69 Zimmerman 
and colleagues71 also tested knowledge of 
pregnancy prevention as well as HIV and STIs. 
Wight and colleagues70 tested practical knowledge 
of sexual health, though this was not further 
defined. The knowledge tested in the remaining 
study, Roberto and colleagues,66 was not clear as no 
description was provided.
Knowledge was tested at the same time as other 
outcomes at periods, ranging from immediately 
after the intervention to 18 months following 
intervention. Seven studies assessed knowledge 
at more than one time point,43,50,58,62,65,69,71 but the 
high attrition rate in three of these studies at the 
later time point meant that only the data for earlier 
time points were extracted, whereas the later time 
points did not meet our quality assessment criteria 
for being methodologically sound.58,65,71
Statistically significant effects in favour of 
the intervention group over the comparison/
control group were found by all but two of the 
studies. Four of the five studies that made a 
comparison with standard sex education found that 
participants in the intervention group significantly 
outperformed the comparison group, statistically, 
in the knowledge test.58,65,70,71 Only Karnell and 
colleagues63 reported that there was no intervention DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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TABLE 34  Summary of intervention effects on self-efficacy
S
e
x
 
r
e
f
u
s
a
l
 
s
e
l
f
 
e
f
fi
c
a
c
y
C
o
n
d
o
m
 
u
s
e
 
s
e
l
f
-
e
f
fi
c
a
c
y
C
o
m
m
u
n
i
c
a
t
i
o
n
 
s
e
l
f
-
e
f
fi
c
a
c
y
S
i
t
u
a
t
i
o
n
a
l
 
s
e
l
f
-
e
f
fi
c
a
c
y
A
b
s
t
i
n
e
n
c
e
 
s
e
l
f
-
e
f
fi
c
a
c
y
C
o
n
d
o
m
 
n
e
g
o
t
i
a
t
i
o
n
 
s
e
l
f
-
e
f
fi
c
a
c
y
Intervention vs standard sex education
Coyle et al.58 ◆  ◆
Karnell et al.63 ‡ ◆
Zimmerman et al.71 ◆ ◆ ◆
Intervention vs control (no intervention, delayed intervention, non-sex education intervention)
Jemmott et al.62 
Roberto et al.66 ◆ ◆  
Stanton et al.69  
Peer-led vs teacher-led interventions
Borgia et al.51 ◆
Stephenson et al.50a ◆ X ♀  ♀ ◆
a  Reported all outcomes separately for young men and young women.
◆, No significant difference between the study groups (assumed for studies not reporting significance or any p-value).
, Outcome favoured the intervention group.
‡,  Outcome favoured the intervention for one subgroup of participants, but for one or more subgroups of participants 
there was no significant difference between the study groups.
X,  Outcome favoured the comparison group.
♀, For the subgroup of females.
effect. Similarly, compared with control groups (e.g. 
no intervention, a delayed intervention or a non-
sex education intervention), four of the five studies 
reported that the intervention group statistically 
significantly outperformed the control group in 
the knowledge test,43,62,64,66 whilst Stanton and 
colleagues69 did not report on whether there was 
any difference between the groups.
Both studies that compared peer- with teacher-led 
interventions50,51 reported that participants in the 
peer-led groups scored statistically significantly 
better on the knowledge outcomes than 
participants in the teacher-led groups.
The impact of the interventions on knowledge 
outcomes is summarised in Table 35.
Knowledge outcomes in subgroups
Stephenson and colleagues3 and Wight and 
colleagues4 reported all of their results separately 
by gender. In addition, three studies that reported 
an intervention effect for a knowledge outcome 
also reported findings according to one or more 
subgroups;51,58,62 however, none stated whether 
the study had been powered to detect an effect 
in the subgroups reported. Three of the studies 
reporting on subgroups reported on differences 
between young men and young women. Wight and 
colleagues70 and Borgia and colleagues51 reported 
that young women were more knowledgeable than 
young men, but neither study reported whether 
the difference between the genders was statistically 
significant or not. Stephenson and colleagues50 
reported that knowledge in the peer-led group Results of the systematic review of effectiveness
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was statistically significantly better at the 6-month 
follow-up for girls, but the reverse was true at 
the 18-month follow-up, when knowledge of 
methods to prevent STIs was significantly better, 
statistically, for boys who had received the peer-led 
intervention.
The other subgroups for which knowledge 
outcomes differed were previous sexual activity 
(Jemmott and colleagues62 reported that the 
intervention effect was statistically significantly 
greater among young people who reported 
having coitus in the previous 3 months in the 
pre-intervention questionnaire); SES (Borgia 
and colleagues51 found the highest SES group 
outperformed the lowest SES group but statistical 
significance not reported); school type (Borgia and 
colleagues51 reported that humanistic/scientific 
school pupils scored more highly than pupils at 
technical or vocational schools, but again did not 
report whether this was statistically significant); and 
school location (a statistically significant greater 
intervention effect on knowledge was reported by 
Coyle and colleagues58 for schools in Texas than 
schools in California).
The duration of most studies was 12 months or 
less.43,51,62–64,66,69,70 Of those with a longer follow-
up, attrition was too great at the later time point 
in three studies to consider that the results could 
be sound according to our quality assessment 
criteria.58,65,71 Therefore, only Stephenson and 
colleagues50 provide evidence that the intervention 
effect on knowledge can be sustained in the longer 
term (i.e. up to18 months post intervention).
Summary – knowledge
Ten of the twelve included studies reported that the 
intervention had a statistically significant effect on 
increasing knowledge, as summarised in Table 35. 
Only two studies did not demonstrate a statistically 
significant difference in knowledge between young 
people in the intervention and comparison63 or 
control69 groups.
Attitudes
Eight of the included studies had an assessment 
of participants’ attitudes among their 
outcomes.43,50,51,58,63,64,66,71 Six of these investigated 
participants’ attitudes towards risky sexual 
behaviour or sexual intercourse,43,50,58,64,66,71 with two 
specifically focused on attitudes towards waiting to 
have sex.66,71 Three studies reported on attitudes 
towards condom use50,58,63 – two on attitudes 
relating to people with AIDS51,64 and one included 
positive and negative attitudes towards alcohol63 
(see Appendix 8, Table 78).
Jemmott and colleagues43 reported statistically 
significantly less favourable attitudes towards risky 
sexual behaviours among the intervention group 
immediately following the intervention, but 3 
months after the intervention this effect had waned 
to a non-statistically significant trend in favour of 
the intervention group over the control group. 
Roberto and colleagues66 were the only authors to 
report a statistically significant effect in favour of 
the intervention group over the control group for 
participants’ attitude towards waiting to have sexual 
intercourse. The other study to focus specifically 
on attitudes to waiting to have sexual intercourse 
reported that there was no significant difference 
between the groups,71 and the other three studies 
that reported attitudes towards sexual intercourse 
also found no significant difference between the 
groups.50,58,64 Similarly, only one of the three studies 
reporting on attitudes towards condom use (Coyle 
and colleagues58) found a statistically significant 
effect in favour of the intervention group, whereas 
the other two studies, Stephenson and colleagues50 
and Karnell and colleagues,63 found no significant 
difference between the groups50 or did not report 
a statistical comparison.63 Both of the studies 
reporting on attitudes of participants towards 
people with AIDS reported significant changes. 
Klepp and colleagues64 found a statistically 
significant effect in favour of the intervention 
group over the control group, whereas as Borgia 
and colleagues,51 assessing peer- and teacher-
led interventions, found that whilst statistically 
significant improvements were observed in both 
groups between the pre-test and the post-test, a 
post-test difference between the two groups was 
not reported. The single study that assessed both 
positive and negative attitudes to alcohol did not 
report on any statistical comparison between the 
groups.63
Summary – attitudes
The effects of the intervention on attitudes is 
summarised below in Table 36. A greater number 
of interventions that were assessed in relation to 
a control group, rather than those interventions 
assessed in comparison with standard sex education 
or to teacher-led interventions, found statistically 
significant effects. Three studies did not report any 
outcomes relating to attitudes.65,69,70DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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TABLE 35  Summary of intervention effects on knowledge outcomes
HIV and/or AIDS 
knowledge STI knowledge
HIV, AIDS and STI 
knowledgea
Sexual health 
knowledge
Intervention vs standard sex education
Coyle et al.58  
Karnell et al.63 ◆
Levy et al.65  
bWight et al.70 
Zimmerman et al.71 
Intervention vs control (no intervention, delayed intervention, non-sex education intervention)
Jemmott et al.43 
Jemmott et al.62 
Klepp et al.64 
Roberto et al.66 
Stanton et al.69 ◆
Peer-led vs teacher-led interventions
Borgia et al.51 
bStephenson et al.50 
a  Zimmerman et al.71 and Roberto et al.66 also included pregnancy prevention knowledge.
b  Reported all outcomes separately for young men and young women.
◆, No significant difference between the study groups (assumed for studies not reporting significance or any p-value).
, Outcome favoured the intervention group.
Behavioural intentions
Outcomes relating to participants’ intentions 
were reported by six studies,7,43,62–64,71 although 
one of these, by Levy and colleagues,65 only 
reported intention outcomes for the subgroup 
of participants who had become sexually active 
during the course of the study. Four of the six 
studies reported on participants’ intentions to 
have sex,63–65,71 one reported on intentions to 
engage in risky sexual behaviour,43 three reported 
on intentions to use condoms62,63,65 (one further 
study, by Zimmerman and colleagues,71 indicated 
that condom use intentions formed part of their 
participant questionnaire but did not report on this 
outcome), and the study by Levy and colleagues65 
reported on participants’ intention to use condoms 
with foam (Appendix 8, Table 79).
Only one of the studies reporting on participants’ 
intention to have sex. Klepp and colleagues64 found 
a statistically significant difference in favour of the 
intervention group at follow-up. Participants in 
the intervention group had a reduced intention 
to have sex in comparison to the control group. 
The three other studies reporting on this outcome 
either reported no significant differences between 
the groups71 or did not report a statistical 
comparison.63,65
The only study reporting intentions to engage 
in risky sexual behaviours found a statistically 
significant effect in favour of the intervention 
participants (participants had weaker intentions 
than the control group to engage in risky 
sex behaviours) both immediately after the 
intervention, and at the three month follow-up.43 
In terms of intention to use condoms, only one 
study reported a statistically significant difference 
between study groups in favour of the intervention 
group for the intention to use condoms.62 Karnell 
and colleagues63 found that overall there was no 
difference between intervention and comparison 
groups, but there was a statistically significant 
difference in favour of the intervention group for 
the subgroup of participants who were already 
sexually active at baseline. The third study 
reporting on the intention to use condoms, by 
Levy and colleagues,65 did not report a statistical 
comparison for this outcome, but did report that 
the subgroup of participants who had become Results of the systematic review of effectiveness
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TABLE 36  Summary of intervention effect on attitudes
Attitude 
towards 
risky sexual 
behaviours
Attitude 
towards sexual 
intercourse
Attitude 
towards 
condom use
Attitude 
towards alcohol
Attitude 
towards people 
with AIDS
Intervention vs standard sex education
Coyle et al.58 ◆ 
Karnell et al.63 ◆ ◆
Zimmerman et al.71 ◆
Intervention vs control (no intervention, delayed intervention, non-sex education intervention)
Jemmott et al.43 
Klepp et al.64 ◆ 
Roberto et al.66 
Peer-led vs teacher-led interventions
Borgia et al.51 ◆
aStephenson et al.50 ◆ ◆
a  Reported all outcomes separately for young men and young women.
◆, No significant difference between the study groups (assumed for studies not reporting significance or any p-value).
, Outcome favoured the intervention group.
sexually active during the course of the study 
in the intervention group were more likely than 
participants in the comparison group to express an 
intention to use condoms with foam.65
Summary – behavioural intentions
Half of the included studies reported on the effects 
of the intervention on behavioural intentions and 
these are summarised in Table 37. An intervention 
effect was most likely to be reported by studies with 
a control group rather than a comparison group.
Infection rates
None of the included studies reported infection 
rates. Coyle and colleagues58 reported whether 
participants had had a HIV or STI test, but the 
outcome of these tests is not known.
Summary of the results of sound 
outcome evaluations
•  Sexual behaviour:
  – Outcomes related to the included sexual 
behaviours were reported under the 
headings: initiation of sexual intercourse; 
condom use; sexual intercourse; 
contraception and pregnancy; sexual 
partners; and other behavioural outcomes.
  – Interventions resulted in few statistically 
significant effects on sexual behaviour. 
Statistically significant effects on at least 
one behavioural outcome were reported 
by seven of the twelve studies. However, 
in three cases the effect was limited to 
a subgroup of participants, and in all 
studies no statistically significant effect 
was observed for some or all of the other 
behavioural outcomes reported on.
  – Five of twelve studies did not report that 
the intervention had any statistically 
significant behavioural effects.
•  Skills and self-efficacy:
  – Two-thirds of the included studies reported 
a self-efficacy outcome, although all studies 
included a skills component within their 
intervention.
  – Most studies reported on more than one 
self-efficacy outcome and reported mixed 
results, statistically significant effects 
for some, but not all participants, or 
statistically significant effects for some, but 
not all self-efficacy outcomes.
  – One study reporting on a single self-
efficacy measure reported a statistically 
significant intervention effect.
  – Two studies, one of which reported a single 
measure, found that the intervention had DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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TABLE 37  Summary of intervention effects on behavioural intentions
Intention to 
engage in risky 
sexual behaviour
Intention to have 
sex
Intention to use 
condoms
Intention to use 
condoms with 
foam
Intervention vs standard sex education
aLevy et al.65a ◆ ◆ 
Karnell et al.63 ◆ ‡
Zimmerman et al.71 ◆
Intervention vs control (no intervention, delayed intervention, non-sex-education intervention)
Jemmott et al.43 
Jemmott et al.62 
Klepp et al.64 
a  Reported for sexually inexperienced (virgins) subgroup.
◆, No significant difference between the study groups (assumed for studies not reporting significance or any p-value).
, Outcome favoured the intervention group.
‡,  Outcome favoured the intervention for one subgroup of participants, but for another subgroup of participants there was 
no significant difference between the study groups.
no statistically significant effect on the 
reported self-efficacy measures.
•  Knowledge:
  – Ten of the twelve included studies reported 
that the intervention had a statistically 
significant effect on increasing knowledge.
•  Attitudes:
  – Nine studies reported attitude outcomes. 
Statistically significant effects of the 
intervention were reported by more of the 
studies that assessed an intervention in 
relation to a control group than those that 
assessed an intervention against standard 
sex education or teacher-led education.
•  Behavioural intentions:
  – Half of the studies reported on behavioural 
intentions. As noted above for attitudes, a 
statistically significant intervention effect 
was more likely to be reported by studies 
with a control group rather than those with 
a comparison group.
•  Infection rates:
  – None of the included studies reported on 
a biological outcome relating to infection 
with STIs. One study reported whether 
participants had undergone an HIV or STI 
test, but the outcome of the tests was not 
reported.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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T
his chapter presents the results of our synthesis 
of the process evaluations included in the 
systematic review of effectiveness reported in 
Chapter 4. Nine of the twelve sound outcome 
evaluations included an integral process 
evaluation (Borgia and colleagues,51 Jemmott and 
colleagues,43,62 Karnell and colleagues,63 Levy and 
colleagues,65 Roberto and colleagues,66 Stephenson 
and colleagues,50 Wight and colleagues,70 
Zimmerman and colleagues71).
Where authors had published additional papers 
reporting the process evaluations, we incorporated 
this additional information into account in the 
synthesis. Details of these ‘linked’ papers can be 
found in Appendix 7.
Methodological 
characteristics
A range of processes were evaluated (Table 38). All 
studies, except Borgia and colleagues,51 evaluated 
both the acceptability of the intervention to 
Chapter 5  
Synthesis of process evaluations
TABLE 38  Processes evaluated within the sound outcome evaluations that included an integral process evaluation (n = 9)
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Borgia et al.51   
Jemmott et al.43    
Jemmott et al.62    
Karnell et al.63    
Levy et al.65  
Roberto et al.66   
Stephenson et al.50      
Wight et al.70     
Zimmerman et al.71   
TOTAL 3 2 2 9 8 1 4 5
providers or recipients, and all studies asked how 
well interventions were implemented (but Jemmott 
and colleagues43,62 did not report findings on 
this). A third of the studies examined: accessibility 
or how many participants the intervention 
reached; the actual content of the intervention; 
and the skills and training of the intervention 
providers. Two studies assessed the collaboration 
and partnerships involved in developing or 
delivering the intervention, and only one evaluated 
the quality of the programme materials. The 
‘other’ processes evaluated were: the duration 
of the intervention;51,62 the assimilation of the 
intervention into classrooms;51 how much the 
young people learned, whether the intervention 
would help them in the future and whether they 
would recommend the intervention to other 
peers,43 and monitoring of sex education in 
comparison schools.50
Whilst some studies evaluated a wide range of 
processes others focused on just two or three. 
For example, in the UK-based RIPPLE trial, 
Stephenson and colleagues50 examined the Synthesis of process evaluations
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proportion of students who reported that they 
received the peer-led sex education (‘accessibility 
and programme reach’); the contextual factors 
influencing the ability of teachers to co-ordinate 
the peer-led programme in schools (‘collaboration 
and partnerships’); student evaluations of the 
peer-education (‘acceptability’); the individual 
and structural factors influencing the extent 
of implementation of peer-led sex education 
(‘implementation’); observation of peer leaders to 
assess their enthusiasm and organisational skills 
(‘skills and training of intervention providers’); and 
the type and extent of sex education delivered in 
the control schools (‘other’).
The most common method used to collect data 
on process was a self-completion questionnaire 
(Table 39). Just over half of the studies also used 
observation (e.g. researchers observing the lessons). 
Both these methods of data collection were used 
to assess intervention implementation and the 
skills and training of intervention providers. Self-
completion questionnaires were also used to assess 
intervention acceptability and accessibility, as were 
interviews and focus groups. A range of ‘other’ 
methods were used: website logs in a computer-
based intervention (Roberto and colleagues66), 
researcher field notes from site visits (Stephenson 
and colleagues50) and group discussion (Wight and 
colleagues70).
TABLE 39  Methods used to collect data on intervention processes within the sound outcome evaluations that included an integral process 
evaluation (n = 9)
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Borgia et al.51  
Jemmott et al.43 
Jemmott et al.62 
Karnell et al.63  
Levy et al.65 
Roberto et al.66  
Stephenson et al.50     
Wight et al.70      
Zimmerman et al.71  
TOTAL 1 3 2 4 8 3 1
All but two studies collected data from intervention 
providers, and all but two collected data from 
intervention participants themselves (Table 40).
Levy and colleagues65 tested the effect of involving 
parents in a 10-lesson curriculum for the 
prevention of pregnancy and STIs. The process 
evaluation therefore monitored the participation 
of parents in the intervention. Other groups 
sampled in the process evaluations were: head 
teachers and other school staff responsible for 
sex education (Stephenson and colleagues50, 
Wight and colleagues70), teacher trainers (Wight 
and colleagues70) and unspecified ‘project staff ’ 
(Zimmerman and colleagues71).
Methodological quality
The methodological quality of the process 
evaluations was mixed (Table 41) (see Appendix 5 
for the criteria used).
Six studies were judged to have taken at least 
a few steps to increase rigour in the sampling 
process.43,50,62,63,70,71 Two studies were judged to have 
made a thorough attempt having sampled a range 
of stakeholders at several time points throughout 
the intervention period.50,70 Half of the studies were 
judged to have taken a least a few steps to increase DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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TABLE 40  Groups sampled in the process evaluations (n = 9)
Intervention participants Intervention providers Other
Borgia et al.51 
Jemmott et al.43  
Jemmott et al.62  
Karnell et al.63  
Levy et al.65 
Roberto et al.66 
Stephenson et al.50   
Wight et al.70   
Zimmerman et al.71   
TOTAL 7 7 4
rigour in data collection.43,50,63,70,71 One study was 
judged to have made a thorough attempt.70 This 
study used a diverse range of data collection 
methods, which included a balance between open-
ended and closed techniques.
Researchers spent extensive periods of time 
collecting data at intervention and control sites 
and supplemented more formal data collection 
techniques (e.g. interviews, observation), with 
documentation of more informal conversations 
with teachers and pupils. Only two studies had 
taken at least a few steps to increase rigour in 
the analysis of the process data (Stephenson 
and colleagues50 and Wight and colleagues70). 
These studies had provided a description of the 
data analysis process, had explored diversity in 
perspective and allowed concepts and themes to 
emerge from the data analysis, as well as exploring 
pre-determined themes and categories. The 
majority of the remaining studies had provided no 
detail at all on the methods used to analyse data, 
making it difficult to judge whether steps were 
taken to increase rigour.
Only the findings in one-third of studies were 
judged to have been at least fairly well grounded 
in or supported by the data (Stephenson and 
colleagues,50 Wight and colleagues,70 and 
Zimmerman and colleagues71).
All of these studies reported the findings in 
separate linked papers or had dedicated sections 
within the outcome paper to report findings. In 
other studies, data to support authors’ conclusions 
about process were extremely limited or in some 
cases completely absent. The same three studies 
were also the only ones to have been judged as 
providing both good breadth and depth in their 
findings. Again, in other studies the limited scope 
and reporting of findings made it difficult to assess 
breadth and depth favourably.
The remaining quality criteria in Table 41 
assessed the extent to which young people’s own 
perspectives had been considered in the process 
evaluation. Only three studies had been judged to 
have a least privileged young people’s perspectives 
‘a little’ (Stephenson and colleagues,50 Wight and 
colleague,70 and Zimmerman and colleagues71). 
These studies were judged to have given equal 
weight to young peoples’ perspectives alongside 
the views of other stakeholders. Of the remainder, 
Borgia and colleagues51 and Levy and colleagues65 
did not collect any data from the young people 
receiving the interventions.
A final step in the quality assessment process was 
for reviewers to assign two types of ‘weight of 
evidence’ to studies. Firstly, a weight (low, medium 
or high) was assigned according to the reliability or 
trustworthiness of the findings (the extent to which 
the methods used were rigorous/could minimise 
bias and error in the findings). A second weight 
(low, medium, high) was assigned according to the 
usefulness of the findings in terms of how well the 
intervention processes were described and whether 
or not the process data could illuminate why or 
how the intervention worked or did not work.
All but four studies were assigned a low weight of 
evidence for the rigour of their findings and all 
but three were assigned a low weight of evidence 
for the usefulness of the findings (Table 42). Three Synthesis of process evaluations
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TABLE 41  Methodological quality of process evaluations (n = 9)
Number of studies
Not at all/not 
stated A few steps Several steps
A thorough 
attempt
1.  Were steps taken to minimise bias/increase 
rigour in sampling?
3 3 1 2
2.  Were steps taken to increase rigour/
minimise bias and error in the data 
collected?
4 3 1 1
3.  Were steps taken to increase rigour/
minimise bias and error in the analysis of the 
process data?
7 1 0 1
No grounding/
support
Limited 
grounding/
support
Fairly well 
grounded/
supported
Good 
grounding/
support
4.  Findings of the process evaluation grounded 
in/supported by the data
0 6 1 2
Limited 
breadth and 
depth
Good/fair 
breadth, 
limited depth
Good/fair 
depth, limited 
breadth
Good breadth 
and depth
5.  Breadth and depth of findings 6 0 0 3
Not at all A little Somewhat A lot
6.  Does the process evaluation privilege the 
perspectives and experiences of young 
people?
6 2 0 1
studies stand out overall as they were judged to 
be medium or high weight of evidence for both 
trustworthiness and usefulness – Stephenson 
and colleagues,50 Wight and colleagues70 and 
Zimmerman and colleagues.71
Synthesis of findings
As mentioned earlier (Chapter 2, Process 
evaluations), the synthesis of process evaluation 
studies addressed two principal questions. Firstly, 
what factors facilitate or hinder the implementation 
of skills-based behavioural interventions in 
schools? Secondly, what factors impact on student 
engagement and intervention acceptability? These 
are explored in the following subsections.
Fidelity of implementation
The fidelity of intervention implementation (i.e. 
the extent to which the intervention was delivered 
as intended) was assessed by all studies, but only 
seven reported findings on this.50,51,63,65,66,70,71 As a 
number of these were multisite cluster RCTs they 
involved the implementation of a standardised 
programme across a number of schools.
Three studies found that implementation fidelity 
varied across and within schools. In the UK, 
Stephenson and colleagues50 found that overall, 
84% of the intended recipients of RIPPLE 
reported that they had received at least some peer 
education, but this varied between 51% and 97% 
across schools. Wight and colleagues70 found that 
although the Scottish-based teacher-delivered 
SHARE programme was implemented in all 12 
experimental schools, there was variation in the 
extent to which all 20 sessions of the programme 
were covered (from 38% to 88% across schools). In 
the USA, Zimmerman and colleagues71 also found 
that implementation of the 16–17 session teacher- 
and peer-delivered ‘Reducing the Risk’ programme 
varied somewhat across schools and classrooms.
The factors influencing the implementation of the 
intervention are discussed in detail below, but a 
particular challenge was consistent implementation 
of some of the interactive and ‘novel’ elements 
of the programmes. In the RIPPLE trial,50 whilst 
most students reported that the intervention had 
covered topics such as HIV, STIs, where to get 
contraception/condoms and medical advice, and 
had looked at condoms, fewer students reported 
that they had practiced putting a condom on DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 42  Weight of evidence judgements for (1) trustworthiness of findings and (2) usefulness of findings
Weight of evidence
Trustworthiness of findings Usefulness of findings
Low Medium High Low Medium High
Borgia et al.51  
Jemmott et al.43  
Jemmott et al.62  
Karnell et al.63  
Levy et al.65  
Roberto et al.66  
Stephenson et al.50  
Wight et al.70  
Zimmerman et al.71  
TOTAL 5 2 2 6 2 1
(76%), discussed how to use condoms with a 
partner (39%) or practiced resisting pressure to 
have sex (55%). (However, greater numbers of 
students in the experimental schools reported that 
they had received skill-based activities than in the 
control schools.) In the SHARE trial70 teachers 
reported making ‘considerable changes’ to five of 
the 20 lessons in the programme. These tended 
to be those lessons that involved role playing to 
develop communication and resistance skills and 
one lesson in which young people got the chance to 
visit a family planning clinic. Parental involvement 
was a novel element of the US-based Youth AIDS 
Prevention Project (YAPP) programme, but Levy 
and colleagues65 reported that, despite substantial 
cost and effort, it was not possible to get parents to 
attend on-site school activities.
From the synthesis, a hierarchy emerged (Figure 4), 
incorporating a number of factors that may impact 
on fidelity of implementation.
School culture
School culture was identified as an overarching 
factor impacting on fidelity of implementation. 
School culture was determined by a range of key 
elements, and most clearly emerged as being 
significant from the SHARE study.70 One element 
that Wight and colleagues70 identified was the 
involvement of key players at a number of levels, 
from the Health Education Board of Scotland 
(HEBS), to guidance teams, sex education co-
ordinators and senior management. Higher levels 
of involvement tended to facilitate implementation. 
Motivation of these key players was also important, 
as was communication between teachers and, 
importantly, communication style: in one school 
that was involved in the SHARE trial, the senior 
management imposed the programme (in all other 
schools there had been consultation with staff) 
and teachers felt unhappy with this ‘imposition’, 
which impacted negatively on implementation. 
A teacher having sufficient time to organise or 
deliver sessions was dependent on whether PSHE 
was considered enough of a priority in the face 
of competing subjects. If management support 
was low, cover for teacher sickness or absence 
was less likely to be supplied and, consequently, 
intervention sessions were missed. Low morale was 
also found to be a barrier against implementation: 
one of the two schools in the RIPPLE trial50 in 
which some classrooms did not receive the peer-led 
intervention there was low morale because the sixth 
form facility for 16- to 18-year-old students was 
closing down.
School administration
Factors relating to school organisation also 
impacted on implementation. Staff absence and 
turnover, timetabling issues and time shortages led, 
generally, to lessons being missed or cut short.50,70 
In the SHARE study, schools found it hard to set 
aside 20 lessons for sex education and, even when 
they felt sex education was a priority, they were 
all too aware that other topics competed with 
the programme. As one teacher put it: ‘… this 
really has distorted my whole programme … I’ve 
not done any study skills, I’ve not done anything Synthesis of process evaluations
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on drugs and alcohol, I’ve hardly done any 
work experience . . . it’s blocked up a lot of my 
programme’ (Buston and colleagues,90 p. 66). 
Although the lessons had been designed to last 
for 40 minutes each, this was found to be rather 
optimistic and around one-third of the sessions 
‘could not be completed’. There were also problems 
with making the trained teachers available for 
the appropriate slots, resulting in some sessions 
being delivered by untrained teachers. This was 
a particular problem in one case, because of the 
inflexibility of the head teacher over timetabling.
Teachers – enthusiasm, expertise, 
autonomy
All of the findings on teachers as intervention 
providers come from Wight and colleagues,70 
who found that the process of actively cultivating 
teacher expertise and enthusiasm was vital in the 
delivery of SHARE. The SHARE teacher training 
was particularly important in this regard and was 
viewed very positively by teachers. Wight and 
colleagues91 evaluated the training extensively and 
found that, in the post-training questionnaire, 86% 
reported that they were ‘very glad’ to have attended 
the course and 13% reported they were ‘glad’. 
In interviews, teachers compared the SHARE 
training very favourably with other in-service 
training that they had received. For example, a 
typical comment from a teacher was: ‘Without a 
doubt, yes, the training was actually one of the – 
and colleagues would say this as well – it was one 
of the best training courses that I’ve ever been 
on’ (p. 528). Wight and colleagues91 noted that 
the perceived success of the training was largely 
attributed to the trainer, who was an experienced 
sexual health educator, and who was felt to be 
clear and in control and able to put teachers at 
their ease. Wight and Abraham92 also note that the 
training succeeded in ensuring that teachers’ own 
self-efficacy was enhanced, so as not to appear to 
threaten their current expertise by introducing new 
methods.
However, despite high levels of acceptability of 
the teacher training, a number of problems with 
the teachers’ implementation of the intervention 
persisted. Some failed to engage with the 
theoretical basis for the intervention, in particular 
the mechanism for behavioural change, via the 
modelling and practising of skills. Wight and 
colleagues91 report that, in interviews, teachers 
seldom referred to skills development unprompted, 
and when interviewers raised the issue they 
talked about this only briefly. They comment that 
‘only one teacher referred to the mechanism by 
which the programme was intended to influence 
behaviour, that is the social-psychological theory 
behind it, and then only obliquely’ (p. 536). In 
the interviews, the teachers never mentioned the 
theoretical aspects of the training that Wight and 
colleagues91 had hypothesised were fundamental 
to achieving behavioural change and which 
distinguished the course from traditional sex DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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education. The authors concluded that ‘many 
teachers saw the skills and tactics required to 
apply the theoretical principles of the SHARE 
programme to be so far removed from their 
established repertoires that it was too great a risk 
to try and develop them’ (Wight and colleagues,91 
p. 540). In practice, this meant that many teachers 
failed to persevere with skills development and 
role play activities. In the words of one teacher: ‘I 
turned round to 3A on Tuesday … I said “you’re 
not going to do this [role play] are you now?” in a 
way that let them opt out because they went “no”, 
but I knew they weren’t going to do it and I didn’t 
have a strategy really for thinking “right, I’ve hit 
a wall, what do I do with them?’’ ’ (Buston and 
colleagues,90 pp. 67–8).
This failure to engage with the theory behind an 
intervention was experienced in a different way by 
Borgia and colleagues,51 who suspected teachers 
of selecting the peer leaders who delivered their 
intervention for their academic skills rather than 
for the qualities that are hypothesised to make a 
good peer leader.
As well as issues relating to teachers’ expertise, 
there were also issues of enthusiasm. Teachers were 
sometimes uncomfortable with talking explicitly 
about sexual issues and some were wary about how 
to handle the question of same-sex relationships. 
Some teachers simply did not see sex education as 
a priority.
There was also some conflict between issues of 
fidelity and issues of professional autonomy: some 
teachers made amendments to the programme 
without consulting the intervention developers, as 
they felt they had the skills and experience to do 
so. Buston and colleagues90 looked at the extent 
to which teachers delivered the intervention as 
intended and found that for 71% of sessions, 
teachers reported having followed the pack ‘very 
closely’, for 23% teachers reported modifying the 
session ‘slightly’ and for 6% they reported making 
‘considerable’ modifications. ‘Considerable’ 
modifications included missing out sessions or 
key exercises, amalgamating sessions, abandoning 
exercises when pupil resistance was experienced 
and modifying teaching methods. Ten teachers 
reported making modifications which they viewed 
as ‘slight’ but which, in the opinions of the packs’ 
authors, would compromise the intervention in 
important ways, for example missing out or not 
completing key exercises.
Peers
Four of the studies that included process 
evaluations used peer educators. Karnell and 
colleagues63 and Zimmerman and colleagues71 used 
peer educators alongside teachers; and Borgia and 
colleagues51 and Stephenson and colleagues50 only 
used peers to deliver their intervention. In none 
of the studies was the age of the peer leader clear 
except in that of Stephenson and colleagues, in 
which they were 16–17 years old.
Only Zimmerman and colleagues71 offer a 
justification for using peer educators, which was 
that they were specifically targeting high sensation 
seekers and impulsive decision-makers, whom they 
presumed relied more on peers than on adults 
when making decisions about their behaviour. 
Borgia and colleagues51 did not offer a rationale for 
employing peer educators, other than wanting to 
see whether it conferred advantages that standard 
practice (i.e. teacher-led sex education) did not.
The process evaluation data showed that selection 
of peer leaders was clearly important. As seen 
above, Borgia and colleagues51 hypothesised that 
there were problems with the criteria by which 
the teachers in their intervention selected peer 
leaders (i.e. they were selected for academic skills 
rather than for the qualities that make an effective 
peer leader). This, they believed, compromised 
the ‘trustfulness and communication’ (p. 514) 
between educators and pupils. Stephenson and 
colleagues50 had other problems with selection: one 
school was unable to recruit enough peer leaders to 
implement the intervention.
Like Borgia and colleagues,51 Stephenson and 
colleagues50 questioned the aptitude of some of 
the recruited peer educators. They report that in 
two schools some classes failed to receive peer-
led sex education due to the disorganisation and 
lack of enthusiasm of the peer educators for the 
programme. Zimmerman and colleagues71 noted 
that although the peer educators performed 
the tasks assigned to them, they did not achieve 
the level of involvement hoped for, ‘making this 
component of the modified curriculum less than 
ideal’ (p. 49). Some peer leaders in Stephenson 
and colleagues’ RIPPLE trial were hampered by 
structural factors, including long gaps between 
training and delivery of sex education and 
timetable clashes for peer educators taking 
examinations.Synthesis of process evaluations
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Researchers’ observations in Stephenson and 
colleagues’study50 show that some important topics 
may not have been addressed in many of the peer-
led sessions (e.g. emergency contraception).
It is not clear across the studies whether 
intervention fidelity was more problematic in 
peer-led interventions than in those delivered by 
teachers or other adults. Although Stephenson 
and colleagues50 report that RIPPLE was not 
implemented at all in one school because the 
school could not recruit enough peer educators 
(as opposed to the teacher-delivered SHARE 
programme, which was implemented in all 
schools), and Zimmerman and colleagues71 found 
that peer facilitators were rarely used in the 
modified ‘Reducing the Risk’ programme, Borgia 
and colleagues51 found that whilst their peer-
led intervention achieved the suggested length 
(median across schools was equal to 10 hours) the 
teacher-led intervention was significantly shorter 
(median across schools was only 8 hours). Borgia 
and colleagues did not explore this finding any 
further.
Parents
Only one of the studies that included a process 
evaluation involved parents as providers of the 
intervention (Levy and colleagues65). This process 
evaluation shows that, although parents seemed 
satisfied and participatory during meetings, they 
only really became actively involved with the 
intervention through the interactive homework 
assignments. The authors reflect that interactive 
homework assignments ‘may provide a practical 
way to involve parents in school-based prevention 
efforts’ (p. 151). However, they also note that 
parents largely failed to attend on-site school 
activities. It is hypothesised that this was a function 
of parents (particularly those on a low income) 
having to balance work and life stresses, but this 
does not seem to be based on empirical data.
Health educators/facilitators
Levy and colleagues’ intervention65 utilised ‘health 
educators’, who were educated to ‘professional 
master’s level’ and who had received extensive 
training in delivery of the programme and HIV/
AIDS. Jemmott and colleagues62 used ‘facilitators’ 
to deliver their intervention, but no details are 
given about their expertise or training or their 
impact on fidelity of implementation.
Computer
One study, that of Roberto and colleagues,66 
delivered the intervention by computer.
The authors note that ‘the nature of the 
intervention provided a very high level of control 
over the implementation’ (p. 68) and that the 
process evaluation showed the intervention had 
been implemented as intended.
Student engagement and 
intervention acceptability
The interventions evaluated by the studies included 
in this review shared two common features. Firstly, 
all interventions were designed to engage young 
people actively in their own learning through 
interactive exercises, such as role plays, discussions 
and small group work. Secondly, all interventions 
were designed to be relevant and appealing to 
young people in general or particular groups of 
young people. The latter was attempted in various 
ways including the use of peer leaders to deliver 
the intervention and attempts to make curriculum 
materials interesting, fun and relevant through, for 
example, the use of fictional teenage characters. 
Although there was evidence from the process 
evaluations to confirm that interventions did 
engage and appeal to many of the young people 
involved, this was not always the case.
Six of the process evaluations contributed findings 
that illuminated issues of student engagement and 
intervention acceptability.50,51,63,66,70,71 A number of 
factors emerged as influences on this issue (Figure 
5).
Appeal of intervention content
Attempts to design interventions that were 
appealing to young people were met with 
some success in the three studies with relevant 
findings. Three-quarters of the participants rated 
the four animated characters who modelled 
skill development in the South-African based 
intervention delivered to (predominantly) Zulu 
youth, evaluated by Karnell and colleagues,51 as 
seeming ‘very’ or ‘extremely’ real to them, and 
74% found the curriculum, delivered by peers and 
teachers, ‘very’ or ‘extremely’ interesting. A positive 
evaluation was also received for the intervention 
delivered by a computer to young people living 
in a rural Appalachian community in the USA, 
evaluated by Roberto and colleagues.66 Young 
people found the programme to be informative, 
clear, useful and interesting and did not rate the 
programme as ‘boring’ or ‘preachy’. Similarly, a 
large proportion of the young people participating 
in the US-based ‘Reducing the Risk’ intervention, 
evaluated by Zimmerman and colleagues,71 an 
intervention delivered by teachers and peers to DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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FIGURE 5  Factors related to student engagement and intervention acceptability.
ethnically diverse ‘high sensation seeking youth’, 
rated the programme as very interesting, easy to 
pay attention to and fun. However, not all parts 
of the intervention were evaluated positively in 
this study. The animated powerpoint presentations 
that introduced the curriculum were not judged 
to be particularly novel and researchers noted 
increasingly negative reactions to this part of 
the intervention. They concluded that it may be 
difficult to ‘yield a high level of sensation value in a 
classroom intervention’ (p. 49).
Qualities of intervention providers
The qualities and expertise of intervention 
providers was another factor that impacted upon 
student engagement and acceptability. The 
focus group data collected by Stephenson and 
colleagues50 as part of the RIPPLE trial conducted 
in schools in central and southern England 
revealed that students receiving peer-led sex 
education were considerably more positive about 
their experience than those in the control schools 
who received the teacher-led sex education that 
was usually delivered in their schools. Those who 
did report greater satisfaction with peer-led sex 
education perceived peer educators as having 
‘greater relevant expertise and respect for pupils, 
holding more similar values about sex, using 
familiar language, being less moralistic and making 
the sessions fun’ (p. 343). The peer educators were 
felt to be more ‘in touch’ with participants as young 
people. However, data from questionnaires show 
that around a third of students receiving peer-led 
sex education did not evaluate it positively. Those 
who found the peer-led component less acceptable 
reported that participation became difficult when 
peer educators were not able to engage boys or 
manage their behaviour.
Peer leaders also encountered difficulties in 
engaging young people in the evaluation 
conducted by Zimmerman and colleagues.71 
Delivering school-based programmes to develop 
skills around practising safer sex is clearly a 
role that requires considerable expertise. As 
already noted in the previous section on fidelity 
of implementation, teachers often struggled to 
engage young people in the interactive elements 
of the SHARE programme70 and teacher control 
over student behaviour and engagement during 
the interactive elements of the ‘Reducing the Risk’ 
curriculum also emerged as a significant issue 
in the evaluation conducted by Zimmerman and 
colleagues.71
Meeting needs
It is important to recognise that whilst many of the 
young people surveyed in the process evaluations 
rated interventions favourably, there was a minority 
of young people for whom interventions were 
less than appealing. As noted above, Stephenson 
and colleagues50 highlight this point in relation 
to the RIPPLE study, with their findings that one-
third of young people did not evaluate peer-led 
sex education in a positive way. They argue that 
dissatisfaction or lack of engagement may be 
related to the possibility that the intervention, 
despite being designed to appeal to young people, 
did not, in fact, meet their own self-identified 
needs. Their process evaluation examined this 
issue directly and found that overall participants 
felt that topics such as sexual feelings, emotions, 
and relationships were not covered well by either 
teachers or peers. Researchers’ observations in 
the RIPPLE trial revealed that some important 
topics may not have been addressed in many of the 
peer-led sessions (e.g. emergency contraception). 
The issues discussed below around the format Synthesis of process evaluations
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and timing of interventions also highlight how 
the failure of school-based interventions may be 
explained by a failure to respond to/acknowledge 
young people’s self-identified needs
Gendered norms and mixed-sex versus 
single-sex groups
The interventions varied according to whether 
activities were delivered in mixed-sex or single-sex 
groups. The RIPPLE trial50 was delivered in mixed-
sex groups, but some of the participants said they 
would have preferred single-sex sessions. However, 
observation data from the evaluation of the 
SHARE trial92 revealed problems with the single-
sex classes they delivered, in particular for young 
men. Gendered norms dominated particularly 
in all male groups, and impaired discussion and 
reflexive insight. Boys tended to conform to macho 
stereotypes or practiced self-censoring. It was 
observed that boys tended to work better in mixed 
sex groups as they were ‘liberated from defensive 
masculine norms’ (p. 31) and became interested 
in the perspectives of young women. Wight and 
Abraham noted that these mixed-sex groups could 
engender confidence amongst young men for 
talking about sex to young women.
Age/timing
Three studies raised the question of the age-
appropriateness of the interventions. Wight and 
Abraham92 concluded that their content was too 
advanced for the pupils in their intervention, as 
pupils’ lack of sexual experience at age 13–14 years 
meant that they failed to identify with the vignettes 
presented to them, which were designed to make 
pupils more aware of gendered interaction and 
power dynamics in sexual relationships, and/or 
found them alien. Pupils were unfamiliar with this 
kind of analysis and, in addition, were concerned 
about disclosing details of their own relationships. 
Wight and Abraham92 modified the intervention 
because of this, but this was judged partially to 
undermine the effectiveness of the intervention. 
The question of age appropriateness also arose in 
the study conducted by Borgia and colleagues,51 
who report that the ‘work groups’ that evaluated 
their programme judged it to be more suitable for 
younger populations (the participants in this study 
were 17–18 years of age).
However, if content can be successfully matched 
to the age of the participants, a related issue is 
appropriate timing: at what age should school-
based sex education start? Stephenson and 
colleagues50 reported that more than half of 
students in both arms of their trial – who were 
the same age as the pupils in the SHARE trial 
evaluated by Wight and colleagues70 – would have 
liked their sex education earlier, although it is not 
reported when exactly they would have liked it to 
start.
Discomfort
One final reason why the interactive, skills-building 
exercises in the SHARE intervention failed was the 
evident discomfort felt by pupils in engaging with 
issues relating to sex in a classroom setting. This 
discomfort expressed itself either in disruptive 
hilarity or in embarrassment. Wight and Abraham92 
comment: ‘An important underlying problem 
was the embarrassment pupils felt at having to 
improvise sexual roles with a class mate under 
peer surveillance. The anticipated interpersonal 
consequences of having one’s words and actions 
attributed to oneself rather than one’s character 
inhibited acting-the-part and reflecting on 
the scripts in the abstract.’ (p. 33). So the very 
element of the intervention that was considered 
by the developers to be its ‘active ingredient’ – 
the interactive nature of many of the sessions – 
combined with the sensitive subject matter, in fact 
worked against its success in a classroom context.
Summary of process synthesis 
findings
•  Fidelity of implementation  Three of the process 
evaluations (including the two most extensive 
evaluations – Stephenson and colleagues50 and 
Wight and colleagues70) reported variation 
in fidelity of implementation. In some cases, 
fidelity was greatly compromised.
•  School culture  School culture (the involvement 
and commitment of key stakeholders, 
management support, the prioritisation 
of PSHE, overall morale) was vital in 
providing an accommodating context for the 
implementation of the intervention. Again, this 
was found to vary widely across schools.
•  School administration  Staff absence and 
turnover, timetabling issues and shortage of 
time acted as important barriers to fidelity of 
implementation.
•  Teachers – enthusiasm, expertise, autonomy  Wight 
and colleagues70 found that enthusiasm, 
expertise and autonomy of teachers were 
vital to the delivery of the intervention. 
Despite thorough and highly acceptable 
training, teachers often failed to engage 
with the more interactive elements of the 
SHARE intervention and with the theory that 
underpinned it.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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•  Peers  Selection of peers with the qualities 
that make an effective leader was important; 
this did not always happen. Some of the 
peer leaders were found to lack enthusiasm, 
organisation and the skills to manage and 
engage participants.
•  Parents  It is feasible to involve parents in 
homework tasks, but less so in attendance of 
on-site activities.
•  Health educators/facilitators  The studies did 
not report on the impact on fidelity of 
implementation of employing health educators 
or other facilitators.
•  Computer  The one study66 that used a computer 
to deliver the intervention reported high 
fidelity of implementation.
•  Content appeal  It is both feasible and important 
to develop sexual health interventions with 
content that is highly acceptable to young 
people. However, acceptability alone does not 
guarantee effectiveness.
•  Provider qualities  It is vital to the success of 
any skills-based intervention that providers, 
whether teachers, peers or other facilitators, 
have sufficient expertise to deliver the 
intervention effectively. Process evaluations 
showed that this was not the case in many of 
the interventions reported on.
•  Meeting needs  It is less likely that interventions 
will impact on behaviour if they do not meet 
young people’s self-identified needs. According 
to Stephenson and colleagues,50 in the case of 
sex education these include sexual feelings, 
emotions and relationships, which were often 
addressed only partially or not at all.
•  Gendered norms  Gendered norms, especially 
the pressure on boys to conform to accepted 
notions of masculinity, inhibit and disrupt 
discussion of sexual issues in the classroom. 
Mixed-sex groups were more successful for 
boys than single-sex groups.
•  Age/timing  Some of the reviewed interventions 
were not age appropriate, either because they 
were felt to be more suitable for a younger age 
group or – due to the sexual inexperience of 
the participants – an older one.
•  Discomfort  Pupils can experience discomfort in 
engaging with interactive interventions in the 
classroom relating to sexual behaviour.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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Introduction
A systematic review was conducted of the literature 
to identify economic evaluations of behavioural 
interventions to prevent STIs in young people. The 
purpose was to assess the current evidence base for 
the cost-effectiveness of behavioural interventions, 
and whether there is a need for further economic 
modelling. If further modelling is necessary, the 
methods used in previous cost-effectiveness studies 
will be analysed and appraised to inform the most 
appropriate approach.
Methods for the systematic 
review
Search strategy
A systematic literature search was undertaken to 
identify economic evaluations for behavioural 
interventions for sexually transmitted interventions 
for young people. Sensitive search strategies 
were developed and tested by an experienced 
information scientist [see Appendix 10 for the 
MEDLINE (Ovid) search strategy]. These strategies 
were used to search the following electronic 
bibliographic databases:
•  The Cochrane Central Register of Controlled 
Trials (CCRCT) (Issue 1, 2008)
•  MEDLINE (via Ovid)
•  MEDLINE In-Process & Other Non-Indexed 
Citations (via Ovid) 
•  EMBASE (via Ovid)
•  Science Citation Index
•  NHS Economic Evaluation Database (NHS 
EED, via NIHR CRD)
•  Health Technology Assessment Database (via 
Cochrane Library)
•  Database of Abstracts of Reviews of 
Effectiveness (DARE) (via Cochrane Library)
•  Econlit
Searches were limited to the period 1990 to 
February 2008.
Inclusion criteria
Titles and (where available) abstracts of references 
identified by the search strategy were assessed 
for potential eligibility against inclusion criteria 
(Table 43) by a health economist. Full papers of 
those which appeared relevant on title or abstract 
were retrieved and independently screened by two 
health economists. Any differences in judgement 
were resolved through discussion.
The quality of these economic evaluations has been 
assessed using a standard checklist adapted from 
Drummond and Jefferson93 (Table 44).
Results
A total of 788 references were identified, of which 
21 full papers were retrieved. Most of these papers 
were excluded because the participants were above 
the upper age limit of the inclusion criteria. Five 
economic evaluations met the inclusion criteria. 
The characteristics and results of the evaluations 
are discussed in more detail below.
Table 45 provides a summary of the characteristics 
and base-case findings of the five published 
economic evaluations (for the results of these 
Chapter 6  
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TABLE 43  Inclusion criteria for the systematic review of cost-effectiveness studies
Inclusion criteria
Population Young people aged 13–19
Intervention Behavioural intervention, defined as: ‘Any activity to encourage young people to adopt sexual behaviours 
that will protect them from acquiring STIs’
Outcomes Cost per STI avoided; cost per QALY gained
Design Economic evaluations, modelling studiesSystematic review of cost-effectiveness studies
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studies, see Table 46). All estimated the cost-
effectiveness of interventions to prevent HIV, but 
only one considered other STIs.59 The studies 
varied in terms of the characteristics of the young 
people included. In terms of sexuality, one study 
included only young gay and bisexual men.94 In 
terms of ethnicity/race, one study included African-
American young people,95 whilst another included 
sub-Saharan African and South East Asian young 
people.96
Four of the studies were conducted in the 
USA59,60,94,95 and the remaining study was conducted 
in two regions: sub-Saharan African and South 
East Asia.96 Three of the studies reported the 
cost-effectiveness of specific interventions that 
had previously been evaluated in a trial or cohort 
study.59,94,95 The other two studies compared the 
cost-effectiveness of a range of interventions, 
including interventions for young people and 
adults.60,96 The duration of the interventions varied 
from 1 day to 2 years. The interventions were 
associated with favourable changes in the number 
of partners, or frequency of condom use.
Pinkerton and colleagues95 evaluated an RCT 
of an intensive one-day sexual risk-reduction 
intervention for African-American males. (Note: 
This trial, by Jemmott and colleagues, was 
included in our systematic review of effectiveness, 
see Chapter 4.43) The intervention was designed 
to increase knowledge of HIV/AIDS and reduce 
risky sexual behaviours and used videos, games, 
role plays and exercises to convey information. 
Participants in the control group attended a careers 
opportunities workshop. Wang and colleagues59 
evaluated a school-based education programme 
‘Safer Choices’ (also included in our systematic 
review of effectiveness).58 Tao and Remafedi94 
evaluated an intervention for gay or bisexual men, 
which included individual risk assessment and 
risk-reduction counselling, peer education and 
referral to further medical services as needed. 
The original study compared sexual behaviour 
4.5 months after the intervention with that at the 
initial risk assessment.97 Cohen and colleagues60 
evaluated a number of interventions for adults 
and young people. They evaluated school-based 
education,58 group counselling for youth98 and a 
youth supervision programme.99
All studies clearly defined the study question and 
explained the competing alternative. They each 
used the correct comparator and the patient 
group of interest was clearly stated. Furthermore, 
the study type appeared to be reasonable. All 
studies were conducted in the USA and so it is 
unclear how these studies relate to the UK NHS. 
The studies evaluated previous trials that had 
found the interventions to be effective. All studies 
estimated the cost-effectiveness of the intervention 
by considering the long-term discounted costs and 
consequences of HIV infection. Except for Hogan 
and colleagues,96 all studies presented sensitivity 
analyses to discuss the impact of key parameters on 
model results.
It is unclear whether the studies valued the costs 
and consequences appropriately. Except for the 
Wang and colleagues study, the studies did not 
include the effect of the intervention on infection 
from other STIs or on unintended pregnancy, 
and this will underestimate the effect of the 
intervention. There are a range of assumptions 
and parameter values used. In particular, 
transmission probability has a large effect on the 
results and the values used by Tao and Remafedi94 
and Wang and colleagues59 are much higher than 
the other studies. Finally, Wang and colleagues59 
have included the effects of reducing unintended 
pregnancy, but these results do not appear credible. 
Based on the results presented, the conclusions 
from three of the studies59,95,96 appear credible.
Hogan and colleagues96 evaluated several 
interventions in developing countries, including 
school-based education provided during regular 
lessons to all students. The effectiveness of this 
intervention was based upon an earlier review of 
the literature.100
Mathematical models were used to translate 
changes in sexual behaviour into the probability 
of HIV transmission. Four of the studies adapted 
a previously published model of HIV transmission 
(the ‘Bernoulli’ model101) to estimate the number 
of HIV infections averted in the subsequent 
year.59,60,95,96 Tao and colleagues94 developed a 
mathematical model to project the number of HIV 
infections averted over a 10-year period. All of 
the models predicted HIV cases averted following 
an intervention using parameters for number of 
sexual partners, number of sexual episodes, HIV 
prevalence and the probability of HIV transmission 
for an unprotected sexual episode. The sexual 
behaviour parameters were derived from evaluation 
of the interventions, for example an empirical 
study. The models incorporated the direct cost 
of the intervention, including staff training. The 
models differed in the way they dealt with medical 
and productivity costs. Three of the models 
included the medical costs for treating future HIV Systematic review of cost-effectiveness studies
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infections.59,94,95 Only one of the models included 
the loss in producti
vity costs.59 Three of the models estimated 
the QALYs associated with averting an HIV 
infection.94–96 The other two models estimated the 
cost per case of HIV averted.59,60
Estimation of outcomes within 
economic evaluations
Four of the studies used a model developed by 
Weinstein and colleagues.101 The Bernoulli model 
of HIV transmission is a cumulative probability 
equation that describes the probability of HIV 
infection based upon HIV prevalence (π), single act 
transmission probability (α), condom effectiveness 
(e) and condom use (f), number of sexual episodes 
(n) and number of sexual partners (m). For 
example, the estimated probability of an uninfected 
person becoming infected is P,
P ef
n
m
= − − + − − { } 1 1 1 1 ( ) | ( )| π π α
The model estimates the probability of becoming 
infected for the intervention and comparator 
groups according to changes in parameters that 
may be affected by the intervention, i.e. condom 
use, number of sexual partners and number of 
sexual episodes. The number of cases averted is 
estimated by multiplying the results by the number 
of people who receive the intervention.
Wang and colleagues59 estimated the probability 
of infection during a 3-month period and then 
converted this 3-month probability into a 1-year 
probability. They used the following equation to 
calculate the total number of cases averted for 
primary transmission:
X N P P
i c = − − − 


 ( ) ( ) 1 1
4 4
where X is the total number of cases averted, N is 
the number of uninfected students, and Pi and Pc 
are the probability of infection for the intervention 
and control groups, respectively.
In addition, the number of secondary transmissions 
is estimated. Secondary transmissions are those 
transmissions from infected intervention students 
to non-infected sexual partners. In this case the 
probability of infection, P, is
P ef
n = − − − 1 1 1 | ( )| α
where α is single act transmission probability, e is 
condom effectiveness, f is frequency of condom use 
and n is number of sexual episodes.
Pinkerton and colleagues95 used similar expressions 
to estimate the number of primary and secondary 
infections associated with anal intercourse. Cohen 
and colleagues60 used this model to estimate 
the cost-effectiveness of a range of behavioural 
interventions. In addition to HIV infections, Wang 
and colleagues used the equations presented 
to estimate the cases of other STI infections 
avoided, i.e. chlamydia, gonorrhoea and pelvic 
inflammatory disease. They also developed a 
pregnancy model to translate contraceptive use 
into cases of pregnancy averted.
Hogan and colleagues96 developed a mathematical 
model of HIV/AIDS, based on the Bernoulli model 
described above, combined with the progression 
from HIV to AIDS and AIDS to death and 
transmission of other STIs.
Tao and Remafedi94 used a dynamic mathematical 
model to estimate the cost-effectiveness of HIV 
prevention for gay and bisexual young people. 
They modelled HIV transmission by calculating 
changes in the number of risky partners (i.e. 
unprotected) and then projected quarterly 
prevalence of HIV in the target population for 
a control and intervention population over 10 
years. They assumed that without intervention, 
risky behaviour in the target population would not 
change during the 10-year period. Participants 
maintained less risky behaviour for only 1 year 
before relapsing to the previous level of risk. The 
target population was classified by participants, 
non-participants, infected and uninfected 
subgroups. The model calculated HIV prevalence 
after 10 years and used parameters for the number 
of risky partners, initial HIV prevalence, the 
probability of HIV transmission in each infected–
uninfected partnership, and the percentage of 
gay and bisexual adolescents recruited into the 
intervention.
The studies used a range of values for the input 
parameters. HIV prevalence rates varied between 
0.1% and 0.6% for US heterosexual adolescents, 
and 2% for gay and bisexual adolescents in 
the USA. The probability of transmission 
of HIV varied between 0.1% to 1.6% for US 
heterosexual adolescents and 6% for gay and 
bisexual adolescents. The increase in condom use 
varied between 11% and 24% for heterosexual 
adolescents, with a 50% increase in gay and DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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bisexual individuals. Wang and colleagues59 did not 
report any change in the number of sexual partners 
and episodes, whilst Pinkerton and colleagues95 
found intervention participants engaged in vaginal 
intercourse on less than half the number of days 
and with half the number of partners.
Estimation of quality-adjusted 
life-years
Tao and Remafedi94 and Pinkerton and colleagues95 
estimated that 16.9 QALYs and 14 QALYs, 
respectively, would be lost by an HIV-infected 
young person based on previous work by Holtgrave 
and colleagues.102 These estimates were based upon 
the person receiving standard HIV-related medical 
treatment (including antiretroviral treatment). 
Hogan and colleagues96 used a life expectancy 
estimate of between 8.5 and 16 years with HIV for 
males, depending on whether or not they received 
treatment.
Estimation of costs
Each of the studies estimated the intervention 
costs, including staff training, renting space, 
condoms, administration and monetary incentives 
for the participants. Wang and colleagues estimated 
costs of US$26 per participant, Pinkerton and 
their colleagues £89. Tao and Remafedi94 reported 
much higher costs of over US$440 per participant. 
The costs for the group counselling and youth 
supervision programmes in the study by Cohen 
and colleagues60 were US$300 and US$57 per 
participant, respectively. Hogan and colleagues96 
reported annual costs of school-based education 
from US$58M to US$77M for 50–95% coverage 
in the sub-Saharan Africa region. The differences 
in the costs were mainly due to staffing costs. For 
example, Tao and Remafedi94 employed several 
staff, including a full-time case manager, two 
directors, a secretary and field worker at a total cost 
of US$184,006, in order to provide an intervention 
for about 500 participants. On the other hand, 
Wang and colleagues included costs for only 
teaching, teacher training and site co-ordination 
costs at a total cost of US$85,599 for almost 4000 
participants.
Three of the studies included the cost of future 
medical care for HIV in the cost-effectiveness 
analyses. Wang and colleagues59 and Pinkerton 
and colleagues95 applied discount rates of 5% and 
3%, respectively, to estimate the cost of medical 
care based on a previous study by Holtgrave and 
colleagues. The cost used for future medical HIV 
care varied between US$78,425 and US$195,188 
per person with HIV. Wang and colleagues59 also 
estimated the medical costs for chlamydia and 
gonorrhoea treatments, based upon costs from the 
public sector analysis from the California Medicaid 
Program. Wang and colleagues estimated the social 
cost of HIV infection in terms of lost productivity 
or foregone wages of US$430,000 per patient. It 
included the costs of earning-related outcomes, 
public assistance and other consequences.
Comparison of results
The base-case results of the cost-effectiveness 
studies are presented in Table 46. A comparison of 
the studies shows a wide range of cost-effectiveness 
estimates depending upon the assumptions and 
parameter values used. For example, Cohen and 
colleagues60 found one of the interventions (‘Safer 
Choices’) to be not cost-effective, with a cost per 
case averted > US$39M. In contrast, Wang and 
colleagues59 found the same intervention to be 
cost saving. Wang and colleagues included the 
effect of other STIs and unintended pregnancy. 
In particular, unintended pregnancy had a large 
effect on the results, with the medical and social 
costs for pregnancy comprising over half the 
total averted costs. However, the effects of the 
intervention in preventing pregnancy appear to 
have been overestimated. They estimated that 18.5 
pregnancies were prevented in 345 ninth-grade 
students (aged 14–15), but this is likely to be higher 
than the conception rate in this age group. The 
under-16 conception rate for England in 2005 was 
7.7 per 1000 girls aged 13–15. Furthermore, there 
were differences between the studies for the values 
for the probability of HIV transmission from 0.001 
to 0.016.
Several of the studies conducted sensitivity 
analyses on the main model parameters. The most 
influential parameters were found to be baseline 
HIV prevalence, baseline number of risky partners, 
cost per person reached by the intervention, 
duration of the effect of the intervention and the 
single sex act transmission rate.
Published economic evaluations – 
summary of methods
A systematic review of cost-effectiveness studies 
identified five economic evaluations of behavioural 
interventions for prevention of HIV, published 
between 1998 and 2005. Only one study evaluated 
other STIs in addition to HIV. All studies used 
mathematical models extrapolating the changes Systematic review of cost-effectiveness studies
74
T
A
B
L
E
 
4
6
 
B
a
s
e
-
c
a
s
e
 
r
e
s
u
l
t
s
 
a
n
d
 
c
o
n
c
l
u
s
i
o
n
s
 
o
f
 
t
h
e
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
n
e
s
s
 
s
t
u
d
i
e
s
A
u
t
h
o
r
T
a
o
 
a
n
d
 
R
e
m
a
f
e
d
i
9
4
W
a
n
g
 
e
t
 
a
l
.
5
9
P
i
n
k
e
r
t
o
n
 
e
t
 
a
l
.
9
5
C
o
h
e
n
 
e
t
 
a
l
.
6
0
H
o
g
a
n
 
e
t
 
a
l
.
9
6
B
a
s
e
-
c
a
s
e
 
r
e
s
u
l
t
s
1
6
.
9
 
Q
A
L
Y
s
 
s
a
v
e
d
 
p
e
r
 
H
I
V
 
i
n
f
e
c
t
i
o
n
 
a
v
e
r
t
e
d
T
o
t
a
l
 
i
n
t
e
r
v
e
n
t
i
o
n
 
c
o
s
t
s
 
i
n
c
l
u
d
i
n
g
 
m
e
d
i
c
a
l
 
t
r
e
a
t
m
e
n
t
 
w
e
r
e
 
U
S
$
1
.
1
M
 
f
o
r
 
1
0
 
y
e
a
r
s
I
C
E
R
 
w
a
s
 
p
r
o
j
e
c
t
e
d
 
t
o
 
U
S
$
6
1
8
0
 
p
e
r
 
Q
A
L
Y
 
s
a
v
e
d
0
.
1
2
 
c
a
s
e
s
 
o
f
 
H
I
V
,
 
2
4
.
3
7
 
c
a
s
e
s
 
o
f
 
c
h
l
a
m
y
d
i
a
,
 
2
.
7
7
 
c
a
s
e
s
 
o
f
 
g
o
n
o
r
r
h
o
e
a
,
 
5
.
8
6
 
c
a
s
e
s
 
o
f
 
P
I
D
 
a
n
d
 
1
8
.
5
 
p
r
e
g
n
a
n
c
i
e
s
 
p
r
e
v
e
n
t
e
d
I
n
t
e
r
v
e
n
t
i
o
n
 
w
a
s
 
c
o
s
t
 
s
a
v
i
n
g
,
 
w
i
t
h
 
U
S
$
2
.
6
5
 
s
a
v
e
d
 
f
o
r
 
e
v
e
r
y
 
d
o
l
l
a
r
 
s
p
e
n
t
 
o
n
 
t
h
e
 
p
r
o
g
r
a
m
m
e
0
.
8
 
o
f
 
a
n
 
i
n
f
e
c
t
i
o
n
 
a
v
e
r
t
e
d
 
a
n
d
 
s
a
v
e
d
 
0
.
1
 
Q
A
L
Y
 
a
t
 
c
o
s
t
 
o
f
 
U
S
$
7
5
4
8
A
v
e
r
t
e
d
 
U
S
$
1
4
7
8
 
i
n
 
f
u
t
u
r
e
 
m
e
d
i
c
a
l
 
c
a
r
e
C
o
s
t
–
u
t
i
l
i
t
y
 
r
a
t
i
o
 
w
a
s
 
U
S
$
5
7
,
0
0
0
 
p
e
r
 
Q
A
L
Y
 
s
a
v
e
d
 
w
h
e
n
 
t
r
a
i
n
i
n
g
 
c
o
s
t
s
 
i
n
c
l
u
d
e
d
 
a
n
d
 
U
S
$
4
1
,
0
0
0
 
p
e
r
 
Q
A
L
Y
 
s
a
v
e
d
 
w
h
e
n
 
t
h
e
y
 
w
e
r
e
 
e
x
c
l
u
d
e
d
C
a
s
e
s
 
H
I
V
 
p
r
e
v
e
n
t
e
d
:
S
c
h
o
o
l
-
b
a
s
e
d
 
e
d
u
c
a
t
i
o
n
 
0
.
0
0
2
7
;
 
g
r
o
u
p
 
c
o
u
n
s
e
l
l
i
n
g
 
f
o
r
 
y
o
u
t
h
 
0
.
0
0
4
4
;
 
y
o
u
t
h
 
s
u
p
e
r
v
i
s
i
o
n
 
p
r
o
g
r
a
m
m
e
 
0
.
0
0
2
3
C
o
s
t
 
p
e
r
 
p
e
r
s
o
n
 
(
U
S
$
)
:
S
c
h
o
o
l
-
b
a
s
e
d
 
e
d
u
c
a
t
i
o
n
 
U
S
$
3
0
5
G
r
o
u
p
 
c
o
u
n
s
e
l
l
i
n
g
 
f
o
r
 
y
o
u
t
h
 
U
S
$
3
0
0
Y
o
u
t
h
 
s
u
p
e
r
v
i
s
i
o
n
 
p
r
o
g
r
a
m
m
e
 
U
S
$
5
7
C
o
s
t
 
p
e
r
 
H
I
V
 
c
a
s
e
 
a
v
e
r
t
e
d
 
(
U
S
$
)
:
S
c
h
o
o
l
-
b
a
s
e
d
 
e
d
u
c
a
t
i
o
n
 
U
S
$
3
9
M
G
r
o
u
p
 
c
o
u
n
s
e
l
l
i
n
g
 
f
o
r
 
y
o
u
t
h
 
U
S
$
1
5
M
Y
o
u
t
h
 
s
u
p
e
r
v
i
s
i
o
n
 
p
r
o
g
r
a
m
m
e
 
U
S
$
6
.
2
M
F
o
r
 
A
f
r
i
c
a
n
 
r
e
g
i
o
n
:
Y
e
a
r
l
y
 
i
n
f
e
c
t
i
o
n
s
 
a
v
e
r
t
e
d
 
(
m
i
l
l
i
o
n
s
)
 
0
.
0
1
Y
e
a
r
l
y
 
c
o
s
t
s
 
(
U
S
$
 
m
i
l
l
i
o
n
s
)
 
5
8
 
a
t
 
5
0
%
 
c
o
v
e
r
a
g
e
C
o
s
t
-
e
f
f
e
c
t
i
v
e
n
e
s
s
 
r
a
t
i
o
 
o
f
 
U
S
$
5
3
0
 
p
e
r
 
D
A
L
Y
 
a
v
e
r
t
e
d
A
u
t
h
o
r
’
s
 
c
o
n
c
l
u
s
i
o
n
s
T
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
 
w
a
s
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
 
e
v
e
n
 
t
h
o
u
g
h
 
t
h
e
 
e
f
f
e
c
t
s
 
o
n
 
b
e
h
a
v
i
o
u
r
 
w
e
r
e
 
p
a
r
t
i
a
l
 
a
n
d
 
s
h
o
r
t
 
t
e
r
m
S
c
h
o
o
l
-
b
a
s
e
d
 
p
r
e
v
e
n
t
i
o
n
 
p
r
o
g
r
a
m
m
e
s
 
s
h
o
u
l
d
 
b
e
 
c
o
n
s
i
d
e
r
e
d
 
b
y
 
p
o
l
i
c
y
-
m
a
k
e
r
s
T
h
e
 
a
u
t
h
o
r
s
 
s
u
g
g
e
s
t
 
s
e
l
e
c
t
i
v
e
l
y
 
i
m
p
l
e
m
e
n
t
i
n
g
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
 
i
n
 
h
i
g
h
-
r
i
s
k
 
H
I
V
 
p
r
e
v
a
l
e
n
c
e
 
c
o
m
m
u
n
i
t
i
e
s
C
o
m
p
a
r
i
n
g
 
e
s
t
i
m
a
t
e
s
 
o
f
 
t
h
e
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
n
e
s
s
 
o
f
 
H
I
V
 
i
n
t
e
r
v
e
n
t
i
o
n
s
 
p
r
o
v
i
d
e
s
 
i
n
s
i
g
h
t
 
t
h
a
t
 
c
a
n
 
h
e
l
p
 
l
o
c
a
l
 
c
o
m
m
u
n
i
t
i
e
s
 
m
a
x
i
m
i
s
e
 
t
h
e
 
i
m
p
a
c
t
 
o
f
 
t
h
e
i
r
 
H
I
V
 
p
r
e
v
e
n
t
i
o
n
 
r
e
s
o
u
r
c
e
s
S
c
h
o
o
l
-
b
a
s
e
d
 
e
d
u
c
a
t
i
o
n
 
i
s
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
 
a
c
c
o
r
d
i
n
g
 
t
o
 
i
n
t
e
r
n
a
t
i
o
n
a
l
 
b
e
n
c
h
m
a
r
k
s
D
A
L
Y
,
 
d
i
s
a
b
i
l
i
t
y
-
a
d
j
u
s
t
e
d
 
l
i
f
e
-
y
e
a
r
;
 
I
C
E
R
,
 
i
n
c
r
e
m
e
n
t
a
l
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
n
e
s
s
 
r
a
t
i
o
.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
75
in sexual behaviour to number of cases of HIV 
averted. With the exception of one study for 
developing countries, all studies evaluated the 
interventions on a US population. All interventions 
were effective at encouraging safer sexual 
behaviour and were estimated to avert cases of HIV 
transmission through modelling. There was a range 
in assumptions and parameter values used in the 
mathematical models, and this led to substantial 
differences in the estimated cost-effectiveness 
of the behavioural interventions. Therefore, no 
existing model was appropriate for this study and 
so we developed a de novo model.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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A
n economic model was developed to assess the 
cost-effectiveness of behavioural interventions. 
The following subsections outline the components 
of this economic evaluation, including the structure 
of the economic model, the sources of information 
for costs and benefits, and results of the analysis.
Selecting a model type
There has been much debate in the literature on 
the most appropriate types of economic model 
to assess the cost-effectiveness of interventions to 
prevent STIs, particularly chlamydia screening.103 
In this section, we discuss the advantages and 
disadvantages of the different types of model.
A review of guidelines for good practice in 
decision-analytic modelling in health technology104 
concluded that ‘Most experts agree that a model 
should be as simple as possible to address 
adequately the decision problem’ (p. 10). Barton 
and colleagues105 and Cooper and colleagues106 
provide overviews of the reasons for selecting 
between the different modelling techniques. 
They advocate the use of decision trees and 
Markov chains where possible, and recommend 
that discrete event simulation (DES) be used if 
the interaction between individuals or between 
individuals and the environment is important. DES 
is a powerful technique for modelling complex and 
dynamic systems.107,108 It can describe interactions 
when, for example, the use of resources is 
dependent on decisions about individuals 
or interaction between individuals or when 
comparing different queuing systems or identifying 
bottlenecks in a system.106,108 However, DES models 
often require more data than other models and are 
more computationally complex.
Static versus dynamic modelling
In the epidemiology of infectious diseases, the 
force of infection is the rate at which susceptible 
individuals become infected. Vaccination against 
infectious disease not only reduces the incidence 
of disease in those immunised, but also indirectly 
protects non-immunised susceptible people,109 a 
concept known as herd immunity. Static models 
assume a constant force of infection and cannot 
take into account reinfection. On the other hand, 
dynamic models are able to capture herd immunity 
effects.
Barham and colleagues26 systematically reviewed 
and critically appraised the economic evaluation 
of one-to-one interventions to reduce STIs and 
teenage conceptions. The review was conducted 
to underpin NICE’s guidance in this area.22 The 
majority of studies examined the cost-effectiveness 
of chlamydia and HIV screening programmes 
in various settings. There were fewer published 
studies of other STIs, and of behavioural 
interventions. The vast majority of studies used 
static modelling techniques. However, three studies 
(out of 55) employed dynamic approaches for the 
cost-effectiveness of chlamydia screening.
Welte and colleagues110 compared a dynamic 
(stochastic network simulation model) with a 
static (decision–analysis) model for evaluating an 
opportunistic screening programme for chlamydia. 
The dynamic model required much more detailed 
data about sexual behaviour and the infectious 
disease than the static model, such as duration 
of partnerships, frequency of sexual intercourse 
in partnerships and transmission probability per 
sexual episode. It produced results that were more 
favourable in terms of cost-effectiveness than the 
static model.
Welte and colleagues110 suggest that dynamic, 
rather than static, models are appropriate for 
the economic evaluation of chlamydia screening 
programmes that might affect the force of 
infection. They state that static models have 
frequently been applied in the past, and these did 
not include the risk of reinfection resulting from 
failed partner referral (Table 47). The only reasons 
against using the dynamic approach were its higher 
complexity, data demand, time and monetary 
costs and need of mathematical modelling 
expertise. On the other hand, static models might 
be the preferred option for estimating the cost-
effectiveness of screening programmes that have no 
impact on the force of infection.
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TABLE 47  Advantages and disadvantages of dynamic versus static modelling for Chlamydia trachomatis prevention (from Welte and 
colleagues110)
Dynamic model Static model
Advantages Takes the infectious character of chlamydia 
appropriately into consideration
Includes the effect of screening on the force of 
infection
Enables the full inclusion of indirect protection 
effects
Enables the assessment of the optimal screening 
duration and target group
Requires fewer data
Can be built quickly at low cost
Easy to understand
Disadvantages Requires detailed data about sexual behaviour 
that are often not available
Very time consuming to build and thus more 
expensive
Rather complex and thus more difficult to 
understand
Limited consideration of the infectious character of 
chlamydia
Assumes constant force of infection
Indirect protection effects are very limited
May render incorrect results with respect to optimal 
screening duration and target group
Recommended 
uses
Prevention measures that have an impact on the 
chlamydia incidence in the population, such as 
large-scale screening programmes
Prevention measures that have no impact on the 
chlamydia incidence in the population
Kretzschmar and colleagues111 developed a 
stochastic simulation model for chlamydia 
screening in the Netherlands. They made several 
assumptions to derive data for the model and 
had limited knowledge about disease-specific 
parameters, such as the probability of transmission 
per sexual episode, the average duration 
of the infectious period, and the fraction of 
asymptomatically infected persons. They suggested 
that their results should be interpreted mainly in 
a qualitative sense and not too much importance 
should be attached to the absolute numbers due to 
the uncertainties in parameter values.
Roberts and colleagues,103 funded by the NIHR 
HTA programme, reviewed economic evaluations 
of various forms of chlamydia screening. They 
found that the majority of studies, all since 2000, 
had used static models. They suggested that 
this reflects the view that the simplicity of static 
models outweighs the limitations of violating the 
assumption of independence. They recommended 
the use of either DES or system dynamics models 
which provide more realistic representations 
of complex systems. These models ‘can take 
into account the full economic consequences 
of interpersonal interactions’ (p. 198). These 
interactions mean that the risk of infection 
depends upon the background STI prevalence, 
and that screened and treated individuals will 
not transmit infection but are susceptible to re-
infection. Screened partners that remain untreated 
can also continue to transmit infection.
Turner and colleagues112 developed a stochastic, 
individual-based network model to evaluate the 
effectiveness of opportunistic chlamydia screening 
(‘The National Chlamydia Screening Programme’). 
They chose to use an individual-based dynamic 
model because population-based models ‘fail 
to capture important individual level effects in 
the sexual network. For example, reinfection 
is dependent on the infection and treatment 
status of current partners, not the average level 
of infection in the community’ (p. 4). For many 
of the model parameters the values were highly 
variable, the parameters of interest could not be 
measured directly or few data were available at 
all. They estimated some of these parameters by 
fitting the model to data. Several parameters were 
unknown: the proportion of individuals desiring 
short partnerships, the proportion of individuals 
changing from wanting short partnerships to 
long partnerships each year, the average duration 
of long partnerships, the annual increase in 
preferred partnership duration and the average 
gap between partnerships. Other parameters that 
were subject to high uncertainty were duration of 
chlamydial infection and transmission probability, 
the proportion seeking treatment and the level of 
partner notification.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
79
Low and colleagues25 developed a dynamic 
model to estimate the cost-effectiveness of active 
population screening for chlamydia. The model 
took into account the effects of ageing and 
replacement (i.e. new young people entering the 
model), partnership formation and dissolution, 
chlamydia transmission and progression, testing 
and treatment, and the complications from 
chlamydia. The authors stated there were no 
data available on the activity groups to estimate 
the propensity to form new partnerships and the 
mixing between activity groups. Instead of direct 
incorporation of data as input parameters, it was 
necessary to adjust the input parameters until a 
reasonable fit to the available data were obtained.
The two models developed for chlamydia 
screening provided very different estimations of 
cost-effectiveness, even though both used similar 
modelling methods (£1350112 versus £26,00025 
per major outcome avoided). The differences 
between these models were due to differences in 
assumptions and data values, and these differences 
far exceed the difference shown comparing the 
results from static and dynamic models (Welte and 
colleagues110).
Discussion and key points
Modelling guidelines suggest that DES is suitable 
for modelling disease process when interaction 
between individuals is important. However, almost 
all previously published studies have used a static 
approach. Dynamic models are considerably 
more complicated, time consuming and require 
more data, which is often not available. Much of 
the discussion on type of modelling has focused 
upon chlamydia screening, as opposed to primary 
prevention, and even in these studies there were 
few data for key model parameters. The additional 
time, expense, and complexity involved in dynamic 
modelling may not actually provide a gain in 
precision.
In view of these points, and the lack of impact of 
school-based behavioural interventions on sexual 
behaviour (and therefore the low probability of 
altering rates of infection) demonstrated in our 
systematic review, we chose to construct a static 
economic model to explore the potential cost-
effectiveness of behavioural interventions under 
various assumptions.
Methods for cost-
effectiveness modelling of 
behavioural interventions 
for prevention of STIs in 
young people
Overview
A comparison of the costs and benefits of 
behavioural interventions for the prevention of 
STIs in young people was made using decision-
analytic models.
The cost-effectiveness of two types of school-based 
behavioural intervention were assessed:
1.  A teacher-led curriculum, spread over 20 
sessions (based on the Scottish SHARE trial70).
2.  A brief peer-led classroom curriculum, spread 
over three sessions (based on the RIPPLE trial 
in Central and Southern England50).
Both interventions provide factual information 
about STIs in addition to the teaching of skills 
associated with the practice of safer sex. These 
two interventions were considered to be broadly 
representative of the interventions included in our 
systematic review. However, they were prioritised 
for economic modelling because, in terms of 
costs and resources, they were considered to be 
more reflective of UK practice than many of the 
other (mostly US) studies in our review. This is 
particularly the case for the SHARE programme, 
which has been implemented by NHS Health 
Scotland.
The comparator was standard sexual health 
education, which is generally provided by teachers 
in schools as part of the PSHE curriculum. In 
the studies included in our systematic review of 
effectiveness (Chapter 4), standard sexual health 
education tended to provide basic information on 
STIs and sexual health, but did not teach skills. It is 
therefore the teaching of safer sex skills and other 
broader activities that distinguishes between the 
behavioural intervention and standard education.
Models were constructed in Microsoft excel 
according to standard modelling methods 
(NICE113). To identify data to populate the model, 
systematic searches were conducted to locate 
studies on the natural history and epidemiology 
of STIs, sexual behaviour and lifestyles, HRQoL, 
and costs. Various websites of relevant organisations Economic evaluation
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were also searched (e.g. HPA) and contact made 
with experts to identify data.
The quality of data used for the model varied. 
Generally, there were few data for children aged 
under 18 years old, and, where there were no 
data, assumptions were made from existing 
data. The baseline clinical data were estimated 
from administrative databases for the UK, and 
prospective studies. The HRQoL data have been 
taken from previous utility studies using validated 
tools for groups of patients with the condition of 
interest.
Costs were derived from published studies (where 
available), and from national and local NHS unit 
costs. Only direct NHS and PSS costs were included 
and hence the model was from the perspective of 
the NHS and PSS.
In the model, the intervention effects last for 
1 year, on the basis that the majority of the 
trials included in our systematic review assessed 
outcomes up to 1 year (see Chapter 4, Length 
of follow-up). The model estimates the lifelong 
costs and benefits from averted STI cases. The 
intervention effect (condom use) was derived from 
the systematic review of effectiveness reported 
in Chapter 4. The economic evaluation focused 
on estimating the number of cases of STI and 
associated complications averted. The outcome is 
reported as cost per QALY gained.
Model structure
We adapted the Bernoulli model, previously 
developed by Weinstein and colleagues,101 as it 
estimates the effect of changes in sexual behaviour 
in terms of STIs averted. This model has been 
described earlier in Chapter 6 (see Results). 
The Bernoulli model of HIV transmission is a 
cumulative probability equation that describes 
the probability of HIV infection based upon HIV 
prevalence (π), single act transmission probability 
(α), condom effectiveness (e) and condom use 
(f), number of sexual episodes (n), and number 
of sexual partners (m). The equation described 
in Chapter 6 is an approximation to the original 
equation, but this approximation is only close 
when the proportion of condom use is either very 
low or extremely high, or when the infectivity is 
minimal (α < 0.001). Consequently, that equation 
is not appropriate for chlamydia, gonorrhoea and 
genital warts. For this reason we split the equation 
for condom users (c) and non-condom users (nc) 
so that, the estimated probability of an uninfected 
person becoming infected is P = fPc + (1 – f)Pnc, 
where risk for a condom user Pc is:
P e
c
n
m
= − − + − − { } 1 1 1 1 ( ) | ( )| π π α
and risk for a non-condom user, Pnc is,
P
n
m
nc = − − + − { } 1 1 1 ( ) | | π π α
The model estimates the probability of becoming 
infected for the intervention and comparator 
groups according to changes in parameters that 
may be affected by the intervention, i.e. condom 
use, number of sexual partners and number of 
sexual episodes. The number of cases averted is 
estimated by multiplying by the number of people 
who receive the intervention.
These cases averted, in turn, would have infected 
further individuals, i.e. through secondary 
transmission. The estimated probability of 
an uninfected person becoming infected is 
P = fPc + (1 – f)Pnc, where risk for a condom user Pc 
is,
P m e
c
n = − − − − ( )| ( ( )| ) 1 1 1 1 π α
and risk for a non-condom user, Pnc is,
P m
n
nc = − − − ( )| ( )| ) 1 1 1 π α
The number of cases averted through secondary 
transmission is estimated by multiplying the risk of 
becoming infected by the number of cases averted 
through primary transmission.
The model estimates the number of STI 
cases averted for HIV and also for chlamydia, 
gonorrhoea and genital warts, according to the risk 
of infection as shown above and the proportion 
of sexually active individuals who receive the 
intervention. For each STI case averted there was a 
HRQoL loss and resource use cost associated due 
to complications, such as PID or infertility. The 
data and assumptions used to derive the model 
parameters are described in the following sections.
The total number of STI cases averted, and 
consequent QALY gain, cost of the intervention 
and the saving in medical costs is estimated for 
males and females for all STIs for 1 year. Thus the 
cost-effectiveness is calculated,
Cost-effectiveness
Cost of
intervention
– ( )
Saving in
medical costs
QALYs gained
=DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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The cost-effectiveness results are shown later (see 
Results of the modelling, below). For the base-case 
analysis, a cohort of children aged 15 years old 
receive the teacher-led intervention.
Assessment of uncertainty
The evaluation of the cost-effectiveness of 
behavioural interventions for preventing STIs is 
based on uncertain information about variables, 
such as clinical effect, HRQoL and resource use. 
This uncertainty was evaluated using deterministic 
and probabilistic sensitivity analyses. One-way 
deterministic sensitivity analyses were conducted 
to evaluate the influence of individual parameters 
on the model results and test the robustness of 
the cost-effectiveness results to variations in the 
structural assumptions and parameter inputs (see 
Sensitivity analysis).
Multiparameter uncertainty in the model was 
addressed using probabilistic sensitivity analysis 
(PSA) (see Probabilistic sensitivity analysis).114 In 
PSA, probability distributions are assigned to the 
point estimates used in the base-case analysis. The 
model is run for a number of iterations (in this case 
1000) according to a different set of parameter 
values, using Monte Carlo simulation methods, 
to give a range of results. The main parameters 
were varied according to the ranges used in the 
one-way deterministic sensitivity analysis. For 
each iteration, parameter values are sampled at 
random from their probability distributions. The 
uncertainty surrounding the cost-effectiveness of 
the behavioural intervention is represented on 
a cost-effectiveness acceptability curve (CEAC) 
according to the probability that the intervention 
will be cost-effective at a particular willingness-to-
pay threshold. Appendix 11 reports the parameters 
included in the PSA, the form of distribution used 
for sampling each parameter, and the upper and 
lower limits assumed for each variable.
Finally, value of information analyses were 
conducted to investigate the expected pay-off from 
further research (see Expected value of perfect 
information for the prevention of STIs).114,115 When 
decisions are based on imperfect or uncertain 
information, there is a risk that a wrong decision 
will be made and there will be a loss in costs and 
health benefits. The expected value of perfect 
information (EVPI) shows the value of reducing the 
uncertainty around the decision of whether or not 
to adopt the intervention. The EVPI is estimated 
for different cost-effectiveness thresholds and this 
gives an indication of an upper bound for further 
research at these thresholds. In order to determine 
where further research would have the most effect 
in reducing uncertainty, a partial EVPI (EVPPI) 
is conducted. In this analysis, the uncertainty 
around particular input parameters in the model is 
investigated.
Data synthesis
STI epidemiology
STI incidence rate
Table 48 shows the incidence rates for young people 
in GUM clinics in the UK in 2006. The diagnosis 
rates of STIs are likely to be an underestimation 
of the true rate of infection incidence, given that 
for many infections, such as chlamydia and HIV, 
a proportion of asymptomatic infections remain 
undiagnosed. In addition, not all young adults are 
diagnosed in the GUM clinic setting. Furthermore, 
we are interested in the prevalence of each of these 
conditions.
We decided that it was not realistic to include 
syphilis or genital herpes in the model. This is due 
to their relatively lower incidence, and the paucity 
of data on their epidemiology and natural history, 
particularly long-term complications. Few other 
economic evaluations have attempted to model the 
effectiveness of preventing these STIs.
Chlamydia
Chlamydia is the most commonly diagnosed 
bacterial STI in UK GUM clinics, constituting 30% 
of all new STI diagnoses in 2006. At least 70% of 
women and 50% of men with chlamydia infections 
show no symptoms and may remain undiagnosed 
TABLE 48  STI incidence from HPA GUM diagnoses in the UK per 100,000 population in 2006116
Age (years)
Chlamydia Gonorrhoea Genital warts
Male Female Male Female Male Female
< 16 13.1 121 2.5 15.5 8.2 54.8
16–19 544 1337 100.6 127.6 296.8 787.4Economic evaluation
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in the absence of screening for asymptomatic 
infection.8
The Department of Health in England has 
commenced the NCSP, which opportunistically 
screens for chlamydia in sexually active young 
men and women attending a range of health-care 
services, including general practice and family 
planning clinics, regardless of whether they have 
symptoms.117 The prevalence of chlamydia in 
England in 2003–4 was 10.0% and 12.1% among 
men and women aged 16–19 years old, and 1.5% 
and 7.5% among men and women less than 16 
years old, respectively117 (Table 49).
The Uppsala Women’s Cohort study118 analysed 
data from 43,715 women in Uppsala, Sweden, aged 
15–24 years. It was estimated that the cumulative 
incidence of chlamydia-associated complications 
by age 35 for those women who tested positive for 
chlamydia would be 5.6%, 2.7% and 6.7% for PID, 
ectopic pregnancy and infertility, respectively (Table 
50). The authors noted that estimates from this 
study were lower than found in previous hospital- 
and clinic-based studies.
We used an estimate, from Ness and colleagues,119 
that 34% of women with PID had long-term 
chronic pelvic pain. Trei and colleagues120 
estimated the incidence of orchitis/epididymitis, 
prostatitis, infertility and urethral stricture among 
male US Air Force officers with and without 
prior chlamydia infections. Among chlamydia-
positive men, the cumulative incidence of orchitis/
epididymitis was 4.28%.
The data for transmission probability was generally 
of poor quality, based upon old case series. The 
transmission probability of chlamydia has been 
estimated to range from 0.0375112 to 0.4559 per 
sex episode, and from 0.2122 to 0.68123,124 per 
sexual relationship. Quinn and colleagues124 
determined the frequency of Chlamydia trachomatis 
genital infection within sexual partnerships 
using highly sensitive polymerase chain reaction 
(PCR) amplification. In a 4-year period, 494 
sexual couples were enrolled. Participants were 
predominantly young African-Americans. In the 78 
couples that included female partners who tested 
positive for chlamydia by PCR, 53 male sexual 
partners (68%) also tested positive by PCR. In the 
76 couples with male partners who tested positive 
by PCR, 53 female sexual partners (70%) also 
tested positive by PCR.
We assumed that the transmission probability per 
relationship was 68% (Table 51). In a similar way to 
Low and colleagues25 and Turner and colleagues,112 
we estimated the per-episode transmission 
probability to be 0.11, based on assuming that the 
infection would be transmitted within 10 sexual 
episodes per relationship (n), i.e. 1 – (1 – tp)1/n.
TABLE 50  Cumulative incidence of complications for chlamydia and gonorrhoea118
Cumulative incidence (%) Source
PID 3.7 Low et al.118, Ness et al.119
Chronic pelvic pain 1.9 Ness et al.119
Ectopic pregnancy 2.7 Low et al.118
Tubal infertility 6.7 Low et al.118
Epididymitis 4.3 Trei et al.120
TABLE 49  Prevalence of STIs (%)
< 16 years old > 16 years old
Source Male Female Male Female
Chlamydia 1.5 7.5 10 12.5 NCSP117
Gonorrhoeaa 0.03 0.16 1.25 1.3 NCSP South London121
Genital wartsa 0.1 0.65 0.53 1.4 HPA116
HIVa 0.13 0.06 0.26 0.12 HPA8
a  Figures have been adjusted to be representative of the UK from original sources as discussed in the following 
subsections.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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TABLE 51  STI transmission probabilities between discordant heterosexual couples
Per relationship Per sex act Source
Chlamydia 0.68 0.11 Quinn et al.124
Gonorrhoea 0.5 0.07 Rothenberg et al. 125
Genital warts 0.65 0.1 HPA126
HIV 0.0015 Fisher et al.127
Gonorrhoea
Gonorrhoea is the second most common bacterial 
STI in the UK, and the majority of diagnoses are 
made in GUM clinics. In 2006, rates of diagnosis 
in GUM clinics were highest among women aged 
16–19 years and men aged 20–24 years, and rates 
of diagnosis were highest in London.
The prevalence of gonococcal infection in young 
people was estimated for south-east London as 
part of the NCSP.121 The tests were conducted 
for screening, diagnosis or through contacts with 
people with chlamydia or gonorrhoea. In the 
screened group the prevalence of gonococcal 
infection for male and females was 3% and 3.2%, 
respectively. The prevalence in London was 2.4 
times higher than for the rest of the UK. We 
adjusted this prevalence, for the rest of the UK, 
for the 16– to 19-year-old age group. The adjusted 
prevalence was 1.25% and 1.3% for males and 
females, respectively (Table 49). In order to estimate 
the prevalence within the younger age group, we 
assumed the same relationship between age groups 
in the incident data reported in Table 48, i.e. the 
prevalence for UK for < 16-year-olds of 0.03% 
and 0.16% for males and females, respectively. 
As there were no available data, we assumed that 
the complication rate from gonorrhoea cases 
was the same as for chlamydia. We assumed that 
the transmission probability per relationship for 
gonorrhoea was 50% (Table 50).122,125 We estimated 
the per-episode transmission probability to be 0.07, 
based on 10 sexual episodes per relationship in the 
same way as for chlamydia.
Genital warts
Genital warts are the most commonly diagnosed 
viral STI in GUM clinics.8 If successfully treated, 
an individual’s infection goes into remission, but 
may recur at a later date. Genital warts can be 
difficult to treat, and patients may experience 
frequent recurrent episodes. Genital warts are 
caused by HPV and 90% of cases of genital warts 
are attributable to HPV 6 and HPV 11.126 HPV 
infection is the primary cause of cervical cancer, 
with the majority of cases attributable to HPV 16 
and 18.
The majority of infections are acquired through 
heterosexual sex and the highest rates are among 
young people.8 A study of antibodies to four types 
of HPV infection (HPV 16, HPV 18, HPV 6 and 
HPV 11) showed that the proportion of females 
who have been infected by HPV increases rapidly 
from 14 to 24 years of age.16 The prevalence of 
HPV 6 and HPV 11 was 6.5% and 14% for females 
aged < 16 and 16 – 19 years, respectively. The 
prevalence of HPV 16 and HPV 18 was similar. 
About 10% of HPV infections develop genital 
warts8 so we assumed that the prevalence of 
genital warts was one-tenth the prevalence of 
HPV 6 and HPV 11. The prevalence for males 
was estimated from female prevalence by using 
the same relationship between males and females 
as seen for incidence. Thus the prevalence was 
0.1% and 0.53% for males aged > 16 years old 
and < 16 years old, respectively. As reported in a 
study of HPV epidemiology,126 we assumed that the 
transmission probability per relationship for genital 
warts was 65%. We estimated the per-episode 
transmission probability to be 0.1, in the same way 
as for chlamydia, based on 10 sexual episodes per 
relationship.
HIV
HIV is a viral infection that is managed with 
lifelong antiretroviral treatment. There were 
estimated to be 73,000 people of all ages in the UK 
living with HIV in 2006.8 The number of deaths 
among HIV-infected people has fallen from 749 in 
1997 to 497 in 2006.8 There were 167 men and 76 
women living with HIV per 100,000 population in 
2006. The prevalence of diagnosed HIV infection 
in 2006 was highest among London residents.8 
Based on the number of adults between the ages 
of 15 and 59 years old in the UK, we estimated 
the average HIV prevalence in the 16- to 19-year-
old age group for men and women to be 0.26% 
and 0.12%, respectively. There are no data on 
prevalence of HIV for adolescents; we assumed Economic evaluation
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prevalence for the > 16-year-old age group to be 
half that of adult prevalence, as suggested by Wang 
and colleagues,59 i.e. 0.13% for young men and 
0.06% for young women.
Fisher and colleagues127 developed the British 
Association for Sexual Health and HIV guidelines 
for post-exposure prophylaxis after sexual exposure 
to HIV. They undertook a literature review and 
reported the risk of HIV transmission following an 
exposure from a known HIV-positive individual to 
be 0.1% for vaginal intercourse. The probability 
of transmission increases to about 0.5%.128,129 in 
the acute phase of the infection (days 20–54) when 
viral load levels are high. We combined these 
data to estimate a mean transmission probability 
over 1 year. Based on these studies, we assumed a 
mean transmission probability of 0.15% per sexual 
episode.
Sexual behaviour
Number of sexual partners per 
individual
The number of sexual partners that young people 
have has been estimated by the UK Office for 
National Statistics (ONS) Omnibus Survey.130 The 
Omnibus Survey is a multipurpose survey with 
approximately 1200 adults (aged 16 or over) in 
private households in the UK each month. It 
reported the number of sexual partners for young 
people in the previous year (aged 16–19 years). 
We used a weighted average to estimate the mean 
number of partners for sexually active individuals 
for 1 year to be 2.1 for males and 2.0 for females 
for 16- to 19-year-olds, and assumed that those 
< 16 years old (i.e. aged 13–15 years old) would 
have a similar number of partners (Table 52).
Frequency of condom use for 
adolescents
According to the Omnibus Survey, 91% of young 
men and 79% of young women aged 16–19 years 
used a condom in the previous year.130 The use 
of condoms was related to the number of sexual 
partners in the previous year. Among men aged 
16–69, 85% of those who had multiple partners 
had used a condom in the past year compared with 
36% of those who had a single partner. There was 
a similar variation for women – 77% of those with 
multiple partners used a condom compared with 
45% of those with just one partner.
The Health Behaviour in School-aged Children 
survey131 was a cross-national study conducted in 
collaboration with the World Health Organization. 
Thirty-five countries drew national samples of 11-, 
13- and 15-year-olds, with approximately 1500 
respondents in each age group for each country. In 
England, 69.1% of 15-year-old boys and 70.9% of 
15-year-old girls reported using condoms the last 
time they had sexual intercourse (Table 52).
Number of episodes of sex
The UK NATSAL reported that the number of 
occasions of heterosexual sex (vaginal, oral or 
anal sex) in the past 4 weeks for 16- to 24-year-
olds, among respondents who had one or more 
heterosexual partners in the year prior to interview, 
was 6.9 (SD = 9.1).132 The Canadian Youth, Sexual 
Health and HIV/AIDS Study was undertaken 
to increase understanding of the factors that 
contribute to the sexual health of Canadian 
youth.133 They questioned grade 9 and 11 (14- to 
17-year-olds) sexually active teenagers on their 
sexual activity. In sexually active males in grade 11, 
19% reported having had sexual intercourse once, 
33% ‘a few times’ and 48% ‘often’. We assumed 
lower sexual activity for the < 16-year-old age 
group and that it would be one-quarter of the 
rate seen in the 16- to 24-year-old group, i.e. 1.7 
episodes per month (Table 52), based on clinical 
advice.
Sexual experience
According to a YouGov survey, commissioned for 
UK Channel 4 Television, 40% of all 14- to 17-year-
olds are sexually active, one in three 15-year-olds 
is sexually active, nearly one-quarter of all 14-year-
olds have had a sexual experience, and 20% of 
those surveyed had their first sexual experience 
at 13 or under.134 The Adolescent Lifestyle Survey 
(ALS) provides a major benchmark of lifestyles and 
behaviours amongst 11- to 14-year-olds (n = 3390) 
in north-east Lincolnshire. By the age of 14 years, 
35% of girls and 30% of boys were sexually active. 
Amongst the sexually active young people just over 
one-half reported using a condom, 25% reported 
using a condom some of the time and 16% never 
using a condom.135 In the Health Behaviour in 
School-aged Children (HBSC) survey131 in England, 
35.7% of 15-year-old boys and 40.4% of 15-year-
old girls reported ever having sexual intercourse 
(Table 52).
Condom effectiveness
Pinkerton and colleagues136 estimated the 
effectiveness of condoms in reducing heterosexual 
HIV transmission to be 90%. A Cochrane 
systematic review by Weller and colleagues137 
estimated that consistent use of condoms results in 
an 80% reduction in HIV incidence. They noted DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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TABLE 52  Sexual behaviour
Male Female Source
Sexually active (%) 35.7 40.4 HBSC131
Sexual episodes per month 1.7 1.7 Assumption
Sexual partners per year 2.1 2 ONS Omnibus Survey130
Condom use at last intercourse (%) 69 71 HBSC131
HBSC, Health Behaviour in School-aged Children survey; ONS, UK Office for National Statistics.
there was insufficient evidence to estimate the 
effectiveness of condoms in preventing other STIs. 
In 1 year, only two of every 100 couples who use 
condoms consistently and correctly will experience 
an unintended pregnancy.138
Fewer studies have estimated the effectiveness 
of condoms for preventing other STIs and 
effectiveness estimates vary widely.139 In a 
systematic review the protective effect for 
chlamydia ranged from 10% to 90%, and for 
gonorrhoea ranged from 13% to 100%.140 The 
authors reported that studies that were limited to 
individuals with known STI exposure were likely to 
estimate the protective effect of condom use more 
accurately. Niccolai and colleagues141 estimated 
the effectiveness of condoms for the prevention of 
chlamydia among people who were exposed to the 
infection and found that consistent condom use was 
significantly associated with a 90% reduction in the 
prevalence of chlamydia. A longitudinal study by 
Winer and colleagues142 suggested that consistent 
use of male condoms reduced the risk of genital 
HPV transmission by 70% in males and 50% in 
females. We assumed that condom effectiveness was 
80% for HIV, 90% for chlamydia and gonorrhoea, 
and 70% for HPV.
Sexual mixing
According to the Chlamydia Screening Studies 
(CLaSS) prevalence study,25 young men aged 16–19 
years old, were 0.8 years older than their partners, 
whilst girls were 2.4 years younger than their 
partners. Therefore, we assumed that boys under 
the age of 16 would have partners also under the 
age of 16. On the other hand, girls under the age 
of 16 would have partners over the age of 16.
Pregnancy
Low and colleagues25 estimated age-related 
pregnancy risk, defined per episode of unprotected 
intercourse, assumed to take into account 
variation in both fertility and use of non-barrier 
contraception. Risk of pregnancy was 0.00035 per 
day for women aged 17.5 years.
Health-related quality of life
Health-related quality of life utilities could have 
important implications on the cost-effectiveness 
of intervention to prevent STIs. Our review found 
many studies that estimated the HRQoL for HIV, 
but few studies have done so for the other STIs. 
We found only two studies that reported utilities 
for health states associated with PID. There were 
several studies for HPV, but these often reported 
values for health states not relevant to this study, 
for example cervical intraepithelial neoplasia 
grades 2 and 3.
Tengs and Lin143 performed a meta-analysis to 
derive pooled utilities for HIV from 25 articles 
reporting 74 unique utility values from 1956 
respondents. Pooling utilities, the authors estimate 
a utility of 0.7 for AIDS, 0.82 for symptomatic HIV, 
and 0.94 for asymptomatic HIV when the time 
trade-off method is used.
Smith and Tsevat144 obtained health-state valuation 
from 56 women with and without PID history, using 
visual analogue scale and time trade-off methods. 
They assumed that PID was an acute condition with 
pain for about 7 days, and that ectopic pregnancy 
was a short-term state, with a possibility of long-
term consequences. Infertility and chronic pelvic 
pain were assumed to be long-term health states. 
The definitions for each of the complications used 
in the analysis are shown in Table 53.
Hu and colleagues145 estimated the cost-
effectiveness of screening for chlamydia in the 
USA. They estimated the quality of life and 
duration of complications as shown in Table 54. 
Hu and colleagues assumed a quality disutility 
loss until age 50 years for infertility. We used 
the assumptions stated earlier for unit costs of Economic evaluation
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TABLE 53  Definitions of STI complications144 for a 25-year-old woman
Complication Definition of complication
Symptomatic acute PID Woman does not require hospital stay; she has pain for about 7 days, with the pain mainly in the 
lower abdomen
Chronic pelvic pain Woman has continuing pain in her lower abdomen and pelvic area; she is limited in moderate 
activities and has little energy and has low mood; the pain may slowly go away as time goes on but 
could also stay the same
Ectopic pregnancy Woman has pregnancy not in the womb, she has pain in the abdomen and is treated to remove the 
pregnancy, either by minor operation or medicine; after the pregnancy is removed, she will soon be 
without pain
Tubal infertility She has no pain but is unable to get pregnant; she feels less satisfied with her partner, her sex life 
and her overall quality of life
TABLE 54  Costs and HRQoL for complications of chlamydia
HRQoL144 Unit cost (£)146 Duration (years)145
Symptomatic acute PID 0.9 137 0.03
Chronic pelvic pain 0.69 236 5
Ectopic pregnancy 0.79 762 0.076
Tubal infertility 0.76 10,798 15
Epididymitis 0.9 142 0.03
TABLE 55  Costs and HRQoL for complications of HPV
Prevalence8 QALY loss147 Unit cost (£)148,156
Genital warts 1 0.03 222
Cervical cancer 0.033 6.4 10,464
TABLE 56  Costs and HRQoL for complications per case of STI for females
Medical costs (£) Source QALY loss Source
Chlamydia 753.37 Adams et al.146 0.27 Quality of life,144 duration145
Gonorrhoea 753.37 Adams et al.146 0.27 Quality of life,144 duration145
Genital warts 562.61 Brown et al.149 0.238 Chesson et al.147
HIV 408,654 Miners et al.150 8.4 Miners et al.150
infertility – that half would receive successful 
treatment for infertility146 and so have assumed 
a lower estimate than Hu and colleagues145 of 15 
years’ disutility for those with infertility.
We estimated the unit cost and QALY loss per cases 
of STI, based on the prevalence of complications of 
STI (Table 54).
Chesson and colleagues147 described a simplified 
model for the economic and health effects of 
HPV, to estimate the cost-effectiveness of HPV 
vaccination of 12-year-old girls in the USA. The 
quality weights, and the estimated durations of 
these reductions in quality of life, were based on 
previously published estimates. They calculated the 
expected number of discounted lifetime QALYs 
lost as a result of HPV-related health outcomes for 
different age groups. The QALY loss was 6.4 for 
cervical cancer and 0.03 for genital warts for 15- to 
19-year-olds (Table 55).DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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Estimation of costs
Cost of chlamydia and gonorrhoea 
treatment
As the analysis reflects an NHS perspective, it uses 
UK-specific resource use and costing data where 
available. Cost data were obtained from a number 
of primary and secondary sources. Unit costs for 
the complications of chlamydia and gonorrhoea 
are shown in Table 56. Adams and colleagues,146 
who evaluated the cost-effectiveness of the NCSP 
in England, estimated the cost of complications 
based on diagnosis and treatment. They assumed 
that only a small proportion of patients would 
have a hospital episode. Unit costs were also 
estimated by Low and colleagues,25 who evaluated 
the cost-effectiveness of population screening for 
chlamydia, but these differed markedly from those 
used by Adams and colleagues,146 and the rationale 
and assumptions used by Low and colleagues25 
were unclear and so were not used.
Adams and colleagues146 made the following 
assumptions when estimating the costs of PID. All 
PID cases were assumed to have had one general 
practice clinic visit, including the cost of testing 
for chlamydia and gonorrhoea. It was assumed 
that 6.5% of PID cases were admitted to inpatient 
hospital care. An equal proportion was assumed 
to be treated as outpatient cases in hospital. The 
cost of an episode for an outpatient hospital 
gynaecology department and an inpatient episode 
of a non-elective, non-surgical treatment of a 
gynaecological condition were taken from the NHS 
reference costs.151 It was assumed that all women 
with ectopic pregnancy were admitted to inpatient 
hospital care for a termination, of which 60% were 
assumed to be medical and the rest surgical.
It was assumed that half of women with tubal factor 
infertility (TFI) had an infertility investigation 
and treatment, either tubal surgery or in vitro 
fertilisation. The average cost of diagnosis and 
treatment was estimated to be the mean of that 
for mild and moderate TFI (£10,727 per live 
birth). Women without an infertility investigation 
or treatment had no costs. It was assumed that 
all men with epididymitis had a consultation in 
a GUM community clinic (general practice or 
GUM), and, of those, 10% were referred to hospital 
inpatient care. It was assumed that 36% of women 
with chronic pelvic pain would have an outpatient 
consultation.152
Cost of HIV treatment
Miners and colleagues150 assessed the cost-
effectiveness of HAART for adults with HIV in 
England compared with two nucleoside reverse 
transcriptase inhibitors (NRTIs). They developed 
a Markov model to describe the progression of 
HIV infection and 20 years of costs and effects. 
The model was run for 20 years with a cohort of 
infected individuals who were 18 years of age at 
the start. HAART was assumed to have a treatment 
effect of 5 years, although the cost was assumed to 
continue until the model ended or the individual 
died. However, a recent study by the antiretroviral 
therapy cohort collaboration153 estimated that life 
expectancy in HIV-infected patients, who were 
treated with combination antiretroviral therapy, 
increased between 1996 and 2005. The average 
number of years remaining to be lived at the age of 
20 years was about two-thirds of that in the general 
population.
We re-estimated the life expectancy of HIV patients 
using lower probabilities of death in each of the 
health states. We changed the discount rate to 
3.5% for costs and benefits113 and updated the 
health-care costs from 1999–2000 to 2005–06 
using the inflation indices from the Personal Social 
Services Research Unit (PSSRU).154 The British 
HIV Association guidelines155 now recommend 
including an non-nucleoside reverse transcriptase 
inhibitor (NNRTI), such as efavirenz, and so we 
have included this in our reanalysis. The model was 
run for 50 years. Individuals with HIV have a lower 
than normal life expectancy. The model estimated 
that they would have 8.4 QALYs lower than an 
uninfected individual. The estimated discounted 
medical cost associated with an HIV infection was 
£408,657 (Table 56).
Cost of treatment of cervical cancer and 
genital warts
Brown and colleagues149 estimated the costs of 
managing HPV-related disease. The first-year cost 
of cervical cancer was estimated to be £10,464 per 
patient, based on a previous study by Wolstenholme 
and Whynes.148 These costs take into account all of 
the resources used, including treatments (surgery, 
radiotherapy and chemotherapy), drugs, inpatient 
palliative care, investigations and follow-up. The 
cost for treating genital warts was approximately 
£10.1M in 2003 for 76,457 incident cases (£132 
per case) and for prevalent cases (55,657) was 
£12.3M (£221 per case). Langley and colleagues156 
estimated the cost of successfully treating genital 
warts in six GUM clinics in England and Wales in 
2000. The cost per successful outcome was £222 
for males and £211 for females. We assumed a unit 
cost of genital warts of £222 and of cervical cancer 
of £10,464 (Table 56).Economic evaluation
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Cost of behavioural intervention
The costs of peer- and teacher-led sexual education 
interventions are based upon the resources used 
in the RIPPLE trial50 and the SHARE trial.70 As 
mentioned earlier, these were the only two UK 
studies to meet the inclusion criteria for our 
systematic review of effectiveness (see Chapter 
2). We have updated the costs to present day 
values using the NHS multiplier for Hospital 
& Community Health Services.154 This method 
converts a cost in a base year to the current year by 
multiplying the base cost by a index that reflects 
changes in costs between these years.
Contact was made with both the RIPPLE and 
SHARE research teams to request data on costs 
and resources. Limited data were available from 
the teams, so most of the resources were estimated 
from systematically extracting data from the study 
publications. The extensive process evaluations 
conducted by both studies yielded some of the data 
we required (see Chapter 5).
For the teacher-led intervention, we used the 
resources from the SHARE trial (Tables 57 and 
58), for which the teachers were taught, in groups 
of 13, on a 5-day training course run by a health 
promotion practitioner. We assumed that all 
teachers that taught SRE would receive training 
and would be retrained every 5 years.
For the peer-led intervention, we used the 
resources from the RIPPLE trial (Table 59), for 
which there was no training for the teachers 
involved, only for peer educators. Furthermore, 
the training was based upon groups of 12 people 
per training session for a 2-day intensive course led 
by a health promotion practitioner. Peer educators 
were assumed to only teach sex education for 1 
year. These interventions were compared to current 
training for SRE, which we assumed consists of half 
a day per school per year for a PSHE co-ordinator.
The training costs for standard sex education 
were assumed to be minimal as the majority of the 
training would take place in house, for example 
during In-Service Training (INSET) days.
Results of the modelling
The model was run with the inputs shown in Tables 
49–56 for 1000 boys and 1000 girls aged 15 years 
old. In the base-case analysis, the costs from the 
TABLE 57  Costs for the peer- and teacher-led sexual education interventions
Unit cost (£) Notes
Teacher’s salary per annum 31,791 National Union of Teachers pay scales, band 6
Health promotion practitioner’s salary 26,700 PSSRU154
Cost for SHARE, per teacher 1307 Updated cost, includes teacher cover, room hire and materials
Cost of one health promotion 
practitioner
960 Assumes 2-day course, half day before and after and 2-day 
preparation/administration
Cost of venue/day 200 For one room; includes lunch and tea/coffee
TABLE 58  SHARE programme costs
Costs  1997 price (£) 2008 price (£)
Full cost of SHARE teacher training, including supply cover, per teacher 900 1307
Total costa 62,100 90,161
Total cost (per teacher) 900 1307
Total cost (per pupil) 14.8 21.5
Total cost (per school) 4777 6935
a  The SHARE trial had 4197 pupils, 69 teachers and 13 schools.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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TABLE 59  RIPPLE programme costs
Cost (£)
Unit costs
Cost of one health promotion practitioner (4 days) 1200
Cost of venue per room 200
RIPPLE teaching pack (not including video) 22
Total costsa
Cost of health promotion practitioner (4 days) 46,300
Cost of venue 7717
Other costs (teaching pack) 6945
Total cost 60,962
Total cost (per pupil) 15
Total cost (per school) 4354
a  The RIPPLE trial had 4063 pupils, 463 peer educators and 14 schools.
teacher-led intervention (SHARE) were used. 
The pooled OR from our meta-analysis for the 
outcome all condom use (see Figure 3, Chapter 4, 
Condom use) had to be converted into a risk ratio 
(RR) for the purposes of economic modelling, but 
this required imputation of the number of young 
people reporting condom use in the Safer Choices 
intervention58. More details of the methodology for 
deriving the RR effect size are shown in Appendix 
12. This produced a pooled RR of 1.05 (95% CI 
0.92 to 1.20). The pooled RR is not statistically 
significant and so caution is advised in the 
interpretation of these results.
The effect of the intervention was assumed to last 
for 1 year, due to the short follow-up in the trials 
(see Chapter 4, Length of follow-up). The base-
case results for the teacher-led intervention (based 
on the SHARE trial) are shown in Table 60. This 
indicates that there would be two STI cases averted 
with a corresponding quality of life gain of 0.35 
QALY and a net cost of £7146. This corresponds 
to an incremental cost-effectiveness ratio (ICER) 
of £20,223 per QALY gained. The results indicate 
that most of the cases averted are for chlamydia 
and the largest QALY gain would be for females 
who are not infected with chlamydia.
Using the same intervention effect estimate for the 
peer-led behavioural intervention (RIPPLE) results 
in the same health gains, in terms of cases averted 
and QALYs gained, but at a higher cost and would 
correspond to an ICER of £80,782 per QALY 
gained (Table 61).
Sensitivity analysis
The parameters in the STI model were varied in a 
series of sensitivity analyses for the base case and 
the results are shown in Table 62 and Figure 6.
Where possible, the parameters were varied 
according to the ranges of the CIs of these 
parameters, otherwise a suitable range was chosen. 
Parameter values for all the STIs were altered 
by the same magnitude, but, for simplicity, only 
the input parameters for chlamydia are shown in 
Table 62 and input parameters for the other STIs 
are shown in Tables 63–66. The results were most 
sensitive to the intervention effect, the transmission 
probability and the number of sexual partners.
The parameters are investigated in more detail in 
Tables 63–67. The model results are most sensitive 
to changes to the model parameters for chlamydia, 
whilst changes to the model parameters for the 
other STIs produce only small changes in the 
model results.
Table 67 shows the effect of changing parameter 
values for STI complications on the results. These 
indicate that the sensitive parameters are those 
related to tubal infertility, whilst those for the other 
complications have little effect on the results.Economic evaluation
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TABLE 61  Base-case results for the peer-led behavioural 
intervention (RIPPLE) compared to standard sex education
Total (£)
Total cost of intervention 30,000
Net cost 28,546
Cost per case averted (all STI) 13,508
Cost per QALY gained 80,782
TABLE 62  Sensitivity analyses for the STI model
Variable Base case
Inputs ICER (£/QALY)
Low High Low High Range (£)
IE condom use 1.05 0.92 1.2 –19,325 1970 NA
Transmission probability 11a 3a 20a 71,391 13,390 58,001
IE number of sex partners 1 0.95 1.05 11,156 58,313 47,157
IE Sex episodes per partner 1 0.95 1.05 12,934 37,762 24,828
BC number of sexual partners 2 1.5 4 30,619 5975 24,644
STI prevalence 7.5a,b 5.3a,b 9.8a,b 28,802 10,830 17,972
Proportion sexually active 36 25 45 35,150 17,693 17,457
BC sex episodes per partner 10 6 14 31,954 15,654 16,300
Intervention cost 4.3 3 5.6 12,865 27,581 14,716
QALY loss per STI case 0.27a 0.19a 0.35a 28,890 15,556 13,334
Condom effectiveness 85a 70a 95a 24,748 18,407 6341
Condom use 70 60 80 22,607 18,686 3921
Unit costs 768.11a,b 537.68a,b 998.54a,b 19,211 21,235 2024
BC, base case; IE, intervention effect; NA, not available.
a  Values shown for chlamydia. Parameters for other STIs were altered by the same magnitude.
b  Values shown for females.
Older teenagers
We investigated the effect of the intervention in 
older teenagers (aged 16–19 years). In this group 
there are more sexually active individuals and 
they have more sexual episodes per month (Table 
68). The results for running the model with these 
parameters and STI prevalence from this age 
group for the teacher-led intervention are shown 
in Table 69. In this age group there are more STI 
cases averted, QALYs gained and medical costs 
averted than in the younger age group. The cost-
effectiveness for this age group is £11,622 per 
QALY gained.
Probabilistic sensitivity analysis
The PSA was conducted for the base-case analysis 
for the teacher-led intervention (i.e. based on the 
SHARE trial). The main parameters were varied 
according to the ranges used in the deterministic 
sensitivity analysis. The PSA parameter values were 
sampled from appropriate distributions for these 
parameters as shown in Appendix 11. The model 
was run for 1000 iterations.
The teacher-led intervention was typically 
associated with increased costs (Figure 7 – scatter 
plot of the incremental cost and QALYs), although 
there is a small proportion (1%) of simulations 
where costs are lower (associated with positive 
incremental outcomes). The percentile-based 95% 
CI for incremental cost is £341 to £12,060. There 
is a wide range for incremental QALYs, as shown in 
Figure 7, from –2.0 to 2.5, with poorer incremental 
outcomes typically being associated with higher 
incremental costs. In 23% of the simulations 
the teacher-led intervention was associated with 
a QALY loss. The percentile-based 95% CI for 
incremental QALYs is –0.7 to 2.
In addition to graphing the incremental cost 
and incremental QALYs for the teacher-led 
intervention, a CEAC was derived, representing 
the proportion of simulations where the teacher-
led intervention is cost-effective for a range of 
willingness-to-pay thresholds, up to £100,000 
(Figure 8). In this analysis the teacher-led 
intervention had a probability of being cost-
effective of 46% at a willingness-to-pay threshold of 
£20,000, and 54% at a willingness-to-pay threshold 
of £30,000.Economic evaluation
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FIGURE 6  Tornado plot for sensitivity analyses for the STI model. BC, base case; IE intervention effect.
TABLE 63  Sensitivity analyses for changes in STI single-sex transmission probability
Variable
Base case 
(%)
Inputs ICER (£/QALY)
Low High Low High Range
Chlamydia 11 3 20 52,726 14,688 38,038
Gonorrhoea 7 2 13 21,697 19,071 2626
HIV 0.15 0.04 0.3 20,882 19,338 1544
Genital warts 10 3 18 20,853 19,908 945
TABLE 64  Sensitivity analyses for changes in STI condom effectiveness
Variable Base case (%)
Inputs (£) ICER (£/QALY)
Low High Low High Range
Chlamydia 90 70 95 25,250 19,422 5,828
Gonorrhoea 90 70 95 20,593 20,148 445
HIV 80 70 95 20,333 20,059 274
Genital warts 70 60 90 20,357 20,008 349DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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93
TABLE 65  Sensitivity analyses for changes in STI unit cost
Variable
Inputs (£) ICER (£/QALY)
Low High Low High Range
Chlamydia 538 999 20,906 19,445 1461
HIV 286,058 531,250 20,411 20,035 376
Gonorrhoea 538 999 20,291 20,146 145
Genital warts 394 731 20,247 20,199 48
Note: Input values shown are those for females.
TABLE 66  Sensitivity analyses for changes in parameter values for QALY gain for STIs
Variable
Inputs (£) ICER (£/QALY)
Low High Low High Range
Chlamydia 0.19 0.35 27,242 16,185 11,057
Gonorrhoea 0.19 0.35 20,755 19,733 1022
Genital warts 0.17 0.31 20,425 20,015 410
HIV 5.9 10.92 20,301 20,145 156
Note: Input values shown are those for females.
TABLE 67  Sensitivity analyses for the STI complications parameter values
ICER range (£/QALY)
Prevalence Quality of life Duration Unit cost
Tubal infertility 9354 24,052 8146 1513
Chronic pelvic pain 1217 1767 1208 40
Ectopic pregnancy 62 46 19 43
PID 19 26 8 11
Range of ICER results between low and high parameter values (± 30%).
TABLE 68  Sexual behaviour parameters for the 16- to 19-year-old age group
Parameter Value Reference
Sexually active Male 56%, female 66% ONS Omnibus Survey130
Sex episodes per month 6.9 NATSAL132
Sex partners per year Male 2.1, female 2 ONS Omnibus Survey130
Condom use Male 55%, female 47% ONS Omnibus Survey130
NATSAL, National Surveys of Sexual Attitudes and Lifestyles; ONS, UK Office for National Statistics.Economic evaluation
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TABLE 69  Results for the teacher-led intervention for the 16- to 
19-year-old age group
Results Total
Cases control 57.7
Cases intervention 54.2
Cases averted, total 3.5
QALY gained 0.4
Total medical costs averted (£) 3498
Net cost, £  5102
Cost per case averted (all STI) (£) 1448
Cost per QALY gained (£) 11,622
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FIGURE 7  Scatter plot of PSA results for 1000 iterations for the teacher-led intervention.
Expected value of perfect 
information for the prevention 
of STIs
Decision-makers may be interested in whether it 
would be worthwhile conducting further research 
to gain more precise information on uncertain 
parameters in the model. For example, in our STI 
model, we may be interested in whether it would 
be better to derive more precise estimates of the 
effect of behavioural interventions on condom 
use or other outcomes (by conducting a further 
trial), better estimates of sexual activity in younger 
people, especially those under 16 years of age 
(using a sexual health survey) and whether either 
of these would be worthwhile, considering what 
the likely health gain for the population would be. 
Value of information analysis attempts to answer 
these questions by analysing the hypothetical case 
for which perfect information could be obtained 
through further research.114 The EVPI is the 
price that one would be willing to pay in order 
to gain access to perfect information through 
further research, and represents an upper bound 
on the value of conducting further research. The 
EVPI varies according to the cost-effectiveness 
threshold. For interventions in which there is 
large uncertainty around whether they should be 
adopted, for example when the ICER is close to the 
cost-effectiveness threshold, the health-care system 
may be prepared to pay more for research which 
informs decisions on these interventions.
For the STI model, the individual EVPI was 
calculated as the difference between the expected 
net benefit with perfect and with current 
information. The total EVPI is estimated for the 
total current and future population of people who DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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FIGURE 8  CEAC of results for 1000 iterations for the teacher- and peer-led interventions.
may benefit from this intervention. We assumed 
that the effective lifetime of the intervention would 
be 10 years. The effective lifetime represents 
the time until a new intervention supersedes or 
replaces it, rather than the duration of effect. 
There are 640,000 children of 15 years of age in 
England and Wales in 2008 (ONS).157 The effective 
population over the lifetime of the intervention 
is 5.2 million (with a discount rate of 3.5%). The 
population EVPI is shown in Figure 9.
At a threshold for cost-effectiveness of £20,000 per 
QALY, the population EVPI is £12.5M, assuming 
a 10-year lifetime for the intervention, suggesting 
a upper limit to expenditure on further research 
to reduce uncertainty. However this overall EVPI 
estimate gives no indication which of the uncertain 
parameters has an impact on the decision whether 
the new technology is cost effective or not. As a 
result, the global EVPI does not help to answer 
the question posed at the beginning of this section 
– whether it would be better to fund an RCT 
(to improve the precision of the effect estimate) 
epidemiological research (on the prevalence of 
STIs and their complications in this population) 
or surveys of sexual lifestyles. The following 
section extends the analysis of EVPI to groups of 
parameters to identify the priorities for research to 
reduce decision uncertainty in the model.
Expected value of perfect information for 
individual parameters
The effect of individual parameters on the 
population EVPI was investigated by running an 
EVPPI analysis.114 This shows the value of reducing 
the uncertainty surrounding particular input 
parameters in the decision model, by conducting 
further research on these parameters in order to 
obtain perfect information.
The PSA was run for 1000 iterations, whilst keeping 
the parameter value(s) of interest constant. This 
process was repeated for 100 different parameter 
values. The EVPIs associated with the inputs of the 
model are illustrated in Figure 10 for a threshold of 
£20,000 per QALY and a 10-year effective lifetime 
for the intervention. The value of information 
associated with the intervention effect for condom 
use is £10.2M, which is substantially higher than 
any other model inputs and accounts for over half Economic evaluation
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of the decision EVPI. Furthermore, the EVPI for 
STI prevalence and condom effectiveness is zero 
and the EVPPI for baseline condom use, sexual 
behaviour and intervention cost is low, indicating 
that future research for these parameters would not 
reduce the decision uncertainty in the model.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Discussion of the systematic 
review of effectiveness
Principal findings of the 
systematic review
Effects on sexual behaviour
Although there were statistically significant 
differences between study groups for outcomes 
such as improved knowledge and greater self-
efficacy, our systematic review showed that, in 
general, schools-based education and skills 
development interventions were limited in 
encouraging safer sexual behaviour amongst young 
people. Few of the studies reported statistically 
significant differences between the interventions 
and their comparators (generally standard sex 
education or control groups) for outcomes such 
as condom use, delaying the initiation of sexual 
activity, frequency of sexual intercourse or number 
of sexual partners. Similarly, when a subset of 
the studies were combined statistically in a meta-
analysis, the pooled effect estimates were not 
statistically significant.
Our synthesis of process data revealed several 
factors that may explain the limited impact of 
these interventions on safe sexual behaviour. 
Interventions were not always implemented 
as intended, with interactive exercises, such as 
role plays, being more likely to be omitted in 
comparison with the information giving aspects 
of the interventions. Barriers to implementation 
ranged from an unsupportive school culture, which 
meant that other timetabled activities were given 
higher priority, to individual provider qualities, 
such as enthusiasm, credibility and expertise. 
Furthermore, not all young people found the 
interventions to be engaging and acceptable. The 
qualities and skills of the intervention providers, 
whether or not the intervention content met young 
peoples’ sexual health needs, the operation of 
gendered norms, and the discomfort felt discussing 
sexual topic in the school environment all affected 
young people’s engagement. These findings build 
on those of Payne and colleagues,158 who found 
significant relationships between implementation 
intensity in schools and factors such as integration 
into school operations and principal support.
Notably both of the UK studies concluded that the 
interventions had not been wholly successful in 
encouraging safer sexual behaviour. The authors of 
both trials discuss the likely reasons for this.
In the SHARE trial there were no statistically 
significant differences between the intervention 
and standard sex education in terms of first 
intercourse without a condom, any evidence of 
protection against STIs (a composite outcome 
measure, defined earlier in Chapter 4, Sexual 
behaviour), frequency of condom use or most 
recent intercourse without a condom (Wight and 
colleagues70). Long-term follow-up of the young 
women at age 20, via NHS linkage data, found 
no statistically significant difference on rates of 
conception or termination. Although their process 
evaluation suggested several factors that may 
account for lack of impact on these outcomes, 
Wight and colleagues highlight the length of 
classroom sessions and the age appropriateness 
of the SHARE programme as key factors. They 
concluded that the classroom sessions were possibly 
too short to enable the young people to fully 
develop sexual negotiation skills. Furthermore, for 
some young people, the skills would not be put into 
practice until they had begun sexual relationships, 
by which time the skills would likely be harder to 
recall. They noted higher than expected baseline 
condom use in their sample, and suggest that the 
potential of school-based sexual health promotion 
might have already been reached by conventional 
provision. In terms of recommendations they 
proposed the need for broader interventions to 
address socioeconomic determinants of health, as 
well as strategies involving parents. It is of note that 
a non-randomised controlled adaptation of SHARE 
as part of the ‘Healthy Respect’ intervention in the 
Lothian and Grampian regions of Scotland (not 
included in our review) also found a lack of impact 
on sexual health behaviour outcomes.159
In the RIPPLE trial there was no significant 
reduction in the primary outcome of unprotected 
first sexual intercourse at age 16 years, and no 
significant difference in rates of abortion at age 
20 years (Stephenson and colleagues50,89). There 
were some positive outcomes, including the finding 
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that girls in the intervention arm were more 
confident about using condoms in the future and 
were significantly less likely to report having had 
sex by 16 years of age, compared with the control 
group. The authors discounted the potential for 
methodological biases to account for the lack of 
impact on unprotected first sexual intercourse (e.g. 
diffusion of the intervention to the comparison 
group). They did, however, point to some of the 
limitations identified by the process evaluation, 
namely, pupil dissatisfaction with mixed-sex 
lessons. One of the recommendations, therefore, 
was that future interventions should be delivered 
to single-sex groups, although in the SHARE 
trial it was found that mixed sex groups might be 
more beneficial for young men. The authors also 
concede that the intervention was relatively brief 
and that a longer or more intense programme 
might be more successful, although, as discussed 
above, this was not borne out by the results of the 
20-session, 2-year SHARE programme.
Another potential explanation for the general lack 
of impact of the studies in this systematic review on 
sexual behavioural outcomes is they did not allow 
long enough to assess outcomes. As mentioned 
in Chapter 4, Length of follow-up, 10 of the 15 
studies followed up participants for less than 1 year. 
As not all of the young people were sexually active, 
and because health-related behaviour is known 
to take time to adopt and become routine,160 it is 
possible that had the young people been followed 
up for longer, significant differences in outcomes 
such as condom use may have been observed. 
However, longer-term follow-up of the RIPPLE 
trial at age 18 showed that there were no significant 
differences between study groups in unprotected 
first sex, regretted or pressured sex (at first and last 
sex), quality of relationship with current partner 
and diagnosed STI.
One of the more optimistic studies in terms 
of impact on safer sexual behaviours was the 
Safer Choices programme, conducted in urban 
schools in Texas and California (Coyle and 
colleagues58). There were statistically significant 
differences between study groups on a number of 
behavioural outcomes. Unfortunately, a process 
evaluation of this intervention was not reported, 
limiting insights into the factors contributing to 
its success. One potential explanation is that the 
intervention was more comprehensive than many 
of the others included in the review. In addition to 
classroom-based education and skills development 
activities, a school health promotion council 
was established, involving all agents within the 
school to plan activities. Young people themselves 
were given a leading role as peer educators. And 
parents were also involved in planning activities 
and were encouraged to take part in ‘homework’ 
with their children to discuss sexual health. 
Linkages with community health services were also 
sought. Inclusive, co-ordinated, multicomponent 
interventions such as this, which seek to influence 
young people by targeting many of the contexts 
in which they live (e.g. classroom, wider-school 
environment, home, community), may be more 
successful than interventions that primarily focus 
on the curriculum.
As mentioned earlier in Chapter 4, Origin of the 
interventions, the results of an evaluation of an 
adaptation of Safer Choices in an ‘alternative’ 
school (for students with behavioural and 
social problems) are awaited (Tortolero and 
colleagues86,87). It will be interesting to see whether 
the results are comparable with the original study. 
Given its promising results, it would be also useful 
to evaluate an adaptation of Safer Choices in the 
UK. Some aspects of the intervention may be 
readily transferable. For example, the National 
Healthy Schools Programme encourages a ‘whole-
school’ ethos, which appears analogous to the 
school health promotion council element of Safer 
Choices. However, qualitative pilot work would be 
required to assess its social and cultural relevance 
to the UK. For instance, whether or not parent and 
teen discussion of sexual health is likely to be an 
acceptable and effective intervention component.
Effects on other outcomes
It is important to acknowledge that although safer 
sexual behaviour and absence of infection are 
important outcomes, positive changes in mediating 
variables are no less valuable. The improvements 
in knowledge, behavioural intentions and self-
efficacy/confidence around negotiating safer sex 
reported in the studies included in this review 
indicate that young people at least have a firm 
foundation upon which to make decisions. Some 
stakeholders consider these improvements to 
be meaningful, and it was on this basis that the 
then Scottish Executive decided to implement 
the SHARE curriculum in Scottish schools.161 The 
FoK intervention is available for use in the USA,162 
although this has probably been rolled out on the 
basis of the more successful outcomes achieved in 
the original evaluation in Baltimore, MD (Stanton 
and colleagues88) (which, as mentioned earlier, did 
not meet our inclusion criteria as the mean age of 
the young people was below 13 years).DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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School-based behavioural interventions are 
therefore appropriate to improve knowledge, self-
efficacy and favourable intended behaviour. The 
consultation exercise conducted to underpin the 
UK government’s strategy for health promotion, 
Choosing Health,21 found that people want to have 
clear and credible information to enable them to 
make informed choices. Furthermore, government 
policies such as ‘Every Child Matters’ endorse 
the right for young people to receive high-quality 
health promotion.23 Therefore, the limited impact 
on sexual behaviour of interventions should not 
hinder the provision of education and support for 
sexual health.
The results of this systematic review also raise the 
question of whether the outcomes measured by the 
studies are sensitive enough to reflect the complex 
sexual behaviours and lifestyles of young people at 
the current time. Condom use may not necessarily 
reflect strategies that some young people use to 
reduce risks. For example, some couples may 
‘negotiate safety’ through seeking testing for STIs 
and, following mutual negative results and with 
effective use of contraception, may then enjoy 
unprotected intercourse. Uptake of STI testing 
in this context may therefore be a useful outcome 
measure for future evaluation studies. This would 
be a particularly useful marker to evaluate the 
effectiveness of interventions that not only aim to 
encourage risk reduction, but also which encourage 
testing to as a form of secondary prevention. This 
is all the more appropriate given wider availability 
in the UK of chlamydia testing.163 An added benefit 
would be the identification of long-term viral 
infections, such as HIV, and timely commencement 
of antiviral treatment. Media campaigns with MSM 
have emphasised the long-term advantages of 
testing and uptake of antiviral treatment, where 
appropriate.
Effects on inequalities in sexual health
There is growing recognition that sexual health 
inequalities exist, and that some groups of young 
people are disproportionately affected by STIs. 
These groups are often characterised by factors 
associated with the broader determinants of 
social and health inequalities, such as gender, 
ethnicity and sexuality. Exploring the extent 
to which interventions can reduce, maintain or 
increase health inequalities requires reporting of 
data suitable for performing subgroup analyses 
in systematic reviews. In the studies included in 
our review, reporting of data useful to assessing 
differential intervention impact according to 
population factors was sparse, and varied in detail. 
Consequently, it was difficult to draw conclusions 
about the likely effects of the interventions on 
health inequalities.
For example, a small number of studies reported 
outcome data according to gender, whereas other 
studies only reported demographic data on gender 
across intervention and control groups at baseline. 
The picture for data on both ethnicity and SES 
was less encouraging; whilst some demographic 
data were reported for these factors, they were 
not presented according to intervention and 
control group at baseline or follow-up. The fact 
that more data were presented on gender than 
other determinants of health may reflect the ease 
of collecting and analysing these data. However, 
considering the apparent ease with which these 
data can be collected, and the valid rationale for 
doing so, it was disappointing that so little was 
actually reported. Whilst subgroup analyses that 
have been not pre-specified should be avoided,164 
and underpowered subgroup analyses in primary 
reports used only for hypothesis generation, more 
extensive reporting of outcome data by potential 
demographic determinants, such as gender, 
ethnicity and SES, would be of value in assessing 
the impact of interventions on sexual health 
inequalities.
The role of theory
The vast majority of the interventions were theory-
based, and the theories tended to be drawn from 
sociopsychological models of health-related 
behaviour change. At their simplest, these theories 
propose that interventions which foster favourable 
attitudes and intentions will, in turn, encourage the 
adoption and maintenance of health-promoting 
behaviours. Whilst many texts on the application 
of theory to explain health-related behaviour 
acknowledge the role of knowledge, attitudes 
and behaviours, it is also acknowledged that 
these cannot necessarily bring about behaviour 
change without structural and environmental 
reinforcements (e.g. service provision, policy, 
legislation, etc.).165
The role of peer norms and role models were 
also considered important. For example, a key 
tenet of Social Learning Theory72–74 is that young 
people will be influenced by the attitudes and 
behaviour of role models, and will, in turn, copy 
them. Accordingly, some of the studies included 
in this review used peers (sometimes chosen for 
their influence) to deliver interventions. The 
studies varied in the extent to which they discussed Discussion
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the conceptual mechanisms through which they 
expected the interventions to operate. Some 
made only passing reference to theory (e.g. Coyle 
and colleagues58), whilst others (e.g. Karnell 
and colleagues63) were more explicit about how 
the theory chosen might encourage favourable 
sexual behaviour. Of course, no one theoretical 
model is without limitations, and it was therefore 
encouraging that many of the interventions were 
based on a range of complementary models.
Despite the predominance of theory-based 
interventions, one of the potential explanations 
for the lack of impact on behaviour in the studies 
included in this review is that the interventions 
were poorly conceived. That is, the theories chosen 
did not adequately guide the intervention in 
helping young people to develop the knowledge, 
attitudes and skills necessary to engage in safer 
sexual behaviour. However, it appears that the 
theories employed were generally appropriate to 
the aims of the interventions. For example, the 
Theory of Planned Behaviour76 (used in three of 
the studies) recognises that, despite favourable 
attitudes and intentions, external factors, such 
as the influence of sexual partners, can limit 
the extent to which intentions can be translated 
into behaviour. To account for this many of the 
interventions drew on the concept of self-efficacy 
to underpin the teaching of skills to use condoms 
correctly and to communicate with partners. The 
aim was to bridge the gap between intention and 
behaviour, particularly in situations when sexual 
partners might favour unprotected sex.
The ‘Youth AIDS Prevention Project’ evaluated 
by Levy and Colleagues65 had a particular focus 
on teaching young people decision-making and 
resistance/negotiation skills. They distinguished 
between ‘use self-efficacy’ (the perceived ability 
to obtain and use contraception) and ‘refusal 
self-efficacy’ (the perceived ability to refuse to 
engage in high-risk behaviours). This distinction is 
reflective of the range of different skills taught by 
some of the studies.
As reported in Chapter 4, under Skills and 
self-efficacy, many of the studies demonstrated 
statistically significant differences between study 
groups in terms of condom use self-efficacy, 
suggesting that the theories were only partially 
successful in achieving behaviour change goals 
(though the influence of non-theory-related 
factors, such as the length of follow-up and the 
appropriateness of specific types of behavioural 
outcome measures, may have also influenced the 
results, as mentioned earlier). There were fewer 
significant differences for other measures such 
as sex refusal self-efficacy and communication 
self-efficacy. The reasons for this disparity are 
not entirely clear, though it is possible that the 
young people felt more confident about using 
condoms correctly (e.g. by practising on anatomical 
models) than they did in terms of communication 
(e.g. in role play scenarios). This explanation is 
supported by the results of the synthesis of the 
process evaluation results (Chapter 5), which found 
that there were barriers to the teaching of sexual 
communication skills. This was a particular issue 
in the SHARE trial,70 in which, despite the fact 
that teachers found their training to be beneficial 
and acceptable, they felt inhibited in facilitating 
role play and other skills-building exercises in the 
classroom. It should therefore be acknowledged 
that whilst an intervention might be well conceived, 
it may not be delivered as intended, and, 
consequently, not remain faithful to its theoretical 
principles.
Another issue to bear in mind is the fact that 
interventions that foster self-efficacy and teach 
sexual health negotiation skills may not necessarily 
be appropriate for all young people. These models 
assume that young people are committed to 
protecting themselves from STIs and that, once 
armed with all the necessary knowledge, skills and 
confidence, will always choose to have safer sex. 
However, this is an unrealistic goal as some young 
people will make a conscious decision to participate 
in unprotected sex, either episodically or routinely. 
The theories underpinning the interventions in 
this systematic review seemed generally more 
geared to enabling young people to recognise 
risks and protect themselves, rather than to help 
those who already have the skills and confidence 
to negotiate safer sex, but choose not to. It is 
important that any future interventions with this 
group should be based on a theoretical perspective 
that accounts for this.
Finally, this systematic review restricted inclusion 
to behavioural interventions in which skills were 
taught within the context of sexual health. It should 
be acknowledged that there are broader school-
based approaches to fostering young people’s 
health (of which sexual health is one outcome), 
which teach broader everyday life skills that can be 
applied in a variety of contexts, including personal 
and sexual relationships.166 The effectiveness of 
such interventions might be a suitable topic for 
future evidence syntheses.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Findings from other systematic 
reviews
The results of other relatively recent systematic 
reviews in this area have been mixed, but generally 
show that behavioural interventions can encourage 
safer sexual behaviours amongst young people, to 
varying degrees.
The Cochrane review of ‘abstinence plus’ 
interventions (i.e. promotion of abstinence from 
sexual activity, but also of condom use and other 
safer sex practices), included 39 randomised or 
quasi-randomised trials, of which 10 were based 
in schools (Underhill and colleagues167). The 
mean age of the participants varied between 
11 to 19 years, and all were based in the USA, 
Canada or the Bahamas. A meta-analysis was 
not performed due to the heterogeneous nature 
of the interventions, and lack of data. Of the 
39 trials, 24 reported a significantly protective 
intervention effect on any sexual risk behaviour 
or biological outcomes. The number of trials 
reporting statistically significant results in favour 
of the intervention varied according to different 
behavioural outcomes: self-reported frequency of 
unprotected vaginal sex (6/12 trials); incidence 
and frequency of all sex (5/21 trials); number of 
partners (4/13 trials); condom use (14/26 trials); 
and sexual initiation (4/19 trials). Statistically 
significant effects on knowledge in favour of the 
intervention were reported in many studies. It was 
concluded that many abstinence-plus programmes 
reduce short- and long-term HIV risk behaviour.
However, a review of abstinence only interventions 
in high-income countries by the same authors 
came to less optimistic conclusions (Underhill 
and colleagues168). Of the 13 randomised or 
quasi-randomised trials included, seven were 
school based. There was no consistent effect on 
unprotected vaginal intercourse, frequency of 
vaginal sex, number of partners, sexual initiation 
or condom use.
Robin and colleagues2 systematically reviewed 
behavioural interventions to prevent HIV/STIs and 
pregnancy amongst young people, and published 
in the 1990s. Of the 20 included studies, nine 
were based in schools. Nine studies were classified 
as having a ‘positive’ effect (defined as a positive 
effect on at least one behavioural or biological 
outcome and no negative effects relative to the 
control group), five studies had ‘null’ effects 
(defined as no differences among groups for any of 
the behavioural or biological outcomes), and three 
had ‘negative’ effects (the intervention had any 
negative impact on one or more of the behavioural 
or biological outcomes, regardless of any positive 
findings).
Johnson and colleagues3 included randomised 
and quasi-experimental trials of HIV prevention 
interventions in young people aged 11–18 years. 
A total of 56 interventions were reviewed, the 
majority of which were delivered in North America, 
and in school or community settings. Statistically 
significant differences in favour of the intervention 
were found for frequency of sex, condom use, skills 
for condom use negotiations, and skills for condom 
use, and communications with a sex partner (based 
on a meta-analysis of effect sizes). Factors cited as 
influencing condom use included interventions 
with condom information and skills training, and 
studies where the comparison group received less 
HIV skills training.
Sales and colleagues169 systematically reviewed STI 
and HIV interventions published in peer-reviewed 
journals between 1994 and 2004, delivered in a 
range of settings for young people aged between 
11 and 22 years. Of the 39 interventions included, 
13 were conducted in schools. Of these three-
quarters reported ‘some behaviour change’ with 
reducing the frequency of unprotected sexual 
intercourse was the most frequent outcome. Several 
studies reported a delay in initiation of intercourse 
and/or a delay in frequency of intercourse. 
Effective interventions were noted to be theory-
based, implemented by trained teachers or health 
educators, and including skills and knowledge-
building activities.
In summary, other published systematic reviews of 
interventions to prevent STIs with young people 
provide a more optimistic picture of the ability 
of behavioural interventions to influence sexual 
behaviour than this systematic review. However, 
these reviews are not wholly comparable with our 
review due to differences in scope and inclusion 
criteria, and, particularly, the fact that they were 
not restricted to school-based interventions.
Methodological quality of 
the outcome and process 
evaluations
The RCTs included in our systematic review were 
of reasonable methodological quality. However, 
poor reporting of factors such as randomisation 
procedure, concealment of allocation and attrition 
prohibited a thorough assessment of quality.Discussion
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It is encouraging that a high proportion of the 
15 outcome evaluations also conducted a process 
evaluation. Process evaluation is essential to explain 
what factors may have contributed to success or 
failure of the intervention, to assess its acceptability 
to the stakeholders involved, the determine 
the fidelity of the intervention delivery, and to 
establish the generalisability and replicability of an 
intervention.170 However, the extensiveness of the 
process evaluations included in this review varied 
from cursory monitoring of intervention activities 
to larger scale, comprehensive quantitative and 
qualitative evaluation of multiple aspects of the 
intervention. The two UK-based studies included in 
the review both conducted comprehensive process 
evaluations, with extensive data reported in a 
number of publications50,70 (see Appendix 7 for a 
bibliography of these).
Improving the quality and extent of process 
evaluations would add much value for assessments 
of the effectiveness of complex interventions, such 
as the ones under consideration in this review. 
Process evaluations of experimental interventions 
should be more than superficial monitoring 
exercises. Ideally, process evaluations should 
collect a range of qualitative and quantitative data 
on intervention fidelity, programme reach, and 
provider and user perspectives on the intervention. 
The collection of qualitative data is particularly 
important for understanding how contextual 
factors affect implementation and acceptability and 
for an assessment of the potential generalisability 
of an intervention.
The wider evidence base
The descriptive map reported in Chapter 3 
provides a useful context within which to discuss 
the results of the systematic review. The majority 
of studies included in the map, and the systematic 
review itself, were conducted in the USA. This 
has been the case in health promotion systematic 
reviews in other areas, such as healthy eating,33 
and reflects the strong tradition of experimental 
evaluation of social interventions in the USA over 
the decades.171,172
Many of the interventions mapped were delivered 
in schools by teachers and/or peers. Although there 
were some examples of outreach interventions 
located in community settings, the predominance 
of school-based activities raises the question of 
whether the needs of the most vulnerable young 
people are being met. School activities are not 
likely to reach those persistently absent from 
school, young people who have left school early, or 
young offenders. They may not necessarily appeal 
to young people who are disaffected by school and 
the education system in general,173 although the 
influence of credible peer educators may help to 
overcome this. As explained earlier, school-based 
interventions were prioritised for our systematic 
review because, in consultation with stakeholders, 
it was considered that they were likely to reach the 
greatest number of young people. The systematic 
review potentially could have focused on a different 
subset of studies from the map that specifically 
included young people classified as being ‘at 
risk’ (refer back to Chapter 3, Table 9). However, 
this would have resulted in a systematic review of 
a more diverse set of interventions, in terms of 
factors such as setting and provider, which would 
have made comparison between studies more 
problematic. This does not, though, preclude 
such a systematic review in the future. One of 
the advantages of this kind of descriptive map is 
that it is a resource that can be used to identify 
and prioritise different topics for future evidence 
syntheses in accordance with policy needs (see 
Chapter 9, Recommendations for research).
Discussion of the results of 
the economic evaluation
Our systematic review of cost-effectiveness studies 
identified only five economic evaluations of 
behavioural interventions for the prevention of 
STIs in young people. These all addressed the 
prevention of HIV, but only one study evaluated 
other STIs in addition to HIV. Those studies 
that did not include other STIs are likely to 
have underestimated the potential benefits of 
the interventions. All studies used mathematical 
models extrapolating the changes in sexual 
behaviour to number of cases of HIV averted. The 
evaluations were published between 1998 and 
2005 and were conducted in the USA. With the 
exception of one study for developing countries, 
all studies evaluated the interventions on a US 
population. All interventions were effective in 
improving sexual behaviour in the study groups 
and thus led to cases of HIV averted. There was a 
range in assumptions and parameter values used in 
the mathematical models and this led to substantial 
differences in the estimated cost-effectiveness of 
the behavioural interventions.
The model developed in this study allows us to 
estimate the cost-effectiveness of behavioural 
interventions for preventing STIs in young people. DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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However, as the meta-analysis in Chapter 4 (see 
Sexual behaviour) has not shown a statistically 
significant intervention effect, the results presented 
should be treated with caution and only be 
regarded as illustrative. Based on a pooled RR 
estimate for condom use of 1.05 (95% CI 0.92 to 
1.20) for behavioural interventions, the model 
estimated that three STI cases would be averted 
(saving 0.5 QALY) in a cohort of 1000 boys and 
1000 girls aged 15 years. The majority of avoided 
STI cases are for chlamydia. The incremental 
cost-effectiveness figures of the teacher- and 
peer-led behavioural interventions were £20,223 
and £80,782 per QALY gained, respectively. The 
relatively high cost for the peer-led intervention 
arises from the assumption that peer educators 
are assumed to provide sex education for only 1 
year, hence training costs are incurred every year, 
whereas teachers are assumed to be retrained 
every 5 years. Sensitivity analyses show the results 
were most sensitive to the intervention effect, the 
STI transmission probability and the number 
of sexual partners in the base-case analysis. The 
model results were also sensitive to changes to the 
model parameters for chlamydia, and especially 
for parameters related to tubal infertility. In a PSA, 
the probability of the teacher-led intervention 
being cost-effective was 46% at a willingness-to-pay 
threshold of £20,000 and 54% at a willingness-to-
pay threshold of £30,000.
Few studies that have estimated the cost-
effectiveness of interventions to prevent STIs have 
used estimates of QALYs.26 Rather, they have used 
other outcome measures such as cost per major 
outcome averted or cost per case avoided.25,59 
Adams and colleagues146 commented that the 
QALY is the common measure used by decision-
makers in the UK and elsewhere, and the use of 
major outcomes averted implies that all of the 
major outcomes are equal, which is unlikely to be 
the case. They recommended that more research is 
needed to determine QALY values for chlamydia 
states. We reviewed quality-of-life studies for STIs 
and a small number of studies that were used to 
estimate quality of life for individuals who have 
complications as a result of STIs.
We also conducted a value of information 
analysis, which found that the upper bound on 
research expenditure would be £12.5M, for a cost-
effectiveness ratio of £20,000 per QALY assuming 
a 10-year lifetime for the intervention (i.e. the time 
until a new intervention supersedes or replaces 
it). An analysis of the individual parameters used 
in the model, revealed that research would be 
best funded to establish the intervention effect for 
condom use from a school-based behavioural STI 
intervention, as this parameter has a substantially 
higher EVPPI than any other model inputs, and 
accounts for more than half of the decision EVPI 
(£10.2M).
Strengths, limitations and 
uncertainties of this report
Systematic review of 
effectiveness
One of the strengths of this review is its adherence 
to rigorous systematic review methods. We 
conducted exhaustive searches, applied explicit 
inclusion criteria to search results, critically 
appraised included studies and used transparent 
methods to synthesise study findings. A further 
strength is our incorporation of two relatively 
new and innovative review elements. Firstly, we 
conducted the review in two stages with an initial 
mapping stage followed by a systematic review 
of a subset of studies. This process facilitated 
the involvement of end-users in the design of 
the review. After our map was completed we 
consulted with our advisory group to ensure that 
any subset of studies we focused on was relevant 
and coherent in terms of policy and practice. 
Secondly we included, quality assessed and 
synthesised process evaluations. This enabled us 
to explore, in a systematic way, factors influencing 
the implementation of the intervention and 
to generate an explanation for the outcomes 
reported.
Despite its strengths the review had limitations. 
It was preferable for the subset of studies in the 
systematic review to be homogeneous in terms of 
intervention characteristics (e.g. provider, setting, 
materials, length/intensity, etc.) to ensure that 
their aggregation in a quantitative meta-analysis 
was meaningful and appropriate (i.e. that ‘like was 
being compared with like’). Whilst prioritising what 
appears on face value to be a fairly standardised 
behavioural intervention (i.e. school-based 
education and skills development sexual health 
promotion) there was, nonetheless, some degree of 
variation between the studies. As mentioned above, 
some interventions were relatively brief whilst 
others more extensive. Some were curriculum 
focused, whilst others were delivered in the context 
of wider school sexual health promotion initiatives, 
and supplemented by activities in the home 
and community. Furthermore, although all were 
included because they included an element of skills Discussion
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development, the type of skills taught, and the 
extent to which this was a focus of the intervention, 
varied. Some were theory-based interventions, 
designed specifically to improve sexual negotiation 
skills, whilst others provided relatively little 
rationale for skills training. This variability should 
be kept in mind in the interpretation of both the 
narrative synthesis and the meta-analysis.
The potential to perform meta-analysis was limited 
primarily by the lack of suitable data from the 
study publications. Common limitations included 
failure to report a measure of variance (e.g. SD) 
to allow continuous outcomes to be combined, or 
poor reporting of the number of young people 
with a given outcome (e.g. using a condom) to 
allow binary outcomes to be pooled. Our attempts 
to contact the authors to kindly request missing 
data were generally unsuccessful, as many did 
not reply to our e-mails. Although some of the 
studies were carried out some years ago, many of 
the authors still appear to be actively researching 
this area. Consequently, only a small proportion 
of the studies were able to be meta-analysed. 
Whilst one of the strengths of the meta-analysis 
was that it was only based on studies judged to be 
methodologically sound, not all of these studies 
were able to be included in it due to poor reporting 
of data.
Another issue to bear in mind is the fact that, 
despite a relatively narrow age range (13–19 
years), it cannot be assumed that teenagers are 
a homogeneous group. There are likely to be 
numerous differences between younger and 
older teenagers in terms of social and sexual 
development. We have endeavoured, where 
possible, to take these differences into account 
in the analysis and interpretation of our results, 
although data on age subgroups are limited. It 
is also important to acknowledge that a number 
of studies that targeted young people aged up to 
their early to mid-twenties were excluded from our 
descriptive map (and hence our systematic review). 
These were not included as the commissioning 
brief for this project specified inclusion of young 
people aged 13–19 years. We also noted that 
much of the epidemiological and sexual lifestyle 
data relating to young people is for the 16–25 age 
group. Further evidence synthesis could therefore 
examine the clinical effectiveness and cost-
effectiveness of behavioural interventions in this 
older group.
Economic evaluation
Our economic evaluation is one of the few 
published examples of an assessment of the 
cost-effectiveness of school-based behavioural 
interventions, particularly in the UK. It was 
informed by a systematic review of effectiveness 
and cost-effectiveness studies, and systematic 
searches for input parameter data.
Despite these strengths it is subject to limitations. 
As reported in Chapter 4 (see Sexual behaviour), 
our meta-analysis did not show a statistically 
significant intervention effect for behavioural 
outcomes. Absence of a statistically significant 
difference between behavioural intervention 
and standard sex education does not necessarily 
indicate that they are equivalent in terms of 
effect. However, rather than present a cost-
minimisation analysis, which would be commonly 
be performed in this situation, we chose to report 
how a simple static model could provide illustrative 
estimates of the likely cost-effectiveness of two 
types of school-based behavioural intervention. A 
quantitative analysis of the impact of uncertainty 
on these illustrative results was undertaken using 
probabilistic sensitivity analysis, along with an 
indication of the likely cost and benefit of future 
primary research, via expected value of perfect 
information analysis. The static nature of the 
model does not take into account the dynamic 
nature of infectious diseases. However, a more 
pragmatic approach was considered appropriate, 
given the absence of key data for parameters 
needed to develop, calibrate and validate a robust 
dynamic model.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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T
here is an extensive evidence base for the 
prevention of STIs in young people. Much 
of it focuses on the prevention of HIV through 
school-based behavioural interventions. The 
literature is dominated by evaluation studies 
conducted in North America, although there is a 
not insignificant volume of evidence from resource-
poor countries. Relatively few examples of UK 
interventions have been published.
This project has focused on one type of behavioural 
intervention – school-based programmes that 
provide information and teach young people sexual 
health negotiation skills. The results show that 
these programmes can bring about improvements 
in knowledge and increased self-efficacy. However, 
there were few significant differences between the 
intervention and comparator in terms of changes 
in behavioural outcomes such as condom use. 
The studies conducted relatively short follow-up 
assessments at a time when many young people 
were becoming sexually active. It is possible that 
favourable behaviour change may have occurred 
with time, particularly as sexual activity becomes 
more routine in young people’s lives.
School-based skills and information interventions 
should therefore be used when the objective is 
to improve knowledge, and to foster favourable 
attitudes, peer norms and behavioural intentions 
(particularly for those not yet sexually active). 
Practitioners and policy-makers should have 
realistic expectations about the potential for 
interventions to influence sexual risk behaviour 
and infection rates until further evaluation 
evidence is available.
There is uncertainty around the results of our 
economic evaluation results due to the uncertainty 
around the effect of intervention on behavioural 
outcomes. The model results were most sensitive to 
changes in parameter values for the intervention 
effect and the transmission probability of STIs. 
Teacher-led interventions are likely to be cheaper 
than peer-led interventions.
Recommendations for 
practice
School-based skills building behavioural 
interventions should be delivered to improve 
knowledge, promote favourable attitudes, and 
increase self-efficacy and the skills necessary to 
engage in safer sexual behaviour, in accordance 
with health policy.21,22 Interventions should be 
culturally relevant and context specific, taking 
into account the self-defined needs of subgroups 
of young people (e.g. young men, young women, 
levels of sexual experience) and, where possible, be 
part of a whole-school approach to sexual health 
promotion. Young people should be involved as 
equal stakeholders in the design and delivery of 
interventions.
Careful consideration should be given to the 
choice of intervention provider. Providers need 
to be enthusiastic and credible, with considerable 
expertise in classroom management and the 
delivery of skill-building activities, such as role 
plays and group discussions. Providers also need 
expertise in handling sensitive discussions about 
sex and relationships, and an appreciation of how 
wider sociocultural norms can influence sexual 
health. Teachers and peers alone may not possess 
all of these skills and qualities.
Attention should be paid to encouraging 
the full implementation of any skills-based 
intervention. The interactive learning elements 
of an intervention have been found to be 
especially vulnerable to being omitted, but 
it is these elements that may be the crucial 
ingredient for empowering young people to 
practice safe sex behaviours. A supportive school 
culture, which includes ‘buy in’ from the senior 
management team, can facilitate full intervention 
implementation. This echoes recommendations 
made by others, including the suggestion that 
improving pupils’ satisfaction with school is a 
prerequisite to effective sexual health promotion.173
Chapter 9  
ConclusionsConclusions
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Recommendations for 
research
Primary research
If a further RCT of school-based sexual health 
education were to be commissioned in the UK it 
would be useful to evaluate the approach taken 
in one of the more effective studies included in 
our review, such as an adaptation of an approach 
similar to the Safer Choices intervention evaluated 
in the USA.
The intervention should comprise a range of 
components, including curriculum activities spread 
over at least two school years (single-sex lessons 
where necessary and feasible), accompanied by 
wider school health promotion activities, plus 
involvement of parents and, where necessary, 
health services (e.g. to encourage STI testing) and 
other relevant stakeholders (e.g. youth workers). 
A possible approach for evaluation would be 
for teachers and/or peers to provide factual 
information about STIs, with specialist trainers 
brought into schools to teach skills development. A 
pilot phase using qualitative research should assess 
the cultural and social relevance to the UK, and 
adaptations made accordingly.
The effectiveness of ‘booster’ sessions for young 
people progressing to further education and 
for those leaving full-time education should be 
explored. The aim would be to encourage sexually 
active young people to maintain protective 
behaviours, and to support those beginning to have 
sex in the adoption of safer behaviours.
All future evaluations should be rigorously 
designed and executed, with long-term follow-up 
of a range of outcomes, including sexual behaviour 
(e.g. condom use), conceptions and abortions, use 
of health services (e.g. STI testing) and rates of 
infections. Evaluations need to adequately measure 
the complexity of some young people’s risk-
reduction strategies, assessing use of negotiated 
safety strategies with partners.
Outcome evaluations should be accompanied by 
extensive process evaluation, and have an integral 
cost-effectiveness evaluation.
Research commissioners, journal editors and 
other relevant research stakeholders should 
encourage researchers to undertake analyses to 
assess the impact of interventions on sexual health 
inequalities. They should further encourage 
complete reporting of data and methods of 
analyses that investigate the impact of an 
intervention on the health outcomes of different 
sociodemographic groups.
Journal editors should subscribe to the revised 
Consolidated Standards of Reporting Trials 
(CONSORT) statement, which is intended to 
improve the overall reporting of RCTs,174 and 
the Transparent Reporting of Evaluations with 
Nonrandomised Designs (TREND) statement 
for improving the reporting of non-randomised 
evaluations of behavioural and public health 
interventions.175 These include guidance on 
appropriate reporting of outcome data and 
subgroup analyses.
Evidence synthesis
Further evidence synthesis would be appropriate 
to identify a subset of studies from our descriptive 
map with a particular focus on interventions aimed 
at young people classified as being vulnerable 
and at risk. It should be acknowledged that this 
would likely result in a more heterogeneous set 
of interventions in terms of setting, provider and 
message.
The effectiveness of skills development 
interventions in other (non-school) settings is 
also an important subject for evidence synthesis, 
complementary to this systematic review.
The effectiveness of broader school-based 
approaches to fostering young people’s health, 
which teach everyday life skills that can be applied 
in a variety of contexts, including personal and 
sexual relationships, might be a suitable topic for 
future evidence syntheses.
Evidence synthesis could also examine the clinical 
effectiveness and cost-effectiveness of behavioural 
interventions in the 16–25 age group.
Cost-effectiveness
As specified above, any future primary research 
conducted should be accompanied by detailed 
economic evaluation to assess cost-effectiveness. 
Detailed data of the costs of mounting the 
intervention should be collected, and the impact 
on HRQoL should be assessed to enable cost–utility 
analysis. The analysis should extend over a time 
horizon that is long enough to capture all of the 
intended costs and consequences (e.g. until young 
people are in their early twenties).
For many of the parameters used to inform our 
economic model there were few or no available DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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data for the < 16-year-old age group, necessitating 
assumptions to be based on extrapolated data from 
older age groups. For example, there were few 
data on self-reported sexual behaviour of under-
16s (e.g. number of sexual partners or episodes). 
The third National Survey of Sexual Attitudes and 
Lifestyles will commence in 2010, although as yet 
it does not appear that data on under-16s will be 
collected. There is a need for surveys such as this to 
collect data on younger teenagers, where possible, 
to inform research and enable the effective 
planning of services.
There is also a need for prospective cohort studies 
to inform the parameters used in economic 
modelling (e.g. transmission probabilities of STIs).
In order to reduce the uncertainty in the 
economic evaluation, analyses indicated that it 
is likely to cost up to £12.5M in order to obtain 
perfect information and that research would 
be best funded to establish the effectiveness of 
the intervention in terms of condom use, as this 
parameter has the largest effect on the uncertainty 
of the model results.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Planned investigation
Background
Epidemiology and policy context
Rates of sexually transmitted infections are 
continuing to increase in the UK, particularly 
among young people. Genital chlamydia is 
currently the most common STI diagnosed in 
GUM clinics in the UK. The number of cases has 
risen steadily since the mid-1990s, and rose by 5% 
(104,733–109,958) between 2004 and 2005.1 There 
have also been increases in rates of gonorrhoea, 
genital herpes and genital warts. Rates of also HIV 
continue to rise. At the end of 2005, an estimated 
63,500 adults aged 15–59 were living with HIV 
in the UK. Young people aged 16–24 account for 
about 11% of HIV diagnoses each year.2
If undiagnosed and untreated, STIs can lead to 
serious long-term complications, such as infertility, 
PID (in women) and epididymitis (in men). Certain 
types of HPV, for example, are associated with 
cervical carcinoma.3 HIV is associated with disease 
progression to AIDS and related complications, 
and, if untreated, results in mortality. The impact 
of increases in the incidence and prevalence of 
STIs over recent years has placed great demand 
on health services. Data from the NATSAL show 
an increase in the number of individuals attending 
GUM services4 over a 10-year period. Between 
1990 and 2000 there was an increase of 4.3–7.6% 
in men and 3.3–6.6% among women. This may 
be explained by increases in rates of STIs, but it 
is also due to widening access to clinic services 
and encouraging asymptomatic screening. The 
average lifetime treatment costs for an HIV-positive 
individual is estimated to be between £135,000 and 
£181,000.5
Prevention of STIs and teenage pregnancy is 
currently a high priority for health policy.6 In 
2001, the National Strategy for Sexual Health and 
HIV was published, demonstrating a commitment 
to tackling sexual ill-health and unintended 
pregnancies through improved prevention and 
treatment.5 A key aim of the strategy is to address 
health inequalities and the needs of vulnerable 
groups, including (amongst others) young people, 
particularly those in, or leaving, care.
Defining risk
Sexual health is influenced by a complex 
interplay between a number of factors, including 
the individual, their sexual partners, and their 
social and economic environment. In terms 
of demographic factors, epidemiological data 
illustrate variability in the incidence and prevalence 
of STIs according to age, gender and geographical 
location. Recent routine surveillance data from the 
HPA show that young women aged 16–19 years 
have the highest rates of infection of gonorrhoea, 
chlamydia and genital warts.1,7,8 The NATSAL 
(2001)9 found that early age at first intercourse 
was significantly associated with pregnancy under 
18 years. HPA data also show a marked difference 
in geographic distribution of gonorrhoea and 
chlamydia infection in young people, with London 
having the highest rate of diagnosis, followed by 
Yorkshire/Humberside and the North West.1,7
Lack of knowledge, low self-efficacy and poor 
condom use/sexual negotiation skills are examples 
of personal risk factors for STIs. These have 
been addressed by interventions that provide 
factual information and skills training. Peer group 
norms also influence risk taking, and peer-led 
interventions have been designed to evaluate the 
effectiveness of harnessing peer influence.10,11
Ethnicity is commonly associated with poor 
health. Data from the NATSAL probability 
survey show that some ethnic populations are 
more at risk than others. Black African and black 
Caribbean respondents were significantly more 
likely to report early sexual debut (before age 
16), previously diagnosed STIs, HIV testing and 
GUM clinic attendance than Indian and Pakistani 
respondents.12 Black Caribbean respondents were 
significantly more likely to report GUM clinic 
attendance, STI diagnosis and ever having an HIV 
test than white men and women. It is suggested 
that the younger age, single marital status and 
early age of first intercourse of black Caribbean 
people relative to other ethnic groups could 
explain the findings.
Socioeconomic status has long been considered 
to be a key determinant of health.13 A number of 
inter-related factors account for this, including low 
income, lack of autonomy, social exclusion, poor 
lifestyles and poor access to health care.14 Low SES 
and other factors related to social disadvantage 
are strongly associated with teenage pregnancy.15 
Research indicates that a combination of access 
to services and the chance to gain the education 
and employment needed to succeed reasonably 
in society is associated with lower rates of teenage 
pregnancy.9,16DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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�Behavioural interventions
There is no precise definition of a behavioural 
intervention, and concepts and practices vary, 
but, in general, a behavioural approach might 
be viewed as an intervention that addresses the 
health needs of an individual or a population, with 
the aim of encouraging favourable health-related 
behaviours. Behaviours are mediated, in part, 
by improving knowledge, self-confidence, self-
efficacy, and encouraging more favourable attitudes 
and behavioural intentions. Some behavioural 
interventions are explicitly based on social or 
psychological theories of behaviour change, for 
example the Stages of Change (‘transtheoretical’) 
model.17
The ‘message’ of the behavioural intervention 
reflects the particular needs of the recipients, 
as well as the underlying ideology/policy of the 
provider. For example, messages could be about 
maintaining safer sex in those who are sexually 
active, reducing risks in those who are at increased 
risk or encouraging abstinence/deferring of sexual 
activity among those who are not yet sexually 
active. Intervention activities can vary, from the 
provision of confidential information and advice 
around sex and STIs to skills training on how to 
use condoms and negotiate safer sex with a partner. 
Sometimes these activities may be integrated within 
the context of screening, testing and health care.
The classification of behavioural interventions 
proposed by Darbes and colleagues (2002)18 will be 
used as a working definition in this study:
•  Behavioural interventions  These are 
interventions that aim to change only 
individual behaviours, without explicit or 
direct attempts to change the norms of the 
community or the target population as a 
whole. Components of such interventions 
would include counselling, HIV testing and 
counselling, peer education, referrals, skills 
training, and the provision of risk-reduction 
materials.
•  Social interventions  These are interventions that 
aim to change not only individual behaviours, 
but also social norms or peer norms. Strategies, 
such as community mobilisation, diffusion, 
building networks, and structural and resource 
support, are often used to bring about changes 
in social norms and/or peer norms.
•  Policy interventions  These are interventions 
that aim to change individual behaviour 
or peer/social norms or structures through 
administrative or legal decisions. Examples 
include needle-exchange programmes, condom 
availability in public settings, and mandated 
HIV education in all schools of a district.
Current UK practice
In current UK practice, behavioural interventions 
to prevent STIs are provided by services such as 
primary care, community family planning, GUM, 
primary care trust health promotion services and 
the voluntary sector (e.g. Brook Advisory Centres). 
Sexual health promotion is also provided in schools 
and colleges as part of the curriculum, as well as 
being a component of school-based health services. 
A variety of people are involved, including health 
professionals, teachers, social workers, youth 
offending teams, prison and probation services, 
and parents and young people themselves. In some 
cases they collaborate to provide multicomponent 
interventions. Behavioural approaches, therefore, 
may potentially encapsulate a wide variety of 
interventions with diversity in terms of provider, 
setting and message.
Cost-effectiveness of behavioural 
interventions
Searches of electronic bibliographic databases 
conducted for this protocol yielded a variety 
of published cost-effectiveness analyses of STI 
prevention interventions. However, not all of these 
featured young people,19 or could be classed as 
behavioural interventions,20 and many were based 
on evaluations of interventions conducted in the 
USA, dating back to the late 1980s/early 1990s.21 
These are of questionable relevance to the UK at 
the current time, where service provision and the 
epidemiology of STIs may be quite different.
For example, Pinkerton and colleagues22reported 
the cost-effectiveness of a RCT of an intensive 
1-day cognitive–behavioural HIV-risk-reduction 
intervention for African-American young men 
in Philadelphia. The intervention, originally 
conducted in 1988, aimed to increase knowledge 
of HIV/AIDS and to weaken problematic attitudes 
towards risky sexual practices. Control group 
participants attended a similarly designed 
workshop, with a focus on career opportunities 
instead of sexual health. The intervention was 
associated with favourable changes in number of 
partners, and use of condoms. A mathematical 
model was used to translate changes in sexual 
behaviour into the probability of HIV transmission 
for intervention and control groups. For each 
infection averted, the savings in future HIV-related 
medical care costs and QALYs was estimated. 
The intervention averted 0.8% of an infection, Appendix 1
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corresponding to savings of around US$1500 in 
future HIV/AIDS-related medical care costs, and 
one-tenth of a QALY over an assumed 1-year 
duration of effectiveness. The cost per QALY saved 
was around US$57,000, which fell to US$28,000 
in the subset of participants who reported sexual 
activity in the 3 months preceding the intervention. 
Results were sensitive to assumed duration of 
intervention effectiveness, discount rates, staff 
training costs, and baseline HIV prevalence in the 
population. The authors debate a key issue, namely 
how relevant the risk-reduction messages and skills-
building techniques used in the 1988 intervention 
are to young people today.
In terms of UK-based cost effectiveness 
assessments, NICE have published public health 
guidance on sexual health.23 The guidance 
covers one type of behavioural approach, that 
is, one-to-one interventions. Effectiveness data 
are derived from an accompanying rapid review 
of international RCTs, evaluating counselling 
interventions. Cost–utility estimates are reported 
for each of the included RCTs, based on a 
hypothetical cohort of 1000 people receiving the 
intervention and the comparator, respectively. 
There was wide variation in estimates, with costs 
per QALY ranging from £3200 to £96,000. 
Variation in the intensity of the intervention, and, 
consequently, the costs for staff time was a key 
driver of cost-effectiveness. The authors noted 
that effect estimates (i.e. rates of STIs) reported in 
the RCTs were higher than would be expected in 
England, suggesting uncertainty in the findings.
In summary, that there is a paucity of published 
cost-effectiveness studies of behavioural approaches 
to STI prevention that are relevant to the UK, 
underscoring the need for up-to-date policy-
relevant cost-effectiveness analysis. It will be 
important for such analysis to carefully assess 
the applicability of data from interventions 
originally designed for specific cultural groups and 
populations in other countries to young people in 
the UK at the current time.
Rationale for the study
There is a large body of published primary research 
on the effectiveness of interventions to prevent 
STIs (and unintended pregnancy) amongst young 
people, much of it non-UK literature. Several 
systematic reviews have been published over the 
years summarising this research.24–26 In 2004, the 
former Health Development Agency (now the 
Centre for Public Health Excellence at NICE) 
assessed these systematic reviews in its series of 
Evidence Briefings.27-29 The briefings suggested 
that we do not yet have a clear picture of the 
effectiveness of behavioural interventions for the 
prevention of STIs amongst young people. There 
was only ‘tentative’ evidence from systematic 
reviews that specific behavioural approaches, such 
as individual risk counselling can be effective, and 
that interventions that promote risk reduction, 
rather than abstinence alone, are more likely to 
be effective. There was ‘insufficient’ evidence 
from systematic reviews to support or discount the 
effectiveness of detached education or outreach 
interventions, or that school-based abstinence only 
approaches are effective. Many of the systematic 
reviews and economic evaluations included in 
the Evidence Briefings are now out of date. A 
thorough assessment of the effectiveness and cost-
effectiveness of behavioural approaches to STI 
prevention in young people, particularly those 
at higher risk, is therefore important to meet the 
needs of policy and practice.
Research aim
Research question: What is the effectiveness 
and cost-effectiveness of different behavioural 
approaches in preventing STIs among young 
people aged 13–19 years?
Objectives 
The main objectives will be as follows:
•  to conduct a systematic review of the 
effectiveness of different behavioural 
approaches to the prevention of STIs
•  to assess the cost-effectiveness of different 
behavioural approaches through economic 
modelling, where appropriate.
Research methods
Systematic review of effectiveness
A two-stage systematic review will be conducted.
Stage one – descriptive mapping exercise
The first stage will be a descriptive mapping of 
studies meeting a set of inclusion criteria (Table 70). 
Relevant studies will be classified on the basis of 
their key characteristics according to a standardised 
classification system for public health and health 
promotion research,30 using the web-based 
systematic review software eppi-reviewer.31 For more 
information on eppi-reviewer visit http://eppi.ioe.
ac.uk/cms/Default.aspx?tabid=184)
It will prove difficult to search for evaluations 
of behavioural interventions to prevent STIs in 
young people who are considered to be high risk, 
as few relevant index terms exist in electronic 
bibliographic databases to enable more specific DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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searches. The purpose of this exercise, therefore, 
is to facilitate a more detailed description of the 
evidence base so that a subset of policy-relevant 
studies may be subjected to detailed systematic 
review. The completed descriptive map will be 
presented to the project’s advisory group, who 
will be asked to help prioritise a subset of studies 
that most closely resemble current UK practice, 
which are most likely to address current policy 
and practice needs (for more information on the 
Advisory Group, see section Advisory group).
Studies will be classified according to:
•  subgroups of young people, based on markers 
of their ‘risk’ of acquiring an STI (e.g. SES, 
ethnicity, educational status, geographical 
location, STI history, HIV status, self-reported 
risk behaviour)
•  STI(s) under focus (e.g. HIV/chlamydia/
gonorrhoea/genital warts/non-specific 
urethritis)
•  intervention evaluated (e.g. education/skills 
training/counselling/provision of resources and 
services)
•  intervention provider (e.g. teacher/youth 
worker/peer/health professional/social worker)
•  intervention setting (e.g. school/community/
youth group/health care/outreach/home)
•  country and location (e.g. UK/rural/urban/
coastal)
•  outcome (e.g. different sexual behavioural 
outcomes/STI infection rates).
Stage two – in-depth systematic review
The second stage will be a detailed systematic 
review in which a prioritised subset of studies 
from the descriptive map will undergo detailed 
data extraction, critical appraisal and synthesis, 
as described below. The inclusion criteria for this 
second stage will be further defined following 
presentation of the completed descriptive map to 
the project’s advisory group.
Literature search
Study reports will be identified from the following 
sources:
•  bibliographic databases (commercial and 
specialist); hand searching of key journals 
(where necessary); citation searches of 
key authors; reference lists of key papers; 
references on key websites; personal contacts/
advisory group; direct requests to key 
informants
•  six published EPPI-Centre reviews, which cover, 
amongst other topics, sexual health.10,32–36
The following electronic bibliographic databases 
will be searched:
•  MEDLINE (via Ovid)
•  MEDLINE In-Process & Other Non-Indexed 
Citations (via Ovid)
•  EMBASE (via Ovid)
•  PsycINFO (via Ovid)
•  Educational Resources Information Centre 
(ERIC) (via CSA)
•  CINAHL (via Ovid)
•  Trials Register of Promoting Health 
Interventions (TRoPHI – the EPPI-Centre 
register of RCTs and non-randomised 
controlled trials)
•  The Cochrane Central Register of Controlled 
Trials (CCRCT)
•  Applied Social Sciences Index and Abstracts 
(ASSIA) (via CSA)
•  POPLINE
•  Sociological Abstracts (SOCABS) (via CSA).
The following websites will also be searched to 
identify relevant studies:
•  The UK National Library for Health (NLH) –
www.library.nhs.uk/Default.aspx
•  UNAIDS –www.unaids.org/en/
•  Google Scholar – http://scholar.google.co.uk
Searches will take place for the period 1985 to the 
present. Non-English language articles will not be 
included.
Highly sensitive search strategies will be developed 
in order to retrieve a high volume of references 
using combinations of controlled vocabulary and 
free-text terms (the latter restricted to the title or 
abstract fields). There will be four sets of search 
terms: young people and STIs and prevention and 
outcome evaluations.
Personal contact will be made with key researchers 
and other systematic reviewers in the fields of STI 
prevention. Requests for further relevant studies 
will be made to the authors of relevant outcome 
evaluations, and to members of the advisory group. 
The reference lists of studies already identified will 
be scanned for potentially relevant reports.
References will be uploaded to eppi-reviewer, 
where they will be stored ready for screening. Appendix 1
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TABLE 1  Stage one – inclusion criteria for descriptive mapping exercise
Population Young people aged 13–19 years (as specified in the HTA commissioning brief)
Design Outcome evaluations (RCT or non-randomised controlled trial)
‘Outcome evaluations’, defined as studies designed to establish whether the intervention changes the 
outcomes specified in the aims of the study. We will only include studies that have used a control or 
comparison group(s) (whether randomised or not). Outcome evaluations that include an integral cost-
effectiveness analysis will also be included and results reported.
We will also consider any process data collected within the outcome evaluations to explore issues of 
acceptability, feasibility and generalisability. Process data will also be used to identify factors associated 
with intervention effectiveness (see section Data Synthesis)
Studies reported in abstract form only (e.g. conference proceedings) will only be included if they are 
published on or after 2005
Intervention We propose an inclusive strategy and define behavioural interventions as ‘any activity to encourage 
young people to adopt behaviours that will protect them from acquiring STIs’
Comparator The commissioning brief states that the comparator should be ‘standard practice’. Current service 
provision in the UK is variable and it is difficult to define standard practice. Potentially eligible studies are 
likely to have included a range of comparators. In some studies the intervention will have been given in 
addition to standard practice (e.g. behavioural skills training in addition to information provision plus vs 
information provision only). We will not exclude studies on the basis of comparator, but will be guided by 
our expert advisory group on which comparators most closely resemble UK practice
Outcomes Studies that report the impact of the intervention on a sexual behavioural outcome will be included. For 
example:
Self-reported condom use (e.g. frequency of use)
Numbers of sexual partners (including abstinence)
Studies reporting incidence/prevalence of STIs are to be included, provided that they have also reported 
a behavioural outcome
Studies reporting pregnancy-related outcomes (e.g. rate of conceptions) can be included, provided that 
they have included a sexual behaviour outcome
In addition to the above, data on other outcomes that mediate behaviour change may be extracted 
where available (e.g. changes in knowledge; attitudes, intentions, skills, self-efficacy)
De-duplication will take place to remove 
duplicate references found within, and between, 
bibliographic databases.
A separate search will be conducted to identify 
systematic reviews of the effectiveness of 
behavioural interventions to prevent STIs. The 
primary purpose will be to check the bibliographies 
of relevant systematic reviews to identify any 
relevant outcome evaluations. The search for 
systematic reviews will be based on those conducted 
for the Evidence Briefings on STIs and HIV.27,28 
As these briefings searched up to 2003, our 
search will commence from 2003 to the present. 
Databases to be searched will include: Cochrane 
Database of Systematic Reviews (CDSR); Database 
of Abstracts of Reviews of Effectiveness (DARE); 
MEDLINE (Ovid); MEDLINE In-Process & Other 
Non-Indexed Citations (Ovid); EMBASE (Ovid); 
CINAHL (Ovid); British Nursing Index; PsycINFO; 
Educational Resources Information Centre (ERIC); 
and Sociological Abstracts.
Study inclusion
The planned inclusion criteria for the descriptive 
mapping exercise are shown in Table 70. Inclusion 
and exclusion criteria will be applied successively 
to titles and abstracts by one reviewer. Full reports 
will be obtained for those studies that appear to 
meet the criteria or where there is insufficient 
information from the title and abstract. Full reports 
will be assessed by two reviewers independently. 
Disagreements will be resolved through discussion 
and recourse to a third reviewer if necessary. 
A QUOROM-style flow chart will be used to 
document the numbers of studies included and 
excluded at each stage of the review.
Data extraction
A standardised framework will be used to collect 
data from outcome evaluations and entered into 
eppi-reviewer. This framework was developed 
specifically for studies in health promotion 
and public health and has been successfully DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
127
used in over 20 published systematic reviews. 
The guidelines enable reviewers to extract 
data on: the development and content of the 
intervention evaluated; the design and results 
of the outcome evaluation; details of any 
integral process evaluation; and data to assess 
the methodological quality of the outcome and 
process evaluation. The guidelines pay particular 
attention to generalisability and applicability of 
the intervention, which will be important in order 
to interpret the transferability of international 
literature to the UK context.
As mentioned earlier (Literature search), some 
of the relevant studies are likely to have been 
included in previous EPPI-Centre systematic 
reviews, and therefore will have already undergone 
data extraction and quality assessment. Data on 
these studies will be retrieved from eppi-reviewer 
for analysis and any further data extraction 
specific to the proposed systematic review. This will 
potentially reduce the workload and is an effective 
use of an existing resource.
Quality assessment
The quality of outcome evaluations will be 
appraised using criteria described in previous 
published EPPI-Centre reviews.10,26,37 This will 
be conducted by two researchers independently. 
Any disagreements will be resolved through 
discussion and recourse to a third team member 
if necessary. Quality criteria include factors such 
as blinding, attrition and loss to follow-up; data 
analysis methods (e.g. intention to intervene, unit 
of analysis); method of allocation to study groups; 
and reliability and validity of data collection and 
analysis methods. Outcome evaluations will be 
categorised into two groups: ‘sound’ and ‘not 
sound’.
‘Sound’ outcome evaluations will be those deemed 
to meet the following four criteria:
1.  employing a control/comparison group 
equivalent to the intervention group on 
sociodemographic and outcome variables
2.  providing pre-intervention data for all 
individuals/groups as recruited into the 
evaluation
3.  providing post-intervention data for all 
individuals/groups, and
4.  reporting on all outcomes – only the results of 
‘sound’ outcome evaluations will be analysed in 
detail.
These criteria, however, only capture some of the 
known sources of bias in outcome evaluations. 
They do not distinguish between RCTs and non-
randomised trials, or between quality of method 
and quality of reporting. We will include, therefore, 
a further category of studies as ‘sound despite 
discrepancies with the four core criteria’. This 
category includes, for example, studies in which 
full pre-intervention data were not presented 
but authors stated that there were no significant 
differences between the groups or differences had 
been accounted for in data analysis.
Data synthesis
Two types of data will be available: numerical 
data in the form of effect sizes from trials, and 
textual data describing interventions, populations, 
outcomes and the results of any process 
evaluations. Statistical methods will be used to 
synthesise effect sizes, where possible, using the 
eppi-reviewer software, and following standard 
methods for statistical meta-analysis.38 Methods 
for the synthesis of process evaluations and 
textual data will be based on methodology from 
our previous work on the synthesis of ‘qualitative’ 
research39,40 and from other groups.41 There will be 
five stages: 
1.  Evidence tables will be prepared to describe 
variation in intervention type, content, setting, 
provider, sample characteristics and type 
of outcome. When available, process data 
will be described on acceptability, barriers 
and facilitators to implementation and 
delivery, coverage/intervention reach, and 
generalisability.
2.  Process data will be synthesised thematically 
using inductive methods that we have 
developed in previous reviews.42 Two reviewers 
will (1) read and re-read these data; (2) 
apply codes to capture the content of these 
data; and (3) group and organise codes into 
higher-order themes. These themes will be 
used to illuminate issues of acceptability, 
barriers and facilitators to implementation 
and delivery, coverage/intervention reach, and 
generalisability, and to generate hypotheses 
about factors related to intervention 
effectiveness.
3.  Checks for statistical heterogeneity will be 
made and, if appropriate and feasible, effect 
sizes on priority outcomes from individual 
trials will be pooled using statistical meta-
analysis.
4.  Variation in effect sizes will be explored 
according to hypotheses developed in Stage Appendix 1
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Two on factors that may influence intervention 
effectiveness (e.g. do interventions with 
characteristics associated with the acceptability 
of interventions have greater effects than 
those that do not?). Sensitivity analyses will 
be conducted to explore heterogeneity due to 
differences in study quality (e.g. sound/sound 
despite discrepancies).
5.  On the basis of the findings of the above four 
stages, conclusions will be drawn on: which 
interventions are effective for encouraging 
sexual risk reduction and reducing STIs; which 
interventions are appropriate and acceptable 
to young people; the barriers and facilitators 
to intervention implementation and how 
these vary according to different types of 
interventions or settings; and which risk groups 
of young people the interventions reach/do not 
reach.
Economic evaluation
A review of economic evaluations of interventions 
to prevent STIs will be conducted. It is not 
intended that the results be reported as a 
systematic review. Rather, the purpose is to identify 
recent relevant evaluations, in order to analyse the 
methodological approaches undertaken, and to 
discern whether and how existing models can be 
adapted for use in the current project.
Where necessary a decision-analytic model will 
be devised to assess the cost-effectiveness of 
behavioural approaches to STI prevention. The 
exact structure of the model will be designed to 
reflect the natural history of STIs, and will be 
validated through discussion with expert advisors. 
Modelling will be conducted according to accepted 
methodology for economic evaluations.43,44 The 
perspective will be the NHS and PSS.
Model structure
The structure and parameters of the model will 
be informed primarily by the systematic review of 
effectiveness studies. Additional targeted searches 
will be undertaken to identify specific data to 
populate the model. These will include searches for 
data on STI epidemiology and natural history; the 
health-related quality-of-life impacts of STIs and 
their complications; and the cost of behavioural 
interventions and health-care costs. Where these 
data cannot be identified through searches, 
estimates will be based on information supplied by 
our expert advisory group and others.
The model will contain a hypothetical cohort 
of individuals and will estimate changes in STI 
incidence and prevalence following introduction 
of a behavioural intervention. Given that there 
is likely to be substantial variation in the types of 
intervention identified in the systematic review of 
effectiveness, the subset of intervention(s) that most 
closely resemble those used in current UK practice 
will be modelled in the cost-effectiveness analysis. 
The advisory group and other experts will help to 
assess the relevance of the published interventions 
to current practice. Where possible examples of 
different ‘types’ of behavioural intervention will 
be modelled (e.g. interventions to provide basic 
factual information provision; interventions to 
teach behavioural skills; and counselling/cognitive 
behavioural therapy interventions).
The model will provide a cost-consequence 
analysis, reporting the costs of interventions 
included in the systematic review and their 
consequences in terms of STIs prevented. 
The model will also estimate the longer term 
consequences of preventing infections (e.g. 
HIV), in terms of benefits (infections averted, 
improvements in health-related quality of life, 
and life years saved) and costs (e.g. assessing and 
treating the infection and its complications). Cost-
effectiveness will be estimated for subgroups where 
the data allow (e.g. those with a previous history of 
STIs; younger teenagers).
Input data
Changes to the incidence of STIs, where reported 
by studies included in the systematic review of 
effectiveness, will be entered into the model. Where 
data on STIs are not reported by effectiveness 
studies, the impact of changes in self-reported 
sexual behaviour on the incidence of STIs will be 
estimated, where possible. For example, Wang and 
colleagues45 adapted the Bernoulli model of HIV 
transmission to estimate the reduction in primary 
and secondary transmission of HIV and other 
STIs associated with a school-based prevention 
programme. The probability of becoming infected 
was estimated by applying the probability of 
adopting risk reducing behaviour (in this case, 
condom use by students in the intervention 
and control groups) to the per-act transmission 
probability for a given disease and a given sexual 
activity. This model could also be used to estimate 
the impact, in terms of avoided infections, of 
programmes aiming to reduce numbers of sexual 
partners, numbers of sexual acts with each partner 
or reduction in high-risk sexual activity.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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Costs and resource estimation
The resources necessary for providing the 
intervention will be estimated from the systematic 
review of effectiveness, and from discussion with 
expert advisers. This will be supplemented by 
data sought from primary care trusts on the 
resources used and costs of interventions run by 
health service professionals (e.g. costs for condoms 
distributed, costs for human resources to provide 
the intervention). Unit costs for these resources 
will be developed based on data in published 
sources, such as the Unit Costs of Health and Social 
Care, PSSRU.46 Data on the cost of assessing and 
treating HIV and other STIs will be sought from 
Southampton University Hospitals Trust (SUHT), 
who routinely supply the Southampton Health 
Technology Assessments Centre (SHTAC) with cost 
data and clinical expertise.
Costs and benefits will be discounted using 
standard rates (3.5%).47 Uncertainty relating to 
input parameters and assumptions will be explored 
using sensitivity analyses (deterministic and, where 
appropriate and feasible, probabilistic). The key 
variables to be explored will include: intervention 
effect estimates (e.g. self-report behaviour, STI 
incidence); baseline STI prevalence estimates, 
baseline risk (e.g. self-reported behaviour, STI 
history); intervention costs; health-related quality 
of life; and STI treatment costs.
Outcomes
Results will be expressed in terms of incremental 
cost-effectiveness ratios (e.g. incremental costs per 
infection averted). For infections associated with 
long-term morbidity and mortality (e.g. HIV), 
results will be expressed in terms of life-years saved 
and incremental cost per QOLY saved). CEACs will 
be generated in any probabilistic sensitivity analysis 
to illustrate the probability of the intervention 
being cost-effective over a range of willingness-
to-pay values. The model will be developed using 
standard software, such as Microsoft Excel and 
Tree-Age Pro. Although de novo modelling is 
planned, the possibility of adapting an existing 
published model along the lines of the proposed 
model will be explored through contact with 
experts in the field.
Ethical arrangements
No specific ethical arrangements necessary.
Outputs of the review
The results will be reported in a final report to the 
HTA programme, for publication as a monograph 
in the Health Technology Assessment series. A 
series of publications describing different aspects 
of the project (e.g. effectiveness results from 
outcome and process evaluations, cost-effectiveness 
results) will be written and submitted to high-
impact academic and practice journals. Abstracts 
will be submitted to relevant major national and 
international conferences.
Competing interests
No member of the team has registered any 
competing interests.
Project management and milestones
Milestones Month
Project initiation
Development of protocol  1–2: Feb–Mar (2008)
Systematic review
Literature searches 1–2: Feb–Mar
Study selection 2–4: Mar–May
Study retrieval 2–4: Mar–May
Production of descriptive map 4–5: May–Jun
Data extraction 5–7: Jun–Aug
Data analysis 6–8: July–Sept
Economic evaluation
Review of economic evaluations 1–3: Feb–Apr
Model conceptualisation 3–4: Apr–May
Input data collection 4–6: May–Jun
Model construction and validation 5–7: Jun–Aug
Run model 8–9: Sep–Oct
Sensitivity analysis 9–10: Oct–Nov
Final report
Drafting of final report 6–10: Jul–Nov
Advisory group review/peer 
review of draft report
11: Dec
Submission and dissemination of 
report
12: Jan (2009)Appendix 1
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Advisory group
User involvement in the review will be sought via a 
multidisciplinary advisory group. We plan to invite 
the following representatives:
•  clinicians specialising in GUM
•  health promotion practitioners specialising in 
sexual health
•  youth workers/practitioners working with 
vulnerable young people
•  voluntary sector representatives
•  policy specialists (e.g. from Department 
of Health/NICE Centre for Public Health 
Excellence)
•  academics (e.g. including health economists 
and experts in the field of sexual health 
research).
Up to three meetings will be held, corresponding 
with the key stages of the project. The first meeting 
will be held around months 4–5 (May–Jun) to 
prioritise a subset of studies from the descriptive 
map and to present an outline conceptualisation of 
the economic model. The second meeting will be 
held around months 8–9 (Sep–Oct). The group will 
also be asked to read and comment on the draft 
report in month 11 (Dec).
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1.  exp Health Promotion/
2.  exp Health Education/
3.  exp Preventive Health Services/
4.  exp Preventive Medicine/
5.  exp Primary Prevention/
6.  Public Health/
7.  exp Social Medicine/
8.  exp Behavior Therapy/
9.  exp behavior control/
10. attitude to health/or health knowledge, 
attitudes, practice/
11. exp Health Behavior/
12. exp Sexual Behavior/
13. exp risk reduction behavior/or exp risk-taking/
or exp condoms/
14. exp unsafe sex/
15. exp safe sex/
16. exp sexual abstinence/
17. exp Sex Education/or exp sexology/
18. ((prevent$or reduc$or educat$or promot$or 
increas$or decreas$or facilitat$or barrier$or 
encourag$) adj2 (sex$or HIV or STI or STIs or 
STD$)).ab,kw,ti.
19. or/1–18
20. exp Sexually Transmitted Diseases/
21. exp Sexually Transmitted Diseases, Bacterial/
22. exp chancroid/or exp chlamydia infections/
or exp lymphogranuloma venereum/or exp 
gonorrhea/or exp granuloma inguinale/or exp 
syphilis/
23. exp HIV Infections/
24. exp Acquired Immunodeficiency Syndrome/
25. Herpes Genitalis/
26. Condylomata Acuminata/
27. (HPV or human papilloma$).ab,kw,ti.
28. ((genital or venereal) adj2 wart$).ab,kw,ti.
29. (STI or STIs or STD or STDs).ab,kw,ti.
30. (Sexual$transmit$adj3 (infect$or disease$)).
ab,kw,ti.
31. 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 
28 or 29 or 30
32. exp Adolescent/
33. (young$adj2 (men or man or woman or women 
or female$or male$or people or person)).
ab,kw,ti.
34. (teenage$or adolescen$or youth or youths).
ab,kw,ti.
35. 32 or 33 or 34
36. 19 and 31 and 35
37. randomized controlled trial.pt.
38. controlled clinical trial.pt.
39. clinical trial.pt.
40. random$.ti,ab.
41. control$.ti,ab.
42. (effectiveness or trial).ti.
43. placebo.ti,ab.
44. intervention$.tw.
45. ((control$or experimental or compar$) 
adj2 (Group$or trial$or study or studies or 
evaluat$or condition)).ti,ab.
46. 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 
45
47. 36 and 46
48. limit 47 to yr=‘1985 – 2008’
49. exp pharmacology, clinical/or exp 
pharmacology/
50. exp surgical procedures, operative/
51. exp Therapeutics/
52. exp HIV infections/dt
53. exp Sexually Transmitted Diseases/dt
54. 49 or 50 or 51 or 52 or 53
55. 48 not 54
56. from 55 keep 1–1000
57. from 55 keep 1001–2000
58. from 55 keep 2001–3000
59. from 55 keep 3001–3668
Appendix 2  
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Trial name or number
Population: Young people aged 13–19 years Yes
↓
Next question
Unclear
↓
Next question
No
→
EXCLUDE
Type:
EXCLUDE1 
(irrelevant 
population)
Design: Outcome evaluation (RCT or non-
randomised controlled trial)
Yes
↓
Next question
Unclear
↓
Next question
No
→
EXCLUDE
EXCLUDE2 
(irrelevant study 
design)
Intervention: Behavioural interventions 
that aim to prevent STIs
Currently defined as: ‘any activity to 
encourage young people to adopt sexual 
behaviours that will protect them from 
acquiring STIs’
Any STI is eligible, including HIV
Yes
↓
Next question
Unclear
↓
Next question
No
→
EXCLUDE
EXCLUDE3 
(irrelevant 
intervention)
Outcomes: Reports impact of the 
intervention on a sexual behavioural 
outcome.
For example:
•  self-reported condom use (e.g. frequency 
of use)
•  numbers of sexual partners (including 
abstinence)
•  studies reporting incidence/prevalence 
of STIs to be included, provided that 
they have also reported a behavioural 
outcome
•  studies reporting pregnancy-related 
outcomes (e.g. rate of conceptions) can 
be included, provided that they have 
included a sexual behaviour outcome.
Yes
↓
Next question
Unclear
↓
Next question
No
→
EXCLUDE
EXCLUDE4 
(irrelevant 
outcome 
measures)
Final decision INCLUDE UNCLEAR
(Discuss)
EXCLUDE Results of 
discussion
Appendix 3  
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Appendix 4  
QUOROM flow chart for systematic 
review of effectiveness
Cactus Design and Illustration Ltd
Figure Number: 00.11.ai   Title: 06-72-02 Proof Stage:  2
Potentially relevant references
identified n = 11,548
References screened on title/abstract
n = 8037
A total of 136* studies included and
keyworded in descriptive map
(as described in a total of 177 papers*)
*one paper described three separate
  studies
Papers retrieved for further
inspection n = 355
Studies meeting inclusion criteria
for systematic review n =15
(as described in a total of 45 papers)
Duplicates removed n = 3511
Papers excluded on title/abstract n = 7682
Excluded due to irrelevant: 
•  Population n = 1959
•  Study design n = 5087
•  Intervention n = 200
•  Outcome measures n = 125
Excluded for other reasons:
•  Published pre-1985 n = 8
•  Not English language n = 291
•  Pre-2005 conference abstract n = 12
Papers excluded after full inspection  n = 158
Excluded due to irrelevant: 
•  Population n = 79
•  Study design n = 53
•  Intervention n = 6
•  Outcome measures n = 20
Excluded for other reasons:
•  Published pre-1985 n = 0
•  Not English language n = 0
•  Pre-2005 conference abstract n = 0
Papers unable to be retrieved n = 36
Additional linked publications identified through
scanning of reference lists and contact with study
authors n =16DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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Appendix 5  
Data extraction and quality 
assessment instrument
Section A: Support for the study
A.1 Source of funding A.1.1 Not stated
A.1.2 Stated (write in)
A.1 Source of funding A.1.1 Not stated
A.1.2 Stated (write in)
Section B: Study design
B.1 What type of study is described? B.1.1 RCT
B.1.2 Cluster RCT
B.1.3 Non-randomised controlled study
B.1.4 Cluster non-randomised controlled study
B.1.5 Process evaluation
B.1.6 Other (describe)
B.2 Country in which intervention was implemented
Note: This is not necessarily the same as the country of the 
research institutions. If the study is conducted in more than one 
country, indicate them all
B.2.1 Germany
B.2.2 The Netherlands
B.2.3 Tanzania
B.2.4 Kenya
B.2.5 USA
B.2.6 UK
B.2.7 Finland
B.2.8 Israel
B.2.9 Norway
B.2.10 Rwanda
B.2.11 Sweden
B.2.12 South Africa
B.2.13 France
B.2.14 Thailand
B.2.15 Iceland
B.2.16 Belgium
B.2.17 Peru
B.2.18 Switzerland
B.2.19 China
B.2.20 The Philippines
B.2.21 Italy
B.2.22 Honduras
B.2.23 Canada
B.2.24 Australia
B.2.25 Holland
B.2.26 New Zealand
B.2.27 Japan
B.2.28 Poland
B.2.29 SingaporeAppendix 5
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B.2.30 Nicaragua
B.2.31 India
B.2.32 Ghana
B.2.33 Indonesia
B.2.34 Greece
B.2.35 Ireland
B.2.36 Nigeria
B.2.37 Other
Section C: Description of intervention
C.1 What is the name of the programme? C.1.1 No name
C.1.2 Named (describe)
C.2 Content of the intervention package
Describe the intervention in detail, whenever possible copying 
the authors’ description from the report word for word. 
Descriptions should cover type, provider and medium. If 
specified in the report, also describe in details what the control/
comparison group(s) were exposed to
C.2.1 Details
C.3 Aim(s) of the intervention C.3.1 Not stated
C.3.2 Not explicitly stated
Write in, as worded by the reviewer
C.3.3 Stated (write in)
Write in, as stated by the authors
C.4 Theoretical model (as stated by the authors)
Indicate ALL of the models which authors state they have used 
in the design of the intervention
C.4.1 Not stated
C.4.2 Unclear
C.4.3 Community-orientated Model
Models which attempt to change attitudes or norms of a distinct 
group (e.g. prostitutes), by targeting a large proportion of the group. 
The intervention may involve self-efficacy or traditional education 
presentations, but also involves changing the context in which 
individuals operate by instilling new norms in all or most of the 
community members, relying on peer support and not on self-
efficacy
C.4.4 Cognitive Theory
These emphasise the causal role of cognition in the development 
of behaviour, including problem behaviours. Interventions derived 
from these theories (rational–emotive therapy, cognitive therapy, 
stress inoculation therapy, anger control) focus therapeutic effort of 
effecting changes in the way people think (e.g. selective perception, 
misattribution, faulty information processing)
C.4.5 Eco-behavioural/Ecological Action Model
These focus attention on the influence of social factors, such as 
external stressors (e.g. poverty, serious life events), societal values, 
and developmental factors, and examine these within the framework 
of theories of learning.
C.4.6 Health Belief Model
This states that the likelihood of an individual adopting preventative 
behaviour(s) is dependent on four personal perceptions: their 
SUSCEPTIBILITY to the condition; the SERIOUSNESS of the 
condition; the BENEFITS and the efficacy of the preventative 
behaviour(s), and the extent of the BARRIERS to the behaviour(s)DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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C.4.7 Learning Theory
Two paradigms of learning are included under this heading: (1) 
respondent (or classical) conditioning, thought to account for the 
acquisition of a range of emotional and affective behaviour (such as 
phobias, anxiety, sexual dysfunction); key therapeutic interventions 
include graded in vivo exposure and systemic desensitisation; and 
(2) operant (or instrumental) conditioning, which highlights the 
impact of environmental stimuli on behaviour; key therapeutic 
interventions include differential reinforcement, extinction, time-out, 
and punishment
C.4.8 Psychodynamic Theory
This derives from the work of Freud, and stresses the importance of 
early life experiences on the development of personality, particularly 
the psychosocial dramas and conflicts of key stages such as Oedipal 
phase.
C.4.9 Social Learning Theory
Social learning theory (sociopsychological/social cognitive/
empowerment/self-esteem/self-efficacy, etc.). This adds cognitive and 
observational learning to the respondent and operant paradigms 
(see above) and essentially says that human beings do not respond 
to stimuli, but interpret them. The key intervention derived from this 
theory is modelling (e.g. skills training)
C.4.10 Systems Theory
This emphasises the interconnectedness of different parts of a 
whole, functioning entity such as the family, and conceptualises the 
problems experienced by individual family members as symptomatic 
of system ‘malfunctioning’. Often problems are thought to arise 
because the family system has failed to re-establish an equilibrium 
following a system-disrupting crisis. Therapeutic strategies are aimed 
at assisting the family’s return to a state of equilibrium and include: 
joining, reframing, and prescribing tasks.
C.4.11 Traditional Education/Reasoned Action Model
Models which assume that information presented to individuals will 
be absorbed directly, improving knowledge, or affecting their attitudes 
or behaviour. The objective is to alter knowledge only, although 
assumptions may be made about knowledge affecting behaviour. 
Models assume that individuals always act in a rational, logical way. 
Progressive media (e.g. video, theatre) may be used but information 
is still given in a didactic way.
C.4.12 Other (specify)
C.5 What year did the intervention start? C.5.1 Stated (describe)
C.5.2 Not stated
C.5.3 Unclear (describe)
C.6 What is the length of the intervention? C.6.1 Stated (describe)
C.6.2 Not stated
C.6.3 Unclear (describe)
C.7 Number of people recruited to provide the 
intervention (or comparison condition)
C.7.1 Reported (write in)
C.7.2 Unclear
C.7.3 Not stated
C.8 How were the people providing the intervention 
recruited?
C.8.1 Stated (write in)
C.8.2 Not statedAppendix 5
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C.9 Was special training given to people providing the 
intervention?
Provide as much detail as possible
C.9.1 Yes (specify)
C.9.2 No
C.9.3 Unclear
C.9.4 Not stated
C.10 Did the authors indicate any costs related to the 
intervention?
Provide as much detail as possible
C.10.1 Yes (write in)
C.10.2 No
Section D: Description of the study sample
D.1 Socioeconomic position
Record numbers/proportion where specified. This relates to 
socioeconomic position in keywording stage: young people 
specified with differential risk because of their socioeconomic 
position
This might include:
•  direct or indirect income measures (e.g. parental income or 
access to free school meals/Medicaid)
•  various established neighbourhood deprivation scores
•  various established social class classification systems
•  authors description, e.g. ‘ residents of a deprived inner-city 
neighbourhood’, ‘young people from a largely middle-class 
background’, etc
D.1.1 Details
D.1.2 Not reported
D.2 Age group
Record age range and numbers/proportion of the population in 
each age group, if specified. We would like to know more about 
whether studies address ‘younger’ or ‘older’ young people
D.2.1 Details
D.2.2 Not reported
D.3 Ethnicity
Write in authors’ quantitative and qualitative description
D.3.1 Details
D.3.2 Not reported
D.4 Region/place of residence
Young people considered at risk in terms of their location (e.g. 
rural, urban, seaside)
Record numbers/proportion of population in each type of region 
if specified
D.4.1 Rural
D.4.2 Urban
D.4.3 Other
D.4.4 Not stated
D.5 Sex
Record numbers/proportion of population in each sex if 
specified
D.5.1 Female
D.5.2 Male
D.5.3 Mixed sex
D.5.4 Not stated
D.6 Information about the family
This might include family size, structure, etc
D.6.1 Details
D.6.2 Not reported
D.7 Information about participants’ religion reported D.7.1 Details
D.7.2 Not reported
D.8 Sexual orientation
Record numbers/proportion of population of each orientation if 
specified
D.8.1 Heterosexual
D.8.2 Gay
D.8.3 Lesbian
D.8.4 Not stated
D.8.5 Other (details)
e.g. young people explicitly experiencing confusion about their sexual 
orientation (details)DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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D.9 Information about participants’ occupation reported
Given the age range of our review population, it is likely that 
occupation will relate to parental occupation. Please state if this 
is the case
D.9.1 Details
D.9.2 Not reported
D.10 Information about participants’ education reported
Young people specified as being at risk because of their 
educational status (e.g. low educational achiever/absent from 
school)
If parental education status reported please provide details – 
this may be a proxy measure of SEP
D.10.1 Details (young people)
D.10.2 Not reported (young people)
D.10.3 Details (parents)
D.10.4 Not reported (parents)
D.11 Social capital
Young people specified as being at risk because they lack social 
capital
‘Social capital’ describes support available through informal 
social networks of neighbourhoods, communities and families 
– in relation to young people, social capital might be related to: 
family structure, and the form and quality of family relationships
D.11.1 Details
D.11.2 Not reported
D.12 Disability
Young people specified as being at risk because they have a 
disability
(e.g. existence of physical or mental illness or disability, learning 
disability)
D.12.1 Details
D.12.2 Not reported
D.13 Information about previous STI reported
Young people at risk because of a previous history of STI
D.13.1 Details
D.13.2 Not reported
D.14 Existing STI (other than HIV)
Young people at risk because of they currently have an STI (not 
including HIV)
D.14.1 Details
D.14.2 Not reported
D.15 HIV positive
Young people at risk because they are diagnosed with, or 
suspected to have, HIV infection
D.15.1 Details
D.15.2 Not reported
D.16 Drug user
Young people at risk because they use, or have used, illicit drugs
D.16.1 Details
D.16.2 Not reported
D.17 Alcohol user
Young people at risk because of their level of alcohol 
consumption
D.17.1 Details
D.17.2 Not reported
D.18 Commercial sex worker
Young people at risk because they sell sex
D.18.1 Details
D.18.2 Not reported
D.19 Sexual behaviour
Young people at risk because of high-risk sexual behaviour or 
potential high-risk sexual behaviour
D.19.1 Details
D.19.2 Not reported
D.20 Looked after young people
Young people at risk because they are looked after (i.e. in care)
D.20.1 Details
D.20.2 Not reported
D.21 Offenders
Young people at risk because they are in the criminal justice 
system (e.g. in prison/detention/correctional programme)
D.21.1 Details
D.21.2 Not reportedAppendix 5
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D.22 Other factor – please specify D.22.1 Details
D.23 Sampling and recruitment procedures D.23.1 Details
D.23.2 Not reported
D.24 Were any incentives provided to recruit people into 
the study?
D.24.1 Yes (specify)
D.24.2 Not stated
D.25 Were participants asked for their consent before 
entering the study?
This refers to the eligible sample
D.25.1 Requested from participants
D.25.2 Requested from others (specify)
D.25.3 Not relevant (e.g. mass media)
D.25.4 Unclear
D.25.5 No/not stated
Section E: Planning and process measures
Questions E.1–11 relate to the planning and development of the intervention and study in general
Questions E.12–19 relate specifically to the process evaluation
E.1 Was the intervention based on a needs assessment?  E.1.1 Not stated
E.1.2 Yes, no further information provided/information unclear
E.1.3 Yes, based on ‘comparative need’
‘Comparative need’ is derived from examining, for example, the 
services provided in one area to one population, and using this as 
the basis to determine the sort of services needed in another area 
with a similar population
E.1.4 Yes, based on ‘felt need’
‘Felt need’ is what people say they want or what they think are the 
problems that need addressing
E.1.5 Yes, other (specify)
E.1.6 No, but another rationale for delivering the intervention/
undertaking the study
E.1.7 Yes, based on ‘normative need’
‘Normative needs’ refers to what expert opinion defines as need
E.1.8 Yes, based on ‘expressed need’
‘Expressed need’ refers to what one can infer about the need of a 
community by observing their use of services
E.1.9 Yes, reference to source of further information given 
(write in)
E.2 Who identified the aim(s) of the intervention? E.2.1 Other (specify)
E.2.2 Not stated
E.2.3 Evaluator
E.2.4 Health promotion practitioner
E.2.5 (A sample of the) study population (specify)
E.2.6 (A sample of the) target population (specify)
E.2.7 Intervention provider
E.2.8 Funder
E.2.9 UnclearDOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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E.3 Who was involved in the development of the 
intervention?
E.3.1 Not stated
E.3.2 Unclear
E.3.3 Evaluator
E.3.4 Funder
E.3.5 Health promotion fractioned
E.3.6 Intervention provider
E.3.7 (A sample of the) study population (specify)
E.3.8 (A sample of the) target population (specify)
E.3.9 Other (specify)
E.4 Was the intervention piloted?
A pilot study involves preliminary use of some or all of the 
elements of the intervention in order to refine the intervention 
or its delivery. This does not include similar interventions tested 
by others
E.4.1 Not stated
E.4.2 Unclear
E.4.3 The authors consider this study to be a pilot
E.4.4 Yes, previously piloted with the study population
E.4.5 Yes, previously piloted with a sample of the target 
population (specify)
E.4.6 Yes, previously piloted with others (specify)
E.4.7 No
E.5 Do the authors indicate any specific barriers to 
developing/delivering the intervention?
E.5.1 Yes (specify)
E.5.2 No
E.6 Do the authors indicate any factors favourable to 
developing/delivering the intervention?
E.6.1 Yes (specify)
E.6.2 No
E.7 Were views on the evaluation design sought? E.7.1 Not stated
E.7.2 Unclear
E.7.3 Yes, from funders
E.7.4 Yes, from health promotion practitioners
E.7.5 Yes, from intervention providers
E.7.6 Yes, from the study population
E.7.7 Yes, from a sample of the target population (specify)
E.7.8 Yes, from others (specify)
E.7.9 No
E.8 Who identified the range of processes/outcomes to be 
addressed?
E.8.1 Not stated
E.8.2 Unclear
E.8.3 Evaluator
E.8.4 Funder
E.8.5 Health promotion practitioner
E.8.6 Intervention provider
E.8.7 (A sample of the) study population (specify)
E.8.8 (A sample of the) target population (specify)
E.8.9 Other (specify)
E.9 Who carried out the evaluation? E.9.1 Not stated
E.9.2 Unclear
E.9.3 Health promotion practitioner
E.9.4 Researcher (specify)
E.9.5 (Individuals from the) target population (specify)
E.9.6 Other (specify)
E.10 Does the report describe how the evaluators were 
selected?
E.10.1 No
E.10.2 Unclear
E.10.3 Yes (specify)Appendix 5
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E.11 Was special training provided for the evaluators? E.11.1 Not stated
E.11.2 Unclear
E.11.3 Yes (specify)
E.11.4 No
E.12 Which processes were evaluated?
Tick as many as appropriate. Specify further where possible
E.12.1 Perceptions, understanding or acceptability of the 
intervention
E.12.2 Accessibility of the intervention/programme reach
E.12.3 Consultation/collaboration/partnerships (specify)
E.12.4 Content of the intervention
E.12.5 Implementation/delivery of the intervention
E.12.6 Costs associated with the intervention
E.12.7 Management and responsibility
E.12.8 Quality of the programme materials
E.12.9 Skills and training of the intervention providers
E.12.10 Other (specify)
E.13 What methods were used to collect data on the 
processes involved?
Tick as many as appropriate. Specify further where possible
E.13.1 Not stated
E.13.2 Unclear
E.13.3 Documentation
E.13.4 Focus group
E.13.5 Interview
E.13.6 Observation
E.13.7 Self-completion report or diary/questionnaire
E.13.8 Other (specify)
E.14 Who were the data collected from? E.14.1 Not stated
E.14.2 Unclear
E.14.3 Intervention provider (write in numbers)
E.14.4 (A sample of the) study population (write in numbers)
E.14.5 Other (specify)
E.15 When did the evaluation take place in relation to the 
intervention?
Tick as many as appropriate. Specify further where possible
E.15.1 Not stated
E.15.2 Unclear
E.15.3 Afterwards (please specify)
E.15.4 Concurrently
E.15.5 For a limited period during the intervention (please 
specify)
E.15.6 Other (please specify)
E.16 About which processes do the authors offer 
conclusions?
Tick as many as appropriate. Write in ALL conclusions
E.16.1 None
E.16.2 Unclear
E.16.3 Acceptability of the intervention
E.16.4 Accessibility of the intervention/programme reach
E.16.5 Consultation/collaboration/partnerships
E.16.6 Content of the intervention
E.16.7 Implementation of the intervention
E.16.8 Costs associated with the intervention
E.16.9 Management and responsibility
E.16.10 Quality of the programme materials
E.16.11 Skills and training of the intervention providers
E.16.12 Other (specify)DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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E.17 Were steps taken to increase rigour/minimise bias and 
error in the sampling for the process evaluation?
Consider whether:
•  the sampling strategy was appropriate to the questions 
posed in the process evaluation (e.g. was the strategy well 
reasoned and justified?)
•  attempts were made to include all relevant stakeholders 
and/or obtain a diverse sample (think about who might have 
been excluded who may have had a different perspective to 
offer)
•  characteristics of the sample critical to the understanding 
of the study context and findings were presented (i.e. do we 
know who the participants are in terms of, for example, role 
in the intervention/evaluation, basic sociodemographics, etc.)
E.17.1 Yes, a fairly thorough attempt was made (please specify)
E.17.2 Yes, several steps were taken (please specify)
E.17.3 Yes, a few steps were taken (please specify)
E.17.4 Unclear (please specify)
E.17.5 No, not at all/not stated/can’t tell(please specify)
E.18 Were steps taken to increase rigour/minimise bias and 
error in the data collected for the process evaluation?
Consider whether:
•  data collection tools were piloted/validated (if quantitative)
•  data collection was comprehensive, flexible and/or 
sensitive enough to provide a complete and/or vivid and 
rich description/evaluation of the processes involved in the 
intervention [e.g. did the researcher’s spend sufficient time at 
the site/with participants? Did they keep ‘following up’? Were 
steps taken to ensure that all participants were able and 
willing to contribute? (e.g. confidentiality, language barriers, 
power relations between adults and young people) Was 
more than one method of data collection used? Was there 
a balance between closed and open-ended data collection 
methods?]
E.18.1 Yes, a fairly thorough attempt was made (please specify)
E.18.2 Yes, several steps were taken (please specify)
E.18.3 Yes, a few steps were taken (please specify)
E.18.4 Unclear (please specify)
E.18.5 No, not at all/not stated/can’t tell (please specify)
E.19 Were steps taken to increase rigour/minimise bias and 
error in the analysis of the process data?
Consider whether:
•  data analysis methods were systematic (e.g. was a method 
described/can a method be discerned?)
•  diversity in perspective was explored
•  the analysis was balanced in the extent to which it was 
guided by preconceptions or by the data (i.e. participants 
views, researcher observations, etc.)
•  the analysis sought to rule out alternative explanations for 
findings (in qualitative research this could be done by, for 
example, searching for negative cases/exceptions, feeding 
back preliminary results to participants, asking a colleague 
to review the data, or reflexivity; in quantitative research this 
may be done by, for example, significance testing)
E.19.1 Yes, a fairly thorough attempt was made (please specify)
E.19.2 Yes, several steps were taken (please specify)
E.19.3 Yes, some steps were taken (please specify)
E.19.4 Unclear (please specify)
E.19.5 No, not at all/not stated/can’t tell(please specify)
E.20 Were the findings of the process evaluation grounded 
in/supported by the data?
Consider whether:
•  enough data are presented to show how the author’s arrived 
at their findings
•  the data presented fit the interpretation/support claims 
about patterns in data
•  the data presented illuminate/illustrate the findings
•  (for qualitative studies) quotes are numbered or otherwise 
identified so that the reader can see that they don’t just 
come from one or two people
E.20.1 Reasonably well grounded/supported (please specify)
E.20.2 Fairly well grounded/supported (please specify)
E.20.3 Limited grounding/support (please specify)Appendix 5
148
E.21 Please rate the findings of the process evaluation in 
terms of their breadth and depth
Consider whether:
(NB: it may be helpful to consider ‘breadth’ as the extent of 
description and ‘depth’ as the extent to which data has been 
transformed/analysed)
•  a range of processes/issues were covered in the evaluation
•  the perspectives of participants are fully explored in terms 
of breadth (contrast of two or more perspectives) and depth 
(insight into a single perspective)
•  both the strengths and weaknesses of the intervention are 
described/explored
•  the context of the intervention has been fully described/
explored
•  richness and complexity has been portrayed (e.g. variation 
explained, meanings illuminated)
•  there has been theoretical/conceptual development
E.21.1 Limited breadth or depth
E.21.2 Good/fair breadth but very little depth
E.21.3 Good/fair depth but very little breadth
E.21.4 Good/fair breadth and depth
E.22 To what extent does the process evaluation privilege 
the perspectives and experiences of young people?
Consider whether:
•  Young people are included in the process evaluation
•  There was a balance between open-ended and fixed 
response options
•  Whether young people were involved in designing the 
research
•  There was a balance between the use of an a priori coding 
framework and induction in the analysis
•  The position of the researchers (did they consider it 
important to listen to the perspectives of young people?)
•  Steps were taken to assure confidentiality and put young 
people at their ease
E.22.1 Not at all
E.22.2 A little (please specify)
E.22.3 Somewhat (please specify)
E.22.4 A lot (please specify)
E.23 Overall, what weight would you assign to this process 
evaluation in terms of the reliability of its findings?
Guidance:
Think (mainly) about the answers you have given to questions 
E17–20 above.
E.23.1 Low
E.23.2 Medium
E.23.3 High
E.24 What weight would you assign to this process 
evaluation in terms of the usefulness of its findings?
Guidance:
Think (mainly) about the answers you have given to questions 
E20–22 above and consider:
•  how well intervention processes are described (e.g. does it 
provide useful information on barriers and facilitators to 
implementation – factors that others implementing the 
intervention would need to consider?)
•  whether the findings can help us to explain the relationship 
between intervention process and outcome (e.g. why the 
intervention worked or did not work; factors influencing 
effectiveness; how the intervention achieved its effects)
E.24.1 Low
E.24.2 Medium
E.24.3 HighDOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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Section F: Methodological characteristics of the study
F.1 Number of participants recruited to intervention and 
control/comparison groups if applicable
On the basis of those from whom baseline data were collected. 
Or number in study population as a whole, if only one group
F.1.1 Not stated
F.1.2 Unclear (please specify)
F.1.3 Reported (please write in)
F.2 What was the unit of allocation into each intervention 
and control/comparison group?
F.2.1 Not relevant (study not a trial)
F.2.2 Not stated
F.2.3 Unclear
F.2.4 Community
F.2.5 Family
F.2.6 Group/class, e.g. tutor group
F.2.7 Individuals
F.2.8 Institution
F.2.9 Region
F.2.10 Other (please specify)
F.3 Was the allocation to intervention and control/
comparison groups done blind?
F.3.1 Not relevant (study not a trial)
F.3.2 Not stated
F.3.3 Unclear (please specify)
F.3.4 Yes
F.3.5 No
F.4 Were participants aware which group they were in for 
the evaluation?
F.4.1 Not relevant (study not a trial)
F.4.2 Not stated
F.4.3 Unclear
F.4.4 Yes
F.4.5 No
F.5 Was outcome measurement done blind?
i.e. Were those assessing the outcomes aware whether the 
participant had been in a control/comparison group or 
intervention group?
F.5.1 Not relevant (study not a trial)
F.5.2 Not stated
F.5.3 Unclear
F.5.4 Yes
F.5.5 No
F.6 What sort of measurement tool(s) is/are used to collect 
outcome data?
F.6.1 Interview
F.6.2 Observation
F.6.3 Practical test
F.6.4 Psychological test
F.6.5 Self-completion report or diary/questionnaire
F.6.6 Clinical test
F.6.7 Other (specify)
F.6.8 Unclear
F.6.9 Not stated
F.7 Number of outcome assessment periods
i.e. How many times were data on outcome variables collected 
after the intervention?
F.7.1 Not stated
F.7.2 Unclear
F.7.3 One
F.7.4 Two
F.7.5 Three
F.7.6 Four or more (specify)Appendix 5
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F.8 Timing(s) of pre-intervention measurements F.8.1 Not stated
F.8.2 Unclear (please specify)
F.8.3 Stated (please write in)
F.8.4 Not relevant
F.9 Timing(s) of post-intervention measurements
Choose one of the categories and indicate the exact timings if 
specified.
Note: ‘Immediately after the intervention’ is at the bottom of the 
list!
F.9.1 Not stated
F.9.2 Unclear
F.9.3 Up to 1 month
F.9.4 Up to 3 months
F.9.5 3–6 months
F.9.6 6–12 months
F.9.7 1–2 years
F.9.8 2–3 years
F.9.9 3–5 years
F.9.10 More than 5 years
F.9.11 None
F.9.12 Immediately after intervention
F.10 Data analysis method F.10.1 Not relevant (study not a trial)
F.10.2 Not stated
F.10.3 Unclear
F.10.4 ‘Intention to intervene’
‘Intention to intervene’ means that data were analysed on the basis 
of the original number of participants recruited into the different 
groups
F.10.5 ‘Intervention received’
‘Intervention received’ means the data were analysed on the basis of 
the number of participants remaining in the groups at the time of 
measurement
F.11 Unit of data analysis
Were the results reported according to the unit of allocation? 
For example, if individuals were allocated to different groups, 
results from individuals should be analysed and reported, 
whereas if schools were allocated to different groups then 
results from each school should be analysed and reported
F.11.1 Not relevant (study not a trial)
F.11.2 Not stated
F.11.3 Unclear (please specify)
F.11.4 Same as unit of allocation
F.11.5 Different from unit of allocation (please specify)
F.12 If a cluster trial do the authors report an intraclass 
correlation
F.12.1 Yes (specify)
F.12.2 No
F.13 Was the instrument used to assess outcomes piloted/
validated?
F.13.1 Reported (specify)
Add in details of any pilot study; validation exercises; references to 
other publications which describe the instrument (or studies in which 
it has been employed)
F.13.2 Unclear
F.13.3 Not reportedDOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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Section G: Avoiding selection bias
G.1 How were subjects allocated to control and 
intervention groups?
Study can ‘pass’ if participants were allocated using an 
acceptable method of randomisation
Note: If method of randomisation is not stated, tick ‘yes’ 
but indicate this in your comments. If you have suspicions 
about whether methods of allocation were randomised by an 
acceptable method, please also indicate these here
G.1.1 Random
e.g. Table of random numbers, computer-generated random 
sequences
G.1.2 Non-random
e.g. Date of birth, day of week, month of year, medical record 
number, order in which participants included in the study, such as 
alternation
G.1.3 No allocation
e.g. Study not a trial
G.1.4 Not clear/not stated
G.2 Which major prognostic factors are baseline values 
reported for?
Note: Major prognostic factors will often be the baseline value of 
all outcomes and at least one socioeconomic variable
G.2.1 Ethnicity
G.2.2 Sex
G.2.3 Marital status
G.2.4 Age
G.2.5 SES (income or class)
G.2.6 Education
G.2.7 Health status
G.2.8 All pre-intervention outcome scores
G.2.9 Some pre-intervention outcome scores
G.3 Were baseline values of major prognostic factors 
reported for each group as allocated (e.g. intervention 
and control group)?
G.3.1 Yes for all individuals in study at baseline measurement
G.3.2 Yes for all individuals remaining in study for follow-up
G.3.3 Yes for some other subgroup of individuals
G.3.4 No
G.3.5 Not applicable (one group in study only)
G.4 Are baseline values of major prognostic factors 
balanced between the groups in the trial?
Note: Major prognostic factors are balanced between groups if 
the groups are drawn from similar populations and have similar 
sociodemographic variables and baseline values of all outcome 
measures. Record the extent to which your decision is supported 
by presented data on outcomes and/or by other information in 
the report (e.g. statements in text)
G.4.1 Not applicable (one group in study only)
G.4.2 Unclear
G.4.3 Balanced
G.4.4 Not balanced
G.4.5 Other (specify)
G.5 Did the analysis adjust for baseline imbalances in 
major prognostic factors between groups?
G.5.1 Not applicable (one group in study only)
G.5.2 Not relevant (groups were equivalent)
G.5.3 Yes
G.5.4 No
Section H: Avoiding attrition bias
H.1 Is the attrition rate reported separately according to 
allocation group?
H.1.1 Yes
H.1.2 No
H.1.3 Not applicable (one group in study only)
H.2 What is the attrition rate? H.2.1 For the intervention group(s)
H.2.2 For the control/comparison group(s)
H.2.3 Overall
H.2.4 Unclear (please specify)
H.2.5 Not relevant (no details on attrition reported)Appendix 5
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Section I: Avoiding selective reporting bias
I.1 What outcomes did the authors say they were intending 
to measure (i.e. as described in the aims of the 
evaluation)?
Select as many as possible and specify data collection 
instrument used where possible
I.1.1 Not stated
I.1.2 Unclear
I.1.3 Access to/availability of resources
I.1.4 Attitudes
I.1.5 Awareness/beliefs
I.1.6 Behaviour (observed)
I.1.7 Behaviour (reported)
I.1.8 Clinical risk factor(s) as determined by a clinical test, e.g. 
blood pressure, cholesterol level
I.1.9 Health problem or state (prevalence and/or incidence)
Including anxiety, depression, other mental health state; other 
examples – pregnancy, coronary heart disease
I.1.10 Intentions
I.1.11 Knowledge
I.1.12 Legislation/regulation
I.1.13 Practical skill
I.1.14 Self-efficacy/self-esteem/self-confidence
I.1.15 Service use
I.1.16 Other
I.2 For whom were outcomes given? I.2.1 Unclear (specify)
I.2.2 Information for some individuals/groups only (specify)
I.2.3 Information for all individuals/groups
I.2.4 Info for study population as a whole
I.3 For which outcomes were data collected at follow-up 
presented?
Compare the outcomes reported with your answers above
I.3.1 Unclear
I.3.2 Information for some outcomes only
I.3.3 Information for all outcomes
I.3.4 No final data reported, only change reported (specify)
I.3.5 Other (specify)
Section J: Decision on soundness of study
J.1 Was selection bias avoided?
1. Study can ‘pass’ if participants were allocated using an 
acceptable method of randomisation (i.e answer at G1.1) OR:
2. Studies can ‘pass’ if (1) baseline values of major prognostic 
factors are reported for each group for virtually all participants 
as allocated (i.e. answer at G.3.1) AND if baseline values of 
major prognostic factors are balanced between groups in the 
trial (i.e. answer at G.4.3) OR imbalances were adjusted for in 
analysis (i.e. answer at G.5.3)
J.1.1 Yes
J.1.2 No
J.2 Was bias due to loss to follow-up avoided?
Study can pass this component if:
1. The attrition rate is reported separately according to 
allocation group (i.e. answer at H.1.1), AND if
2. The attrition rate differs across groups by less than 10% and 
is less than 30% overall (i.e. answer at H.2) OR baseline values 
of major prognostic factors were balanced between groups for 
all those remaining in the study for analysis (i.e. answer at G.5)
Note: For studies which are not trials, this question should 
simply read ‘Is the attrition rate less than 30% of the original 
participants?’
J.2.1 Yes
J.2.2 NoDOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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J.3 Was selective reporting bias avoided?
Studies can pass this component if authors report on all 
outcomes they intended to measure as described in the aims of 
the study
J.3.1 Yes
J.3.2 No
J.4 Is the study sound?
To be sound a study has to avoid all three of the specified types 
of bias
J.4.1 Not sound
J.4.2 Sound
J.4.3 Reviewers judge study sound despite discrepancy with 
quality criteria (clarify)
Section K: Outcomes
DO NOT COMPLETE THIS SECTION UNLESS THE STUDY HAS BEEN JUDGED BY BOTH REVIEWERS TO BE SOUND
Where available, please include ALL analyses relevant to any of the PROGRESS-Plus risk factors. These may take the form of 
well-reported subgroup analyses, or the authors may simply state that there was no difference in outcomes between males 
and females, for example
K.1 What was the impact of the intervention on sexual 
behaviour?
•  Please add in results for this outcome measure. Use tables 
where necessary
•  Please report for all time periods at which the outcome was 
measured (e.g. immediately post intervention; 3 months’ 
follow-up, 6 months’ follow-up, etc.)
•  Please also report the time period over which the behaviour 
took place (e.g. use of condoms at most recent intercourse; 
use of condoms during past 6 weeks, etc.)
•  Please specify which kind of sexual activity, if reported (e.g. 
vaginal, anal, oral)
Note: To insert tables check the ‘HTML editor’ box in the 
dialogue window. This only works with Internet Explorer (not 
Firefox)
K.1.1 Frequency of sex
Please add in results for this outcome measure. Use tables where 
necessary
Please specify which kind of sexual activity, if reported (e.g. vaginal, 
anal, oral)
K.1.2 Number of sexual partners
Please add in results for this outcome measure. Use tables where 
necessary
Please record whether casual or regular partner (or other 
classification of partners)
K.1.3 Delaying onset of sexual activity
Please add in results for this outcome measure. Use tables where 
necessary
K.1.4 Abstinence from sexual activity
Please add in results for this outcome measure. Use tables where 
necessary
K.1.5 Condom use for vaginal intercourse
Please add in results for this outcome measure. Use tables where 
necessary
Results might be expressed as the proportion of young people using 
condoms, and/or proportion of episodes in which a condom was/was 
not used
Please record if data are reported for different types of partner (e.g. 
casual partner, regular partner)
K.1.6 Condom use for anal intercourse
Please add in results for this outcome measure. Use tables where 
necessary
Results might be expressed as the proportion of young people using 
condoms, and/or proportion of episodes in which a condom was/was 
not used
Please record if data are reported for different types of partner (e.g. 
casual partner, regular partner)
K.1.7 Number of young people reporting having sex
Please add in results for this outcome measure. Use tables where 
necessary
Can include number becoming sexually active during the studyAppendix 5
154
K.1.8 Use of other (non-condom) contraception method
Please add in results for this outcome measure. Use tables where 
necessary
K.1.9 Age at first sexual intercourse
Please add in results for this outcome measure. Use tables where 
necessary
K.1.10 Use of drugs/alcohol during sex
Please add in results for this outcome measure. Use tables where 
necessary
K.1.11 Refusal of sex/unprotected sex
K.1.12 Other (please define)
Please add in results for this outcome measure. Use tables where 
necessary
K.1.13 Not applicable – outcome not measured
K.2 What was the impact of the intervention on biological 
outcomes?
Please add in results for this outcome measure. Use tables 
where necessary
K.2.1 Incidence of sexually transmitted infection (STI)
Please add in results for this outcome measure. Use tables where 
necessary
Please specify which STI, if reported
K.2.2 Pregnancy
Please add in results for this outcome measure. Use tables where 
necessary
K.2.3 Other (please define)
Please add in results for this outcome measure. Use tables where 
necessary
K.2.4 Not applicable – outcome not measured
K.3 What was the impact of the intervention on knowledge 
of STIs?
Please add in results for this outcome measure. Use tables 
where necessary
K.3.1 Specify
Please add in results for this outcome measure. Use tables where 
necessary
K.3.2 Not applicable – outcome not measured
K.4 What was the impact of the intervention on attitudes 
towards STIs?
Please add in results for this outcome measure. Use tables 
where necessary
K.4.1 Specify
Please add in results for this outcome measure. Use tables where 
necessary
K.4.2 Not applicable – outcome not measured
K.5 What was the impact of the intervention on 
behavioural intentions?
Please add in results for this outcome measure. Use tables 
where necessary
K.5.1 Specify
Please add in results for this outcome measure. Use tables where 
necessary
K.5.2 Not applicable – outcome not measured
K.6 What was the impact of the intervention on self-
efficacy?
Please add in results for this outcome measure. Use tables 
where necessary
K.6.1 Specify
Please add in results for this outcome measure. Use tables where 
necessary
K.6.2 Not applicable – outcome not measured
K.7 What was the impact of the intervention on skills?
Please add in results for this outcome measure. Use tables 
where necessary
K.7.1 Specify
Please add in results for this outcome measure. Use tables where 
necessary
K.7.2 Not applicable – outcome not measuredDOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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K.8 What was the impact of the intervention on beliefs?
Please add in results for this outcome measure. Use tables 
where necessary
K.8.1 Specify
Please add in results for this outcome measure. Use tables where 
necessary
K.8.2 Not applicable – outcome not measured
K.9 What was the impact of the intervention on other 
outcomes? (specify)
Please add in results for this outcome measure. Use tables 
where necessary
K.9.1 Specify
Please add in results for this outcome measure. Use tables where 
necessary
Section L: ...And finally
L.1 Please check the keywords applied in the mapping stage 
for accuracy
In the light of the data extracted, please check whether any of 
the existing keywords are superfluous, or whether any additional 
keywords should be added
L.1.1 Changes to be made to the keywording
Please record any changes to be made to the keywording
L.2 Reviewer’s comments
Add in here any comments you may have on issues not covered 
by the preceding questions, as well as your general impressions 
of the study
L.2.1 Specify
L.2 Reviewer’s comments
Add in here any comments you may have on issues not covered 
by the preceding questions, as well as your general impressions 
of the study
L.2.1 SpecifyDOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Appendix 6  
Evidence tables for the RCTs with 
integral process evaluations included 
in the systematic reviewAppendix 6
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t
y
 
A
f
r
i
c
a
n
-
A
m
e
r
i
c
a
n
s
.
 
C
o
v
e
r
e
d
 
t
r
a
n
s
m
i
s
s
i
o
n
 
o
f
 
S
T
I
s
 
(
i
n
c
l
u
d
i
n
g
 
H
I
V
)
,
 
a
b
s
t
i
n
e
n
c
e
,
 
u
n
p
r
o
t
e
c
t
e
d
 
s
e
x
u
a
l
 
i
n
t
e
r
c
o
u
r
s
e
,
 
m
u
l
t
i
p
l
e
 
p
a
r
t
n
e
r
s
,
 
a
n
d
 
v
a
g
i
n
a
l
 
a
n
d
 
a
n
a
l
 
i
n
t
e
r
c
o
u
r
s
e
,
 
a
n
d
 
p
r
o
m
o
t
e
d
 
t
h
e
 
u
s
e
 
o
f
 
c
o
n
d
o
m
s
.
 
I
n
c
l
u
d
e
d
 
m
a
n
y
 
i
n
t
e
r
a
c
t
i
v
e
 
s
e
s
s
i
o
n
s
 
a
n
d
 
m
o
d
e
l
l
e
d
 
c
o
r
r
e
c
t
 
u
s
e
 
o
f
 
c
o
n
d
o
m
s
.
L
e
n
g
t
h
/
i
n
t
e
n
s
i
t
y
:
 
5
-
h
o
u
r
 
s
m
a
l
l
 
g
r
o
u
p
 
i
n
t
e
r
v
e
n
t
i
o
n
s
C
o
m
p
a
r
a
t
o
r
:
 
A
 
g
e
n
e
r
a
l
 
h
e
a
l
t
h
 
p
r
o
m
o
t
i
o
n
 
i
n
t
e
r
v
e
n
t
i
o
n
I
m
p
l
e
m
e
n
t
a
t
i
o
n
C
o
n
t
e
n
t
S
k
i
l
l
s
 
a
n
d
 
t
r
a
i
n
i
n
g
 
o
f
 
t
h
e
 
p
r
o
v
i
d
e
r
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A
u
t
h
o
r
s
/
d
a
t
e
;
c
o
u
n
t
r
y
/
a
r
e
a
P
o
p
u
l
a
t
i
o
n
 
d
e
t
a
i
l
s
D
e
t
a
i
l
s
 
o
f
 
i
n
t
e
r
v
e
n
t
i
o
n
P
r
o
c
e
s
s
e
s
 
e
v
a
l
u
a
t
e
d
J
e
m
m
o
t
t
 
e
t
 
a
l
.
 
1
9
9
2
;
4
3
 
P
h
i
l
a
d
e
l
p
h
i
a
,
 
U
S
A
B
l
a
c
k
 
m
a
l
e
s
,
 
m
e
a
n
 
a
g
e
 
1
4
.
6
4
 
y
e
a
r
s
A
i
m
s
:
 
T
h
e
 
A
I
D
S
 
r
i
s
k
 
r
e
d
u
c
t
i
o
n
 
c
o
n
d
i
t
i
o
n
 
w
a
s
 
‘
d
e
s
i
g
n
e
d
 
t
o
 
i
n
c
r
e
a
s
e
 
t
h
e
i
r
 
k
n
o
w
l
e
d
g
e
 
o
f
 
A
I
D
S
 
a
n
d
 
S
T
D
s
 
a
n
d
 
t
o
 
w
e
a
k
e
n
 
p
r
o
b
l
e
m
a
t
i
c
 
a
t
t
i
t
u
d
e
s
 
t
o
w
a
r
d
s
 
r
i
s
k
y
 
s
e
x
u
a
l
 
b
e
h
a
v
i
o
u
r
s
’
 
(
p
.
 
3
7
3
)
P
r
o
v
i
d
e
r
s
:
 
F
a
c
i
l
i
t
a
t
o
r
s
T
r
a
i
n
i
n
g
:
 
F
a
c
i
l
i
t
a
t
o
r
s
 
r
e
c
e
i
v
e
d
 
6
 
h
o
u
r
s
 
o
f
 
t
r
a
i
n
i
n
g
S
e
t
t
i
n
g
:
 
S
c
h
o
o
l
C
o
n
t
e
n
t
:
 
‘
P
a
r
t
i
c
i
p
a
n
t
s
 
i
n
 
t
h
e
 
A
I
D
S
 
r
i
s
k
-
r
e
d
u
c
t
i
o
n
 
c
o
n
d
i
t
i
o
n
 
r
e
c
e
i
v
e
d
 
a
 
5
-
h
o
u
r
 
i
n
t
e
r
v
e
n
t
i
o
n
 
d
e
s
i
g
n
e
d
 
t
o
 
i
n
c
r
e
a
s
e
 
t
h
e
i
r
 
k
n
o
w
l
e
d
g
e
 
o
f
 
A
I
D
S
 
a
n
d
 
S
T
D
s
 
a
n
d
 
t
o
 
w
e
a
k
e
n
 
p
r
o
b
l
e
m
a
t
i
c
 
a
t
t
i
t
u
d
e
s
 
t
o
w
a
r
d
s
 
r
i
s
k
y
 
s
e
x
u
a
l
 
b
e
h
a
v
i
o
u
r
s
.
 
T
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
 
i
n
c
l
u
d
e
d
 
i
n
f
o
r
m
a
t
i
o
n
 
a
b
o
u
t
 
r
i
s
k
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
i
n
t
r
a
v
e
n
o
u
s
 
d
r
u
g
 
u
s
e
 
a
n
d
 
s
p
e
c
i
fi
c
 
s
e
x
u
a
l
 
a
c
t
i
v
i
t
i
e
s
.
 
V
i
d
e
o
t
a
p
e
s
,
 
g
a
m
e
s
,
 
e
x
e
r
c
i
s
e
s
,
 
a
n
d
 
o
t
h
e
r
 
c
u
l
t
u
r
a
l
l
y
 
a
n
d
 
d
e
v
e
l
o
p
m
e
n
t
a
l
l
y
 
a
p
p
r
o
p
r
i
a
t
e
 
m
a
t
e
r
i
a
l
s
 
w
e
r
e
 
u
s
e
d
 
t
o
 
r
e
i
n
f
o
r
c
e
 
l
e
a
r
n
i
n
g
 
a
n
d
 
t
o
 
e
n
c
o
u
r
a
g
e
 
a
c
t
i
v
e
 
p
a
r
t
i
c
i
p
a
t
i
o
n
.
 
A
l
l
 
m
a
t
e
r
i
a
l
s
 
h
a
d
 
b
e
e
n
 
e
x
t
e
n
s
i
v
e
l
y
 
p
i
l
o
t
 
t
e
s
t
e
d
 
a
n
d
 
w
e
r
e
 
s
e
l
e
c
t
e
d
 
n
o
t
 
o
n
l
y
 
t
o
 
p
r
o
v
i
d
e
 
a
c
c
u
r
a
t
e
 
i
n
f
o
r
m
a
t
i
o
n
,
 
b
u
t
 
a
l
s
o
 
t
o
 
d
o
 
s
o
 
i
n
 
w
a
y
s
 
t
h
a
t
 
w
o
u
l
d
 
b
e
 
i
n
t
e
r
e
s
t
i
n
g
 
t
o
 
i
n
n
e
r
-
c
i
t
y
 
b
l
a
c
k
 
m
a
l
e
 
a
d
o
l
e
s
c
e
n
t
s
.
’
 
(
p
.
 
3
7
3
)
L
e
n
g
t
h
/
i
n
t
e
n
s
i
t
y
:
 
1
 
5
-
h
o
u
r
 
i
n
t
e
r
v
e
n
t
i
o
n
C
o
m
p
a
r
a
t
o
r
:
 
A
n
 
i
n
t
e
r
v
e
n
t
i
o
n
 
c
o
n
c
e
r
n
i
n
g
 
c
a
r
e
e
r
 
p
l
a
n
n
i
n
g
 
a
n
d
 
o
p
p
o
r
t
u
n
i
t
i
e
s
P
e
r
c
e
p
t
i
o
n
s
,
 
u
n
d
e
r
s
t
a
n
d
i
n
g
 
o
r
 
a
c
c
e
p
t
a
b
i
l
i
t
y
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
A
c
c
e
s
s
i
b
i
l
i
t
y
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
/
p
r
o
g
r
a
m
m
e
 
r
e
a
c
h
I
m
p
l
e
m
e
n
t
a
t
i
o
n
/
d
e
l
i
v
e
r
y
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
O
t
h
e
r
K
a
r
n
e
l
l
 
e
t
 
a
l
.
 
2
0
0
6
;
6
3
 
P
i
e
t
e
r
m
a
r
i
t
z
b
u
r
g
 
K
w
a
-
Z
u
l
u
-
N
a
t
a
l
,
 
S
o
u
t
h
 
A
f
r
i
c
a
S
t
u
d
e
n
t
s
 
o
f
 
m
e
d
i
a
n
 
a
g
e
 
1
6
,
 
p
r
e
d
o
m
i
n
a
n
t
l
y
 
(
9
4
%
)
 
Z
u
l
u
 
e
t
h
n
i
c
 
g
r
o
u
p
A
i
m
s
:
 
T
h
e
 
o
b
j
e
c
t
i
v
e
s
 
o
f
 
t
h
e
 
p
r
o
g
r
a
m
m
e
 
w
e
r
e
 
t
o
 
i
m
p
a
r
t
 
k
e
y
 
H
I
V
 
a
n
d
 
a
l
c
o
h
o
l
 
r
e
l
a
t
e
d
 
f
a
c
t
s
,
 
e
n
h
a
n
c
e
 
s
t
u
d
e
n
t
s
’
 
u
n
d
e
r
s
t
a
n
d
i
n
g
 
o
f
 
t
h
e
 
c
o
n
s
e
q
u
e
n
c
e
s
 
o
f
 
d
r
i
n
k
i
n
g
 
a
l
c
o
h
o
l
 
a
n
d
 
h
a
v
i
n
g
 
u
n
p
r
o
t
e
c
t
e
d
 
s
e
x
,
 
a
i
d
 
s
t
u
d
e
n
t
s
’
 
i
d
e
n
t
i
fi
c
a
t
i
o
n
 
o
f
 
p
o
s
i
t
i
v
e
 
a
l
t
e
r
n
a
t
i
v
e
s
 
t
o
 
d
r
i
n
k
i
n
g
 
a
l
c
o
h
o
l
 
o
r
 
h
a
v
i
n
g
 
s
e
x
,
 
e
x
p
o
s
e
 
s
t
u
d
e
n
t
s
 
t
o
 
s
p
e
c
i
fi
c
 
t
e
c
h
n
i
q
u
e
s
 
f
o
r
 
r
e
s
i
s
t
i
n
g
 
p
r
e
s
s
u
r
e
 
t
o
 
d
r
i
n
k
 
o
r
 
h
a
v
e
 
s
e
x
,
 
g
i
v
e
 
s
t
u
d
e
n
t
s
 
t
h
e
 
o
p
p
o
r
t
u
n
i
t
y
 
t
o
 
p
r
a
c
t
i
c
e
 
s
u
c
h
 
t
e
c
h
n
i
q
u
e
s
 
t
h
r
o
u
g
h
 
r
o
l
e
 
p
l
a
y
 
e
x
e
r
c
i
s
e
s
,
 
a
n
d
 
e
n
h
a
n
c
e
 
s
t
u
d
e
n
t
s
’
 
a
b
i
l
i
t
y
 
t
o
 
p
l
a
n
 
a
h
e
a
d
 
t
o
 
a
v
o
i
d
 
s
i
t
u
a
t
i
o
n
s
 
i
n
 
w
h
i
c
h
 
t
h
e
y
 
w
o
u
l
d
 
b
e
 
l
i
k
e
l
y
 
t
o
 
e
n
g
a
g
e
 
i
n
 
r
i
s
k
 
b
e
h
a
v
i
o
u
r
s
P
r
o
v
i
d
e
r
(
s
)
:
 
T
e
a
c
h
e
r
s
 
a
n
d
 
p
e
e
r
s
T
r
a
i
n
i
n
g
:
 
P
e
e
r
s
 
r
e
c
e
i
v
e
d
 
2
 
d
a
y
s
’
 
t
r
a
i
n
i
n
g
S
e
t
t
i
n
g
:
 
S
c
h
o
o
l
C
o
n
t
e
n
t
:
 
P
r
i
m
a
r
i
l
y
 
f
o
c
u
s
e
d
 
o
n
 
s
k
i
l
l
s
 
d
e
v
e
l
o
p
m
e
n
t
;
 
s
p
e
c
i
fi
c
 
t
e
c
h
n
i
q
u
e
s
,
 
p
r
a
c
t
i
s
e
d
 
t
h
r
o
u
g
h
 
r
o
l
e
 
p
l
a
y
 
e
x
e
r
c
i
s
e
s
,
 
t
o
 
r
e
s
i
s
t
 
p
r
e
s
s
u
r
e
 
t
o
 
h
a
v
e
 
u
n
s
a
f
e
 
s
e
x
 
a
n
d
 
u
s
e
 
a
l
c
o
h
o
l
.
 
T
h
e
 
c
e
n
t
r
e
p
i
e
c
e
 
w
a
s
 
f
o
u
r
 
m
o
n
o
l
o
g
u
e
s
 
b
y
 
fi
c
t
i
o
n
a
l
 
t
e
e
n
a
g
e
 
c
h
a
r
a
c
t
e
r
s
 
d
e
s
c
r
i
b
i
n
g
 
t
h
e
i
r
 
d
i
l
e
m
m
a
s
 
r
e
g
a
r
d
i
n
g
 
h
a
v
i
n
g
 
s
e
x
 
a
n
d
 
u
s
i
n
g
 
a
l
c
o
h
o
l
.
 
T
h
e
s
e
 
f
o
r
m
e
d
 
t
h
e
 
b
a
s
i
s
 
f
o
r
 
c
l
a
s
s
 
d
i
s
c
u
s
s
i
o
n
 
–
 
l
e
d
 
b
y
 
p
e
e
r
 
l
e
a
d
e
r
s
 
–
 
a
n
d
 
g
r
o
u
p
 
a
s
s
i
g
n
m
e
n
t
s
L
e
n
g
t
h
/
i
n
t
e
n
s
i
t
y
:
 
1
0
 
u
n
i
t
s
 
o
f
 
3
0
 
m
i
n
u
t
e
s
 
e
a
c
h
 
d
e
l
i
v
e
r
e
d
 
o
v
e
r
 
8
 
w
e
e
k
s
C
o
m
p
a
r
a
t
o
r
:
 
‘
L
i
f
e
 
O
r
i
e
n
t
a
t
i
o
n
’
 
i
n
s
t
r
u
c
t
i
o
n
P
e
r
c
e
p
t
i
o
n
s
,
 
u
n
d
e
r
s
t
a
n
d
i
n
g
 
o
r
 
a
c
c
e
p
t
a
b
i
l
i
t
y
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
I
m
p
l
e
m
e
n
t
a
t
i
o
n
/
d
e
l
i
v
e
r
y
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
S
k
i
l
l
s
 
a
n
d
 
t
r
a
i
n
i
n
g
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
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r
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A
u
t
h
o
r
s
/
d
a
t
e
;
c
o
u
n
t
r
y
/
a
r
e
a
P
o
p
u
l
a
t
i
o
n
 
d
e
t
a
i
l
s
D
e
t
a
i
l
s
 
o
f
 
i
n
t
e
r
v
e
n
t
i
o
n
P
r
o
c
e
s
s
e
s
 
e
v
a
l
u
a
t
e
d
L
e
v
y
 
e
t
 
a
l
.
 
1
9
9
5
;
6
5
 
C
h
i
c
a
g
o
,
 
U
S
A
1
2
-
 
t
o
 
1
4
-
y
e
a
r
-
o
l
d
s
,
 
m
a
j
o
r
i
t
y
 
A
f
r
i
c
a
n
-
A
m
e
r
i
c
a
n
 
(
6
4
.
3
%
 
i
n
 
c
o
n
t
r
o
l
 
g
r
o
u
p
,
 
4
7
.
8
%
 
i
n
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
 
g
r
o
u
p
)
A
i
m
s
:
 
T
o
 
a
s
s
e
s
s
 
t
h
e
 
i
m
p
a
c
t
 
o
f
 
a
 
s
c
h
o
o
l
-
b
a
s
e
d
 
A
I
D
S
 
p
r
e
v
e
n
t
i
o
n
 
p
r
o
g
r
a
m
m
e
 
o
n
 
s
t
u
d
e
n
t
 
p
a
r
t
i
c
i
p
a
t
i
o
n
 
i
n
 
s
e
x
u
a
l
 
r
i
s
k
 
a
n
d
 
p
r
o
t
e
c
t
i
v
e
 
b
e
h
a
v
i
o
u
r
s
 
s
u
c
h
 
a
s
 
u
s
e
 
o
f
 
c
o
n
d
o
m
s
 
a
n
d
 
u
s
e
 
o
f
 
c
o
n
d
o
m
s
 
w
i
t
h
 
f
o
a
m
 
a
n
d
 
i
n
t
e
n
t
i
o
n
 
t
o
 
p
a
r
t
i
c
i
p
a
t
e
 
i
n
 
s
u
c
h
 
b
e
h
a
v
i
o
u
r
s
P
r
o
v
i
d
e
r
s
:
 
‘
T
r
a
i
n
e
d
’
 
h
e
a
l
t
h
 
e
d
u
c
a
t
o
r
s
T
r
a
i
n
i
n
g
:
 
N
o
 
f
u
r
t
h
e
r
 
d
e
t
a
i
l
s
 
g
i
v
e
n
S
e
t
t
i
n
g
:
 
S
c
h
o
o
l
C
o
n
t
e
n
t
:
 
U
s
e
d
 
a
n
 
i
n
t
e
g
r
a
t
e
d
 
a
p
p
r
o
a
c
h
 
t
o
 
m
u
l
t
i
p
l
e
 
r
i
s
k
 
r
e
d
u
c
t
i
o
n
 
a
n
d
 
p
r
e
v
e
n
t
i
o
n
 
u
s
i
n
g
 
k
n
o
w
l
e
d
g
e
 
t
r
a
n
s
f
e
r
,
 
a
c
t
i
v
e
 
l
e
a
r
n
i
n
g
 
a
n
d
 
s
k
i
l
l
s
-
b
u
i
l
d
i
n
g
 
t
e
c
h
n
i
q
u
e
s
 
t
o
 
i
n
fl
u
e
n
c
e
 
s
t
u
d
e
n
t
 
k
n
o
w
l
e
d
g
e
,
 
a
t
t
i
t
u
d
e
s
,
 
i
n
t
e
n
t
i
o
n
s
 
a
n
d
 
b
e
h
a
v
i
o
u
r
 
a
n
d
 
t
o
 
a
f
f
e
c
t
 
p
e
e
r
 
n
o
r
m
s
.
 
T
o
p
i
c
s
 
i
n
c
l
u
d
e
d
 
H
I
V
/
A
I
D
S
,
 
p
r
e
g
n
a
n
c
y
 
a
n
d
 
S
T
D
 
p
r
e
v
e
n
t
i
o
n
,
 
a
n
d
 
e
n
h
a
n
c
e
m
e
n
t
 
o
f
 
d
e
c
i
s
i
o
n
-
m
a
k
i
n
g
 
a
n
d
 
r
e
s
i
s
t
a
n
c
e
/
n
e
g
o
t
i
a
t
i
o
n
 
s
k
i
l
l
s
.
 
S
p
e
c
i
fi
c
 
a
c
t
i
v
i
t
i
e
s
 
c
o
n
s
i
s
t
e
d
 
o
f
 
l
e
c
t
u
r
e
s
,
 
c
l
a
s
s
 
d
i
s
c
u
s
s
i
o
n
s
,
 
v
i
d
e
o
 
p
r
e
s
e
n
t
a
t
i
o
n
s
,
 
s
m
a
l
l
 
g
r
o
u
p
 
e
x
e
r
c
i
s
e
s
,
 
r
o
l
e
 
p
l
a
y
s
,
 
b
r
a
i
n
s
t
o
r
m
i
n
g
,
 
e
d
u
c
a
t
i
o
n
a
l
 
c
o
m
p
e
t
i
t
i
o
n
s
 
a
n
d
 
d
i
s
c
u
s
s
i
o
n
 
o
f
 
a
n
o
n
y
m
o
u
s
 
q
u
e
s
t
i
o
n
s
 
f
r
o
m
 
s
t
u
d
e
n
t
s
S
t
u
d
e
n
t
s
 
i
n
 
b
o
t
h
 
e
x
p
e
r
i
m
e
n
t
a
l
 
c
o
n
d
i
t
i
o
n
s
 
w
e
r
e
 
r
e
q
u
i
r
e
d
 
t
o
 
c
o
m
p
l
e
t
e
 
h
o
m
e
w
o
r
k
 
a
s
s
i
g
n
m
e
n
t
s
 
a
n
d
 
a
l
l
 
p
a
r
e
n
t
s
 
w
e
r
e
 
i
n
v
i
t
e
d
 
t
o
 
a
t
t
e
n
d
 
a
 
Y
o
u
t
h
 
A
I
D
S
 
P
r
e
v
e
n
t
i
o
n
 
P
r
o
j
e
c
t
 
(
Y
A
P
P
)
 
o
r
i
e
n
t
a
t
i
o
n
 
m
e
e
t
i
n
g
I
n
 
t
h
e
 
p
a
r
e
n
t
-
i
n
t
e
r
a
c
t
i
v
e
 
c
o
n
d
i
t
i
o
n
,
 
s
t
u
d
e
n
t
s
 
w
e
r
e
 
r
e
q
u
i
r
e
d
 
t
o
 
c
o
m
p
l
e
t
e
 
a
d
d
i
t
i
o
n
a
l
 
h
o
m
e
w
o
r
k
 
a
s
s
i
g
n
m
e
n
t
s
 
(
t
w
o
 
e
x
t
r
a
 
i
n
 
7
t
h
 
g
r
a
d
e
,
 
o
n
e
 
e
x
t
r
a
 
i
n
 
8
t
h
 
g
r
a
d
e
)
 
w
i
t
h
 
a
 
p
a
r
e
n
t
 
o
r
 
g
u
a
r
d
i
a
n
,
 
w
h
o
 
a
l
s
o
 
w
a
s
 
e
n
c
o
u
r
a
g
e
d
 
t
o
 
a
t
t
e
n
d
 
m
o
r
e
 
i
n
t
e
n
s
i
v
e
 
p
a
r
e
n
t
 
m
e
e
t
i
n
g
s
 
a
b
o
u
t
 
t
h
e
 
p
r
o
g
r
a
m
m
e
,
 
t
o
 
b
e
c
o
m
e
 
i
n
v
o
l
v
e
d
 
w
i
t
h
 
t
h
e
 
s
c
h
o
o
l
 
p
r
o
g
r
a
m
m
e
,
 
a
n
d
 
t
o
 
d
i
s
c
u
s
s
 
H
I
V
/
A
I
D
S
 
w
i
t
h
 
t
h
e
i
r
 
c
h
i
l
d
r
e
n
L
e
n
g
t
h
/
i
n
t
e
n
s
i
t
y
:
 
1
5
-
l
e
s
s
o
n
 
c
u
r
r
i
c
u
l
u
m
;
 
l
e
s
s
o
n
s
 
l
a
s
t
e
d
 
b
e
t
w
e
e
n
 
3
8
 
a
n
d
 
5
0
 
m
i
n
u
t
e
s
C
o
m
p
a
r
a
t
o
r
:
 
T
h
e
 
c
o
n
t
r
o
l
 
g
r
o
u
p
 
r
e
c
e
i
v
e
d
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
 
t
h
e
 
f
o
l
l
o
w
i
n
g
 
y
e
a
r
;
 
i
n
 
t
h
e
 
y
e
a
r
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
t
h
e
y
 
r
e
c
e
i
v
e
d
 
‘
b
a
s
i
c
 
m
i
n
i
m
a
l
’
 
A
I
D
S
 
e
d
u
c
a
t
i
o
n
P
e
r
c
e
p
t
i
o
n
s
,
 
u
n
d
e
r
s
t
a
n
d
i
n
g
 
o
r
 
a
c
c
e
p
t
a
b
i
l
i
t
y
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
I
m
p
l
e
m
e
n
t
a
t
i
o
n
/
d
e
l
i
v
e
r
y
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
R
o
b
e
r
t
o
 
e
t
 
a
l
.
 
2
0
0
7
;
6
6
 
‘
a
 
r
u
r
a
l
 
A
p
p
a
l
a
c
h
i
a
n
 
c
o
u
n
t
y
’
,
 
U
S
A
E
x
p
e
r
i
m
e
n
t
a
l
 
s
c
h
o
o
l
,
 
s
t
u
d
e
n
t
s
 
w
i
t
h
 
a
 
m
e
a
n
 
a
g
e
 
o
f
 
1
5
.
5
0
 
y
e
a
r
s
;
 
c
o
n
t
r
o
l
 
s
c
h
o
o
l
,
 
s
t
u
d
e
n
t
s
 
w
i
t
h
 
a
 
m
e
a
n
 
a
g
e
 
o
f
 
1
5
.
6
8
 
y
e
a
r
s
;
 
m
a
j
o
r
i
t
y
 
o
f
 
b
o
t
h
 
g
r
o
u
p
s
 
E
u
r
o
p
e
a
n
-
A
m
e
r
i
c
a
n
A
i
m
s
:
 
T
h
e
 
a
u
t
h
o
r
s
 
t
a
l
k
 
o
f
 
t
h
e
 
i
m
p
o
r
t
a
n
c
e
 
o
f
 
i
n
c
r
e
a
s
i
n
g
 
p
e
r
c
e
p
t
i
o
n
s
 
o
f
 
‘
p
e
r
s
o
n
a
l
l
y
 
r
e
l
e
v
a
n
t
 
(
s
u
s
c
e
p
t
i
b
i
l
i
t
y
)
 
a
n
d
 
s
e
r
i
o
u
s
 
(
s
e
v
e
r
i
t
y
)
 
t
h
r
e
a
t
’
 
a
n
d
 
o
f
 
‘
a
n
 
e
f
f
e
c
t
i
v
e
 
m
e
a
n
s
 
o
f
 
r
e
d
u
c
i
n
g
 
t
h
e
 
t
h
r
e
a
t
 
(
r
e
s
p
o
n
s
e
 
e
f
fi
c
a
c
y
)
 
t
h
a
t
 
t
h
e
y
 
a
r
e
 
c
a
p
a
b
l
e
 
o
f
 
p
e
r
f
o
r
m
i
n
g
 
(
s
e
l
f
-
e
f
fi
c
a
c
y
)
.
 
T
h
u
s
,
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
 
w
a
s
 
c
r
e
a
t
e
d
 
t
o
 
i
n
c
r
e
a
s
e
 
p
e
r
c
e
p
t
i
o
n
s
 
o
f
 
t
h
e
s
e
 
f
o
u
r
 
v
a
r
i
a
b
l
e
s
’
 
(
p
.
 
5
6
)
.
 
U
l
t
i
m
a
t
e
l
y
,
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
 
w
a
s
 
t
o
 
e
n
c
o
u
r
a
g
e
 
s
t
u
d
e
n
t
s
 
t
o
 
e
n
g
a
g
e
 
i
n
 
t
h
e
 
r
e
c
o
m
m
e
n
d
e
d
 
b
e
h
a
v
i
o
u
r
s
:
 
‘
t
o
 
d
e
l
a
y
 
i
n
i
t
i
a
t
i
o
n
 
o
f
 
s
e
x
u
a
l
 
a
c
t
i
v
i
t
y
 
a
n
d
 
t
o
 
i
n
c
r
e
a
s
e
 
u
s
e
 
o
f
 
c
o
n
d
o
m
s
 
f
o
r
 
t
h
o
s
e
 
w
h
o
 
w
e
r
e
 
s
e
x
u
a
l
l
y
 
a
c
t
i
v
e
’
 
(
p
.
 
5
6
)
.
P
r
o
v
i
d
e
r
(
s
)
:
 
C
o
m
p
u
t
e
r
T
r
a
i
n
i
n
g
:
 
N
/
A
S
e
t
t
i
n
g
:
 
S
c
h
o
o
l
C
o
n
t
e
n
t
:
 
C
o
m
p
u
t
e
r
-
b
a
s
e
d
 
a
c
t
i
v
i
t
i
e
s
,
 
i
n
c
l
u
d
i
n
g
 
a
 
‘
t
r
u
t
h
 
o
r
 
m
y
t
h
’
 
s
e
s
s
i
o
n
,
 
a
n
 
e
x
e
r
c
i
s
e
 
o
n
 
r
i
s
k
y
 
b
e
h
a
v
i
o
u
r
 
a
n
d
 
a
 
r
e
f
u
s
a
l
 
s
k
i
l
l
 
a
c
t
i
v
i
t
y
L
e
n
g
t
h
/
I
n
t
e
n
s
i
t
y
:
 
7
 
w
e
e
k
s
,
 
6
 
a
c
t
i
v
i
t
i
e
s
 
(
a
l
l
 
s
i
x
 
r
e
p
e
a
t
e
d
 
i
n
 
w
e
e
k
 
7
)
,
 
e
a
c
h
 
o
f
 
1
5
 
m
i
n
u
t
e
s
’
 
d
u
r
a
t
i
o
n
C
o
m
p
a
r
a
t
o
r
:
 
R
e
c
e
i
v
e
d
 
n
o
t
h
i
n
g
P
e
r
c
e
p
t
i
o
n
s
,
 
u
n
d
e
r
s
t
a
n
d
i
n
g
 
o
r
 
a
c
c
e
p
t
a
b
i
l
i
t
y
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
A
c
c
e
s
s
i
b
i
l
i
t
y
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
/
p
r
o
g
r
a
m
m
e
 
r
e
a
c
h
I
m
p
l
e
m
e
n
t
a
t
i
o
n
/
d
e
l
i
v
e
r
y
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
nAppendix 6
160
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
161
A
u
t
h
o
r
s
/
d
a
t
e
;
c
o
u
n
t
r
y
/
a
r
e
a
P
o
p
u
l
a
t
i
o
n
 
d
e
t
a
i
l
s
D
e
t
a
i
l
s
 
o
f
 
i
n
t
e
r
v
e
n
t
i
o
n
P
r
o
c
e
s
s
e
s
 
e
v
a
l
u
a
t
e
d
S
t
e
p
h
e
n
s
o
n
 
e
t
 
a
l
.
 
2
0
0
4
;
5
0
 
C
e
n
t
r
a
l
 
a
n
d
 
S
o
u
t
h
e
r
n
 
E
n
g
l
a
n
d
,
 
U
K
P
a
r
t
i
c
i
p
a
n
t
s
 
1
3
–
1
4
 
y
e
a
r
s
,
 
p
e
e
r
 
l
e
a
d
e
r
s
 
1
6
–
1
7
 
y
e
a
r
s
A
i
m
s
:
 
R
e
s
e
a
r
c
h
e
r
s
 
a
i
m
e
d
 
t
o
 
i
n
v
e
s
t
i
g
a
t
e
 
t
h
e
 
e
f
f
e
c
t
i
v
e
n
e
s
s
 
o
f
 
p
e
e
r
-
l
e
d
 
v
s
 
t
e
a
c
h
e
r
-
l
e
d
 
S
R
E
 
a
t
 
r
e
d
u
c
i
n
g
 
t
e
r
m
i
n
a
t
i
o
n
 
o
f
 
p
r
e
g
n
a
n
c
y
 
a
n
d
 
u
n
p
r
o
t
e
c
t
e
d
 
s
e
x
u
a
l
 
i
n
t
e
r
c
o
u
r
s
e
,
 
a
n
d
 
a
t
 
i
m
p
r
o
v
i
n
g
 
t
h
e
 
q
u
a
l
i
t
y
 
o
f
 
s
e
x
u
a
l
 
r
e
l
a
t
i
o
n
s
h
i
p
s
P
r
o
v
i
d
e
r
(
s
)
:
 
P
e
e
r
s
T
r
a
i
n
i
n
g
:
 
2
 
d
a
y
s
’
 
i
n
t
e
n
s
i
v
e
 
t
r
a
i
n
i
n
g
S
e
t
t
i
n
g
:
 
S
c
h
o
o
l
C
o
n
t
e
n
t
:
 
I
n
t
e
r
a
c
t
i
v
e
 
s
e
s
s
i
o
n
s
 
o
n
 
r
e
l
a
t
i
o
n
s
h
i
p
s
,
 
S
T
I
s
,
 
c
o
n
d
o
m
s
 
a
n
d
 
c
o
n
t
r
a
c
e
p
t
i
o
n
.
 
T
e
a
c
h
e
r
s
 
w
e
r
e
 
n
o
t
 
i
n
 
a
t
t
e
n
d
a
n
c
e
 
d
u
r
i
n
g
 
t
h
e
 
s
e
s
s
i
o
n
.
 
S
e
s
s
i
o
n
s
 
i
n
v
o
l
v
e
d
 
g
a
m
e
s
 
a
n
d
 
s
m
a
l
l
 
g
r
o
u
p
 
w
o
r
k
,
 
d
i
s
c
u
s
s
i
o
n
s
,
 
b
r
a
i
n
s
t
o
r
m
s
,
 
r
o
l
e
 
p
l
a
y
i
n
g
 
a
n
d
 
d
e
m
o
n
s
t
r
a
t
i
n
g
 
h
o
w
 
t
o
 
u
s
e
 
c
o
n
d
o
m
s
.
 
‘
T
h
e
 
a
p
p
r
o
a
c
h
 
e
m
p
h
a
s
i
z
e
s
 
d
e
v
e
l
o
p
m
e
n
t
 
o
f
 
s
k
i
l
l
s
 
f
o
r
 
s
e
x
u
a
l
 
n
e
g
o
t
i
a
t
i
o
n
 
a
s
 
w
e
l
l
 
a
s
 
k
n
o
w
l
e
d
g
e
 
a
b
o
u
t
 
p
r
e
g
n
a
n
c
y
,
 
c
o
n
t
r
a
c
e
p
t
i
o
n
,
 
S
T
I
s
,
 
a
n
d
 
t
h
e
 
u
s
e
 
o
f
 
s
e
x
u
a
l
 
h
e
a
l
t
h
 
a
n
d
 
c
o
n
t
r
a
c
e
p
t
i
v
e
 
s
e
r
v
i
c
e
s
’
L
e
n
g
t
h
/
i
n
t
e
n
s
i
t
y
:
 
D
e
l
i
v
e
r
e
d
 
d
u
r
i
n
g
 
t
h
e
 
s
u
m
m
e
r
 
t
e
r
m
 
i
n
 
3
 
1
-
h
o
u
r
 
s
e
s
s
i
o
n
s
C
o
m
p
a
r
a
t
o
r
:
 
U
s
u
a
l
 
t
e
a
c
h
e
r
-
l
e
d
 
s
e
x
 
e
d
u
c
a
t
i
o
n
A
c
c
e
p
t
a
b
i
l
i
t
y
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
A
c
c
e
s
s
i
b
i
l
i
t
y
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
/
p
r
o
g
r
a
m
m
e
 
r
e
a
c
h
C
o
n
s
u
l
t
a
t
i
o
n
/
c
o
l
l
a
b
o
r
a
t
i
o
n
/
p
a
r
t
n
e
r
s
h
i
p
s
I
m
p
l
e
m
e
n
t
a
t
i
o
n
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
S
k
i
l
l
s
 
a
n
d
 
t
r
a
i
n
i
n
g
 
o
f
 
t
h
e
 
p
r
o
v
i
d
e
r
s
O
t
h
e
r
W
i
g
h
t
 
e
t
 
a
l
.
 
2
0
0
2
;
7
0
 
S
c
o
t
l
a
n
d
,
 
U
K
P
u
p
i
l
s
 
a
g
e
d
 
b
e
t
w
e
e
n
 
1
3
–
1
4
 
y
e
a
r
s
A
i
m
s
:
 
T
h
e
 
a
i
m
s
 
w
e
r
e
 
t
o
 
r
e
d
u
c
e
 
u
n
s
a
f
e
 
s
e
x
u
a
l
 
b
e
h
a
v
i
o
u
r
s
,
 
r
e
d
u
c
e
 
u
n
i
n
t
e
n
d
e
d
 
p
r
e
g
n
a
n
c
i
e
s
 
a
n
d
 
i
m
p
r
o
v
e
 
t
h
e
 
q
u
a
l
i
t
y
 
o
f
 
s
e
x
u
a
l
 
r
e
l
a
t
i
o
n
s
h
i
p
s
P
r
o
v
i
d
e
r
(
s
)
:
 
T
e
a
c
h
e
r
s
T
r
a
i
n
i
n
g
:
 
5
 
d
a
y
s
’
 
t
e
a
c
h
e
r
 
t
r
a
i
n
i
n
g
S
e
t
t
i
n
g
:
 
S
c
h
o
o
l
C
o
n
t
e
n
t
:
 
T
h
e
 
S
H
A
R
E
 
p
r
o
g
r
a
m
m
e
 
a
d
v
i
s
e
s
 
t
e
e
n
a
g
e
r
s
 
t
o
 
d
e
l
a
y
 
s
e
x
u
a
l
 
i
n
t
e
r
c
o
u
r
s
e
 
u
n
t
i
l
 
t
h
e
y
 
a
r
e
 
s
u
r
e
 
t
h
e
y
 
a
r
e
 
r
e
a
d
y
 
a
n
d
 
t
o
 
a
l
w
a
y
s
 
u
s
e
 
a
 
c
o
n
d
o
m
 
u
n
t
i
l
 
t
h
e
y
 
p
l
a
n
 
t
o
 
h
a
v
e
 
c
h
i
l
d
r
e
n
.
 
I
t
 
c
o
m
b
i
n
e
s
 
a
c
t
i
v
e
 
l
e
a
r
n
i
n
g
 
(
s
m
a
l
l
 
g
r
o
u
p
 
w
o
r
k
 
a
n
d
 
g
a
m
e
s
)
,
 
i
n
f
o
r
m
a
t
i
o
n
 
l
e
a
fl
e
t
s
 
o
n
 
s
e
x
u
a
l
 
h
e
a
l
t
h
,
 
a
n
d
 
d
e
v
e
l
o
p
m
e
n
t
 
o
f
 
s
k
i
l
l
s
,
 
p
r
i
m
a
r
i
l
y
 
t
h
r
o
u
g
h
 
t
h
e
 
u
s
e
 
o
f
 
i
n
t
e
r
a
c
t
i
v
e
 
v
i
d
e
o
 
b
u
t
 
a
l
s
o
 
t
h
r
o
u
g
h
 
r
o
l
e
 
p
l
a
y
i
n
g
.
 
I
t
 
i
n
c
l
u
d
e
d
 
s
e
s
s
i
o
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TABLE 70  Behavioural outcomes – initiation of sex
Sexual initiationa Statistical significance
Intervention vs standard sex education
Coyle et al.58 n Estimated 
effect size
Standard 
error
95% CI No statistically significant differences 
between students in the Safer Choices 
and comparison schools at follow-up 2565 1.13 0.24 (0.71 to 
1.82)
Wight et al.70 Intervention Control Difference (95% CI)
Young men 23.6% 23.9% –0.4 (–5.7 to 4.9) p-value 0.89
Young women 31.8% 33.0% –1.2 (–5.3 to 3.0) p-value 0.59
Zimmerman et al.71 Outcome reported for only the difference between baseline and Time 3 and not data extracted due 
to unacceptably high attrition at Time 3 (Time 3 did not pass as sound)
Intervention vs control (no intervention, delayed intervention, non-sex education intervention)
Klepp et al.64 Intervention schools Comparison schools
6.6% 16.5% Net effect 9.9, p = 0.19 (sexual initiation 
baseline to follow-up)
Roberto et al.66 Experimental group Control group
8% (n = 10) 18% (n = 33) p < 0.01, OR 2.93; control group 
adolescents nearly three times more 
likely to initiate sexual activity between 
pre-test and post-test
Stanton et al.69 Outcome data only reported at 9 months and not data extracted as this time point did not pass as 
sound
Peer-led vs teacher-led interventions
Stephenson et al.50 Intervention Control
6 month – boys 242/1980 196/1660 UEI: 1.07 (0.76 to 1.50)
AEI: 1.06 (0.74 to 1.52)
6 month – girls 230/1895 221/1588 UEI: 0.86 (0.69 to 1.07)
AEI: 0.92 (0.75 to 1.11)
18-month – boys 543/1700 444/1300 UEI: 0.90 (0.65 to 1.23)
AEI: 0.92 (0.65 to 1.28)
18-month – girls 610/1615 562/1297 UEI: 0.80 (0.66 to 0.97)
AEI: 0.82 (0.68 to 0.98)
AEI, adjusted effect for intervention; UEI, unadjusted effect for intervention.
a  A sexual initiation outcome was not reported by: Levy and colleagues65 and Karnell and colleagues63 (intervention vs 
standard sex education); Jemmott and colleagues62 (intervention vs control); and Borgia and colleagues51 (peer-led vs 
teacher-led intervention).
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i
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c
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c
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n
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r
t
e
d
 
a
s
 
‘
h
a
d
 
s
e
x
 
m
o
r
e
 
t
h
a
n
 
o
n
c
e
’
.
T
A
B
L
E
 
7
2
 
B
e
h
a
v
i
o
u
r
a
l
 
o
u
t
c
o
m
e
s
 
–
 
s
e
x
u
a
l
 
i
n
t
e
r
c
o
u
r
s
e
 
(
c
o
n
t
i
n
u
e
d
)Appendix 8
174
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
175
T
A
B
L
E
 
7
3
 
B
e
h
a
v
i
o
u
r
a
l
 
o
u
t
c
o
m
e
s
 
–
 
c
o
n
t
r
a
c
e
p
t
i
o
n
C
o
n
t
r
a
c
e
p
t
i
o
n
a
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
I
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
s
t
a
n
d
a
r
d
 
s
e
x
 
e
d
u
c
a
t
i
o
n
C
o
y
l
e
 
e
t
 
a
l
.
5
8
n
E
s
t
i
m
a
t
e
d
 
e
f
f
e
c
t
 
s
i
z
e
S
t
a
n
d
a
r
d
 
e
r
r
o
r
9
5
%
 
C
I
P
r
o
t
e
c
t
i
o
n
 
a
g
a
i
n
s
t
 
p
r
e
g
n
a
n
c
y
 
a
t
 
l
a
s
t
 
i
n
t
e
r
c
o
u
r
s
e
b
9
9
8
1
.
6
2
0
.
2
2
1
.
0
5
 
t
o
 
2
.
5
0
0
.
0
3
W
i
g
h
t
 
e
t
 
a
l
.
7
0
M
o
s
t
 
r
e
c
e
n
t
 
i
n
t
e
r
c
o
u
r
s
e
 
w
i
t
h
 
o
r
a
l
 
c
o
n
t
r
a
c
e
p
t
i
o
n
,
 
w
i
t
h
 
o
r
 
w
i
t
h
o
u
t
 
c
o
n
d
o
m
 
I
n
t
e
r
v
e
n
t
i
o
n
C
o
n
t
r
o
l
D
i
f
f
e
r
e
n
c
e
 
(
9
5
%
 
C
I
)
Y
o
u
n
g
 
m
e
n
 
(
s
e
x
u
a
l
l
y
 
e
x
p
e
r
i
e
n
c
e
d
)
1
8
.
7
2
1
.
2
–
2
.
5
 
(
–
8
.
0
 
t
o
 
2
.
9
)
 
p
 
=
 
0
.
3
8
Y
o
u
n
g
 
w
o
m
e
n
 
(
s
e
x
u
a
l
l
y
 
e
x
p
e
r
i
e
n
c
e
d
)
3
0
.
4
2
8
.
0
2
.
4
 
(
–
4
.
1
 
t
o
 
8
.
9
)
 
p
 
=
 
0
.
4
8
U
n
i
n
t
e
n
d
e
d
 
p
r
e
g
n
a
n
c
i
e
s
Y
o
u
n
g
 
w
o
m
e
n
(
4
8
/
1
2
0
1
)
 
4
.
0
(
3
5
/
9
1
6
)
 
3
.
8
1
.
0
 
(
0
.
6
 
t
o
 
1
.
8
)
,
 
p
 
=
 
0
.
9
1
I
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
c
o
n
t
r
o
l
 
(
n
o
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
d
e
l
a
y
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
n
o
n
-
s
e
x
 
e
d
u
c
a
t
i
o
n
 
i
n
t
e
r
v
e
n
t
i
o
n
)
S
t
a
n
t
o
n
 
e
t
 
a
l
.
6
9
B
i
r
t
h
 
c
o
n
t
r
o
l
 
p
i
l
l
 
a
n
d
 
c
o
n
d
o
m
 
u
s
e
d
 
a
t
 
l
a
s
t
 
s
e
x
u
a
l
 
i
n
t
e
r
c
o
u
r
s
e
F
o
c
u
s
 
o
n
 
K
i
d
s
C
o
n
t
r
o
l
D
o
e
s
 
n
o
t
 
r
e
p
o
r
t
 
a
 
s
t
a
t
i
s
t
i
c
a
l
 
c
o
m
p
a
r
i
s
o
n
B
a
s
e
l
i
n
e
0
.
2
8
0
.
2
6
T
h
r
e
e
-
m
o
n
t
h
 
a
d
j
u
s
t
e
d
 
m
e
a
n
 
a
g
a
i
n
s
t
 
b
a
s
e
l
i
n
e
0
.
2
3
0
.
3
3
S
i
x
-
m
o
n
t
h
 
a
d
j
u
s
t
e
d
 
m
e
a
n
 
a
g
a
i
n
s
t
 
b
a
s
e
l
i
n
e
0
.
3
0
0
.
3
0
c
o
n
t
i
n
u
e
dAppendix 8
176
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
177
C
o
n
t
r
a
c
e
p
t
i
o
n
a
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
P
e
e
r
-
l
e
d
 
v
s
 
t
e
a
c
h
e
r
-
l
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
s
S
t
e
p
h
e
n
s
o
n
 
e
t
 
a
l
.
5
0
U
s
e
d
 
c
o
n
t
r
a
c
e
p
t
i
o
n
 
a
t
 
fi
r
s
t
 
s
e
x
I
n
t
e
r
v
e
n
t
i
o
n
C
o
n
t
r
o
l
S
i
x
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
b
o
y
s
2
0
4
/
2
3
8
 
(
8
5
.
7
1
%
)
1
5
6
/
1
9
3
 
(
8
0
.
8
3
%
)
U
E
I
:
 
1
.
4
8
 
(
0
.
9
9
 
t
o
 
2
.
2
2
)
;
 
A
E
I
:
 
1
.
6
3
 
(
0
.
9
9
 
t
o
 
2
.
6
7
)
S
i
x
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
g
i
r
l
s
1
8
2
/
2
3
0
 
(
7
9
.
1
3
%
)
1
6
4
/
2
1
5
 
(
7
6
.
2
8
%
)
U
E
I
:
 
1
.
2
1
 
(
0
.
8
3
 
t
o
 
1
.
7
7
)
;
 
A
E
I
:
 
1
.
1
4
 
(
0
.
8
1
 
t
o
 
1
.
6
2
)
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
b
o
y
s
4
4
3
/
5
2
8
 
(
8
3
.
9
0
%
)
3
6
7
/
4
3
2
 
(
8
4
.
9
5
%
)
U
E
I
:
 
0
.
9
2
 
(
0
.
6
4
 
t
o
 
1
.
3
3
)
;
 
A
E
I
:
 
1
.
0
1
 
(
0
.
6
8
 
t
o
 
1
.
4
9
)
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
g
i
r
l
s
4
9
6
/
6
0
2
 
(
8
2
.
3
9
%
)
4
5
0
/
5
5
0
 
(
8
1
.
8
2
%
)
U
E
I
:
 
1
.
0
3
 
(
0
.
8
1
 
t
o
 
1
.
3
1
)
;
 
A
E
I
:
 
0
.
9
0
 
(
0
.
7
3
 
t
o
 
1
.
1
1
)
U
s
e
d
 
c
o
n
t
r
a
c
e
p
t
i
o
n
 
a
t
 
l
a
s
t
 
s
e
x
I
n
t
e
r
v
e
n
t
i
o
n
C
o
n
t
r
o
l
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
b
o
y
s
3
0
1
/
3
5
2
 
(
8
5
.
5
1
%
)
2
2
9
/
2
6
4
 
(
8
6
.
7
4
%
)
U
E
I
:
 
0
.
9
1
 
(
0
.
5
2
 
t
o
 
1
.
5
9
)
;
 
A
E
I
:
 
1
.
0
6
 
(
0
.
7
0
 
t
o
 
1
.
6
3
)
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
g
i
r
l
s
4
3
1
/
5
0
9
 
(
8
4
.
6
8
%
)
3
4
1
/
4
0
9
 
(
8
3
.
3
7
%
)
U
E
I
:
 
1
.
0
9
 
(
0
.
7
4
 
t
o
 
1
.
6
3
)
;
 
A
E
I
:
 
1
.
0
6
 
(
0
.
7
0
 
t
o
 
1
.
6
3
)
N
o
 
u
n
i
n
t
e
n
d
e
d
 
p
r
e
g
n
a
n
c
y
I
n
t
e
r
v
e
n
t
i
o
n
C
o
n
t
r
o
l
G
i
r
l
s
 
b
y
 
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
1
2
2
1
/
1
2
6
3
 
(
9
6
.
6
7
%
)
1
5
8
4
/
1
6
2
1
 
(
9
7
.
7
2
%
)
U
E
I
:
 
1
.
5
1
 
(
1
.
0
5
 
t
o
 
2
.
1
8
)
;
 
A
E
I
:
 
1
.
4
0
 
(
0
.
9
7
 
t
o
 
2
.
0
2
)
C
o
m
p
a
r
e
d
 
w
i
t
h
 
t
h
e
 
c
o
n
t
r
o
l
 
a
r
m
,
 
g
i
r
l
s
 
i
n
 
t
h
e
 
p
e
e
r
-
l
e
d
 
a
r
m
 
r
e
p
o
r
t
e
d
 
s
o
m
e
w
h
a
t
 
f
e
w
e
r
 
u
n
i
n
t
e
n
d
e
d
 
p
r
e
g
n
a
n
c
i
e
s
 
[
3
7
 
(
2
.
3
%
)
 
v
s
 
4
2
 
(
3
.
3
%
)
]
 
(
p
 
=
 
0
.
0
7
)
A
b
o
r
t
i
o
n
s
 
b
y
 
a
g
e
 
2
0
I
n
t
e
r
v
e
n
t
i
o
n
C
o
n
t
r
o
l
A
d
j
u
s
t
e
d
 
O
R
 
(
9
5
%
 
C
I
)
F
r
o
m
 
m
a
t
c
h
i
n
g
 
t
o
 
r
o
u
t
i
n
e
 
d
a
t
a
c
1
1
9
/
2
3
8
0
 
(
5
.
0
%
,
 
9
5
%
 
C
I
 
4
.
0
 
t
o
 
6
.
3
)
1
1
3
/
2
2
6
0
 
(
5
.
0
%
,
 
C
I
 
4
.
0
 
t
o
 
6
.
4
)
1
.
0
7
 
(
0
.
8
0
 
t
o
 
1
.
4
2
)
L
i
v
e
 
b
i
r
t
h
s
 
b
y
 
a
g
e
 
2
0
.
5
I
n
t
e
r
v
e
n
t
i
o
n
C
o
n
t
r
o
l
F
r
o
m
 
m
a
t
c
h
i
n
g
 
t
o
 
r
o
u
t
i
n
e
 
d
a
t
a
 
c
1
7
8
/
2
3
7
3
 
(
7
.
5
%
,
 
9
5
%
 
C
I
 
5
.
9
 
t
o
 
9
.
6
)
2
3
7
/
2
2
3
6
 
(
1
0
.
6
 
9
5
%
 
C
I
 
6
.
8
 
t
o
1
6
.
1
)
0
.
7
7
 
(
0
.
5
1
 
t
o
 
1
.
1
5
)
A
E
I
,
 
a
d
j
u
s
t
e
d
 
e
f
f
e
c
t
 
f
o
r
 
i
n
t
e
r
v
e
n
t
i
o
n
;
 
U
E
I
,
 
u
n
a
d
j
u
s
t
e
d
 
e
f
f
e
c
t
 
f
o
r
 
i
n
t
e
r
v
e
n
t
i
o
n
.
a
 
A
 
c
o
n
t
r
a
c
e
p
t
i
o
n
 
o
u
t
c
o
m
e
 
w
a
s
 
n
o
t
 
r
e
p
o
r
t
e
d
 
b
y
:
 
L
e
v
y
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
,
6
5
 
K
a
r
n
e
l
l
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
6
3
 
a
n
d
 
Z
i
m
m
e
r
m
a
n
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
7
1
 
(
i
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
s
t
a
n
d
a
r
d
 
s
e
x
 
e
d
u
c
a
t
i
o
n
)
;
 
J
e
m
m
o
t
t
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
,
6
2
 
K
l
e
p
p
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
,
6
4
 
a
n
d
 
R
o
b
e
r
t
o
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
,
6
6
 
(
i
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
c
o
n
t
r
o
l
)
;
 
a
n
d
 
B
o
r
g
i
a
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
5
1
 
(
p
e
e
r
-
l
e
d
 
v
s
 
t
e
a
c
h
e
r
-
l
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
)
.
b
 
C
o
n
d
o
m
 
a
l
o
n
e
,
 
c
o
n
d
o
m
 
a
n
d
 
c
o
n
t
r
a
c
e
p
t
i
v
e
 
p
i
l
l
s
,
 
o
r
 
c
o
n
t
r
a
c
e
p
t
i
v
e
 
p
i
l
l
s
 
a
l
o
n
e
.
c
 
D
e
n
o
m
i
n
a
t
o
r
s
 
c
a
l
c
u
l
a
t
e
d
 
b
y
 
r
e
v
i
e
w
e
r
 
a
n
d
 
r
o
u
n
d
e
d
.
T
A
B
L
E
 
7
3
 
B
e
h
a
v
i
o
u
r
a
l
 
o
u
t
c
o
m
e
s
 
–
 
c
o
n
t
r
a
c
e
p
t
i
o
n
 
(
c
o
n
t
i
n
u
e
d
)Appendix 8
176
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
177
T
A
B
L
E
 
7
4
 
B
e
h
a
v
i
o
u
r
a
l
 
o
u
t
c
o
m
e
s
 
–
 
s
e
x
u
a
l
 
p
a
r
t
n
e
r
s
S
e
x
u
a
l
 
p
a
r
t
n
e
r
s
a
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
I
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
s
t
a
n
d
a
r
d
 
s
e
x
 
e
d
u
c
a
t
i
o
n
C
o
y
l
e
 
e
t
 
a
l
.
5
8
n
E
s
t
i
m
a
t
e
d
 
e
f
f
e
c
t
 
s
i
z
e
S
t
a
n
d
a
r
d
 
e
r
r
o
r
R
a
t
i
o
b
N
u
m
b
e
r
 
o
f
 
s
e
x
u
a
l
 
p
a
r
t
n
e
r
s
 
w
i
t
h
o
u
t
 
a
 
c
o
n
d
o
m
 
i
n
 
l
a
s
t
 
3
 
m
o
n
t
h
s
1
0
0
2
0
.
6
8
0
.
2
1
–
1
.
8
1
0
.
0
7
N
u
m
b
e
r
 
o
f
 
s
e
x
 
p
a
r
t
n
e
r
s
 
i
n
 
l
a
s
t
 
3
 
m
o
n
t
h
s
9
9
8
0
.
9
1
0
.
1
6
0
.
5
7
0
.
5
7
L
e
v
y
 
e
t
 
a
l
.
6
5
I
n
t
e
r
v
e
n
t
i
o
n
 
 
(
c
h
a
n
g
e
r
s
 
s
u
b
g
r
o
u
p
,
 
n
 
=
 
1
8
6
)
C
o
n
t
r
o
l
 
 
(
c
h
a
n
g
e
r
s
 
s
u
b
g
r
o
u
p
,
 
n
 
=
 
1
2
4
)
N
o
 
s
i
g
n
i
fi
c
a
n
c
e
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
 
r
e
p
o
r
t
e
d
N
u
m
b
e
r
 
o
f
 
p
a
r
t
n
e
r
s
 
i
n
 
t
h
e
 
p
a
s
t
 
1
2
 
m
o
n
t
h
s
1
.
3
5
 
(
S
D
 
=
 
1
.
3
5
)
1
.
4
0
 
(
S
D
 
=
 
1
.
5
0
)
I
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
c
o
n
t
r
o
l
 
(
n
o
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
d
e
l
a
y
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
n
o
n
-
s
e
x
 
e
d
u
c
a
t
i
o
n
 
i
n
t
e
r
v
e
n
t
i
o
n
)
J
e
m
m
o
t
t
 
e
t
 
a
l
.
6
2
N
u
m
b
e
r
 
o
f
 
c
o
i
t
a
l
 
p
a
r
t
n
e
r
s
H
I
V
 
p
r
e
v
e
n
t
i
o
n
 
 
(
a
d
j
u
s
t
e
d
 
m
e
a
n
 
±
 
s
t
a
n
d
a
r
d
 
e
r
r
o
r
s
)
C
o
n
t
r
o
l
 
 
(
a
d
j
u
s
t
e
d
 
m
e
a
n
 
±
 
s
t
a
n
d
a
r
d
 
e
r
r
o
r
s
)
P
r
e
-
i
n
t
e
r
v
e
n
t
i
o
n
0
.
5
5
5
 
±
 
0
.
1
3
0
0
.
9
3
5
 
±
 
0
.
1
3
9
3
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
0
.
6
4
2
 
±
 
0
.
2
6
6
0
.
8
4
4
 
±
 
0
.
2
8
7
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
0
.
3
7
8
 
±
 
0
.
0
9
6
0
.
6
1
1
 
±
 
0
.
1
0
3
N
u
m
b
e
r
 
o
f
 
a
n
a
l
 
s
e
x
 
p
a
r
t
n
e
r
s
P
r
e
-
i
n
t
e
r
v
e
n
t
i
o
n
0
.
2
0
1
 
±
 
0
.
0
6
0
0
.
1
9
4
 
±
 
0
.
0
6
6
3
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
0
.
1
3
9
 
±
 
0
.
0
6
6
0
.
2
4
1
 
±
 
0
.
0
7
3
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
0
.
0
7
3
 
±
 
0
.
0
4
3
0
.
2
2
6
 
±
 
0
.
0
4
8
I
n
t
e
r
v
e
n
t
i
o
n
 
g
r
o
u
p
:
 
a
n
a
l
 
i
n
t
e
r
c
o
u
r
s
e
 
w
i
t
h
 
f
e
w
e
r
 
p
a
r
t
n
e
r
s
 
[
F
(
1
,
 
4
0
9
)
 
=
 
8
.
2
9
,
 
p
 
=
 
0
.
0
0
4
]
 
t
h
a
n
 
c
o
n
t
r
o
l
 
g
r
o
u
p
c
o
n
t
i
n
u
e
dAppendix 8
178
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
179
S
e
x
u
a
l
 
p
a
r
t
n
e
r
s
a
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
J
e
m
m
o
t
t
 
e
t
 
a
l
.
4
3
A
I
D
S
 
p
r
e
v
e
n
t
i
o
n
C
o
n
t
r
o
l
D
i
f
f
e
r
e
n
c
e
 
(
9
5
%
 
C
I
)
N
u
m
b
e
r
 
o
f
 
c
o
i
t
a
l
 
p
a
r
t
n
e
r
s
0
.
8
5
1
.
7
9
–
0
.
9
3
 
(
–
1
.
5
3
 
t
o
 
–
0
.
3
3
)
N
o
 
s
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
 
a
m
o
n
g
 
g
r
o
u
p
 
c
o
m
p
a
r
i
s
o
n
s
 
r
e
p
o
r
t
e
d
N
u
m
b
e
r
 
o
f
 
c
o
i
t
a
l
 
p
a
r
t
n
e
r
s
 
i
n
v
o
l
v
e
d
 
w
i
t
h
 
o
t
h
e
r
 
m
e
n
0
.
1
9
1
.
7
5
–
1
.
5
5
 
(
–
2
.
6
7
 
t
o
 
–
0
.
4
3
)
N
u
m
b
e
r
 
o
f
 
f
e
m
a
l
e
 
a
n
a
l
 
s
e
x
 
p
a
r
t
n
e
r
s
0
.
1
3
0
.
6
1
–
0
.
4
7
 
(
–
0
.
8
6
 
t
o
 
0
.
0
8
)
R
o
b
e
r
t
o
 
e
t
 
a
l
.
6
6
N
u
m
b
e
r
 
o
f
 
p
a
r
t
n
e
r
s
 
i
n
 
t
h
e
 
l
a
s
t
 
4
 
m
o
n
t
h
s
E
x
p
e
r
i
m
e
n
t
a
l
 
g
r
o
u
p
C
o
n
t
r
o
l
 
g
r
o
u
p
P
r
e
-
t
e
s
t
1
.
0
3
1
.
0
8
A
N
O
V
A
 
F
(
1
,
 
9
0
)
 
=
 
2
.
5
7
,
 
e
t
a
-
s
q
u
a
r
e
d
 
=
 
0
.
0
3
.
 
p
 
=
 
0
.
0
5
5
;
 
e
x
p
e
r
i
m
e
n
t
a
l
 
g
r
o
u
p
 
o
u
t
p
e
r
f
o
r
m
e
d
 
c
o
n
t
r
o
l
 
g
r
o
u
p
P
o
s
t
-
t
e
s
t
1
.
0
7
1
.
6
4
P
e
e
r
-
l
e
d
 
v
s
 
t
e
a
c
h
e
r
-
l
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
s
B
o
r
g
i
a
 
e
t
 
a
l
.
5
1
T
e
a
c
h
e
r
 
l
e
d
 
[
m
e
a
n
 
(
S
D
)
]
P
e
e
r
 
l
e
d
 
[
m
e
a
n
 
(
S
D
)
]
P
o
s
t
-
i
n
t
e
r
v
e
n
t
i
o
n
 
t
h
e
r
e
 
w
e
r
e
 
s
i
g
n
i
fi
c
a
n
t
 
c
h
a
n
g
e
s
 
(
p
 
<
 
0
.
0
1
)
 
i
n
 
t
h
e
 
t
e
a
c
h
e
r
-
l
e
d
 
a
r
m
:
 
t
h
e
r
e
 
w
a
s
 
a
n
 
i
n
c
r
e
a
s
e
 
i
n
 
t
h
e
 
p
e
r
c
e
n
t
a
g
e
 
o
f
 
s
t
u
d
e
n
t
s
 
w
i
t
h
 
m
o
r
e
 
t
h
a
n
 
o
n
e
 
p
a
r
t
n
e
r
 
a
n
d
 
a
 
d
e
c
r
e
a
s
e
 
i
n
 
t
h
e
 
p
e
r
c
e
n
t
a
g
e
 
o
f
 
a
b
s
t
i
n
e
n
t
 
s
t
u
d
e
n
t
s
;
 
i
n
 
t
h
e
 
p
e
e
r
-
l
e
d
 
a
r
m
,
 
b
o
t
h
 
o
f
 
t
h
e
s
e
 
p
e
r
c
e
n
t
a
g
e
s
 
i
n
c
r
e
a
s
e
d
N
u
m
b
e
r
 
o
f
 
s
e
x
u
a
l
 
p
a
r
t
n
e
r
s
 
i
n
 
t
h
e
 
p
r
e
v
i
o
u
s
 
3
 
m
o
n
t
h
s
N
u
m
b
e
r
 
o
f
 
p
a
r
t
n
e
r
s
O
n
e
 
p
a
r
t
n
e
r
M
o
r
e
 
t
h
a
n
 
o
n
e
 
p
a
r
t
n
e
r
N
u
m
b
e
r
 
o
f
 
p
a
r
t
n
e
r
s
O
n
e
 
p
a
r
t
n
e
r
M
o
r
e
 
t
h
a
n
 
o
n
e
 
p
a
r
t
n
e
r
P
r
e
-
t
e
s
t
3
0
.
3
6
4
.
5
5
.
2
2
8
.
1
6
5
.
1
6
.
8
P
o
s
t
-
t
e
s
t
2
5
.
7
6
4
.
8
9
.
5
3
2
.
7
5
4
.
7
1
2
.
6
a
 
A
 
s
e
x
u
a
l
 
p
a
r
t
n
e
r
s
 
o
u
t
c
o
m
e
 
w
a
s
 
n
o
t
 
r
e
p
o
r
t
e
d
 
b
y
:
 
K
a
r
n
e
l
l
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
,
6
3
 
W
i
g
h
t
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
7
0
 
a
n
d
 
Z
i
m
m
e
r
m
a
n
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
7
1
 
(
i
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
s
t
a
n
d
a
r
d
 
s
e
x
 
e
d
u
c
a
t
i
o
n
)
;
 
K
l
e
p
p
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
6
4
 
a
n
d
 
S
t
a
n
t
o
n
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
6
9
 
(
i
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
c
o
n
t
r
o
l
)
;
 
a
n
d
 
S
t
e
p
h
e
n
s
o
n
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
5
0
 
(
p
e
e
r
-
l
e
d
 
v
s
 
t
e
a
c
h
e
r
-
l
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
)
.
b
 
R
a
t
i
o
 
o
f
 
g
r
o
u
p
 
e
s
t
i
m
a
t
e
 
t
o
 
g
r
o
u
p
 
s
t
a
n
d
a
r
d
 
e
r
r
o
r
.
T
A
B
L
E
 
7
4
 
B
e
h
a
v
i
o
u
r
a
l
 
o
u
t
c
o
m
e
s
 
–
 
s
e
x
u
a
l
 
p
a
r
t
n
e
r
s
 
(
c
o
n
t
i
n
u
e
d
)Appendix 8
178
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
179
T
A
B
L
E
 
7
5
 
B
e
h
a
v
i
o
u
r
a
l
 
o
u
t
c
o
m
e
s
 
–
 
o
t
h
e
r
 
o
u
t
c
o
m
e
s
O
t
h
e
r
 
b
e
h
a
v
i
o
u
r
a
l
 
o
u
t
c
o
m
e
s
R
e
s
u
l
t
s
I
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
s
t
a
n
d
a
r
d
 
s
e
x
 
e
d
u
c
a
t
i
o
n
C
o
y
l
e
 
e
t
 
a
l
.
5
8
n
E
s
t
i
m
a
t
e
d
 
e
f
f
e
c
t
 
s
i
z
e
S
t
a
n
d
a
r
d
 
e
r
r
o
r
9
5
%
 
C
I
p
-
v
a
l
u
e
T
e
s
t
e
d
 
f
o
r
 
H
I
V
1
0
3
9
0
.
7
8
0
.
3
7
(
0
.
3
8
 
t
o
 
1
.
5
9
)
0
.
4
9
T
e
s
t
e
d
 
f
o
r
 
o
t
h
e
r
 
S
T
D
s
1
0
3
8
1
.
0
5
0
.
3
4
(
0
.
5
4
 
t
o
 
2
.
0
4
)
0
.
0
8
8
W
i
g
h
t
 
e
t
 
a
l
.
7
0
A
n
y
 
e
v
i
d
e
n
c
e
 
o
f
 
s
e
x
 
u
n
p
r
o
t
e
c
t
e
d
 
a
g
a
i
n
s
t
 
S
T
D
s
 
e
v
e
r
 
 
(
w
h
o
l
e
 
f
o
l
l
o
w
-
u
p
 
s
a
m
p
l
e
)
I
n
t
e
r
v
e
n
t
i
o
n
C
o
n
t
r
o
l
D
i
f
f
e
r
e
n
c
e
 
 
(
9
5
%
 
C
I
)
p
-
v
a
l
u
e
 
f
o
r
 
d
i
f
f
e
r
e
n
c
e
Y
o
u
n
g
 
m
e
n
 
1
4
.
0
1
3
.
9
0
.
1
 
(
–
2
.
1
 
t
o
 
2
.
3
)
 
0
.
9
3
Y
o
u
n
g
 
w
o
m
e
n
2
3
.
7
2
2
.
2
1
.
6
 
(
–
2
.
4
 
t
o
 
2
.
9
)
 
0
.
4
5
I
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
c
o
n
t
r
o
l
 
(
n
o
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
d
e
l
a
y
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
n
o
n
-
s
e
x
 
e
d
u
c
a
t
i
o
n
 
i
n
t
e
r
v
e
n
t
i
o
n
)
J
e
m
m
o
t
t
 
e
t
 
a
l
.
6
2
R
i
s
k
y
 
s
e
x
u
a
l
 
b
e
h
a
v
i
o
u
r
 
i
n
d
e
x
 
d
a
t
a
 
c
o
u
l
d
 
n
o
t
 
b
e
 
e
x
t
r
a
c
t
e
d
 
b
e
c
a
u
s
e
 
l
a
b
e
l
s
 
o
n
 
t
h
e
 
y
-
a
x
i
s
 
o
f
 
fi
g
u
r
e
 
2
 
i
n
 
t
h
e
 
p
u
b
l
i
c
a
t
i
o
n
6
2
 
c
o
n
t
a
i
n
 
d
u
p
l
i
c
a
t
e
 
v
a
l
u
e
s
 
a
n
d
 
t
h
e
 
t
e
x
t
 
d
o
e
s
 
n
o
t
 
c
l
a
r
i
f
y
 
w
h
a
t
 
t
h
e
 
s
c
a
l
e
 
s
h
o
u
l
d
 
b
e
L
e
s
s
 
H
I
V
 
r
i
s
k
-
a
s
s
o
c
i
a
t
e
d
 
s
e
x
u
a
l
 
b
e
h
a
v
i
o
u
r
 
i
n
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
 
g
r
o
u
p
 
t
h
a
n
 
t
h
e
 
c
o
n
t
r
o
l
 
g
r
o
u
p
 
[
F
(
1
,
 
4
4
5
)
 
=
 
7
.
3
6
,
 
p
 
=
 
0
.
0
0
7
]
J
e
m
m
o
t
t
 
e
t
 
a
l
.
4
3
A
I
D
S
 
p
r
e
v
e
n
t
i
o
n
C
o
n
t
r
o
l
D
i
f
f
e
r
e
n
c
e
 
(
9
5
%
 
C
I
)
R
i
s
k
y
 
b
e
h
a
v
i
o
u
r
 
(
s
u
m
m
a
r
y
 
m
e
a
s
u
r
e
)
0
.
1
3
0
.
6
1
–
0
.
4
7
 
(
–
0
.
8
6
 
t
o
 
0
.
0
8
)
N
o
 
s
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
 
b
e
t
w
e
e
n
 
g
r
o
u
p
 
c
o
m
p
a
r
i
s
o
n
s
 
r
e
p
o
r
t
e
dAppendix 8
180
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
181
T
A
B
L
E
 
7
6
 
K
n
o
w
l
e
d
g
e
 
o
u
t
c
o
m
e
s
K
n
o
w
l
e
d
g
e
 
o
u
t
c
o
m
e
s
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
I
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
s
t
a
n
d
a
r
d
 
s
e
x
 
e
d
u
c
a
t
i
o
n
C
o
y
l
e
 
e
t
 
a
l
.
5
8
O
u
t
p
u
t
 
f
r
o
m
 
m
u
l
t
i
l
e
v
e
l
 
m
o
d
e
l
 
(
m
u
l
t
i
l
e
v
e
l
 
m
o
d
e
l
,
 
s
c
a
l
e
 
r
a
n
g
e
 
0
–
1
)
n
E
s
t
i
m
a
t
e
d
 
E
f
f
e
c
t
 
s
i
z
e
S
t
a
n
d
a
r
d
 
e
r
r
o
r
R
a
t
i
o
 
o
f
 
g
r
o
u
p
 
e
s
t
i
m
a
t
e
 
t
o
 
g
r
o
u
p
 
s
t
a
n
d
a
r
d
 
e
r
r
o
r
5
 
i
t
e
m
s
:
 
p
o
s
s
i
b
l
e
 
a
n
s
w
e
r
s
 
=
 
t
r
u
e
;
 
f
a
l
s
e
;
 
o
r
 
n
o
t
 
s
u
r
e
K
n
o
w
l
e
d
g
e
 
o
f
 
H
I
V
3
4
9
4
0
.
1
3
0
.
0
3
5
.
3
0
p
 
=
 
0
.
0
0
5
 
i
t
e
m
s
:
 
p
o
s
s
i
b
l
e
 
a
n
s
w
e
r
s
 
=
 
y
e
s
;
 
n
o
;
 
o
r
 
n
o
t
 
s
u
r
e
K
n
o
w
l
e
d
g
e
 
o
f
 
o
t
h
e
r
 
S
T
D
s
3
2
0
7
0
.
1
1
0
.
0
0
2
5
.
3
6
p
 
=
 
0
.
0
0
K
a
r
n
e
l
l
 
e
t
 
a
l
.
6
3
1
0
 
t
r
u
e
/
f
a
l
s
e
 
i
t
e
m
s
;
 
n
u
m
b
e
r
 
o
f
 
c
o
r
r
e
c
t
 
r
e
s
p
o
n
s
e
s
 
s
u
m
m
e
d
 
t
o
 
c
r
e
a
t
e
 
a
n
 
i
n
d
e
x
 
w
i
t
h
 
a
 
m
a
x
i
m
u
m
 
v
a
l
u
e
 
o
f
 
1
0
G
e
n
e
r
a
l
 
k
n
o
w
l
e
d
g
e
 
r
e
g
a
r
d
i
n
g
 
p
r
e
v
e
n
t
i
o
n
 
o
f
 
H
I
V
 
a
n
d
 
o
t
h
e
r
 
S
T
D
s
N
o
 
n
u
m
e
r
i
c
a
l
 
d
a
t
a
 
r
e
p
o
r
t
e
d
T
e
x
t
 
r
e
p
o
r
t
s
 
n
o
 
i
n
t
e
r
v
e
n
t
i
o
n
 
e
f
f
e
c
t
L
e
v
y
 
e
t
 
a
l
.
6
5
2
6
 
i
t
e
m
s
:
 
r
a
n
g
e
 
o
f
 
s
c
o
r
e
s
 
n
o
t
 
s
t
a
t
e
d
,
 
b
u
t
 
p
r
e
s
u
m
e
d
 
t
o
 
b
e
 
0
–
2
6
K
n
o
w
l
e
d
g
e
 
o
f
 
A
I
D
S
 
f
a
c
t
s
P
a
r
e
n
t
:
 
m
e
a
n
 
s
c
o
r
e
N
o
n
-
p
a
r
e
n
t
:
 
m
e
a
n
 
s
c
o
r
e
C
o
n
t
r
o
l
:
 
m
e
a
n
 
s
c
o
r
e
T
h
e
 
c
o
n
t
r
o
l
 
v
s
 
c
o
m
b
i
n
e
d
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
d
i
f
f
e
r
e
n
c
e
s
 
b
e
t
w
e
e
n
 
7
t
h
 
a
n
d
 
8
t
h
 
g
r
a
d
e
 
w
e
r
e
 
s
i
g
n
i
fi
c
a
n
t
 
(
p
 
<
 
0
.
0
0
1
)
T
h
e
 
n
o
n
-
p
a
r
e
n
t
 
v
s
 
p
a
r
e
n
t
 
d
i
f
f
e
r
e
n
c
e
s
 
b
e
t
w
e
e
n
 
7
t
h
 
a
n
d
 
8
t
h
 
g
r
a
d
e
 
w
e
r
e
 
n
o
t
 
s
i
g
n
i
fi
c
a
n
t
7
t
h
 
g
r
a
d
e
 
p
r
e
-
t
e
s
t
1
7
.
9
8
1
7
.
5
9
1
7
.
9
8
8
t
h
 
g
r
a
d
e
2
3
.
4
4
2
2
.
9
5
2
3
.
4
4
W
i
g
h
t
 
e
t
 
a
l
.
 
(
S
H
A
R
E
)
7
0
8
 
q
u
e
s
t
i
o
n
s
 
o
n
 
p
r
a
c
t
i
c
a
l
 
k
n
o
w
l
e
d
g
e
 
a
b
o
u
t
 
s
e
x
u
a
l
 
h
e
a
l
t
h
 
l
e
d
 
t
o
 
c
a
l
c
u
l
a
t
i
o
n
 
o
f
 
a
 
m
e
a
n
 
s
c
o
r
e
 
r
a
n
g
e
 
o
f
 
 
–
8
 
t
o
 
+
8
P
r
a
c
t
i
c
a
l
 
k
n
o
w
l
e
d
g
e
 
a
b
o
u
t
 
s
e
x
u
a
l
 
h
e
a
l
t
h
I
n
t
e
r
v
e
n
t
i
o
n
:
 
m
e
a
n
 
s
c
o
r
e
C
o
n
t
r
o
l
:
 
m
e
a
n
 
s
c
o
r
e
Y
o
u
n
g
 
m
e
n
4
.
3
5
3
.
6
6
D
i
f
f
e
r
e
n
c
e
 
(
9
5
%
 
C
I
)
:
0
.
7
 
(
0
.
2
 
t
o
 
1
.
2
)
,
 
p
 
=
 
 
0
.
0
0
3
Y
o
u
n
g
 
w
o
m
e
n
5
.
1
1
4
.
6
6
D
i
f
f
e
r
e
n
c
e
 
(
9
5
%
 
C
I
)
:
0
.
5
 
(
0
.
1
 
t
o
 
0
.
9
)
,
 
p
 
=
 
0
.
0
0
8
Z
i
m
m
e
r
m
a
n
 
e
t
 
a
l
.
7
1
1
0
 
t
r
u
e
/
f
a
l
s
e
 
i
t
e
m
s
;
 
c
o
r
r
e
c
t
 
r
e
s
p
o
n
s
e
s
 
s
u
m
m
e
d
 
t
o
 
c
r
e
a
t
e
 
a
n
 
i
n
d
e
x
 
w
i
t
h
 
a
 
m
a
x
i
m
u
m
 
v
a
l
u
e
 
o
f
 
1
0
K
n
o
w
l
e
d
g
e
 
o
f
 
p
r
e
v
e
n
t
i
o
n
 
o
f
 
p
r
e
g
n
a
n
c
y
 
a
n
d
 
S
T
D
s
 
i
n
c
l
u
d
i
n
g
 
H
I
V
M
o
d
i
fi
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
:
 
m
e
a
n
 
s
c
o
r
e
O
r
i
g
i
n
a
l
 
i
n
t
e
r
v
e
n
t
i
o
n
:
 
m
e
a
n
 
s
c
o
r
e
S
t
a
n
d
a
r
d
:
 
m
e
a
n
 
s
c
o
r
e
‘
K
n
o
w
l
e
d
g
e
 
g
a
i
n
s
 
w
e
r
e
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
g
r
e
a
t
e
r
 
f
o
r
 
b
o
t
h
 
i
n
t
e
r
v
e
n
t
i
o
n
 
g
r
o
u
p
s
 
t
h
a
n
 
f
o
r
 
t
h
e
 
c
o
m
p
a
r
i
s
o
n
 
g
r
o
u
p
’
‘
O
v
e
r
a
l
l
 
g
r
o
u
p
 
d
i
f
f
e
r
e
n
c
e
s
 
b
e
t
w
e
e
n
 
T
i
m
e
 
1
 
a
n
d
 
T
i
m
e
 
2
 
s
i
g
n
i
fi
c
a
n
t
 
a
t
 
p
 
<
 
0
.
0
0
1
’
T
i
m
e
 
1
4
.
0
3
3
.
8
0
3
.
6
1
T
i
m
e
 
2
5
.
3
5
5
.
2
2
4
.
2
8Appendix 8
180
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
181
K
n
o
w
l
e
d
g
e
 
o
u
t
c
o
m
e
s
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
I
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
c
o
n
t
r
o
l
 
(
n
o
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
d
e
l
a
y
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
n
o
n
-
s
e
x
 
e
d
u
c
a
t
i
o
n
 
i
n
t
e
r
v
e
n
t
i
o
n
)
J
e
m
m
o
t
t
 
e
t
 
a
l
.
6
2
5
6
-
i
t
e
m
 
i
n
v
e
n
t
o
r
y
 
r
e
g
a
r
d
i
n
g
 
t
h
e
 
t
r
a
n
s
m
i
s
s
i
o
n
 
a
n
d
 
c
o
n
s
e
q
u
e
n
c
e
s
 
o
f
 
A
I
D
S
 
a
n
d
 
S
T
D
s
;
 
a
 
s
i
n
g
l
e
 
s
u
m
m
a
r
y
 
s
c
o
r
e
 
r
e
fl
e
c
t
s
 
t
h
e
 
n
u
m
b
e
r
 
o
f
 
t
r
u
e
/
f
a
l
s
e
 
i
t
e
m
s
 
c
o
r
r
e
c
t
l
y
 
a
n
s
w
e
r
e
d
;
 
h
i
g
h
e
r
 
s
c
o
r
e
s
 
i
n
d
i
c
a
t
e
 
g
r
e
a
t
e
r
 
k
n
o
w
l
e
d
g
e
H
I
V
 
r
i
s
k
-
r
e
d
u
c
t
i
o
n
 
k
n
o
w
l
e
d
g
e
a
H
I
V
 
p
r
e
v
e
n
t
i
o
n
C
o
n
t
r
o
l
A
d
o
l
e
s
c
e
n
t
s
 
w
h
o
 
h
a
d
 
r
e
c
e
i
v
e
d
 
t
h
e
 
H
I
V
 
r
i
s
k
-
r
e
d
u
c
t
i
o
n
 
i
n
t
e
r
v
e
n
t
i
o
n
 
s
c
o
r
e
d
 
h
i
g
h
e
r
 
i
n
 
H
I
V
 
r
i
s
k
-
r
e
d
u
c
t
i
o
n
 
k
n
o
w
l
e
d
g
e
P
r
e
-
i
n
t
e
r
v
e
n
t
i
o
n
3
9
/
5
6
 
3
8
.
3
/
5
6
P
o
s
t
-
i
n
t
e
r
v
e
n
t
i
o
n
4
0
.
2
/
5
6
 
±
 
0
.
5
3
6
.
8
/
5
6
 
±
 
0
.
5
F
(
1
,
 
4
9
3
)
 
=
 
2
4
.
1
7
,
 
p
 
=
 
0
.
0
0
0
1
3
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
4
0
.
5
/
5
6
 
±
 
0
.
5
3
8
/
5
6
 
±
 
0
.
5
F
(
1
,
 
4
7
7
)
 
=
 
2
0
.
5
0
,
 
p
 
=
 
0
.
0
0
0
1
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
4
0
.
4
/
5
6
 
±
 
0
.
5
3
8
.
7
/
5
6
 
±
 
0
.
5
F
(
1
,
 
4
5
7
)
 
=
 
6
.
0
2
,
 
p
 
=
 
0
.
0
1
4
J
e
m
m
o
t
t
 
e
t
 
a
l
.
4
3
5
7
 
t
r
u
e
/
f
a
l
s
e
 
q
u
e
s
t
i
o
n
s
 
a
b
o
u
t
 
A
I
D
S
 
a
n
d
 
S
T
D
s
;
 
t
h
e
 
n
u
m
b
e
r
 
c
o
r
r
e
c
t
 
o
u
t
 
o
f
 
5
7
 
w
a
s
 
c
a
l
c
u
l
a
t
e
d
A
I
D
S
 
a
n
d
 
S
T
D
 
k
n
o
w
l
e
d
g
e
A
I
D
S
 
p
r
e
v
e
n
t
i
o
n
C
o
n
t
r
o
l
D
i
f
f
e
r
e
n
c
e
 
(
9
5
%
 
C
I
 
o
f
 
d
i
f
f
e
r
e
n
c
e
)
P
a
r
t
i
c
i
p
a
n
t
s
 
i
n
 
t
h
e
 
A
I
D
S
 
c
o
n
d
i
t
i
o
n
 
h
a
d
 
g
r
e
a
t
e
r
 
k
n
o
w
l
e
d
g
e
P
o
s
t
-
i
n
t
e
r
v
e
n
t
i
o
n
4
6
.
2
2
4
0
.
3
7
5
.
8
5
 
(
3
.
2
3
 
t
o
 
8
.
4
8
)
F
 
(
1
,
 
1
5
1
)
 
=
 
1
9
.
5
8
,
 
p
 
<
 
0
.
0
0
0
1
.
3
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
4
7
.
2
0
4
4
.
4
0
2
.
8
 
(
0
.
7
2
 
t
o
 
4
.
8
8
)
F
(
1
,
 
1
4
7
)
 
=
 
9
.
4
6
,
 
p
 
<
 
0
.
0
0
3
K
l
e
p
p
 
e
t
 
a
l
.
6
4
1
8
 
s
t
a
t
e
m
e
n
t
s
 
r
e
g
a
r
d
i
n
g
 
H
I
V
 
t
r
a
n
s
m
i
s
s
i
o
n
 
r
o
u
t
e
s
 
a
n
d
 
A
I
D
S
.
 
P
o
s
s
i
b
l
e
 
a
n
s
w
e
r
s
 
‘
c
o
r
r
e
c
t
,
’
 
‘
i
n
c
o
r
r
e
c
t
,
’
 
o
r
 
‘
d
o
 
n
o
t
 
k
n
o
w
’
 
r
e
c
o
d
e
d
 
t
o
 
0
 
(
w
r
o
n
g
 
a
n
s
w
e
r
 
o
r
 
‘
d
o
 
n
o
t
 
k
n
o
w
’
)
 
v
s
 
1
 
(
c
o
r
r
e
c
t
 
a
n
s
w
e
r
)
 
a
n
d
 
s
u
m
m
e
d
 
t
o
 
f
o
r
m
 
a
 
k
n
o
w
l
e
d
g
e
 
s
c
o
r
e
H
I
V
 
t
r
a
n
s
m
i
s
s
i
o
n
 
r
o
u
t
e
s
 
a
n
d
 
A
I
D
S
I
n
t
e
r
v
e
n
t
i
o
n
 
s
c
h
o
o
l
s
:
 
m
e
a
n
 
s
c
o
r
e
C
o
m
p
a
r
i
s
o
n
 
s
c
h
o
o
l
s
:
 
m
e
a
n
 
s
c
o
r
e
B
a
s
e
l
i
n
e
1
1
.
5
1
1
.
2
F
o
l
l
o
w
-
u
p
1
3
.
8
1
1
.
1
N
e
t
 
e
f
f
e
c
t
 
2
.
4
,
 
p
 
=
 
0
.
0
0
0
4
S
t
a
n
t
o
n
 
e
t
 
a
l
.
6
9
3
0
 
k
n
o
w
l
e
d
g
e
 
(
t
r
u
e
/
f
a
l
s
e
)
 
q
u
e
s
t
i
o
n
s
H
I
V
/
A
I
D
S
 
k
n
o
w
l
e
d
g
e
F
o
c
u
s
 
o
n
 
K
i
d
s
C
o
n
t
r
o
l
B
a
s
e
l
i
n
e
 
%
 
c
o
r
r
e
c
t
7
6
.
1
8
p
 
<
 
0
.
0
5
 
f
o
r
 
d
i
f
f
e
r
e
n
c
e
 
a
t
 
b
a
s
e
l
i
n
e
,
 
c
o
n
t
r
o
l
l
e
d
 
f
o
r
 
i
n
 
a
n
a
l
y
s
i
s
7
3
.
9
7
3
-
m
o
n
t
h
 
a
d
j
u
s
t
e
d
 
m
e
a
n
 
a
g
a
i
n
s
t
 
b
a
s
e
l
i
n
e
 
(
%
)
7
8
.
5
2
7
8
.
1
1
6
-
m
o
n
t
h
 
a
d
j
u
s
t
e
d
 
m
e
a
n
 
a
g
a
i
n
s
t
 
b
a
s
e
l
i
n
e
 
(
%
)
7
7
.
2
2
7
7
.
6
1
c
o
n
t
i
n
u
e
dAppendix 8
182
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
183
K
n
o
w
l
e
d
g
e
 
o
u
t
c
o
m
e
s
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
R
o
b
e
r
t
o
 
e
t
 
a
l
.
6
6
1
2
 
s
t
a
t
e
m
e
n
t
s
 
r
e
g
a
r
d
i
n
g
 
k
n
o
w
l
e
d
g
e
 
(
n
o
t
 
d
e
fi
n
e
d
,
 
b
u
t
 
p
r
e
g
n
a
n
c
y
,
 
S
T
D
 
a
n
d
 
H
I
V
 
w
e
r
e
 
t
h
e
 
f
o
c
u
s
 
o
f
 
t
h
e
 
p
a
p
e
r
;
 
r
e
s
p
o
n
s
e
 
c
a
t
e
g
o
r
i
e
s
 
o
f
 
‘
t
r
u
e
’
,
’
 
‘
f
a
l
s
e
’
 
a
n
d
 
‘
d
o
n
’
t
 
k
n
o
w
’
,
 
w
i
t
h
 
‘
d
o
n
’
t
 
k
n
o
w
’
 
r
e
s
p
o
n
s
e
s
 
s
c
o
r
e
d
 
a
s
 
i
n
c
o
r
r
e
c
t
K
n
o
w
l
e
d
g
e
E
x
p
e
r
i
m
e
n
t
a
l
 
g
r
o
u
p
C
o
n
t
r
o
l
 
g
r
o
u
p
P
r
e
-
t
e
s
t
6
.
6
0
6
.
8
5
P
o
s
t
-
t
e
s
t
7
.
9
6
6
.
6
0
A
N
O
V
A
:
 
F
(
1
,
 
3
2
3
)
 
=
 
2
9
.
6
9
,
 
p
 
<
 
0
.
0
0
1
;
 
e
x
p
e
r
i
m
e
n
t
a
l
 
g
r
o
u
p
 
o
u
t
p
e
r
f
o
r
m
e
d
 
t
h
e
 
c
o
n
t
r
o
l
 
g
r
o
u
p
E
t
a
-
s
q
u
a
r
e
d
 
=
 
0
.
0
9
P
e
e
r
-
l
e
d
 
v
s
 
t
e
a
c
h
e
r
-
l
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
s
B
o
r
g
i
a
 
e
t
 
a
l
.
5
1
7
 
q
u
e
s
t
i
o
n
s
,
 
e
a
c
h
 
w
i
t
h
 
fi
v
e
 
p
o
s
s
i
b
l
e
 
a
n
s
w
e
r
s
,
 
s
c
o
r
e
d
 
1
 
=
 
‘
c
o
r
r
e
c
t
 
a
n
s
w
e
r
’
,
 
0
 
=
 
‘
w
r
o
n
g
 
a
n
s
w
e
r
’
;
 
t
o
t
a
l
 
s
c
a
l
e
 
s
c
o
r
e
 
w
a
s
 
c
o
m
p
u
t
e
d
 
a
s
 
a
 
s
u
m
 
o
f
 
e
a
c
h
 
i
t
e
m
 
s
c
o
r
e
 
a
n
d
 
t
h
e
n
 
s
t
a
n
d
a
r
d
i
s
e
d
 
t
o
 
0
–
1
0
0
 
r
a
n
g
e
K
n
o
w
l
e
d
g
e
 
o
f
 
H
I
V
 
t
r
a
n
s
m
i
s
s
i
o
n
 
a
n
d
 
p
r
e
v
e
n
t
i
o
n
T
e
a
c
h
e
r
 
l
e
d
:
 
[
m
e
a
n
 
(
S
D
)
]
P
e
e
r
 
l
e
d
:
 
[
m
e
a
n
 
(
S
D
)
]
S
i
g
n
i
fi
c
a
n
t
 
i
n
c
r
e
a
s
e
 
i
n
 
b
o
t
h
 
a
r
m
s
 
p
r
e
-
t
e
s
t
 
t
o
 
p
o
s
t
-
t
e
s
t
 
p
 
<
 
0
.
0
5
‘
I
n
 
t
h
e
 
p
e
e
r
-
l
e
d
 
a
r
m
,
 
i
m
p
r
o
v
e
m
e
n
t
 
i
n
 
t
h
e
 
k
n
o
w
l
e
d
g
e
 
s
c
o
r
e
 
w
a
s
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
g
r
e
a
t
e
r
 
c
o
m
p
a
r
e
d
 
t
o
 
t
h
a
t
 
i
n
 
t
h
e
 
t
e
a
c
h
e
r
-
l
e
d
 
a
r
m
’
P
r
e
-
t
e
s
t
4
0
.
6
/
1
0
0
 
(
2
1
.
1
)
4
3
.
0
/
1
0
0
 
(
2
0
.
6
)
P
o
s
t
-
t
e
s
t
5
5
.
2
/
1
0
0
 
(
2
4
.
1
)
6
3
.
7
/
1
0
0
 
(
2
5
.
6
)
S
t
e
p
h
e
n
s
o
n
 
e
t
 
a
l
.
5
0
S
T
I
 
a
c
q
u
i
s
i
t
i
o
n
 
p
r
e
v
e
n
t
i
o
n
 
k
n
o
w
l
e
d
g
e
:
 
n
u
m
b
e
r
 
c
o
r
r
e
c
t
 
o
f
 
3
 
b
i
n
a
r
y
 
q
u
e
s
t
i
o
n
s
b
S
T
I
 
a
c
q
u
i
s
i
t
i
o
n
 
p
r
e
v
e
n
t
i
o
n
 
k
n
o
w
l
e
d
g
e
I
n
t
e
r
v
e
n
t
i
o
n
C
o
n
t
r
o
l
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
b
o
y
s
1
0
9
8
 
(
5
2
.
7
%
)
8
3
8
 
(
4
7
.
8
%
)
U
E
I
c
1
.
2
4
 
(
0
.
9
6
 
t
o
 
1
.
6
0
)
A
E
I
c
 
1
.
2
4
 
(
0
.
9
6
 
t
o
 
1
.
5
9
)
 
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
g
i
r
l
s
1
3
3
7
 
(
6
7
.
0
%
)
1
0
1
8
 
(
6
1
.
8
%
)
U
E
I
 
1
.
2
7
 
(
1
.
0
1
 
t
o
 
1
.
6
0
)
A
E
I
 
1
.
2
7
 
(
1
.
0
1
 
t
o
 
1
.
5
9
)
‘
K
n
o
w
l
e
d
g
e
 
o
f
 
m
e
t
h
o
d
s
 
t
o
 
p
r
e
v
e
n
t
 
S
T
I
s
 
w
a
s
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
b
e
t
t
e
r
 
a
f
t
e
r
 
p
e
e
r
-
l
e
d
 
S
R
E
 
a
t
 
fi
r
s
t
 
f
o
l
l
o
w
-
u
p
 
f
o
r
 
g
i
r
l
s
 
(
p
 
=
 
0
.
0
0
0
2
)
’
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
b
o
y
s
1
2
6
5
 
(
6
8
.
7
%
)
9
0
9
 
(
6
4
.
1
%
)
U
E
I
 
1
.
3
3
 
(
1
.
0
3
 
t
o
 
1
.
7
3
)
A
E
I
 
1
.
3
1
 
(
1
.
0
2
 
t
o
 
1
.
6
8
)
‘
K
n
o
w
l
e
d
g
e
 
o
f
 
m
e
t
h
o
d
s
 
t
o
 
p
r
e
v
e
n
t
 
S
T
I
s
 
w
a
s
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
b
e
t
t
e
r
 
a
f
t
e
r
 
p
e
e
r
-
l
e
d
 
S
R
E
 
a
t
 
s
e
c
o
n
d
 
f
o
l
l
o
w
-
u
p
 
f
o
r
 
b
o
y
s
 
p
 
=
 
0
.
0
0
1
’
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
g
i
r
l
s
1
4
4
7
 
(
8
2
.
3
%
)
1
0
6
8
 
(
7
7
.
8
%
)
U
E
I
 
1
.
3
5
 
(
1
.
0
0
 
t
o
 
1
.
8
2
)
A
E
I
 
1
.
3
4
 
(
0
.
9
7
 
t
o
 
1
.
8
4
)
A
E
I
,
 
a
d
j
u
s
t
e
d
 
e
f
f
e
c
t
 
f
o
r
 
i
n
t
e
r
v
e
n
t
i
o
n
;
 
U
E
I
,
 
u
n
a
d
j
u
s
t
e
d
 
e
f
f
e
c
t
 
f
o
r
 
i
n
t
e
r
v
e
n
t
i
o
n
.
a
 
A
d
j
u
s
t
e
d
 
m
e
a
n
s
 
a
n
d
 
S
E
M
 
(
a
l
l
 
e
s
t
i
m
a
t
e
d
 
b
y
 
t
h
e
 
r
e
v
i
e
w
e
r
,
 
w
i
t
h
 
d
i
f
fi
c
u
l
t
y
,
 
f
r
o
m
 
v
e
r
y
 
s
m
a
l
l
 
fi
g
u
r
e
)
.
b
 
S
t
e
p
h
e
n
s
o
n
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
 
a
l
s
o
 
r
e
p
o
r
t
 
o
n
 
t
h
e
 
o
u
t
c
o
m
e
 
o
f
 
S
T
I
s
 
k
n
o
w
l
e
d
g
e
 
(
n
u
m
b
e
r
 
c
o
r
r
e
c
t
 
o
f
 
4
 
b
i
n
a
r
y
 
q
u
e
s
t
i
o
n
s
)
,
 
w
h
i
c
h
 
i
s
 
n
o
t
 
s
h
o
w
n
 
h
e
r
e
.
c
 
A
l
l
 
o
f
 
t
h
e
 
S
T
I
 
a
c
q
u
i
s
i
t
i
o
n
 
p
r
e
v
e
n
t
i
o
n
 
k
n
o
w
l
e
d
g
e
 
i
n
t
e
r
v
e
n
t
i
o
n
 
e
f
f
e
c
t
s
 
a
r
e
 
r
e
p
o
r
t
e
d
 
a
s
 
O
R
s
.
T
A
B
L
E
 
7
6
 
K
n
o
w
l
e
d
g
e
 
o
u
t
c
o
m
e
s
 
(
c
o
n
t
i
n
u
e
d
)Appendix 8
182
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
183
T
A
B
L
E
 
7
7
 
S
k
i
l
l
s
 
a
n
d
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
o
u
t
c
o
m
e
s
O
u
t
c
o
m
e
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
I
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
s
t
a
n
d
a
r
d
 
s
e
x
 
e
d
u
c
a
t
i
o
n
C
o
y
l
e
 
e
t
 
a
l
.
5
8
O
u
t
p
u
t
 
f
r
o
m
 
m
u
l
t
i
l
e
v
e
l
 
m
o
d
e
l
 
(
m
u
l
t
i
l
e
v
e
l
 
m
o
d
e
l
,
 
s
c
a
l
e
 
r
a
n
g
e
 
0
–
1
)
S
e
l
f
-
e
f
fi
c
a
c
y
n
E
s
t
i
m
a
t
e
d
 
e
f
f
e
c
t
 
s
i
z
e
S
t
a
n
d
a
r
d
 
e
r
r
o
r
R
a
t
i
o
a
R
e
f
u
s
i
n
g
 
s
e
x
3
3
3
5
0
.
0
3
0
.
0
3
0
.
9
9
p
 
=
 
0
.
3
;
 
n
o
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
s
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
C
o
n
d
o
m
 
u
s
e
3
5
2
8
0
.
1
3
0
.
0
2
5
.
2
6
p
 
=
 
0
.
0
0
;
 
s
t
u
d
e
n
t
s
 
i
n
 
i
n
t
e
r
v
e
n
t
i
o
n
 
s
c
h
o
o
l
s
 
h
a
d
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
h
i
g
h
e
r
 
s
c
o
r
e
s
 
o
n
 
t
h
e
 
c
o
n
d
o
m
 
u
s
e
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
s
c
a
l
e
 
t
h
a
n
 
s
t
u
d
e
n
t
s
 
i
n
 
c
o
m
p
a
r
i
s
o
n
 
s
c
h
o
o
l
s
C
o
m
m
u
n
i
c
a
t
i
o
n
3
3
2
8
0
.
0
1
0
.
0
0
2
0
.
2
0
p
 
=
 
0
.
8
4
;
 
n
o
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
s
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
K
a
r
n
e
l
l
 
e
t
 
a
l
.
6
3
S
e
x
 
r
e
f
u
s
a
l
 
s
e
l
f
-
e
f
fi
c
a
c
y
:
 
a
s
s
e
s
s
e
d
 
u
s
i
n
g
 
a
 
5
-
p
o
i
n
t
 
(
c
a
t
e
g
o
r
i
e
s
 
o
f
 
c
o
n
fi
d
e
n
c
e
)
 
L
i
k
e
r
t
-
t
y
p
e
 
s
c
a
l
e
 
w
i
t
h
 
6
 
i
t
e
m
s
 
m
e
a
s
u
r
i
n
g
 
i
n
d
i
v
i
d
u
a
l
s
’
 
a
b
i
l
i
t
y
 
t
o
 
r
e
f
u
s
e
 
s
e
x
 
i
n
 
v
a
r
i
o
u
s
 
s
i
t
u
a
t
i
o
n
s
C
o
n
d
o
m
 
u
s
e
 
s
e
l
f
-
e
f
fi
c
a
c
y
:
 
a
s
s
e
s
s
e
d
 
u
s
i
n
g
 
a
 
5
-
p
o
i
n
t
 
(
c
a
t
e
g
o
r
i
e
s
 
o
f
 
c
o
n
fi
d
e
n
c
e
)
 
L
i
k
e
r
t
-
t
y
p
e
 
s
c
a
l
e
 
w
i
t
h
 
5
 
i
t
e
m
s
S
e
x
 
r
e
f
u
s
a
l
 
s
e
l
f
-
e
f
fi
c
a
c
y
I
n
t
e
r
v
e
n
t
i
o
n
 
c
h
a
n
g
e
 
C
o
m
p
a
r
i
s
o
n
 
c
h
a
n
g
e
I
n
t
e
r
v
e
n
t
i
o
n
 
e
f
f
e
c
t
 
R
e
s
u
l
t
s
 
s
h
o
w
e
d
 
a
n
 
i
n
t
e
r
v
e
n
t
i
o
n
 
e
f
f
e
c
t
 
a
m
o
n
g
 
f
e
m
a
l
e
 
s
t
u
d
e
n
t
s
 
o
n
 
s
e
x
 
r
e
f
u
s
a
l
 
s
e
l
f
-
e
f
fi
c
a
c
y
;
 
f
e
m
a
l
e
 
s
t
u
d
e
n
t
s
 
i
n
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
 
g
r
o
u
p
 
b
e
c
a
m
e
 
m
o
r
e
 
c
o
n
fi
d
e
n
t
 
a
b
o
u
t
 
t
h
e
i
r
 
a
b
i
l
i
t
y
 
t
o
 
r
e
f
u
s
e
 
s
e
x
 
t
h
a
n
 
f
e
m
a
l
e
 
s
t
u
d
e
n
t
s
 
i
n
 
t
h
e
 
c
o
m
p
a
r
i
s
o
n
 
g
r
o
u
p
 
(
p
 
<
 
0
.
5
)
O
v
e
r
a
l
l
0
.
0
8
–
0
.
1
6
0
.
2
4
M
a
l
e
–
0
.
1
6
–
0
.
0
5
–
0
.
1
1
F
e
m
a
l
e
0
.
2
7
–
0
.
2
6
0
.
5
3
 
(
p
 
<
 
0
.
0
5
)
H
a
d
 
h
a
d
 
s
e
x
 
a
t
 
p
r
e
-
t
e
s
t
0
.
0
2
0
.
0
5
–
0
.
0
3
H
a
d
 
n
o
t
 
h
a
d
 
s
e
x
 
a
t
 
p
r
e
-
t
e
s
t
0
.
1
4
–
0
.
2
6
0
.
4
0
C
o
n
d
o
m
 
u
s
e
 
s
e
l
f
-
e
f
fi
c
a
c
y
I
n
t
e
r
v
e
n
t
i
o
n
 
c
h
a
n
g
e
C
o
m
p
a
r
i
s
o
n
 
c
h
a
n
g
e
I
n
t
e
r
v
e
n
t
i
o
n
 
e
f
f
e
c
t
N
o
 
i
n
t
e
r
v
e
n
t
i
o
n
 
e
f
f
e
c
t
 
w
a
s
 
r
e
p
o
r
t
e
d
 
f
o
r
 
c
o
n
d
o
m
 
u
s
e
 
s
e
l
f
-
e
f
fi
c
a
c
y
O
v
e
r
a
l
l
 
–
0
.
0
8
–
0
.
0
6
–
0
.
2
M
a
l
e
–
0
.
1
0
–
0
.
3
0
0
.
2
0
F
e
m
a
l
e
–
0
.
0
3
0
.
1
2
–
0
.
1
5
H
a
d
 
h
a
d
 
s
e
x
 
a
t
 
p
r
e
-
t
e
s
t
–
0
.
2
1
–
0
.
1
7
–
0
.
0
4
H
a
d
 
n
o
t
 
h
a
d
 
s
e
x
 
a
t
 
p
r
e
-
t
e
s
t
 
0
.
0
1
0
.
0
0
0
.
0
1
L
e
v
y
 
e
t
 
a
l
.
6
5
N
o
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
o
u
t
c
o
m
e
 
m
e
a
s
u
r
e
d
c
o
n
t
i
n
u
e
dAppendix 8
184
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
185
O
u
t
c
o
m
e
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
W
i
g
h
t
 
e
t
 
a
l
.
7
0
N
o
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
o
u
t
c
o
m
e
 
m
e
a
s
u
r
e
d
Z
i
m
m
e
r
m
a
n
 
e
t
 
a
l
.
7
1
b
R
e
f
u
s
a
l
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
–
 
6
-
i
t
e
m
 
s
c
a
l
e
 
m
e
a
s
u
r
i
n
g
 
a
b
i
l
i
t
y
 
t
o
 
r
e
f
u
s
e
 
s
e
x
 
i
n
 
v
a
r
i
o
u
s
 
s
i
t
u
a
t
i
o
n
s
:
 
1
 
=
 
‘
d
e
fi
n
i
t
e
l
y
 
c
a
n
’
t
 
s
a
y
 
n
o
’
 
t
o
 
5
 
=
 
‘
d
e
fi
n
i
t
e
l
y
 
c
a
n
 
s
a
y
 
n
o
’
C
o
n
d
o
m
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
–
 
5
 
i
t
e
m
s
:
 
1
 
=
 
‘
d
i
s
a
g
r
e
e
 
a
 
l
o
t
’
 
t
o
 
5
 
=
 
‘
a
g
r
e
e
 
a
 
l
o
t
’
S
i
t
u
a
t
i
o
n
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
(
n
e
g
o
t
i
a
t
e
 
p
o
t
e
n
t
i
a
l
l
y
 
r
i
s
k
y
 
s
i
t
u
a
t
i
o
n
s
)
 
–
 
4
 
i
t
e
m
s
:
 
1
 
=
 
‘
I
 
d
e
fi
n
i
t
e
l
y
 
c
a
n
’
t
 
d
o
 
t
h
i
s
’
 
t
o
 
5
 
=
 
‘
I
 
d
e
fi
n
i
t
e
l
y
 
c
a
n
 
d
o
 
t
h
i
s
’
R
e
f
u
s
a
l
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
(
m
e
a
n
 
s
c
o
r
e
s
)
M
o
d
i
fi
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
O
r
i
g
i
n
a
l
 
i
n
t
e
r
v
e
n
t
i
o
n
S
t
a
n
d
a
r
d
C
h
a
n
g
e
s
 
i
n
 
m
e
d
i
a
t
i
n
g
 
v
a
r
i
a
b
l
e
s
 
d
i
d
 
n
o
t
 
d
i
f
f
e
r
 
a
m
o
n
g
 
g
r
o
u
p
s
 
a
t
 
e
i
t
h
e
r
 
f
o
l
l
o
w
-
u
p
T
i
m
e
 
1
3
.
7
8
3
.
7
1
3
.
7
5
T
i
m
e
 
2
3
.
8
6
3
.
7
3
3
.
7
4
C
o
n
d
o
m
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
(
m
e
a
n
 
s
c
o
r
e
s
)
M
o
d
i
fi
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
O
r
i
g
i
n
a
l
 
i
n
t
e
r
v
e
n
t
i
o
n
S
t
a
n
d
a
r
d
T
i
m
e
 
1
4
.
2
8
4
.
1
4
4
.
2
1
T
i
m
e
 
2
4
.
2
5
4
.
1
7
4
.
2
4
S
i
t
u
a
t
i
o
n
a
l
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
(
m
e
a
n
 
s
c
o
r
e
s
)
M
o
d
i
fi
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
O
r
i
g
i
n
a
l
 
i
n
t
e
r
v
e
n
t
i
o
n
S
t
a
n
d
a
r
d
T
i
m
e
 
1
3
.
7
7
3
.
6
5
3
.
7
3
T
i
m
e
 
2
3
.
9
3
3
.
8
2
3
.
7
9
I
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
c
o
n
t
r
o
l
 
(
n
o
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
d
e
l
a
y
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
n
o
n
-
s
e
x
 
e
d
u
c
a
t
i
o
n
 
i
n
t
e
r
v
e
n
t
i
o
n
)
J
e
m
m
o
t
t
 
e
t
 
a
l
.
6
2
A
l
l
 
r
a
t
i
n
g
s
 
w
e
r
e
 
m
a
d
e
 
o
n
 
7
-
p
o
i
n
t
 
s
c
a
l
e
s
C
o
n
d
o
m
 
u
s
e
 
s
e
l
f
-
e
f
fi
c
a
c
y
c
 
(
m
e
a
n
 
±
 
S
E
M
)
H
I
V
 
p
r
e
v
e
n
t
i
o
n
C
o
n
t
r
o
l
I
m
m
e
d
i
a
t
e
l
y
 
p
o
s
t
 
i
n
t
e
r
v
e
n
t
i
o
n
 
t
h
e
 
a
d
o
l
e
s
c
e
n
t
s
 
w
h
o
 
h
a
d
 
r
e
c
e
i
v
e
d
 
t
h
e
 
H
I
V
 
p
r
e
v
e
n
t
i
o
n
 
i
n
t
e
r
v
e
n
t
i
o
n
 
h
a
d
 
g
r
e
a
t
e
r
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
t
o
 
u
s
e
 
c
o
n
d
o
m
s
 
[
F
(
1
,
 
4
8
8
)
 
=
 
4
.
0
8
,
 
p
 
=
 
0
.
0
4
4
]
;
 
t
h
e
 
s
a
m
e
 
w
a
s
 
t
r
u
e
 
a
t
 
3
 
m
o
n
t
h
s
 
[
F
(
1
,
 
4
7
2
)
 
=
 
3
.
8
8
,
 
p
 
=
 
0
.
0
5
]
,
 
a
n
d
 
6
 
m
o
n
t
h
s
 
[
F
(
1
,
 
4
5
2
)
 
=
 
5
.
0
0
,
 
p
 
=
 
0
.
0
2
6
]
P
r
e
-
i
n
t
e
r
v
e
n
t
i
o
n
4
.
7
2
 
(
n
o
t
 
p
o
s
s
i
b
l
e
 
t
o
 
r
e
a
d
 
S
E
M
s
)
4
.
6
5
 
(
n
o
t
 
p
o
s
s
i
b
l
e
 
t
o
 
r
e
a
d
 
S
E
M
s
)
P
o
s
t
-
i
n
t
e
r
v
e
n
t
i
o
n
5
.
1
1
 
±
 
0
.
0
7
4
.
8
5
 
±
 
0
.
1
3
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
5
.
2
5
 
±
 
0
.
0
7
5
.
0
5
 
±
 
0
.
1
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
5
.
4
 
±
 
0
.
0
7
5
.
1
 
±
 
0
.
1
J
e
m
m
o
t
t
 
e
t
 
a
l
.
4
3
N
o
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
o
u
t
c
o
m
e
 
m
e
a
s
u
r
e
d
K
l
e
p
p
 
e
t
 
a
l
.
6
4
N
o
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
o
u
t
c
o
m
e
 
m
e
a
s
u
r
e
d
T
A
B
L
E
 
7
7
 
S
k
i
l
l
s
 
a
n
d
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
o
u
t
c
o
m
e
s
 
(
c
o
n
t
i
n
u
e
d
)Appendix 8
184
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
185
O
u
t
c
o
m
e
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
S
t
a
n
t
o
n
 
e
t
 
a
l
.
6
9
A
b
s
t
i
n
e
n
c
e
 
s
e
l
f
-
e
f
fi
c
a
c
y
:
 
5
 
s
t
a
t
e
m
e
n
t
s
,
 
e
a
c
h
 
w
i
t
h
 
a
 
5
-
p
o
i
n
t
 
L
i
k
e
r
t
 
s
c
a
l
e
 
(
1
 
=
 
‘
S
t
r
o
n
g
l
y
 
a
g
r
e
e
’
 
t
o
 
5
 
=
 
‘
S
t
r
o
n
g
l
y
 
d
i
s
a
g
r
e
e
’
,
 
o
r
 
v
i
c
e
 
v
e
r
s
a
,
 
d
e
p
e
n
d
i
n
g
 
o
n
 
t
h
e
 
q
u
e
s
t
i
o
n
)
C
o
n
d
o
m
 
u
s
e
 
s
e
l
f
-
e
f
fi
c
a
c
y
:
 
7
 
s
t
a
t
e
m
e
n
t
s
,
 
e
a
c
h
 
w
i
t
h
 
a
 
5
-
p
o
i
n
t
 
L
i
k
e
r
t
 
s
c
a
l
e
 
(
1
 
=
 
‘
S
t
r
o
n
g
l
y
 
a
g
r
e
e
’
 
t
o
 
5
 
=
 
‘
S
t
r
o
n
g
l
y
 
d
i
s
a
g
r
e
e
’
,
 
o
r
 
v
i
c
e
 
v
e
r
s
a
,
 
d
e
p
e
n
d
i
n
g
 
o
n
 
t
h
e
 
q
u
e
s
t
i
o
n
)
A
b
s
t
i
n
e
n
c
e
 
s
e
l
f
-
e
f
fi
c
a
c
y
F
o
K
C
o
n
t
r
o
l
A
t
 
6
 
m
o
n
t
h
s
 
p
o
s
t
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
F
o
K
 
y
o
u
t
h
 
d
e
m
o
n
s
t
r
a
t
e
d
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
h
i
g
h
e
r
 
p
e
r
c
e
p
t
i
o
n
s
 
o
f
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
r
e
g
a
r
d
i
n
g
 
a
b
s
t
i
n
e
n
c
e
 
(
3
.
6
0
 
v
s
 
3
.
7
4
,
 
p
 
<
 
0
.
0
1
)
,
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
C
o
n
t
r
o
l
 
y
o
u
t
h
F
o
r
 
t
h
e
 
y
o
u
t
h
 
w
h
o
 
c
o
m
p
l
e
t
e
d
 
t
h
e
i
r
 
a
s
s
i
g
n
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
F
o
K
 
a
g
a
i
n
 
c
o
n
f
e
r
r
e
d
 
s
i
g
n
i
fi
c
a
n
t
 
p
r
o
t
e
c
t
i
o
n
 
a
t
 
6
 
m
o
n
t
h
s
;
 
F
o
K
 
h
a
d
 
h
i
g
h
e
r
 
p
e
r
c
e
p
t
i
o
n
s
 
o
f
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
t
h
a
n
 
C
o
n
t
r
o
l
 
y
o
u
t
h
 
(
3
.
7
2
 
v
s
 
3
.
6
0
,
 
p
 
<
 
0
.
0
5
)
Y
o
u
t
h
 
w
h
o
 
w
e
r
e
 
v
i
r
g
i
n
s
 
a
t
 
b
a
s
e
l
i
n
e
:
 
F
o
K
 
y
o
u
t
h
 
a
g
a
i
n
 
d
e
m
o
n
s
t
r
a
t
e
d
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
h
i
g
h
e
r
 
p
e
r
c
e
p
t
i
o
n
s
 
o
f
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
t
o
 
r
e
f
u
s
e
 
s
e
x
 
t
h
a
n
 
C
o
n
t
r
o
l
 
y
o
u
t
h
 
(
3
.
7
8
 
v
s
 
3
.
6
3
,
 
p
 
<
 
0
.
0
1
)
 
a
t
 
6
 
m
o
n
t
h
s
 
p
o
s
t
 
i
n
t
e
r
v
e
n
t
i
o
n
Y
o
u
t
h
 
s
e
x
u
a
l
l
y
 
e
x
p
e
r
i
e
n
c
e
d
 
a
t
 
b
a
s
e
l
i
n
e
:
 
n
o
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
s
 
b
e
t
w
e
e
n
 
c
o
n
t
r
o
l
 
a
n
d
 
F
o
K
 
y
o
u
t
h
 
w
e
r
e
 
r
e
p
o
r
t
e
d
B
a
s
e
l
i
n
e
:
 
m
e
a
n
 
L
i
k
e
r
t
 
s
c
a
l
e
 
s
c
o
r
e
3
.
7
3
3
.
7
6
3
-
m
o
n
t
h
 
a
d
j
u
s
t
e
d
 
m
e
a
n
 
a
g
a
i
n
s
t
 
b
a
s
e
l
i
n
e
3
.
7
7
0
3
.
7
1
9
6
-
m
o
n
t
h
 
a
d
j
u
s
t
e
d
 
m
e
a
n
 
a
g
a
i
n
s
t
 
b
a
s
e
l
i
n
e
3
.
7
3
7
 
(
p
 
<
 
0
.
0
1
)
3
.
5
9
7
C
o
n
d
o
m
 
u
s
e
 
s
e
l
f
-
e
f
fi
c
a
c
y
F
o
c
u
s
 
o
n
 
K
i
d
s
C
o
n
t
r
o
l
S
i
x
 
m
o
n
t
h
s
 
p
o
s
t
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
F
o
K
 
y
o
u
t
h
 
d
e
m
o
n
s
t
r
a
t
e
d
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
h
i
g
h
e
r
 
p
e
r
c
e
p
t
i
o
n
s
 
o
f
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
t
o
 
u
s
e
 
c
o
n
d
o
m
s
 
t
h
a
n
 
C
o
n
t
r
o
l
 
y
o
u
t
h
 
(
4
.
3
6
 
v
s
 
4
.
1
7
,
 
p
 
<
 
0
.
0
5
)
A
m
o
n
g
 
y
o
u
t
h
 
w
h
o
 
h
a
d
 
c
o
m
p
l
e
t
e
d
 
t
h
e
i
r
 
a
s
s
i
g
n
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
a
t
 
6
 
m
o
n
t
h
s
,
 
p
e
r
c
e
i
v
e
d
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
w
a
s
 
m
a
r
g
i
n
a
l
l
y
 
h
i
g
h
e
r
 
f
o
r
 
F
o
K
 
t
h
a
n
 
C
o
n
t
r
o
l
 
y
o
u
t
h
 
(
4
.
3
2
 
v
s
 
4
.
1
6
,
 
p
 
<
 
0
.
1
0
)
.
Y
o
u
t
h
 
w
h
o
 
w
e
r
e
 
v
i
r
g
i
n
s
 
a
t
 
b
a
s
e
l
i
n
e
:
 
d
a
t
a
 
n
o
t
 
p
r
e
s
e
n
t
e
d
Y
o
u
t
h
 
s
e
x
u
a
l
l
y
 
e
x
p
e
r
i
e
n
c
e
d
 
a
t
 
b
a
s
e
l
i
n
e
:
 
a
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
 
i
n
 
f
a
v
o
u
r
 
o
f
 
F
o
K
 
a
t
 
t
h
e
 
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
o
n
l
y
 
(
F
o
K
 
4
.
3
5
7
 
v
s
 
C
o
n
t
r
o
l
 
4
.
1
7
1
,
 
p
 
<
 
0
.
0
5
)
B
a
s
e
l
i
n
e
:
 
m
e
a
n
 
L
i
k
e
r
t
 
s
c
a
l
e
 
s
c
o
r
e
4
.
2
1
 
(
p
 
<
 
0
.
0
5
 
f
o
r
 
d
i
f
f
e
r
e
n
c
e
 
w
i
t
h
 
c
o
n
t
r
o
l
)
4
.
3
8
3
-
m
o
n
t
h
 
a
d
j
u
s
t
e
d
 
m
e
a
n
 
a
g
a
i
n
s
t
 
b
a
s
e
l
i
n
e
4
.
4
0
7
4
.
2
9
6
-
m
o
n
t
h
 
a
d
j
u
s
t
e
d
 
m
e
a
n
 
a
g
a
i
n
s
t
 
b
a
s
e
l
i
n
e
4
.
3
5
7
 
(
p
 
<
 
0
.
0
5
)
4
.
1
7
1
c
o
n
t
i
n
u
e
dAppendix 8
186
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
187
O
u
t
c
o
m
e
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
R
o
b
e
r
t
o
 
e
t
 
a
l
.
6
6
C
o
n
d
o
m
 
n
e
g
o
t
i
a
t
i
o
n
:
 
m
e
a
s
u
r
e
d
 
u
s
i
n
g
 
4
 
5
-
p
o
i
n
t
 
L
i
k
e
r
t
-
t
y
p
e
 
i
t
e
m
s
C
o
n
d
o
m
 
u
s
e
 
s
e
l
f
-
e
f
fi
c
a
c
y
:
 
m
e
a
s
u
r
e
d
 
u
s
i
n
g
 
4
 
5
-
p
o
i
n
t
 
L
i
k
e
r
t
-
t
y
p
e
 
i
t
e
m
s
S
i
t
u
a
t
i
o
n
a
l
 
s
e
l
f
-
e
f
fi
c
a
c
y
:
 
m
e
a
s
u
r
e
d
 
u
s
i
n
g
 
3
 
5
-
p
o
i
n
t
 
L
i
k
e
r
t
-
t
y
p
e
 
i
t
e
m
s
R
e
f
u
s
a
l
 
s
e
l
f
-
e
f
fi
c
a
c
y
:
 
m
e
a
s
u
r
e
d
 
u
s
i
n
g
 
5
 
5
-
p
o
i
n
t
 
L
i
k
e
r
t
-
t
y
p
e
 
i
t
e
m
s
E
x
p
e
r
i
m
e
n
t
a
l
 
g
r
o
u
p
C
o
n
t
r
o
l
 
g
r
o
u
p
C
o
n
d
o
m
 
n
e
g
o
t
i
a
t
i
o
n
P
r
e
-
t
e
s
t
4
.
4
0
4
.
2
2
F
(
1
,
 
3
2
1
)
 
=
 
4
.
5
3
 
(
p
 
<
 
0
.
0
5
;
 
e
x
p
e
r
i
m
e
n
t
a
l
 
g
r
o
u
p
 
o
u
t
p
e
r
f
o
r
m
e
d
 
c
o
n
t
r
o
l
 
g
r
o
u
p
)
,
 
e
t
a
-
s
q
u
a
r
e
d
 
=
 
0
.
0
2
P
o
s
t
-
t
e
s
t
4
.
4
4
3
.
9
8
C
o
n
d
o
m
 
s
e
l
f
-
e
f
fi
c
a
c
y
P
r
e
-
t
e
s
t
4
.
0
4
4
.
1
5
F
(
1
,
 
3
2
2
)
 
=
 
2
.
1
3
,
 
e
t
a
-
s
q
u
a
r
e
d
 
=
 
0
.
0
1
P
o
s
t
-
t
e
s
t
4
.
1
8
4
.
1
1
S
i
t
u
a
t
i
o
n
a
l
 
s
e
l
f
-
e
f
fi
c
a
c
y
P
r
e
-
t
e
s
t
3
.
8
9
3
.
7
4
F
(
1
,
 
3
2
2
)
 
=
 
4
.
0
8
 
(
p
 
<
 
0
.
0
5
;
 
e
x
p
e
r
i
m
e
n
t
a
l
 
g
r
o
u
p
 
o
u
t
p
e
r
f
o
r
m
e
d
 
c
o
n
t
r
o
l
 
g
r
o
u
p
)
,
 
e
t
a
-
s
q
u
a
r
e
d
 
=
 
0
.
0
1
P
o
s
t
-
t
e
s
t
4
.
0
5
3
.
6
4
R
e
f
u
s
a
l
 
s
e
l
f
-
e
f
fi
c
a
c
y
P
r
e
-
t
e
s
t
4
.
1
2
3
.
8
5
F
(
1
,
 
3
2
2
)
 
=
 
0
.
6
2
,
 
e
t
a
-
s
q
u
a
r
e
d
 
=
 
0
.
0
2
P
o
s
t
-
t
e
s
t
4
.
2
4
3
.
8
6
P
e
e
r
-
l
e
d
 
v
s
 
t
e
a
c
h
e
r
-
l
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
s
B
o
r
g
i
a
 
e
t
 
a
l
.
5
1
S
k
i
l
l
s
 
i
n
 
p
r
e
v
e
n
t
i
o
n
,
 
c
o
m
m
u
n
i
c
a
t
i
o
n
 
a
n
d
 
n
e
g
o
t
i
a
t
i
o
n
 
(
1
1
 
i
t
e
m
s
,
 
e
a
c
h
 
w
i
t
h
 
o
r
d
i
n
a
l
 
r
e
s
p
o
n
s
e
 
m
e
a
s
u
r
i
n
g
 
s
e
l
f
-
p
e
r
c
e
i
v
e
d
 
a
b
i
l
i
t
y
:
 
‘
m
u
c
h
’
 
=
 
s
c
o
r
e
 
4
,
 
‘
s
u
f
fi
c
i
e
n
t
l
y
’
 
=
 
3
,
 
‘
l
i
t
t
l
e
’
 
=
 
2
,
 
‘
n
o
t
 
a
t
 
a
l
l
’
=
1
)
;
 
t
o
t
a
l
 
s
c
a
l
e
 
s
c
o
r
e
 
w
a
s
 
c
o
m
p
u
t
e
d
 
a
s
 
a
 
s
u
m
 
o
f
 
e
a
c
h
 
i
t
e
m
 
s
c
o
r
e
 
a
n
d
 
t
h
e
n
 
s
t
a
n
d
a
r
d
i
s
e
d
 
t
o
 
0
–
1
0
0
 
r
a
n
g
e
P
r
e
v
e
n
t
i
o
n
 
s
k
i
l
l
s
T
e
a
c
h
e
r
 
l
e
d
 
[
m
e
a
n
 
(
S
D
)
]
P
e
e
r
 
l
e
d
 
[
m
e
a
n
 
(
S
D
)
]
T
h
e
 
t
o
t
a
l
 
s
c
o
r
e
s
 
f
o
r
 
p
r
e
v
e
n
t
i
o
n
 
s
k
i
l
l
s
 
i
n
c
r
e
a
s
e
d
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
(
p
 
<
 
0
.
0
5
)
 
f
r
o
m
 
p
r
e
-
t
e
s
t
 
t
o
 
p
o
s
t
-
t
e
s
t
 
w
i
t
h
i
n
 
b
o
t
h
 
a
r
m
s
T
h
e
 
c
h
a
n
g
e
s
 
i
n
 
p
r
e
v
e
n
t
i
o
n
 
s
k
i
l
l
s
 
d
i
d
 
n
o
t
 
d
i
f
f
e
r
 
b
e
t
w
e
e
n
 
t
h
e
 
t
r
i
a
l
 
a
r
m
s
;
 
h
o
w
e
v
e
r
,
 
r
e
g
a
r
d
l
e
s
s
 
o
f
 
t
h
e
 
a
r
m
,
 
a
l
l
 
i
m
p
r
o
v
e
m
e
n
t
s
 
w
e
r
e
 
g
r
e
a
t
e
r
 
f
o
r
 
f
e
m
a
l
e
s
,
 
a
n
d
 
s
e
x
u
a
l
 
a
c
t
i
v
i
t
y
 
a
t
 
b
a
s
e
l
i
n
e
 
w
a
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
g
r
e
a
t
e
r
 
i
m
p
r
o
v
e
m
e
n
t
 
i
n
 
p
r
e
v
e
n
t
i
o
n
 
s
k
i
l
l
s
 
(
r
e
g
r
e
s
s
i
o
n
 
c
o
e
f
fi
c
i
e
n
t
 
i
n
 
s
e
x
u
a
l
l
y
 
a
c
t
i
v
e
 
v
s
 
n
o
t
 
a
c
t
i
v
e
 
=
 
1
.
5
 
(
9
5
%
 
C
I
 
0
.
1
 
t
o
 
2
.
9
)
P
r
e
-
t
e
s
t
6
9
.
1
 
(
1
4
.
4
)
6
8
.
3
 
(
1
5
.
0
)
P
o
s
t
-
t
e
s
t
7
0
.
6
 
(
1
5
.
3
)
6
9
.
9
 
(
1
5
.
3
)
T
A
B
L
E
 
7
7
 
S
k
i
l
l
s
 
a
n
d
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
o
u
t
c
o
m
e
s
 
(
c
o
n
t
i
n
u
e
d
)Appendix 8
186
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
187
O
u
t
c
o
m
e
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
S
t
e
p
h
e
n
s
o
n
 
e
t
 
a
l
.
5
0
N
u
m
b
e
r
s
 
a
r
e
 
t
h
o
s
e
 
w
h
o
 
a
n
s
w
e
r
e
d
 
‘
e
a
s
y
’
 
o
r
 
‘
v
e
r
y
 
e
a
s
y
’
C
o
n
fi
d
e
n
c
e
 
a
b
o
u
t
 
s
a
y
i
n
g
 
n
o
 
t
o
 
u
n
w
a
n
t
e
d
 
s
e
x
u
a
l
 
a
c
t
i
v
i
t
y
:
 
5
-
p
o
i
n
t
 
o
r
d
i
n
a
l
 
s
c
a
l
e
 
(
a
s
 
b
e
l
o
w
)
d
S
a
y
i
n
g
 
n
o
 
t
o
 
u
n
s
a
f
e
 
s
e
x
 
(
6
 
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
)
I
n
t
e
r
v
e
n
t
i
o
n
C
o
n
t
r
o
l
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
b
o
y
s
1
2
0
6
 
(
5
9
.
5
%
)
9
7
7
 
(
5
9
.
6
%
)
U
E
I
 
0
.
9
8
 
(
0
.
8
7
 
t
o
 
1
.
0
9
)
A
E
I
 
0
.
9
9
 
(
0
.
8
7
 
t
o
 
1
.
1
1
)
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
g
i
r
l
s
1
3
8
8
 
(
7
0
.
6
%
)
1
1
9
8
 
(
7
5
.
3
%
)
U
E
I
 
0
.
8
6
 
(
0
.
7
1
 
t
o
 
1
.
0
4
)
A
E
I
 
0
.
8
6
 
(
0
.
7
1
 
t
o
 
1
.
0
4
)
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
b
o
y
s
1
1
8
3
 
(
6
7
.
3
%
)
8
7
2
 
(
6
8
.
6
%
)
U
E
I
 
1
.
0
0
 
(
0
.
8
3
 
t
o
 
1
.
2
1
)
A
E
I
 
1
.
0
1
 
(
0
.
8
4
 
t
o
 
1
.
2
1
)
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
g
i
r
l
s
1
3
6
7
 
(
7
9
.
7
%
)
1
0
8
2
 
(
8
3
.
7
%
)
U
E
I
 
0
.
8
6
 
(
0
.
7
5
 
t
o
 
0
.
9
9
)
A
E
I
 
0
.
8
6
 
(
0
.
7
4
 
t
o
 
1
.
0
0
)
C
o
m
p
a
r
e
d
 
w
i
t
h
 
t
h
e
 
c
o
n
t
r
o
l
 
g
r
o
u
p
,
 
g
i
r
l
s
 
i
n
 
t
h
e
 
p
e
e
r
-
l
e
d
 
a
r
m
 
w
e
r
e
 
l
e
s
s
 
c
o
n
fi
d
e
n
t
 
a
b
o
u
t
 
r
e
f
u
s
i
n
g
 
t
o
 
d
o
 
s
o
m
e
t
h
i
n
g
 
t
h
e
y
 
d
i
d
 
n
o
t
 
w
a
n
t
 
t
o
 
d
o
 
s
e
x
u
a
l
l
y
 
(
p
 
=
 
0
.
0
4
)
C
o
n
fi
d
e
n
c
e
 
a
b
o
u
t
 
u
s
i
n
g
 
c
o
n
d
o
m
s
:
 
a
v
e
r
a
g
e
 
o
f
 
2
 
5
-
p
o
i
n
t
 
s
c
a
l
e
s
 
(
1
 
=
 
‘
v
e
r
y
 
d
i
f
fi
c
u
l
t
’
,
 
2
 
=
 
‘
d
i
f
fi
c
u
l
t
’
,
 
3
 
=
 
‘
u
n
s
u
r
e
’
,
 
4
 
=
 
‘
e
a
s
y
’
,
 
5
 
=
 
‘
v
e
r
y
 
e
a
s
y
’
)
C
o
n
fi
d
e
n
c
e
 
a
b
o
u
t
 
u
s
i
n
g
 
c
o
n
d
o
m
s
 
I
n
t
e
r
v
e
n
t
i
o
n
 
(
m
e
a
n
 
s
c
o
r
e
 
±
 
S
D
)
C
o
n
t
r
o
l
 
(
m
e
a
n
 
s
c
o
r
e
 
±
 
S
D
)
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
b
o
y
s
4
.
1
8
 
±
 
0
.
7
4
,
 
n
 
=
 
2
0
3
8
4
.
1
5
 
±
 
0
.
7
5
,
 
n
 
=
 
1
6
6
0
 
U
E
I
 
0
.
0
6
 
(
–
0
.
0
1
 
t
o
 
0
.
1
4
)
A
E
I
 
0
.
0
7
 
(
–
0
.
0
1
 
t
o
 
0
.
0
5
)
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
g
i
r
l
s
3
.
8
1
 
±
 
0
.
7
5
,
 
n
 
=
 
1
9
6
5
3
.
7
8
 
±
 
0
.
7
9
,
 
n
 
=
 
1
6
0
0
U
E
I
 
0
.
0
9
 
(
0
.
0
1
 
t
o
 
0
.
1
6
)
A
E
I
 
0
.
0
9
 
(
0
.
0
2
 
t
o
 
0
.
1
2
)
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
b
o
y
s
4
.
3
8
 
±
 
0
.
6
7
,
 
n
 
=
 
1
7
6
0
4
.
3
6
 
±
 
0
.
6
7
,
 
n
 
=
 
1
2
7
8
U
E
I
 
0
.
0
2
 
(
–
0
.
0
5
 
t
o
 
0
.
0
9
)
A
E
I
 
0
.
0
3
 
(
–
0
.
0
4
 
t
o
 
0
.
0
6
)
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
g
i
r
l
s
4
.
1
4
 
±
 
0
.
7
0
,
 
n
 
=
 
1
7
1
5
4
.
1
4
 
±
 
0
.
7
1
,
 
n
 
=
 
1
2
9
2
U
E
I
 
0
.
0
4
 
(
0
.
0
0
3
 
t
o
 
0
.
0
9
)
A
E
I
 
0
.
0
5
 
(
0
.
0
1
 
t
o
 
0
.
0
9
)
C
o
m
p
a
r
e
d
 
w
i
t
h
 
t
h
e
 
c
o
n
t
r
o
l
 
g
r
o
u
p
,
 
g
i
r
l
s
 
i
n
 
t
h
e
 
p
e
e
r
-
l
e
d
 
a
r
m
 
b
e
c
a
m
e
 
m
o
r
e
 
c
o
n
fi
d
e
n
t
 
a
b
o
u
t
 
u
s
i
n
g
 
c
o
n
d
o
m
s
 
[
m
e
a
n
 
s
c
o
r
e
 
3
.
3
6
 
o
u
t
 
o
f
 
5
 
(
0
.
8
0
)
 
v
s
 
3
.
4
9
 
(
0
.
7
9
)
 
r
e
s
p
e
c
t
i
v
e
l
y
 
a
t
 
b
a
s
e
l
i
n
e
,
 
a
n
d
 
4
.
1
4
 
(
0
.
7
0
)
 
v
s
 
4
.
1
4
 
(
0
.
7
1
)
 
a
t
 
s
e
c
o
n
d
 
f
o
l
l
o
w
-
u
p
,
 
p
 
=
 
0
.
0
0
9
]
c
o
n
t
i
n
u
e
dAppendix 8
188
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
189
O
u
t
c
o
m
e
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
C
o
n
fi
d
e
n
c
e
 
a
b
o
u
t
 
d
i
s
c
u
s
s
i
n
g
 
s
e
x
 
a
n
d
 
c
o
n
t
r
a
c
e
p
t
i
o
n
 
w
i
t
h
 
a
 
p
a
r
t
n
e
r
:
 
a
v
e
r
a
g
e
 
o
f
 
2
 
5
-
p
o
i
n
t
 
s
c
a
l
e
s
 
(
a
s
 
a
b
o
v
e
)
C
o
n
fi
d
e
n
c
e
 
a
b
o
u
t
 
d
i
s
c
u
s
s
i
n
g
 
s
e
x
 
a
n
d
 
c
o
n
t
r
a
c
e
p
t
i
o
n
 
w
i
t
h
 
a
 
p
a
r
t
n
e
r
I
n
t
e
r
v
e
n
t
i
o
n
C
o
n
t
r
o
l
T
h
e
 
a
r
m
s
 
d
i
d
 
n
o
t
 
d
i
f
f
e
r
 
f
o
r
 
g
i
r
l
s
 
o
r
 
b
o
y
s
 
a
t
 
e
i
t
h
e
r
 
f
o
l
l
o
w
-
u
p
 
f
o
r
 
c
o
n
fi
d
e
n
c
e
 
a
b
o
u
t
 
d
i
s
c
u
s
s
i
n
g
 
c
o
n
t
r
a
c
e
p
t
i
o
n
 
o
r
 
s
e
x
 
w
i
t
h
 
a
 
p
a
r
t
n
e
r
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
b
o
y
s
3
.
8
3
 
±
 
0
.
8
4
,
 
n
 
=
 
2
0
3
0
3
.
7
9
 
±
 
0
.
8
6
,
 
n
 
=
 
1
6
4
3
U
E
I
 
0
.
0
5
 
(
–
0
.
0
3
 
t
o
 
0
.
1
3
)
A
E
I
 
0
.
0
5
 
(
–
0
.
0
3
 
t
o
 
0
.
1
3
)
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
g
i
r
l
s
3
.
7
5
 
±
 
0
.
8
4
,
 
n
 
=
 
1
5
9
5
3
.
7
4
 
±
 
0
.
8
4
,
 
n
 
=
 
1
9
6
7
U
E
I
 
0
.
0
2
 
(
–
0
.
0
3
 
t
o
 
0
.
0
7
)
A
E
I
 
0
.
0
2
 
(
–
0
.
0
3
 
t
o
 
0
.
0
8
)
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
b
o
y
s
4
.
0
7
 
±
 
0
.
8
1
,
 
n
 
=
 
1
7
6
0
4
.
0
6
 
±
 
0
.
7
6
,
 
n
 
=
 
1
2
7
8
U
E
I
 
0
.
0
0
3
 
(
–
0
.
0
6
 
t
o
 
0
.
0
6
)
A
E
I
 
0
.
0
0
1
 
(
–
0
.
0
5
 
t
o
 
0
.
0
6
)
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
g
i
r
l
s
4
.
0
6
 
±
 
0
.
7
7
,
 
n
 
=
 
1
7
1
3
4
.
1
0
 
±
 
0
.
7
8
,
 
n
 
=
 
1
2
9
3
U
E
I
 
–
0
.
0
1
 
(
–
0
.
0
7
 
t
o
 
0
.
0
6
)
A
E
I
 
–
0
.
0
1
 
(
–
0
.
0
7
 
t
o
 
0
.
0
5
)
A
E
I
,
 
a
d
j
u
s
t
e
d
 
e
f
f
e
c
t
 
f
o
r
 
i
n
t
e
r
v
e
n
t
i
o
n
;
 
U
E
I
,
 
u
n
a
d
j
u
s
t
e
d
 
e
f
f
e
c
t
 
f
o
r
 
i
n
t
e
r
v
e
n
t
i
o
n
.
a
 
R
a
t
i
o
 
o
f
 
g
r
o
u
p
 
e
s
t
i
m
a
t
e
 
t
o
 
g
r
o
u
p
 
s
t
a
n
d
a
r
d
 
e
r
r
o
r
.
 
T
h
e
 
r
a
t
i
o
 
o
f
 
t
h
e
 
g
r
o
u
p
 
c
o
e
f
fi
c
i
e
n
t
 
e
s
t
i
m
a
t
e
 
t
o
 
i
t
s
 
s
t
a
n
d
a
r
d
 
e
r
r
o
r
 
r
e
fl
e
c
t
s
 
t
h
e
 
i
m
p
a
c
t
 
o
f
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
:
 
w
h
e
n
 
t
h
e
 
r
a
t
i
o
 
e
x
c
e
e
d
s
 
1
.
9
6
 
i
n
 
a
b
s
o
l
u
t
e
 
v
a
l
u
e
,
 
t
h
e
 
r
e
s
u
l
t
 
i
s
 
s
i
g
n
i
fi
c
a
n
t
 
a
t
 
p
 
<
 
0
.
0
5
.
b
 
D
a
t
a
 
f
o
r
 
T
i
m
e
1
 
v
s
 
T
i
m
e
 
3
 
c
o
m
p
a
r
i
s
o
n
 
n
o
t
 
d
a
t
a
 
e
x
t
r
a
c
t
e
d
 
d
u
e
 
t
o
 
t
h
e
 
h
i
g
h
 
a
t
t
r
i
t
i
o
n
 
a
t
 
T
i
m
e
 
3
.
 
F
o
l
l
o
w
e
d
 
u
p
 
a
t
 
T
i
m
e
 
2
,
 
n
 
=
 
1
8
1
1
.
c
 
A
d
j
u
s
t
e
d
 
m
e
a
n
s
 
a
n
d
 
S
E
M
 
(
a
l
l
 
e
s
t
i
m
a
t
e
d
 
b
y
 
t
h
e
 
r
e
v
i
e
w
e
r
,
 
w
i
t
h
 
d
i
f
fi
c
u
l
t
y
,
 
f
r
o
m
 
v
e
r
y
 
s
m
a
l
l
 
fi
g
u
r
e
)
.
d
 
F
o
r
 
t
h
e
s
e
 
o
u
t
c
o
m
e
s
 
t
h
e
 
e
f
f
e
c
t
s
 
a
r
e
 
a
l
l
 
O
R
s
.
T
A
B
L
E
 
7
7
 
S
k
i
l
l
s
 
a
n
d
 
s
e
l
f
-
e
f
fi
c
a
c
y
 
o
u
t
c
o
m
e
s
 
(
c
o
n
t
i
n
u
e
d
)Appendix 8
188
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
189
T
A
B
L
E
 
7
8
 
A
t
t
i
t
u
d
e
 
o
u
t
c
o
m
e
s
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
I
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
s
t
a
n
d
a
r
d
 
s
e
x
 
e
d
u
c
a
t
i
o
n
C
o
y
l
e
 
e
t
 
a
l
.
5
8
n
E
s
t
i
m
a
t
e
d
 
e
f
f
e
c
t
 
s
i
z
e
S
t
a
n
d
a
r
d
 
e
r
r
o
r
R
a
t
i
o
 
o
f
 
g
r
o
u
p
 
e
s
t
i
m
a
t
e
 
t
o
 
g
r
o
u
p
 
s
t
a
n
d
a
r
d
 
e
r
r
o
r
 
A
t
t
i
t
u
d
e
 
t
o
w
a
r
d
s
 
s
e
x
u
a
l
 
i
n
t
e
r
c
o
u
r
s
e
N
u
m
e
r
i
c
a
l
 
d
a
t
a
 
n
o
t
 
r
e
p
o
r
t
e
d
N
o
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
 
e
x
i
s
t
e
d
 
b
e
t
w
e
e
n
 
s
t
u
d
e
n
t
s
 
i
n
 
t
h
e
 
t
w
o
 
p
r
o
g
r
a
m
m
e
s
 
i
n
 
t
h
e
i
r
 
a
t
t
i
t
u
d
e
 
t
o
w
a
r
d
s
 
s
e
x
u
a
l
 
i
n
t
e
r
c
o
u
r
s
e
 
(
p
 
=
 
0
.
2
5
)
A
t
t
i
t
u
d
e
s
 
t
o
w
a
r
d
s
 
c
o
n
d
o
m
 
u
s
e
N
u
m
e
r
i
c
a
l
 
d
a
t
a
 
n
o
t
 
r
e
p
o
r
t
e
d
S
t
u
d
e
n
t
s
 
i
n
 
i
n
t
e
r
v
e
n
t
i
o
n
 
s
c
h
o
o
l
s
 
e
x
p
r
e
s
s
e
d
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
m
o
r
e
 
p
o
s
i
t
i
v
e
 
a
t
t
i
t
u
d
e
s
 
t
o
w
a
r
d
s
 
c
o
n
d
o
m
 
u
s
e
 
a
t
 
f
o
l
l
o
w
-
u
p
 
t
h
a
n
 
s
t
u
d
e
n
t
s
 
i
n
 
c
o
m
p
a
r
i
s
o
n
 
s
c
h
o
o
l
s
 
(
p
 
=
 
0
.
0
0
)
K
a
r
n
e
l
l
 
e
t
 
a
l
.
6
3
P
o
s
i
t
i
v
e
 
a
t
t
i
t
u
d
e
s
 
t
o
w
a
r
d
s
 
c
o
n
d
o
m
 
u
s
e
I
n
t
e
r
v
e
n
t
i
o
n
 
c
h
a
n
g
e
C
o
m
p
a
r
i
s
o
n
 
c
h
a
n
g
e
I
n
t
e
r
v
e
n
t
i
o
n
 
e
f
f
e
c
t
O
v
e
r
a
l
l
0
.
1
7
0
.
0
8
0
.
0
9
N
o
 
r
e
p
o
r
t
 
o
f
 
a
n
y
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
s
H
a
d
 
s
e
x
 
a
t
 
p
r
e
-
t
e
s
t
0
.
1
7
0
.
0
1
0
.
1
6
H
a
d
 
n
o
t
 
h
a
d
 
s
e
x
 
a
t
 
p
r
e
-
t
e
s
t
0
.
1
7
0
.
1
3
0
.
0
4
P
o
s
i
t
i
v
e
 
a
t
t
i
t
u
d
e
s
 
a
b
o
u
t
 
a
l
c
o
h
o
l
O
v
e
r
a
l
l
–
0
.
0
1
0
.
1
6
–
0
.
1
7
N
o
 
r
e
p
o
r
t
 
o
f
 
a
n
y
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
s
M
a
l
e
0
.
0
9
0
.
0
3
0
.
0
6
F
e
m
a
l
e
–
0
.
1
3
0
.
2
2
–
0
.
3
5
N
e
g
a
t
i
v
e
 
a
t
t
i
t
u
d
e
s
 
a
b
o
u
t
 
a
l
c
o
h
o
l
O
v
e
r
a
l
l
–
0
.
1
5
–
0
.
0
8
–
0
.
0
7
N
o
 
r
e
p
o
r
t
 
o
f
 
a
n
y
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
s
M
a
l
e
–
0
.
0
5
–
0
.
1
6
0
.
1
1
F
e
m
a
l
e
–
0
.
2
2
–
0
.
0
6
–
0
.
1
6
L
e
v
y
 
e
t
 
a
l
.
6
5
O
u
t
c
o
m
e
 
n
o
t
 
r
e
p
o
r
t
e
d
c
o
n
t
i
n
u
e
dAppendix 8
190
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
191
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
W
i
g
h
t
 
e
t
 
a
l
.
7
0
A
t
t
i
t
u
d
e
s
 
n
o
t
 
m
e
a
s
u
r
e
d
Z
i
m
m
e
r
m
a
n
 
e
t
 
a
l
.
7
1
A
t
t
i
t
u
d
e
 
a
b
o
u
t
 
w
a
i
t
i
n
g
 
t
o
 
h
a
v
e
 
s
e
x
 
(
r
a
n
g
e
 
1
–
4
)
M
o
d
i
fi
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
 
(
m
e
a
n
 
s
c
o
r
e
)
O
r
i
g
i
n
a
l
 
i
n
t
e
r
v
e
n
t
i
o
n
 
(
m
e
a
n
 
s
c
o
r
e
)
S
t
a
n
d
a
r
d
 
(
m
e
a
n
 
s
c
o
r
e
)
N
o
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
 
b
e
t
w
e
e
n
 
t
h
e
 
g
r
o
u
p
s
T
i
m
e
 
1
2
.
7
5
2
.
8
4
2
.
8
1
T
i
m
e
 
2
2
.
6
9
2
.
7
1
2
.
6
6
I
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
c
o
n
t
r
o
l
 
(
n
o
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
d
e
l
a
y
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
n
o
n
-
s
e
x
 
e
d
u
c
a
t
i
o
n
 
i
n
t
e
r
v
e
n
t
i
o
n
)
J
e
m
m
o
t
t
 
e
t
 
a
l
.
6
2
A
t
t
i
t
u
d
e
s
 
n
o
t
 
m
e
a
s
u
r
e
d
J
e
m
m
o
t
t
 
e
t
 
a
l
.
4
3
A
t
t
i
t
u
d
e
 
t
o
w
a
r
d
s
 
r
i
s
k
y
 
s
e
x
u
a
l
 
b
e
h
a
v
i
o
u
r
s
A
I
D
S
 
p
r
e
v
e
n
t
i
o
n
C
o
n
t
r
o
l
D
i
f
f
e
r
e
n
c
e
 
(
9
5
%
 
C
I
 
o
f
 
d
i
f
f
e
r
e
n
c
e
)
P
o
s
t
-
i
n
t
e
r
v
e
n
t
i
o
n
3
.
0
2
3
.
4
8
–
0
.
4
6
 
(
–
0
.
7
7
 
t
o
 
–
0
.
1
5
)
P
a
r
t
i
c
i
p
a
n
t
s
 
i
n
 
t
h
e
 
A
I
D
S
 
c
o
n
d
i
t
i
o
n
 
e
x
p
r
e
s
s
e
d
 
l
e
s
s
 
f
a
v
o
u
r
a
b
l
e
 
a
t
t
i
t
u
d
e
s
 
t
o
w
a
r
d
s
 
r
i
s
k
y
 
s
e
x
u
a
l
 
b
e
h
a
v
i
o
u
r
s
 
[
F
(
1
,
 
1
5
0
)
 
=
 
8
.
4
2
,
 
p
 
<
 
0
.
0
0
4
)
 
t
h
a
n
 
p
a
r
t
i
c
i
p
a
n
t
s
 
i
n
 
t
h
e
 
c
o
n
t
r
o
l
 
g
r
o
u
p
3
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
3
.
1
3
3
.
3
8
–
0
.
5
4
 
(
0
.
0
4
)
D
i
f
f
e
r
e
n
c
e
 
i
n
 
t
h
e
 
g
r
o
u
p
s
 
w
a
s
 
n
o
 
l
o
n
g
e
r
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
fi
c
a
n
t
 
 
[
F
(
1
,
 
1
4
4
)
 
=
 
2
.
8
2
,
 
p
 
<
 
0
.
1
0
K
l
e
p
p
 
e
t
 
a
l
.
6
4
A
t
t
i
t
u
d
e
s
 
t
o
w
a
r
d
s
 
p
e
o
p
l
e
 
w
i
t
h
 
A
I
D
S
I
n
t
e
r
v
e
n
t
i
o
n
 
s
c
h
o
o
l
s
 
(
m
e
a
n
 
s
c
o
r
e
)
C
o
m
p
a
r
i
s
o
n
 
s
c
h
o
o
l
s
 
(
m
e
a
n
 
s
c
o
r
e
)
B
a
s
e
l
i
n
e
6
.
4
6
.
9
F
o
l
l
o
w
-
u
p
8
.
8
6
.
5
N
e
t
 
e
f
f
e
c
t
 
2
.
8
,
 
p
 
=
 
0
.
0
0
1
5
A
t
t
i
t
u
d
e
s
 
t
o
w
a
r
d
s
 
e
n
g
a
g
i
n
g
 
i
n
 
s
e
x
u
a
l
 
i
n
t
e
r
c
o
u
r
s
e
I
n
t
e
r
v
e
n
t
i
o
n
 
s
c
h
o
o
l
s
 
(
m
e
a
n
 
s
c
o
r
e
)
C
o
m
p
a
r
i
s
o
n
 
s
c
h
o
o
l
s
 
(
m
e
a
n
 
s
c
o
r
e
)
B
a
s
e
l
i
n
e
4
0
.
7
7
4
1
.
5
F
o
l
l
o
w
-
u
p
5
0
.
0
4
7
.
0
N
e
t
 
e
f
f
e
c
t
 
3
.
8
,
 
p
 
=
 
0
.
2
7
R
o
b
e
r
t
o
 
e
t
 
a
l
.
6
6
A
t
t
i
t
u
d
e
 
t
o
w
a
r
d
s
 
w
a
i
t
i
n
g
 
t
o
 
h
a
v
e
 
s
e
x
E
x
p
e
r
i
m
e
n
t
a
l
 
g
r
o
u
p
C
o
n
t
r
o
l
 
g
r
o
u
p
P
r
e
-
t
e
s
t
3
.
7
7
3
.
6
8
A
N
O
V
A
:
 
F
(
1
,
 
3
1
8
)
 
=
 
2
.
9
2
,
 
e
t
a
-
s
q
u
a
r
e
d
 
=
 
0
.
1
,
 
p
 
<
 
0
.
0
5
,
 
e
x
p
e
r
i
m
e
n
t
a
l
 
g
r
o
u
p
 
o
u
t
p
e
r
f
o
r
m
e
d
 
c
o
n
t
r
o
l
 
g
r
o
u
p
P
o
s
t
-
t
e
s
t
3
.
7
1
3
.
4
4
S
t
a
n
t
o
n
 
e
t
 
a
l
.
6
9
A
t
t
i
t
u
d
e
s
 
n
o
t
 
m
e
a
s
u
r
e
d
T
A
B
L
E
 
7
8
 
A
t
t
i
t
u
d
e
 
o
u
t
c
o
m
e
s
 
(
c
o
n
t
i
n
u
e
d
)Appendix 8
190
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
191
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
P
e
e
r
-
l
e
d
 
v
s
 
t
e
a
c
h
e
r
-
l
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
s
B
o
r
g
i
a
 
e
t
 
a
l
.
5
1
A
t
t
i
t
u
d
e
s
 
t
o
w
a
r
d
s
 
p
e
r
s
o
n
s
 
w
i
t
h
 
A
I
D
S
T
e
a
c
h
e
r
 
l
e
d
 
[
m
e
a
n
 
(
S
D
)
]
P
e
e
r
 
l
e
d
 
[
m
e
a
n
 
(
S
D
)
]
T
h
e
 
t
o
t
a
l
 
s
c
o
r
e
s
 
f
o
r
 
a
t
t
i
t
u
d
e
s
 
i
n
c
r
e
a
s
e
d
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
(
W
i
l
c
o
x
o
n
 
t
e
s
t
 
p
 
<
 
0
.
0
5
)
 
f
r
o
m
 
p
r
e
-
t
e
s
t
 
t
o
 
p
o
s
t
-
t
e
s
t
 
w
i
t
h
i
n
 
b
o
t
h
 
a
r
m
s
P
r
e
-
t
e
s
t
4
2
.
0
 
(
2
6
.
0
)
4
5
.
6
 
(
2
4
.
9
)
P
o
s
t
-
t
e
s
t
4
8
.
3
 
(
2
6
.
7
)
4
9
.
2
 
(
2
5
.
6
)
S
t
e
p
h
e
n
s
o
n
 
e
t
 
a
l
.
5
0
P
o
s
i
t
i
v
e
 
a
t
t
i
t
u
d
e
 
t
o
w
a
r
d
s
 
u
s
i
n
g
 
c
o
n
d
o
m
s
I
n
t
e
r
v
e
n
t
i
o
n
 
(
p
e
e
r
 
l
e
d
,
 
%
)
C
o
n
t
r
o
l
 
(
t
e
a
c
h
e
r
-
l
e
d
,
 
%
)
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
 
–
 
b
o
y
s
S
c
o
r
e
 
1
 
=
 
1
.
3
7
S
c
o
r
e
 
2
 
=
 
1
.
4
3
S
c
o
r
e
 
3
 
=
 
7
.
1
3
S
c
o
r
e
 
4
 
=
 
3
4
.
0
1
S
c
o
r
e
 
5
 
=
 
5
6
.
0
6
S
c
o
r
e
 
1
 
=
 
1
.
8
3
S
c
o
r
e
 
2
 
=
 
1
.
4
5
S
c
o
r
e
 
3
 
=
 
7
.
9
9
S
c
o
r
e
 
4
 
=
 
3
6
.
5
6
S
c
o
r
e
 
5
 
=
 
5
2
.
1
7
U
E
I
 
1
.
1
4
 
(
0
.
9
4
 
t
o
 
1
.
3
7
)
A
E
I
 
1
.
1
5
 
(
0
.
9
5
 
t
o
 
1
.
3
9
)
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
 
–
 
g
i
r
l
s
S
c
o
r
e
 
1
 
=
 
0
.
7
8
S
c
o
r
e
 
2
 
=
 
0
.
8
9
S
c
o
r
e
 
3
 
=
 
3
.
8
6
S
c
o
r
e
 
4
 
=
 
2
2
.
0
4
S
c
o
r
e
 
5
 
=
 
7
2
.
4
3
S
c
o
r
e
 
1
 
=
 
0
.
7
7
S
c
o
r
e
 
2
 
=
 
0
.
9
6
S
c
o
r
e
 
3
 
=
 
3
.
9
3
S
c
o
r
e
 
4
 
=
 
2
5
.
1
6
S
c
o
r
e
 
5
 
=
 
6
9
.
1
8
U
E
I
 
1
.
1
8
 
(
0
.
9
4
 
t
o
 
1
.
4
8
)
A
E
I
 
1
.
1
5
 
(
0
.
9
2
 
t
o
 
1
.
4
4
)
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
b
o
y
s
S
c
o
r
e
 
1
 
=
 
1
.
3
9
S
c
o
r
e
 
2
 
=
 
1
.
0
5
S
c
o
r
e
 
3
 
=
 
5
.
8
7
S
c
o
r
e
 
4
 
=
 
3
2
.
7
9
S
c
o
r
e
 
5
 
=
 
5
8
.
9
0
S
c
o
r
e
 
1
 
=
 
1
.
4
6
S
c
o
r
e
 
2
 
=
 
0
.
7
3
S
c
o
r
e
 
3
 
=
 
7
.
2
0
S
c
o
r
e
 
4
 
=
 
3
2
.
4
7
S
c
o
r
e
 
5
 
=
 
5
8
.
1
4
U
E
I
 
1
.
0
9
 
(
0
.
9
3
 
t
o
 
1
.
2
9
)
A
E
I
 
1
.
0
9
 
(
0
.
9
2
 
t
o
 
1
.
2
9
)
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
g
i
r
l
s
S
c
o
r
e
 
1
 
=
 
0
.
5
9
S
c
o
r
e
 
2
 
=
 
0
.
4
7
S
c
o
r
e
 
3
 
=
 
2
.
4
7
S
c
o
r
e
 
4
 
=
 
2
1
.
5
9
S
c
o
r
e
 
5
 
=
 
7
4
.
8
8
S
c
o
r
e
 
1
 
=
 
1
.
0
3
S
c
o
r
e
 
2
 
=
 
0
.
9
5
S
c
o
r
e
 
3
 
=
 
3
.
3
2
S
c
o
r
e
 
4
 
=
 
2
3
.
1
8
S
c
o
r
e
 
5
 
=
 
7
1
.
5
2
U
E
I
 
1
.
2
0
 
(
0
.
9
8
 
t
o
 
1
.
4
8
)
A
E
I
 
1
.
1
9
 
(
0
.
9
8
 
t
o
 
1
.
4
5
)
c
o
n
t
i
n
u
e
dAppendix 8
192
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
193
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
P
o
s
i
t
i
v
e
 
a
t
t
i
t
u
d
e
s
 
t
o
 
s
e
x
I
n
t
e
r
v
e
n
t
i
o
n
C
o
n
t
r
o
l
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
 
–
 
b
o
y
s
3
.
7
9
 
(
0
.
5
8
)
3
.
7
9
 
(
0
.
5
8
)
U
E
I
 
0
.
0
0
3
 
(
–
0
.
0
3
 
t
o
 
0
.
0
4
)
A
E
I
 
0
.
0
0
2
 
(
–
0
.
0
4
 
t
o
 
0
.
0
4
)
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
 
–
 
g
i
r
l
s
3
.
7
0
 
(
0
.
5
4
)
3
.
7
0
 
(
0
.
5
6
)
U
E
I
 
0
.
0
2
 
(
–
0
.
0
3
 
t
o
 
0
.
0
7
)
A
E
I
 
0
.
0
1
 
(
–
0
.
0
4
 
t
o
 
0
.
0
6
)
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
b
o
y
s
3
.
8
4
 
(
0
.
5
6
)
3
.
8
2
 
(
0
.
5
6
)
U
E
I
 
0
.
0
4
 
(
–
0
.
0
1
 
t
o
 
0
.
0
9
)
A
E
I
 
0
.
0
4
 
(
–
0
.
0
1
 
t
o
 
0
.
1
0
)
1
8
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
–
 
g
i
r
l
s
3
.
8
0
 
(
0
.
5
6
)
3
.
7
8
 
(
0
.
5
7
)
U
E
I
 
0
.
0
4
 
(
–
0
.
0
1
 
t
o
 
0
.
0
9
)
A
E
I
 
0
.
0
4
 
(
–
0
.
0
1
 
t
o
 
0
.
0
9
)
A
E
I
,
 
a
d
j
u
s
t
e
d
 
e
f
f
e
c
t
 
f
o
r
 
i
n
t
e
r
v
e
n
t
i
o
n
;
 
U
E
I
,
 
u
n
a
d
j
u
s
t
e
d
 
e
f
f
e
c
t
 
f
o
r
 
i
n
t
e
r
v
e
n
t
i
o
n
.
T
A
B
L
E
 
7
8
 
A
t
t
i
t
u
d
e
 
o
u
t
c
o
m
e
s
 
(
c
o
n
t
i
n
u
e
d
)Appendix 8
192
DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
193
T
A
B
L
E
 
7
9
 
B
e
h
a
v
i
o
u
r
a
l
 
i
n
t
e
n
t
i
o
n
 
o
u
t
c
o
m
e
s
I
n
t
e
n
t
i
o
n
s
 
o
u
t
c
o
m
e
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
I
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
s
t
a
n
d
a
r
d
 
s
e
x
 
e
d
u
c
a
t
i
o
n
C
o
y
l
e
 
e
t
 
a
l
.
5
8
O
u
t
c
o
m
e
 
n
o
t
 
m
e
a
s
u
r
e
d
K
a
r
n
e
l
l
 
e
t
 
a
l
.
6
3
I
n
t
e
n
t
i
o
n
 
t
o
 
h
a
v
e
 
s
e
x
u
a
l
 
i
n
t
e
r
c
o
u
r
s
e
 
i
n
 
t
h
e
 
n
e
x
t
 
3
 
m
o
n
t
h
s
I
n
t
e
r
v
e
n
t
i
o
n
 
c
h
a
n
g
e
C
o
m
p
a
r
i
s
o
n
 
c
h
a
n
g
e
I
n
t
e
r
v
e
n
t
i
o
n
 
e
f
f
e
c
t
O
v
e
r
a
l
l
0
.
0
0
0
.
0
6
–
0
.
0
6
H
a
d
 
s
e
x
 
a
t
 
p
r
e
-
t
e
s
t
–
0
.
0
6
–
0
.
2
4
0
.
1
8
H
a
d
 
n
o
t
 
h
a
d
 
s
e
x
 
a
t
 
p
r
e
-
t
e
s
t
–
0
.
0
6
0
.
2
5
–
0
.
3
1
I
n
t
e
n
t
i
o
n
 
t
o
 
u
s
e
 
a
 
c
o
n
d
o
m
 
c
o
n
s
i
s
t
e
n
t
l
y
 
d
u
r
i
n
g
 
s
e
x
u
a
l
 
i
n
t
e
r
c
o
u
r
s
e
 
o
v
e
r
 
t
h
e
 
n
e
x
t
 
3
 
m
o
n
t
h
s
O
v
e
r
a
l
l
0
.
1
8
–
0
.
0
1
0
.
1
9
H
a
d
 
s
e
x
 
a
t
 
p
r
e
-
t
e
s
t
0
.
4
5
–
0
.
3
2
0
.
7
7
I
n
t
e
r
v
e
n
t
i
o
n
 
e
f
f
e
c
t
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
fi
c
a
n
t
 
p
 
<
 
0
.
0
1
H
a
d
 
n
o
t
 
h
a
d
 
s
e
x
 
a
t
 
p
r
e
t
e
s
t
0
.
1
7
0
.
1
2
0
.
0
5
L
e
v
y
 
e
t
 
a
l
.
6
5
A
l
l
 
f
o
r
 
s
u
b
g
r
o
u
p
 
o
f
 
c
h
a
n
g
e
r
s
T
r
e
a
t
m
e
n
t
C
o
n
t
r
o
l
 
(
m
e
a
n
 
s
c
o
r
e
)
I
n
t
e
n
d
 
o
n
 
p
o
s
s
i
b
l
y
 
h
a
v
i
n
g
 
s
e
x
8
4
.
8
8
8
.
7
F
o
r
 
t
h
o
s
e
 
w
h
o
 
p
l
a
n
 
o
n
 
h
a
v
i
n
g
 
s
e
x
,
 
t
h
e
y
 
i
n
t
e
n
d
 
o
n
 
p
o
s
s
i
b
l
y
 
u
s
i
n
g
 
c
o
n
d
o
m
s
9
8
.
7
9
7
.
2
F
o
r
 
t
h
o
s
e
 
w
h
o
 
p
l
a
n
 
o
n
 
h
a
v
i
n
g
 
s
e
x
,
 
t
h
e
y
 
i
n
t
e
n
d
 
o
n
 
p
o
s
s
i
b
l
y
 
u
s
i
n
g
 
c
o
n
d
o
m
s
 
w
i
t
h
 
f
o
a
m
 
8
4
.
6
6
2
.
9
p
 
<
 
0
.
0
0
1
W
i
g
h
t
 
e
t
 
a
l
.
7
0
O
u
t
c
o
m
e
 
n
o
t
 
m
e
a
s
u
r
e
d
Z
i
m
m
e
r
m
a
n
 
e
t
 
a
l
.
7
1
I
n
t
e
n
t
i
o
n
 
t
o
 
h
a
v
e
 
s
e
x
u
a
l
 
i
n
t
e
r
c
o
u
r
s
e
 
(
s
c
o
r
e
 
r
a
n
g
e
 
1
–
5
)
M
o
d
i
fi
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
 
(
m
e
a
n
 
s
c
o
r
e
)
O
r
i
g
i
n
a
l
 
i
n
t
e
r
v
e
n
t
i
o
n
 
(
m
e
a
n
 
s
c
o
r
e
)
S
t
a
n
d
a
r
d
 
(
m
e
a
n
 
s
c
o
r
e
)
N
o
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
s
 
b
e
t
w
e
e
n
 
t
h
e
 
g
r
o
u
p
s
T
i
m
e
 
1
2
.
4
8
2
.
3
6
2
.
6
0
T
i
m
e
 
2
2
.
6
5
2
.
5
9
2
.
6
8
I
n
t
e
n
t
i
o
n
 
t
o
 
u
s
e
 
c
o
n
d
o
m
s
 
c
o
n
s
i
s
t
e
n
t
l
y
D
a
t
a
 
n
o
t
 
r
e
p
o
r
t
e
d
 
f
o
r
 
t
h
i
s
 
o
u
t
c
o
m
e
c
o
n
t
i
n
u
e
dAppendix 8
194
I
n
t
e
n
t
i
o
n
s
 
o
u
t
c
o
m
e
R
e
s
u
l
t
s
S
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
I
n
t
e
r
v
e
n
t
i
o
n
 
v
s
 
c
o
n
t
r
o
l
 
(
n
o
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
d
e
l
a
y
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
,
 
n
o
n
-
s
e
x
 
e
d
u
c
a
t
i
o
n
 
i
n
t
e
r
v
e
n
t
i
o
n
)
J
e
m
m
o
t
t
 
e
t
 
a
l
.
6
2
C
o
n
d
o
m
 
u
s
e
 
i
n
t
e
n
t
i
o
n
s
 
a
H
I
V
 
p
r
e
v
e
n
t
i
o
n
C
o
n
t
r
o
l
P
r
e
-
i
n
t
e
r
v
e
n
t
i
o
n
5
.
5
 
(
n
o
t
 
p
o
s
s
i
b
l
e
 
t
o
 
d
a
t
a
 
e
x
t
r
a
c
t
 
S
E
M
)
5
.
3
5
 
(
n
o
t
 
p
o
s
s
i
b
l
e
 
t
o
 
d
a
t
a
 
e
x
t
r
a
c
t
 
S
E
M
)
P
o
s
t
 
i
n
t
e
r
v
e
n
t
i
o
n
5
.
5
 
±
 
0
.
1
5
.
1
 
±
 
0
.
1
I
n
t
e
r
v
e
n
t
i
o
n
 
g
r
o
u
p
 
h
a
d
 
fi
r
m
e
r
 
c
o
n
d
o
m
 
u
s
e
 
i
n
t
e
n
t
i
o
n
 
t
h
a
n
 
t
h
o
s
e
 
i
n
 
t
h
e
 
c
o
n
t
r
o
l
 
g
r
o
u
p
 
[
F
(
1
,
 
4
8
8
)
 
=
 
5
.
4
2
,
 
p
 
=
 
0
.
0
2
]
3
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
5
.
8
5
 
±
 
0
.
1
5
.
4
5
 
±
 
0
.
1
C
o
n
d
o
m
 
u
s
e
 
i
n
t
e
n
t
i
o
n
s
 
m
a
i
n
t
a
i
n
e
d
 
[
F
(
1
,
 
4
7
2
)
 
=
 
5
.
8
9
,
 
p
 
=
 
0
.
0
1
6
]
6
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
5
.
8
 
±
 
0
.
1
5
.
5
 
±
 
0
.
1
C
o
n
d
o
m
 
u
s
e
 
i
n
t
e
n
t
i
o
n
s
 
m
a
i
n
t
a
i
n
e
d
 
[
F
(
1
,
 
4
5
2
)
 
=
 
3
.
8
9
,
 
p
 
=
 
0
.
0
4
9
]
J
e
m
m
o
t
t
 
e
t
 
a
l
.
4
3
I
n
t
e
n
t
i
o
n
 
t
o
 
e
n
g
a
g
e
 
i
n
 
r
i
s
k
y
 
s
e
x
u
a
l
 
b
e
h
a
v
i
o
u
r
A
I
D
S
 
p
r
e
v
e
n
t
i
o
n
C
o
n
t
r
o
l
D
i
f
f
e
r
e
n
c
e
 
(
9
5
%
 
C
I
 
o
f
 
d
i
f
f
e
r
e
n
c
e
)
P
o
s
t
 
i
n
t
e
r
v
e
n
t
i
o
n
2
.
8
3
3
.
4
0
–
0
.
5
7
 
(
–
0
.
8
4
 
t
o
 
0
.
3
0
)
A
I
D
S
 
p
r
e
v
e
n
t
i
o
n
 
p
a
r
t
i
c
i
p
a
n
t
s
 
h
a
d
 
w
e
a
k
e
r
 
i
n
t
e
n
t
i
o
n
s
 
t
o
 
e
n
g
a
g
e
 
i
n
 
r
i
s
k
y
 
s
e
x
u
a
l
 
b
e
h
a
v
i
o
r
s
 
t
h
a
n
 
p
a
r
t
i
c
i
p
a
n
t
s
 
i
n
 
t
h
e
 
c
o
n
t
r
o
l
 
g
r
o
u
p
 
[
F
(
1
,
 
1
5
0
)
 
=
 
1
7
.
4
5
,
 
p
 
<
0
.
0
0
0
1
]
3
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
2
.
8
7
3
.
3
0
–
0
.
4
3
 
(
–
0
.
7
4
 
t
o
 
0
.
1
2
)
A
I
D
S
 
p
r
e
v
e
n
t
i
o
n
 
p
a
r
t
i
c
i
p
a
n
t
s
 
h
a
d
 
w
e
a
k
e
r
 
i
n
t
e
n
t
i
o
n
s
 
t
o
 
e
n
g
a
g
e
 
i
n
 
r
i
s
k
y
 
s
e
x
u
a
l
 
b
e
h
a
v
i
o
r
s
 
t
h
a
n
 
p
a
r
t
i
c
i
p
a
n
t
s
 
i
n
 
t
h
e
 
c
o
n
t
r
o
l
 
g
r
o
u
p
 
[
F
(
1
,
 
1
4
4
)
 
=
 
7
.
5
8
,
 
p
 
<
 
0
.
0
0
7
]
K
l
e
p
p
 
e
t
 
a
l
.
6
4
I
n
t
e
n
t
i
o
n
 
t
o
 
e
n
g
a
g
e
 
i
n
 
s
e
x
u
a
l
 
i
n
t
e
r
c
o
u
r
s
e
 
i
n
 
t
h
e
 
n
e
x
t
 
3
 
m
o
n
t
h
s
I
n
t
e
r
v
e
n
t
i
o
n
 
s
c
h
o
o
l
s
 
(
%
)
C
o
m
p
a
r
i
s
o
n
 
s
c
h
o
o
l
s
 
(
%
)
B
a
s
e
l
i
n
e
2
8
.
3
3
1
.
1
F
o
l
l
o
w
-
u
p
1
0
.
0
2
4
.
1
N
e
t
 
e
f
f
e
c
t
 
1
1
.
3
,
 
p
 
=
 
0
.
0
0
6
R
o
b
e
r
t
o
 
e
t
 
a
l
.
6
6
O
u
t
c
o
m
e
 
n
o
t
 
m
e
a
s
u
r
e
d
S
t
a
n
t
o
n
 
e
t
 
a
l
.
6
9
O
u
t
c
o
m
e
 
n
o
t
 
m
e
a
s
u
r
e
d
P
e
e
r
-
l
e
d
 
v
s
 
t
e
a
c
h
e
r
-
l
e
d
 
i
n
t
e
r
v
e
n
t
i
o
n
s
B
o
r
g
i
a
 
e
t
 
a
l
.
5
1
O
u
t
c
o
m
e
 
n
o
t
 
m
e
a
s
u
r
e
d
S
t
e
p
h
e
n
s
o
n
 
e
t
 
a
l
.
5
0
O
u
t
c
o
m
e
 
n
o
t
 
m
e
a
s
u
r
e
d
a
 
A
d
j
u
s
t
e
d
 
m
e
a
n
s
 
a
n
d
 
S
E
M
 
(
a
l
l
 
e
s
t
i
m
a
t
e
d
 
b
y
 
t
h
e
 
r
e
v
i
e
w
e
r
,
 
w
i
t
h
 
d
i
f
fi
c
u
l
t
y
,
 
f
r
o
m
 
v
e
r
y
 
s
m
a
l
l
 
fi
g
u
r
e
)
.
T
A
B
L
E
 
7
9
 
B
e
h
a
v
i
o
u
r
a
l
 
i
n
t
e
n
t
i
o
n
 
o
u
t
c
o
m
e
s
 
(
c
o
n
t
i
n
u
e
d
)
,
,DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
195
Appendix 9  
Additional meta-analysis
This appendix presents additional results from the meta-analysis (Chapter 4, Synthesis of results of sound 
outcome evaluations), for the outcomes of condom use at first and last intercourse, with subgroup analyses 
for boys and girls where reported by the trials.
Condom use at first intercourse
Subgroup Study Outcome Group 1
Group 
2
Odds 
ratio
CI lower | 
upper
Condom 
use: first 
intercourse
Coyle et al.58 – 
Safer Choices 
Condom use at first 
intercourse (initiators only, 
7-month follow-up)
0.000 | 
0.000
0.000 | 
0.000
0.680 0.265 | 1.742
Condom 
use: first 
intercourse
Stephenson et al.50 
– RIPPLE 
Combined: used condom at 
first sex 6 months
0.000 | 
0.000
0.000 | 
0.000
1.103 0.584 | 2.083
Condom 
use: first 
intercourse
Wight et al.70 – 
SHARE 
Combined: condom use (at first 
intercourse) after first year
0.000 | 
0.000
0.000 | 
0.000
0.994 0.377 | 2.617
Total 0.958 0.603 | 1.522
Heterogeneity statistic Q = 0.704, df = 2, p = 0.703, I2 = 0%.
File draw N = 2.
Test statistic (combined effect) z = 0.181, p = 0.856.
Meta-analysis method: inverse variance (fixed effects model).
Item Effect (CI) Weight % Size
Condom use – ﬁrst intercourse
Coyle 1999
58 Safer 
Choices IT19200
0.68 (0.27 to 1.74) 24.2 0
Stephenson 2004
50
Ripple ITT1203818
1.10 (0.58 to 2.08) 53.0 876
Wight 2002
70
SHARE IT18196
0.99 (0.38 to 2.62) 22.8 4952
0.96 (0.60 to 1.52)
0.14 1.00 7.39
Favours intervention Favours controlAppendix 9
196
Condom use at first intercourse – boys only
Subgroup Study Outcome Group 1 Group 2 Odds ratio
CI lower | 
upper
Condom use: 
boys, first sex
Stephenson et 
al.50 – RIPPLE
Used condom at first sex, 
BOYS 6 months
198.000 | 
40.000
152.000 | 
41.000
1.335 0.507 | 3.516
Condom use: 
boys, first sex
Wight et al.70 – 
SHARE
Condom use BOYS (at 
first intercourse) after 
first year
1042.000 | 
57.000
1154.000 | 
70.000
1.109 0.228 | 5.404
Total 1.269 0.556 | 2.900
Heterogeneity statistic Q = 0.0385, df = 1, p = 0.845, I2 = 0%.
File draw N = 1.
Test statistic (combined effect) z = 0.566, p = 0.571.
Meta-analysis method: inverse variance (fixed effects model).
Item Effect (CI) Weight % Size
Condom use – boys – ﬁrst sex
Stephenson 2004
50
Ripple ITT1203818
1.34 (0.51 to 3.52) 72.8 431
Wight 2002
70
SHARE IT18196
1.11 (0.23 to 5.40) 27.2 2323
1.27 (0.56 to 2.90)
0.14 1.00 7.39
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Condom use at first intercourse – girls only
Subgroup Study Outcome Group 1 Group 2 Odds ratio
CI lower | 
upper
Condom use: 
girls, first sex
Stephenson et 
al.50 – RIPPLE
Used condom at first sex, 
GIRLS 6 months
168.000 | 
62.000
159.000 | 
56.000
0.954 0.411 | 2.217
Condom use: 
girls, first sex
Wight et al.70 – 
SHARE
Condom use GIRLS (at 
first intercourse) after first 
year
1182.000 | 
127.000
1200.000 | 
120.000
0.931 0.274 | 3.165
Total 0.947 0.473 | 1.895
Heterogeneity statistic Q = 0.00109, df = 1, p = 0.974, I2 = 0%.
File draw N = 1.
Test statistic (combined effect) z = 0.155 p = 0.877.
Meta-analysis method: inverse variance (fixed effects model).
Item Effect (CI) Weight % Size
Condom use – girls – ﬁrst sex
Stephenson 2004
50
Ripple ITT1203818
0.95 (0.41 to 2.22) 67.8 445
Wight 2002
70
SHARE IT18196
0.93 (0.27 to 3.16) 32.2 2629
0.95 (0.47 to 1.90)
0.14 1.00 7.39
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Condom use at last intercourse
Subgroup Study Outcome Group 1 Group 2 Odds ratio
CI lower | 
upper
Condom 
use: last 
intercourse
Coyle et al.58 – 
Safer Choices
Condom use last 
intercourse (7-month 
follow-up)
0.000 | 
0.000
0.000 | 
0.000
1.910 1.125 | 3.242
Condom 
use: last 
intercourse
Stanton et al.69 – 
FoK-WV 
Used a condom in last 
episode at 3 months
635.000 | 
235.000
191.000 | 
70.000
0.990 0.635 | 1.545
Condom 
use: last 
intercourse
Stephenson et al.50 
– RIPPLE
Combined: used condom 
at last sex 18 months
0.000 | 
0.000
0.000 | 
0.000
0.982 0.759 | 1.271
Condom 
use: last 
intercourse
Wight et al.70 – 
SHARE
Combined outcome: 
condom use (last 
intercourse) 3–6 months
0.000 | 
0.000
0.000 | 
0.000
1.001 0.367 | 2.726
Condom 
use: last 
intercourse
Zimmerman et 
al.71
Condom use at last sex 
(one academic year)
807.000 | 
342.000
595.000 | 
256.000
1.015 0.340 | 3.034
Total 1.082 0.887 | 1.319
Heterogeneity statistic Q = 5.16, df = 4, p = 0.271, I2 = 22.5%.
File draw N = 4.
Test statistic (combined effect) z = 0.777, p = 0.437.
Meta-analysis method: inverse variance (fixed effects model).
Item Effect (CI) Weight % Size
Condom use – last intercourse
Coyle 1999
58 Safer 
Choices IT19200
1.91 (1.13 to 3.24) 14.0 0
Stanton 2005
69
FOK-WV ITT1203840
0.99 (0.63 to 1.54) 19.8 1131
Stephenson 2004
50
Ripple ITT1203818
0.98 (0.76 to 1.27) 59.0 1534
Wight 2002
70
SHARE IT18196
1.00 (0.37 to 2.73) 3.9 2145
Zimmerman 2008
71 1.02 (0.34 to 3.03) 3.3 2000
1.08 (0.89 to 1.32)
0.14 1.00 7.39
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Condom use at last intercourse – boys only
Subgroup Study Outcome Group 1 Group 2 Odds ratio
CI lower | 
upper
Used condom: 
last sex, boys
Stephenson et al.50 
– RIPPLE
Used condom at last 
sex: boys, 18 months
251.000 | 
101.000
203.000 | 
61.000
0.747 0.299 | 1.866
Used condom: 
last sex, boys
Wight et al.70 – 
SHARE
Condom use (last 
intercourse), boys, 3–6 
months
281.000 | 
142.000
295.000 | 
158.000
1.060 0.212 | 5.302
Total 0.814 0.367 | 1.803
Heterogeneity statistic Q = 0.137, df = 1, p = 0.711, I2 = 0%.
File draw N = 1.
Test statistic (combined effect) z = 0.508 p = 0.611.
Meta-analysis method: inverse variance (fixed effects model).
Item Effect (CI) Weight % Size
Used condom – last sex – boys
Stephenson 2004
50
Ripple ITT1203818
0.75 (0.30 to 1.87) 75.6 616
Wight 2002
70
SHARE IT18196
1.06 (0.21 to 5.30) 24.4 876
0.81 (0.37 to 1.80)
0.14 1.00 7.39
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Condom use at last intercourse – girls only
Subgroup Item Outcome Group 1 Group 2 Odds ratio
CI lower | 
upper
Used a 
condom: last 
sex, girls
Stephenson et al.50 
– RIPPLE
Used condom at last 
sex, girls, 18 months
318.000 | 
191.000
255.000 | 
154.000
1.005 0.769 | 1.315
Used a 
condom: last 
sex, girls
Wight et al.70
 – SHARE
Condom use (last 
intercourse), girls, 3–6 
months
355.000 | 
289.000
350.000 | 
275.000
0.965 0.268 | 3.472
  Total     1.004 0.772 | 1.306
Heterogeneity statistic Q = 0.00376, df = 1, p = 0.951, I2 = 0%.
File draw N = 1.
Test statistic (combined effect) z = 0.0279, p = 0.978.
Meta-analysis method: inverse variance (fixed effects model).
Item Effect (CI) Weight % Size
Used condom – last sex – girls
Stephenson 2004
50
Ripple ITT1203818
1.01 (0.77 to 1.32) 95.8 918
Wight 2002
70
SHARE IT18196
0.97 (0.27 to 3.47) 4.2 1269
1.00 (0.77 to 1.31)
0.14 1.00 7.39
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1.  exp Sexually Transmitted Diseases/(206406)
2.  ‘Chlamydia Infections’/(10291)
3.  ‘Gonorrhea’/(10081)
4.  ‘Pelvic Inflammatory Disease’/(4138)
5.  exp HIV Infections/(169184)
6.  ‘Acquired Immunodeficiency Syndrome’/
(66750)
7.  Herpes Genitalis/(3235)
8.  Condylomata Acuminata/(3667)
9.  Syphilis/(13099)
10. ‘Papillomavirus Infections’/(7419)
11. (sexual$transmit$adj3 infection$).ti,ab. (3419)
12. (sexual$transmit$adj3 disease$).ti,ab. (9770)
13. (STIs or STI or STDs or STD).ti,ab. (9292)
14. Unsafe Sex/(734)
15. sexually transmitted infection$.mp. (2819)
16. Risk Reduction Behavior/(1911)
17. ‘Condoms’/(4967)
18. contracept$.ti. (22186)
19. Safe Sex/(1228)
20. sexual health.mp. (1980)
21. sexual abstinence/(893)
22. safe$sex.ti,ab. (1284)
23. or/1–22 (255030)
24. exp preventive health services/(305696)
25. ‘Patient Education’/(50147)
26. exp Behavior Therapy/(35650)
27. Sex Education/(6714)
28. exp Health Promotion/(31991)
29. ‘Counseling’/(21084)
30. exp School Health Services/(15174)
31. adolescent health services/(3156)
32. ((behavio?r$or conduct or attitude$or 
intent$or knowledge or self-confidence or 
information or skill$or risk or health) adj5 
(train$or chang$or alter$or prevent$or 
reduc$or promot$or increas$or decreas$or 
improv$or program$or curricul$or educat$or 
project$or campaign$or approach$or 
facilitat$or advice or counsel$or provi$)).ti,ab. 
(538730)
33. (cognitive adj3 therap$).ti,ab. (4901)
34. (behavio$adj3 therap$).ti,ab. (8106)
35. or/24–34 (832512)
36. 23 and 35 (38822)
37. exp ECONOMICS/(383052)
38. exp ‘Costs and Cost Analysis’/(133267)
39. ‘Cost-Benefit Analysis’/(41727)
40. Quality-Adjusted Life Years/(3230)
41. exp MODELS, ECONOMIC/(5632)
42. exp FEES/and CHARGES/(7184)
43. exp BUDGETS/(9655)
44. ((cost$or economic) adj2 (benefit$or utilit$or 
minim$or effective$or evaluat$)).ti,ab. (55745)
45. (value adj2 (money or monetary)).tw. (648)
46. (economic adj2 burden).tw. (1591)
47. or/37–46 (412594)
48. letter.pt. (607009)
49. editorial.pt. (212191)
50. comment.pt. (343880)
51. or/48–50 (869840)
52. 47 not 51 (379235)
53. 36 and 52 (2718)
54. (teenage$or adolescent$).ti,ab. (96096)
55. (young adj3 (people or person$or adult$)).
ti,ab. (48296)
56. ‘Adolescent’/(1211252)
57. 54 or 55 or 56 (1249068)
58. 53 and 57 (580)
59. limit 58 to yr = ‘1990 – 2007’ (535)
60. limit 59 to english language (511)
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Appendix 11  
Distributions used for the 
probabilistic sensitivity analyses
T
able 80 shows the distributions used for 
parameters in the economic model. The main 
parameters were varied according to the ranges 
shown in the one way sensitivity analyses in the 
main report (Table 62). These ranges were used as 
the 95% CIs to estimate parameters for the normal 
distribution. In the case of the parameters which 
used the triangular distribution, the ranges shown 
are the outer bounds of the distribution.
Some of the parameters varied according to a 
proportional increase or decrease from the baseline 
value. These are shown in the table as those values 
with a mean of 1. For these parameters the new 
value used in the PSA is the baseline multiplied by 
the proportional change.Appendix 11
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TABLE 80  Parameters used for the probabilistic sensitivity analysis
Parameter name
Base-
case 
mean
Lower 
95% CI
Upper 
95% CI Distribution Parameters
Intervention
Cost of programme (£/individual) 4.3 3 5.6 Gamma α = 42
β = 0.103
Sexually active 1 0.7 1.3 Log normal µ = 0.000
σ = 0.158
Intervention effect, condom use 1.07 1.01 1.13 Log normal µ = 0.049
σ = 0.068
Baseline
Condom use 1 0.85 1.15 Log normal µ = 0.000
σ = 0.077
Sexual episodes per partner 10 6 14 Log normal µ = 2.303
σ = 0.216
Number of sexual partners per year 1 0.75 1.25 Log normal µ = 0.000
σ = 0.130
Model parameters
Single sex act transmission probability 1 0.3 1.8 Log normal µ = 0.000
σ = 0.457
STI prevalence rate 1 0.7 1.3 Log normal µ = 0.000
σ = 0.158
Condom effectiveness in preventing 
HIV
1 0.85a 1.05a Triangle Min. = 0.85, max. = 1.05
Mode = 1
STI complications, all STIs
Prevalence 1 0.7 1.3 Log normal µ = 0.000
σ = 0.158
Quality of life 1 0.8a 1.2a Triangle Min. = 0.8, max. = 1.2
Mode = 1
Unit costs (£) 1 0.7 1.3 Log normal µ = 0.000
σ = 0.158
All parameters shown as log-normal are sampled from normal distributions – the sampled value is exponentiated for use 
in the model. The normal distributions have a mean (µ) equal to the natural logarithm of the base-case mean (column 2) 
and standard deviation (σ) calculated from the natural logarithm of the upper and lower 95% confidence limits using the 
following formula:
ln( ) ln( )
* .
UCI LCI −
2 1 96
See Briggs and colleagues114 for details and explanation of this approach.
a  These values are used for the outer bounds of the distribution.DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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F
or the purposes of economic modelling, a 
pooled RR for the general outcome of condom 
use was required. In our synthesis of the results of 
sound outcome evaluations for sexual behaviour we 
report a pooled OR for the outcome ‘All condom 
use’ of 1.07 (95% CI 0.88 to 1.30) (see Figure 3 in 
Chapter 4, Condom use). The pooled OR therefore 
had to be converted into a pooled RR.
However, for one of the studies in the meta-
analysis, the results of the Safer Choices 
intervention by Coyle and colleagues,58 the trial 
publication reported only the following data from 
the output of a multilevel model:
Outcome n
Effect 
size 
(OR) SE
95% 
CI  p-value
Use of 
condoms 
at last 
intercourse
1018 1.91 0.27 1.13 to 
3.21
0.02
The numbers of young people in the intervention 
and comparison groups, and the numbers of 
young people reporting condom use in these two 
study groups, were not reported. For the OR meta-
analysis, we were able to enter the reported Coyle 
effect size directly into our meta-analysis software. 
Conversion of the results of the Coyle study in a 
RR meta-analysis, however, required imputation 
of the number of young people reporting condom 
use, i.e. completing a 2 × 2 data table for the Coyle 
and colleagues study. (Note: We wrote to the study 
author to request the relevant data but did not 
receive a reply.)
We imputed values for group size, number of 
young people reporting condom use and number 
not reporting condom use, such that an OR as 
close as possible to the reported OR of 1.91 was 
generated:
Intervention 
group
Comparison 
group
Group size 571 447
Event 370 219
No event 201 228
The imputed values above generate an OR of 1.916 
for the Coyle and colleagues study, with a 95% CI 
for the OR of 1.49 to 2.47. These imputed values 
were then used to include the Coyle study in a RR 
meta-analysis of all condom use (Figure 11). The 
pooled random effect RR estimate for condom 
use used in the economic model was therefore 
1.05 (95% CI 0.92 to 1.20) (test for heterogeneity 
p = 0.00141, I2 = 74.7%).
The pooled RR and the pooled OR presented in 
Figure 3 in Chapter 4 (under Condom use) are 
consistent in that they both show a non-statistically 
significant intervention effect.
Appendix 12  
Generation of pooled risk ratio effect 
estimate for condom use required 
for the economic modelAppendix 12
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Item Effect (CI) Weight % Size
All condom use (alternative MA for economic evaluation 
using RR) 2
Coyle 1999
58 Safer 
Choices IT19200
1.32 (1.18 to 1.48) 21.9 1018
Levy 1995
65
1398D1451
0.93 (0.76 to 1.14) 16.0 310
Stanton 2005
69
FOK-WV ITT1203840
1.00 (0.89 to 1.12) 21.4 1131
Stephenson 2004
50
Ripple ITT1203818
0.99 (0.90 to 1.09) 23.0 1534
Wight 2002
70
SHARE IT18196
1.00 (0.68 to 1.49) 7.7 2145
Zimmerman 2008
71 1.00 (0.72 to 1.39) 9.9 2000
1.05 (0.92 to 1.20)
0.67 1.00 1.49
Favours intervention Favours control
FIGURE 11  Meta-analysis plot for the outcome ‘All condom use’ (relative risk).DOI: 10.3310/hta14070  Health Technology Assessment 2010; Vol. 14: No. 7
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Feedback
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your views about this report.
The Correspondence Page on the HTA website 
(www.hta.ac.uk) is a convenient way to publish  
your comments. If you prefer, you can send your comments  
to the address below, telling us whether you would like  
us to transfer them to the website.
We look forward to hearing from you.